CN116847882A - HIV vaccine and how to use it - Google Patents

Abstract

The invention provides HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, and vectors expressing such fusion polypeptides for inducing immune responses against HIV-1; including such fusion polypeptides, polynucleotides or vectors Pharmaceutical and immunogenic compositions and kits, and methods for treating and/or preventing HIV‑1. The present invention also provides methods for designing antiviral vaccines, including vaccines that elicit an immune response to HIV-1.

Description

HIV vaccines and methods of use

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 63/137,521, filed on January 14, 2021; U.S. Provisional Application No. 63/149,820, filed on February 16, 2021, and U.S. Provisional Application No. 63/170,900, filed on April 5, 2021, under 35 U.S.C. §119(e), which are hereby incorporated by reference in their entirety for all purposes.

Sequence Listing

This application contains a sequence listing, which is submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy was created on December 12, 2021, is named 1355-WO-PCT.txt, and is 512,244 bytes in size.

Background Art

HIV remains one of the leading causes of global population mobility and mortality, with more than 38 million infections and 690,000 deaths worldwide in 2019 (UNAIDS.Fact Sheet-World AIDS Day 2020.unaidsorg/en/resources/fact-sheet.2020). In the past three decades, HIV treatment has improved significantly. The development of highly active antiretroviral therapy has improved the survival rate of HIV patients and reduced the incidence of HIV-related immunosuppression and opportunistic infections (Johnson et al., PLoS Med. 2013; 10(4): e1001418; May et al., AIDS. (2014) 28(8): 1193-202; Rodger et al., AIDS. (2013) 27(6): 973-9; Samji et al., PLoS One. (2013) 8(12): e81355). In recent years, antiretroviral therapy (ART) regimens have been simplified to a once-daily pill, with long-acting oral and injectable treatments on the horizon (Swindells et al., N Engl J Med. (2020) 382(12):1112-23; Orkin et al., N Engl J Med. (2020) 382(12):1124-35; Link et al., Nature. (2020) 584(7822):614-8). Despite these advances in treatment, there have been only two documented cures to date, both of which required strict immunosuppression and bone marrow transplantation (Gupta et al., Lancet HIV. (2020) 7(5):e340-e7; Hutter et al., N Engl J Med. (2009) 360(7):692-8). Unlike many self-limiting infectious diseases, HIV virus integrates itself into its host genome and establishes latency in resting memory CD4+T cells (Eisele et al., Immunity. (2012) 37 (3): 377-88). These cells form HIV latent reservoirs that cannot be removed by standard antiretroviral therapy. Reservoir cells are also protected from immune surveillance and clearance mechanisms because these cells do not express viral antigens, allowing these cells to escape recognition and clearance of cytotoxic T cells. The reservoir is long-term, and although a decrease in reservoir size can be detected, viral rebound is observed after stopping ART (Henrich et al., Ann Intern Med. (2014) 161 (5): 319-27; Henrich et al., J Infect Dis. (2013) 207 (11): 1694-702). Activation of the reservoir with latency reversal agents will need to be combined with effective mechanisms to stimulate cytotoxic T cells and eliminate infected reservoir cells (Ait-Ammar et al., Front Microbiol. (2019) 10: 3060; Mothe et al., Front Immunol. (2020) 11: 823; Fidler et al., Lancet. (2020) 395 (10227): 888-98). Therapeutic vaccines designed to generate antigen-specific effector T cell responses can be an additional component of HIV treatment strategies.

T cell vaccines have important prospects in therapeutic areas such as oncology. In some cancers, high levels of tumor-infiltrating CD8+ lymphocytes are associated with better prognosis, which has led to great interest in developing vaccines that can induce tumor-specific cytotoxic CD8+ T cells. Although previous methods have achieved limited success (Rosenberg et al., Nature Medicine. (2004) 10 (9): 909-15), the use of novel delivery platforms, antigen discovery and improved techniques for immunomodulation have brought some hope (Ott et al., Nature. (2017) 547 (7662): 217-21). Similarly, T cells play an important role in the control of HIV viremia. Antigen-specific T cells that appear in acute HIV infection are responsible for driving the initial decline in viremia (Borrow et al., J Virol. (1994) 68 (9): 6103-10; Koup et al., J Virol. (1994) 68 (7): 4650-5). Long-term non-progressors or elite controllers in HIV-infected people are characterized by strong and effective antigen-specific T cell responses. In SIV infection (a non-human primate model of human HIV infection), antigen-specific T cells produced naturally or by vaccination are associated with viral control (Schmitz et al., Science. (1999) 283 (5403): 857-60; Jin et al., J Exp Med. (1999) 189 (6): 991-8). Despite these data, T cell vaccines used for prevention have limited success in inducing T cell responses of limited breadth or efficacy (Buchbinder et al., Lancet. (2008) 372 (9653): 1881-93; Janes et al., J Infect Dis. (2013) 208 (8): 1231-9; Excler et al., Curr Opin HIV AIDS. (2016) 11 (6): 607-13). Therapeutic vaccine trials with T cell vaccines have also shown limited efficacy (Mothe et al., Front Immunol. (2020) 11: 823; Colby et al., Nature Medicine. (2020) 26 (4): 498-501). These trials use viral vectors such as adenovirus (human and chimpanzee) and modified vaccinia virus Ankara (MVA) and full-length viral antigens or shorter constructs (Barouch et al., Lancet. (2018) 392 (10143): 232-43; Mothe et al., EClinical Medicine. (2019) 11: 65-80). Data from these studies suggest that the breadth of antigen-specific T cells generated after vaccination is low. Although these vaccine-induced T cells secrete IFN-γ in standard ELISpot assays, the lack of efficacy demonstrated suggests that these T cells may not have full cytotoxic activity.

Immunogen design is an integral part of any therapeutic HIV vaccine to generate the correct antigen-specific response, target conserved regions, and have cytotoxic activity. Natural infection has demonstrated that immune responses tend to focus on highly immunodominant variable regions within HIV, such as variable regions in HIV envelope or Nef, or variable regions in HIV Gag (Addo et al., J Virol. (2003) 77 (3): 2081-92; Betts et al., J Virol. 2001; 75 (24): 11983-91). These responses generate T cells from which the virus can quickly escape without paying an adaptive cost (Liu et al., J Virol. (2006) 80 (19): 9519-29). Effective HIV vaccines will need to avoid these regions and drive the establishment of de novo responses, which focus immune responses on conserved regions of the virus, where the conserved regions are required to be conserved to maintain viral function.

Previous HIV vaccines have focused primarily on designing immunogens by addressing global HIV viral diversity and providing universal coverage, and have generated full-length sequences or have adapted algorithms to generate constructs of conserved regions (Korber et al., Hum Vaccin Immunother. (2020) 16 (3): 713-722; Fischer et al., Nature Medicine. (2007) 13 (1): 100-6). All of these methods have primarily evaluated consensus sequences, which evaluate inter-patient variability to determine conserved regions, and connect these conserved regions to provide total sequence coverage. However, there are several circulating quasispecies in HIV-infected individuals. Some of these viral quasispecies are generated due to T cell-driven pressure and reflect the pre-existing escape pathways of the virus when T cell responses against it appear (Liu et al., J Virol. (2006) 80 (19): 9519-29; Korber et al., 2020, supra; Price et al., Proc Natl Acad Sci U S A. (1997) 94 (5): 1890-5). Previous vaccines targeting conserved regions did not take into account quasispecies and the identification of highly conserved immunogenic regions, which may partly explain their limited efficacy (Hanke et al., Expert Rev Vaccines. (2019) 18 (10): 1029-41).

Summary of the invention

The present invention provides fusion polypeptides comprising multiple polypeptide fragments of one or more human immunodeficiency virus-1 (HIV-1) proteins encoded by two or more HIV genes selected from gag, pol and nef. In some embodiments, the multiple polypeptide fragments comprise or consist of polypeptide fragments encoded by HIV-1 genes Pol and Nef, for example, polypeptide fragments encoded by HIV-1 genes env, tat, rev, vpr, vif and/or vpu are not included. In some embodiments, the multiple polypeptide fragments comprise or consist of polypeptide fragments encoded by HIV-1 genes Gag, Pol and Nef, for example, polypeptide fragments encoded by HIV-1 genes env, tat, rev, vpr, vif and/or vpu are not included. In some embodiments, the multiple polypeptide fragments are derived from conserved regions in a viral proteome sequence population. In some embodiments, the conserved region is more than 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% conservative among HIV-1 species in the interpatient population. In some embodiments, the conserved region is conserved between one or more of HIV-1 clades A-K, such as one or more of clades A, B, C, D and G, or recombinant forms of one or more of HIV-1 clades A-K, and combinations thereof. In some embodiments, the fusion polypeptide comprises at least 4 and at most 6 polypeptide fragments, for example, 4, 5 or 6 polypeptide fragments. In some embodiments, each polypeptide fragment is at least 10 amino acids in length and at most about 225 amino acids in length, for example, at least 10 amino acids in length and at most 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 , 39, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220 or 225 amino acids. In some embodiments, the full length of the fusion polypeptide comprises at least about 330 amino acids and at most about 505 amino acids (without the signal peptide) or at most about 550 amino acids (including the signal peptide), such as at least about 330 amino acids and at most about 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, or 550 amino acids. In some embodiments, the total length of the fusion polypeptide is no longer than 550 amino acids (including the signal peptide) or no longer than 505 amino acids (without the signal peptide), e.g., no longer than 545, 540, 535, 530, 525, 520, 515, 510, 505, 500, 495, 490, 485, 480, 475, 470, 465, 460, 455, 450, 445, 440, 435, 430, 425, 420, 415, 410, 405, 400, 390, 385, 380, 375, 370, 365, 360, 355, 350, 345, 340, 335, or 330 amino acids. In some embodiments, the full length of the fusion polypeptide comprises at least 350 amino acids and at most 385 amino acids, for example, at least 350 amino acids and at most 365 amino acids. In some embodiments, the full length of the fusion polypeptide comprises at least 390 amino acids and at most 395 amino acids. In some embodiments, each polypeptide fragment comprises one or more predicted T cell epitopes or consists of these epitopes. In some embodiments, the fusion polypeptide comprises three or more predicted T cell epitopes, for example, four, five, six or more predicted T cell epitopes. In some embodiments, the fusion polypeptide comprises one or more polypeptide fragments, which are combined with one or more human HLA class I alleles (e.g., 1, 2, 3, 4, 5 or 6 alleles) within a single subject or between multiple patients or presented by these alleles. In some embodiments, the fusion polypeptide comprises one or more polypeptide fragments, which are at least combined with human A*0201 HLA class I molecules or presented by the molecule. In some embodiments, the fusion polypeptide comprises one or more polypeptide fragments, which are processed in the cell and presented by one or more human HLA class II alleles (e.g., 1, 2, 3, 4, 5 or 6 alleles) in, for example, a single subject. In some embodiments, one or more of these polypeptide fragments are adjacent to or fused to adjacent fragments. In some embodiments, one or more of these polypeptide fragments are bound to adjacent fragments by one or more peptide linkers. In some embodiments, one or more peptide linkers are selected from polyalanine, polyglycine, Gln-Glu-Glu (QEE), lysine (L), isoleucine (I), Leu-Ile (LI), Lys-Ile-Leu (KIL), Leu-Ile-Lys (LIK), Pro-Pro-Val (PPV), Ser-Glu-Gly (SEG), cleavable linkers, flexible linkers, rigid linkers, and combinations thereof. In some embodiments, the flexible linker is selected from Gln-Glu-Glu (QEE) (SEQ ID NO: 51), Lysine (L), Isoleucine (I), Leu-Ile (LI), Lys-Ile-Leu (KIL) (SEQ ID NO: 52), Leu-Ile-Lys (LIK) (SEQ ID NO: 53), Pro-Pro-Val (PPV) (SEQ ID NO: 54), Ser-Glu-Gly (SEG) (SEQ ID NO: 55). In some embodiments, the flexible linker comprises a polyalanine linker or a polyglycine linker, for example, comprising 2 or 3 consecutive alanine residues, for example, AA, AAA (SEQ ID NO: 48), AAY (SEQ ID NO: 49) or AAX or consisting of these consecutive alanine residues, wherein X is any amino acid (e.g., A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, Y) (SEQ ID NO: 50). In some embodiments, the flexible linker comprises or consists of GG, GGS (SEQ ID NO: 57), GSG (SEQ ID NO: 58) or GGGS (SEQ ID NO: 59). In some embodiments, the cleavable linker is selected from 2A cleavable peptides (e.g., foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine teschovirus-1 (P2A) and sphenotype virus (T2A)), furin recognition/cleavage sequences (e.g., RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and RRKR (SEQ ID NO: 62)), and combinations, derivatives or variants thereof. In some embodiments, the cleavable linker comprises or consists of a furin recognition/cleavage site selected from RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and RRKR (SEQ ID NO: 62). In some embodiments, the cleavable linker comprises or consists of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical to ATNFSLLKQAGDVEENPGP (SEQ ID NO:63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO:64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO:65), QCTNYALLKLAGDVESNPGP (SEQ ID NO:66), or EGRGSLLTCGDVEENPGP (SEQ ID NO:67). The amino acid sequence of the peptide sequence of SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66) or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67) may also be present in the peptide sequence of SEQ ID NO: 68 or may consist of the amino acid sequence of SEQ ID NO: 69. In some embodiments, the fusion polypeptide comprises two, three, four, five, six or more polypeptide fragments comprising or consisting of amino acid residues corresponding to Gag 1-53, Gag 147-369, Pol56-117, Pol 129-320, Pol 367-431, Pol 542-606, Pol 586-606, Pol683-708, Pol 747-827, Pol 840-909, Pol 840-920, Pol 932-1003, Nef 64-76, Nef 64-99, or Nef 117-148, wherein the Gag, Pol, and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2, and 3, respectively. In some embodiments, the fusion polypeptide does not include any polypeptide fragment corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the fusion polypeptide does not comprise any polypeptide fragment having an amino acid sequence of any one of SEQ ID NOs: 35-47 or a fragment or subsequence thereof, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 35-47 or a fragment or subsequence thereof. In some embodiments, the fusion polypeptide comprises two, three, four, five, six, or more polypeptide fragments selected from SEQ ID NOs: 4-33. In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide fragments, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively: (a) corresponding to the following amino acid residues: Gag 1-53, Gag 147-369, Pol 683-708 and Nef 117-148; (b) corresponding to the following amino acid residues: Pol 56-117, Pol 129-320, Pol 367-431 and Nef64-99; (c) corresponding to the following amino acid residues: Pol542-606, Pol 747-827, Pol 840-920, Pol 932-1003 and Nef 64-99; (d) corresponding to the following amino acid residues: Gag 1-53, Gag 147-369, Pol 683-708, Pol 747-827, Pol 840-920 and Nef 117-148; (e) corresponding to the following amino acid residues: Pol 56-117, Pol 129-320, Pol 367-431, Pol 542-606, Pol 932-1003 and Nef 64-99; (f) corresponding to the following amino acid residues: Gag 147-369, Pol 586-606, Pol 683-708 and Pol 840-920; (g) corresponding to the following amino acid residues: Pol 129-320, Pol 747-827, Pol 932-1003 and Nef 64-76; or (h) corresponding to the following amino acid residues: Gag: 147-369, Pol 747-827, Pol 840-909 and Nef 64-76. In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide fragments: (a) SEQ ID NO: 4, 6, 18 and 32, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 4, 6, 18 and 32, respectively; (b) SEQ ID NO: 5, 7, 19 and 33, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 5, 7, 19 and 33, respectively. %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 5, 7, 19 and 33; (c) SEQ ID NOs: 8, 10, 12 and 30, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 10, 12 and 30, respectively; (d) SEQ ID NOs: 9, 11, 13 and 31, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 14, 20, 24, 26 and 30, or fragments thereof that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 14, 20, 24, 26 and 30, respectively; (f) SEQ ID NOs: 1 NO:15, 21, 25, 27 and 31, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:15, 21, 25, 27 and 31, respectively; (g) SEQ ID NO:4, 6, 18, 20, 24 and 32, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:4, 6, 18, 20, 24 and 32, respectively. %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:4, 6, 18, 20, 24 and 32; (h) SEQ ID NO:5, 7, 19, 21, 25 and 33, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:5, 7, 19, 21, 25 and 33, respectively; (i) SEQ ID NO: NO:8, 10, 12, 14, 26 and 30, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:8, 10, 12, 14, 26 and 30, respectively; (j) SEQ ID NO:9, 11, 13, 15, 27 and 31, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:8, 10, 12, 14, 26 and 30, respectively; %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 11, 13, 15, 27 and 31; (k) SEQ ID NOs: 6, 16, 18 and 24, or sequence fragments at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 16, 18 and 24, respectively; (l) SEQ ID NOs: 7, 17, 19 and 25, or sequence fragments at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 17, 19 and 25; (m) SEQ ID NOs: 10, 20, 26 and 28, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 10, 20, 26 and 28, respectively; (n) SEQ ID NOs: 11, 21, 27 and 29, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 21, 27 and 29; (o) SEQ ID NOs: 6, 20, 22 and 28, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 20, 22 and 28, respectively; (p) SEQ ID NOs: 7, 21, 23 and 29, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 23 and 29; (q) SEQ ID NOs: 6, 16, 18 and 24, or fragments thereof that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 16, 18 and 24, respectively; (r) SEQ ID NOs: 7, 17, 19 and 25, or fragments thereof that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 17, 19 and 25; (s) SEQ ID NOs: 10, 20, 26 and 28, or fragments of sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 10, 20, 26 and 28, respectively; or (t) SEQ ID NOs: 11, 21, 27 and 29, or fragments of sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: NO:11, 21, 27 and 29 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments. In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide fragments, optionally bound or linked by one or more linkers, in order from N-terminus to C-terminus: SEQ ID NOs: 6, 4, 18, and 32, or sequence fragments at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 7, 5, 33, and 19, or sequence fragments at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 7, 5, 33, and 19, respectively. %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 5, 33 and 19; SEQ ID NOs: 12, 30, 8 and 10, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 12, 30, 8 and 10, respectively; SEQ ID NOs: 9, 31, 13 and 11, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 14, 26, 20, 30 and 24, or fragments thereof that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 14, 26, 20, 30 and 24, respectively; SEQ ID NOs: 15, 31, 21, 27 and 25, or fragments thereof that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 14, 26, 20, 30 and 24, respectively; 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 12, 14, 16, 18, 19, 20, 21, 27 and 25, or fragments thereof that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 12, 14, 16, 18, 19, 20, 21, 27 and 25, or fragments thereof that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 12, 14, 16, 18, 19, 20, 21, 27 and 25, or fragments thereof that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 33, 5 and 19; SEQ ID NOs: 8, 30, 12 and 10, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 30, 12 and 10, respectively; SEQ ID NOs: 13, 31, 9 and 11, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 13, 31, 9 and 11; or fragments of sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 30, 14, 20 and 24, respectively; or fragments of sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 30, 14, 20 and 24, respectively; 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 4, 20, 18 and 32, or fragments thereof that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 4, 20, 18 and 32, respectively; NO:6, 20, 4, 24, 32 and 18, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:6, 20, 4, 24, 32 and 18, respectively; SEQ ID NO:7, 21, 5, 25, 33 and 19, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:7, 21, 5, 25, 33 and 19, respectively. %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 5, 25, 33 and 19; SEQ ID NOs: 8, 30, 14, 12, 26 and 10, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 30, 14, 12, 26 and 10, respectively; NO:8, 12, 30, 26, 14 and 10, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:8, 12, 30, 26, 14 and 10, respectively; SEQ ID NO:9, 13, 31, 27, 15 and 11, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:9, 13, 31, 27, 15 and 11, respectively. %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 20, 32, 24, 4, 6 and 18, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 20, 32, 24, 4, 6 and 18, respectively; NO:7, 25, 19, 5, 33 and 21, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:7, 25, 19, 5, 33 and 21, respectively; SEQ ID NO:26, 30, 12, 14, 8 and 10, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:26, 30, 12, 14, 8 and 10, respectively 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 31, 9, 27, 13 and 11, or fragments thereof that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 31, 9, 27, 13 and 11, respectively; NO:24, 6, 16 and 18, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:24, 6, 16 and 18, respectively; SEQ ID NO:7, 19, 17 and 25, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:7, 19, 17 and 25, respectively; NO:24, 16, 6 and 18, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:24, 16, 6 and 18, respectively; SEQ ID NO:7, 25, 17 and 19, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:7, 25, 17 and 19, respectively; 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 21, 27, 11 and 29, or fragments thereof that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 21, 27, 11 and 29, respectively; NO: 26, 10, 20 and 28, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 26, 10, 20 and 28, respectively; SEQ ID NO: 11, 27, 21 and 29, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 11, 27, 21 and 29, respectively; NO:22, 6, 20 and 28, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:22, 6, 20 and 28, respectively; SEQ ID NO:23, 7, 21 and 29, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:23, 7, 21 and 29, respectively; 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 23 and 29, or fragments of sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 23 and 29, respectively. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223, and 227. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223.

Also provided are composite fusion polypeptides comprising at least a first fusion polypeptide and a second fusion polypeptide, the first and second fusion polypeptides being independently selected from the fusion polypeptides described above and herein. In some embodiments, the composite fusion polypeptide comprises or consists of the following first fusion polypeptide and the second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide of SEQ ID NOs: 70 and 71, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; a fusion polypeptide of SEQ ID NOs: 72 and 73, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively. 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:76 and 77; a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:78 and 79, respectively; a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:80 and 81, respectively. 82 and 83, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively; a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively. 84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85; a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively; a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively. 88 and 89; a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively; a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively. 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86; a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively. 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87; a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively; a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively. 84 and 88, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; a fusion polypeptide of SEQ ID NOs: 85 and 89, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively. 85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively; a fusion polypeptide of SEQ ID NOs:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively; a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91; a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively; a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively. 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively. 94 and 96; a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively; a fusion polypeptide of SEQ ID NOs:220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively; a fusion polypeptide of SEQ ID NOs:220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221; a fusion polypeptide of SEQ ID NOs: 98 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; a fusion polypeptide of SEQ ID NOs: 99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively; or a fusion polypeptide of SEQ ID NOs:100 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:100 and 101, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:100 and 101. In some embodiments, the composite fusion polypeptide comprises or consists of the following first and second fusion polypeptides, optionally bound or linked by one or more linkers, in order from N-terminus to C-terminus: a fusion polypeptide of SEQ ID NOs: 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; 71 and 70, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70; a fusion polypeptide of SEQ ID NOs: 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; a fusion polypeptide of SEQ ID NOs: 73 and 72, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72; a fusion polypeptide of SEQ ID NOs: 74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; a fusion polypeptide of SEQ ID NOs: 75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97%, 98%, 99%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 77 and 76; a fusion polypeptide of SEQ ID NOs: 78 and 79, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; a fusion polypeptide of SEQ ID NOs: 79 and 80%, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively. 80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:81 and 80; a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively; a fusion polypeptide of SEQ ID NOs:83 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 83, respectively. 83 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 82; a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively; a fusion polypeptide of SEQ ID NOs:85 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:8 85 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 84; a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively; 87 and 86; a fusion polypeptide of SEQ ID NOs: 87 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; a fusion polypeptide of SEQ ID NOs: 89 and 90, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; 89, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 89 and 88; a fusion polypeptide of SEQ ID NOs: 82 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; a fusion polypeptide of SEQ ID NOs: 85 and 82, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 82, respectively. 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 82 and 86, respectively; 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; 88 and 82; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively; 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 87 and 85; a fusion polypeptide of SEQ ID NOs: 88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; a fusion polypeptide of SEQ ID NOs: 87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 88; a fusion polypeptide of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 84, respectively; 85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 89 and 85; a fusion polypeptide of SEQ ID NOs: 85 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; a fusion polypeptide of SEQ ID NOs: 101 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85; a fusion polypeptide of SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; 91 and 90; a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:92 and 93, respectively; a fusion polypeptide of SEQ ID NOs:93 and 92, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:92 and 93, respectively; 93 and 92; a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively; a fusion polypeptide of SEQ ID NOs:95 and 94, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 94, respectively. 95 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; 97 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96; a fusion polypeptide of SEQ ID NOs: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; a fusion polypeptide of SEQ ID NOs: 96 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95; a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; a fusion polypeptide of SEQ ID NOs: 221 and 220, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220; a fusion polypeptide of SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; a fusion polypeptide of SEQ ID NOs: 100 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98; a fusion polypeptide of SEQ ID NOs: 99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; a fusion polypeptide of SEQ ID NOs: 101 and 99, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively. 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99; a fusion polypeptide of SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; a fusion polypeptide of SEQ ID NOs: 99 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98; a fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or a fusion polypeptide of SEQ ID NOs: 101 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO: 101 and 100. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are bound or connected by a cleavable linker. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are bound or linked by a cleavable linker selected from the group consisting of: 2A cleavable peptides (e.g., foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine teschovirus-1 (P2A), and sphenotype moth virus (T2A)), furin recognition/cleavage sequences (e.g., RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), and RRKR (SEQ ID NO: 62)), and combinations, derivatives, or variants thereof. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are bound or linked by a furin recognition/cleavage site selected from the group consisting of: RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), and RRKR (SEQ ID NO: 62). In some embodiments, the first fusion polypeptide and the second fusion polypeptide are bound or linked by a 2A cleavable peptide comprising or consisting of the amino acid sequence of ATNFSLLKQAGDVEENPGP (SEQ ID NO:63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO:64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO:65), QCTNYALLKLAGDVESNPGP (SEQ ID NO:66), or EGRGSLLTCGDVEENPGP (SEQ ID NO:67), or a 2A cleavable peptide that is conjugated to or linked to ATNFSLLKQAGDVEENPGP (SEQ ID NO:63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO:64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO:65), QCTNYALLKLAGDVESNPGP (SEQ ID NO:66), or EGRGSLLTCGDVEENPGP (SEQ ID NO:67). ID NO:66) or EGRGSLLTCGDVEENPGP (SEQ ID NO:67) or EGRGSLLTCGDVEENPGP (SEQ ID NO:68) or EGRGSLLTCGDVEENPGP (SEQ ID NO:69) or EGRGSLLTCGDVEENPGP (SEQ ID NO:60) or EGRGSLLTCGDVEENPGP (SEQ ID NO:61) or EGRGSLLTCGDVEENPGP (SEQ ID NO:62) or EGRGSLLTCGDVEENPGP (SEQ ID NO:63) or EGRGSLLTCGDVEENPGP (SEQ ID NO:64) or EGRGSLLTCGDVEENPGP (SEQ ID NO:65) or EGRGSLLTCGDVEENPGP (SEQ ID NO:66) or EGRGSLLTCGDVEENPGP (SEQ ID NO:67) or EGRGSLLTCGDVEENPGP (SEQ ID NO:66) or EGRGSLLTCGDVE NO: 105-112, 200-209, 222-223 and 227. In some embodiments, the composite fusion polypeptide comprises or consists of an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 209, 222 and 223, or an amino acid sequence that is identical to any one of SEQ ID NO: 209, 222 and 223. Any of NO:209, 222 and 223 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence.

Regarding other embodiments of fusion polypeptides and composite fusion polypeptides, in some embodiments, the fusion polypeptide or composite fusion polypeptide further comprises an N-terminal signal peptide or leader sequence. In some embodiments, the signal peptide or leader sequence is from a source protein selected from the group consisting of serum proteins, cytokines, chemokines, chaperone proteins, invariant proteins, and proteins that direct proteins to the lysosomal compartment. In some embodiments, the signal peptide or leader sequence is from a source protein selected from the group consisting of colony stimulating factor 2 (CSF2, GM-CSF), tissue plasminogen activator (PLAT, t-PA), C-C motif chemokine ligand 7 (CCL7, MCP-3), C-X-C motif chemokine ligand 10 (CXCL10, IP-10), catenin β1 (CTNNB1), CD74 (p33; DHLAG; HLADG; Ia-GAMMA, invariant chain), serum albumin (ALB), polyubiquitin B/C (UBB/UBC), calreticulin (CALR), vesicular stomatitis virus G protein (VSV-G), lysosomal associated membrane protein 1 (LAMP-1), and lysosomal associated membrane protein 2 (LAMP-2). In some embodiments, the signal peptide or leader sequence is selected from the amino acid sequence of any one of SEQ ID NO: 115-126, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 115-126. In some embodiments, the fusion polypeptide and/or the composite fusion polypeptide is recombinantly produced or chemically synthesized. In some embodiments, the fusion polypeptide and/or the composite fusion polypeptide can induce, promote or stimulate a human immune response. In some embodiments, the fusion polypeptide and/or the composite fusion polypeptide can induce, promote or stimulate a human immune response against HIV-1. In some embodiments, the fusion polypeptide and/or the composite fusion polypeptide can induce, promote or stimulate the proliferation and/or activation of one or more cell types selected from monocyte-derived dendritic cells (DC), CD8+ T cells and CD4+ T cells.

Also provided are polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides as described above and herein. In some embodiments, the polynucleotides include cDNA, mRNA, self-amplifying RNA (SAM, saRNA), self-replicating RNA or self-amplifying replicon RNA (RepRNA). In some embodiments, the polynucleotides include self-replicating or self-amplifying alphavirus replicons. In some embodiments, the polynucleotides include SEQ ID NO: 130-167, 210-219 and 225-226. Any one of the nucleic acid sequence, or with SEQ ID NO: 130-167, 210-219 and 225-226. Any one of at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical nucleic acid sequence. In some embodiments, the polynucleotide comprises a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226. Also provided are expression cassettes comprising one or more polynucleotides described herein, which are operably linked to one or more regulatory sequences, such as promoters. In some embodiments, the polynucleotides are operably linked to and under the control of a constitutive promoter. In some embodiments, the promoter is selected from the group consisting of a CMV promoter, a CAG promoter, and an EF1a promoter.

Also provided are liposome complexes, such as lipid nanoparticles (LNPs), comprising one or more polynucleotides described herein, such as polynucleotides encoding one or more polypeptides having an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227; for example, comprising one or more polynucleotides of SEQ ID NOs: NO:130-167, 210-219 and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:130-167, 210-219 and 225-226. In some embodiments, the liposome complex, such as a lipid nanoparticle (LNP), comprises one or more polynucleotides described herein, such as polynucleotides encoding one or more polypeptides having an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223; for example, comprising one or more polynucleotides of: SEQ ID NOs: 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226.

Also provided are vectors comprising one or more polynucleotides or one or more expression cassettes described herein. In some embodiments, the vector comprises or consists of one or more polynucleotides encoding one or more fusion polypeptides comprising, in order from N-terminus to C-terminus, the following polypeptide fragments optionally bound or linked by one or more linkers: SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17; SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11; SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21; SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17; SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11; SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: NO:25, 23, 15, 21 and 19; SEQ ID NO:20, 6, 4, 18, 16 and 26, and SEQ ID NO:7, 19, 5, 21, 27 and 17; SEQ ID NO:8, 24, 14, 12, 22 and 10, and SEQ ID NO:9, 13, 25, 23, 15 and 11; SEQ ID NO:18, 26, 20, 4, 6 and 16, and SEQ ID NO:7, 21, 17, 5, 27 and 19; SEQ ID NO:22, 24, 12, 14, 8 and 10, and SEQ ID NO:15, 25, 9, 23, 13 and 11; SEQ ID NO:24, 6, 4, 20, 18 and 32, and SEQ ID NO:8, 30, 14, 12, 26 and 10; SEQ ID NO:24, 6, 4, 20, 18 and 32, and SEQ ID NO:7, 21, 5, 25, 33 and 19; SEQ ID NO:24, 6, 4, 20, 18 and 32, and SEQ ID NO:8, 30, 14, 12, 26 and 10; SEQ ID NO:8, 30, 14, 12, 26 and 10, and SEQ ID NO:9, 13, 31, 27, 15 and 11; SEQ ID NO:6, 20, 4, 24, 32 and 18, and SEQ ID NO:8, 12, 30, 26, 14 and 10; SEQ ID NO:7, 21, 5, 25, 33 and 19 and SEQ ID NO:9, 13, 31, 27, 15 and 11; SEQ ID NO:20, 32, 24, 4, 6 and 18, and SEQ ID NO:26, 30, 12, 14, 8 and 10; SEQ ID NO:7, 25, 19, 5, 33 and 21, and SEQ ID NO:15, 31, 9, 27, 13 and 11; SEQ ID NO:24, 6, 16 and 18, and SEQ ID NO:26, 20, 10 and 28; SEQ ID NO:24, 6, 16 and 18, and SEQ ID NO:26, 10, 20 and 28; SEQ ID NO:24, 6, 16 and 18, and SEQ ID NO:7, 25, 17 and 19; SEQ ID NO:7, 19, 17 and 25, and SEQ ID NO:21, 27, 11 and 29; SEQ ID NO:24, 16, 6 and 18, and SEQ ID NO:27, 11, 21 and 29; SEQ ID NO:7, 25, 17 and 19, and SEQ ID NO:11, 27, 21 and 29; SEQ ID NO:7, 25, 17 and 19, and SEQ ID NO:21, 27, 11 and 29; SEQ ID NO:22, 6, 20 and 28, and SEQ ID NO:23, 7, 21 and 29; SEQ ID NO:22, 20, 6 and 28, and SEQ ID NO:7, 21, 23 and 29; SEQ ID NO:26, 10, 20 and 28, and SEQ ID NO:21, 27, 11 and 29; SEQ ID NO:22, 6, 16, 20, 18, 28, 26 and 10; or SEQ ID NO:7, 21, 19, 17, 27, 25, 29 and 11. In some embodiments, the vector comprises one or more polynucleotides encoding one or more fusion polypeptides comprising or consisting of the amino acid sequence of any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223, and 227. In some embodiments, the vector comprises one or more polynucleotides encoding one or more fusion polypeptides comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a fusion polypeptide of SEQ ID NOs: 70 and 71, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; a fusion polypeptide of SEQ ID NOs: 72 and 73, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively. 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 72 and 73; a fusion polypeptide of SEQ ID NOs: 74 and 75, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; a fusion polypeptide of SEQ ID NOs: 76 and 77, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively. 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:76 and 77; a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:78 and 79, respectively; a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:80 and 81, respectively. 82 and 83, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively; a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively. 84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85; a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively; a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively. 88 and 89; a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively; a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively. 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87; a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively; a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively. 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 88, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively. 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89; a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively; a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91; a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively; a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively. 94 and 95; a fusion polypeptide of SEQ ID NOs:96 and 97, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; 94 and 96; a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively; a fusion polypeptide of SEQ ID NOs:220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively; a fusion polypeptide of SEQ ID NOs:220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221; a fusion polypeptide of SEQ ID NOs: 98 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; a fusion polypeptide of SEQ ID NOs: 99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:100 and 101, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:100 and 101. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, in order from N-terminus to C-terminus and optionally bound or connected by one or more linkers: a fusion polypeptide of SEQ ID NOs: 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; 71 and 70, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70; a fusion polypeptide of SEQ ID NOs: 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; a fusion polypeptide of SEQ ID NOs: 73 and 72, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72; a fusion polypeptide of SEQ ID NOs: 74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; a fusion polypeptide of SEQ ID NOs: 75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76; a fusion polypeptide of SEQ ID NOs: 78 and 79, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; a fusion polypeptide of SEQ ID NOs: 79 and 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; 80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:81 and 80; a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively; a fusion polypeptide of SEQ ID NOs:83 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 83, respectively. 83 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 82; a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively; a fusion polypeptide of SEQ ID NOs:85 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:8 85 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 84; a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively; a fusion polypeptide of SEQ ID NOs:87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 88, respectively. 87 and 86; a fusion polypeptide of SEQ ID NOs:87 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:87 and 86; a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:88 and 89, respectively; 89, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 89 and 88; a fusion polypeptide of SEQ ID NOs: 82 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; a fusion polypeptide of SEQ ID NOs: 85 and 82, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 82; a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 86, respectively; a fusion polypeptide of SEQ ID NOs:86 and 82, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 86, respectively; 86 and 82; a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; a fusion polypeptide of SEQ ID NOs:88 and 82, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; 88 and 82; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively; 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 87 and 85; a fusion polypeptide of SEQ ID NOs: 88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; a fusion polypeptide of SEQ ID NOs: 87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 88; a fusion polypeptide of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 84, respectively; 85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 89 and 85; a fusion polypeptide of SEQ ID NOs: 85 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; a fusion polypeptide of SEQ ID NOs: 101 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85; a fusion polypeptide of SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; 91 and 90; a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively; a fusion polypeptide of SEQ ID NOs:93 and 92, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively; 93 and 92; a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively; a fusion polypeptide of SEQ ID NOs:95 and 94, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 94, respectively. 95 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; 97 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96; a fusion polypeptide of SEQ ID NOs: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; a fusion polypeptide of SEQ ID NOs: 96 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95; a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; a fusion polypeptide of SEQ ID NOs: 221 and 220, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220; a fusion polypeptide of SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; a fusion polypeptide of SEQ ID NOs: 100 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98; a fusion polypeptide of SEQ ID NOs: 99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; a fusion polypeptide of SEQ ID NOs: 101 and 99, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively. 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99; a fusion polypeptide of SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; a fusion polypeptide of SEQ ID NOs: 99 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98; a fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or a fusion polypeptide of SEQ ID NOs: 101 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:101 and 100. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:86 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 85, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 86, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 88, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:83 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:85 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227. In some embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 209, 222, and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223. In some embodiments, the first and second fusion polypeptides do not comprise any polypeptide fragments corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol321-366, Pol432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116, and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol, and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2, and 3, respectively. In some embodiments, the first and second fusion polypeptides do not comprise any polypeptide fragments having an amino acid sequence of SEQ ID NOs:35-47, or a fragment or subsequence thereof, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:35-47, or a fragment or subsequence thereof. In some embodiments, the vector comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226. In some embodiments, the vector comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226. In some embodiments, the following first and second polynucleotides: polynucleotides of SEQ ID NOs: 130 and 132, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively; polynucleotides of SEQ ID NOs: 130 and 134, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively; 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively; polynucleotides of SEQ ID NOs: 131 and 135, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; polynucleotides of SEQ ID NOs: 132 and 136, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; polynucleotides of SEQ ID NOs: 132 and 136, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136; a polynucleotide of SEQ ID NOs: 133 and 135, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively; a polynucleotide of SEQ ID NOs: 133 and 137, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137; a polynucleotide of SEQ ID NOs: 134 and 136, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively; a polynucleotide of SEQ ID NOs: 135 and 137, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137; a polynucleotide of SEQ ID NOs: 138 and 141, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively; a polynucleotide of SEQ ID NOs: 138 and 144, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively; 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144; a polynucleotide of SEQ ID NOs: 139 and 142, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively; a polynucleotide of SEQ ID NOs: 139 and 145, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145; a polynucleotide of SEQ ID NOs: 140 and 146, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; a polynucleotide of SEQ ID NOs: 142 and 148, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148; a polynucleotide of SEQ ID NOs: 150 and 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; a polynucleotide of SEQ ID NOs: 150 and 155, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155; a polynucleotide of SEQ ID NOs: 151 and 153, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; a polynucleotide of SEQ ID NOs: 151 and 156, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156; polynucleotides of SEQ ID NOs: 152 and 158, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively; polynucleotides of SEQ ID NOs: 153 and 159, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively. 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159; polynucleotides of SEQ ID NOs: 154 and 157, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively; polynucleotides of SEQ ID NOs: 155 and 158, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively; a polynucleotide of SEQ ID NOs: 160 and 161, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 161 and 162, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161; a polynucleotide of SEQ ID NOs: 162 and 163, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively; a polynucleotide of SEQ ID NOs: 164 and 165, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165; a polynucleotide of SEQ ID NOs: 166 and 167, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively; a polynucleotide of SEQ ID NOs: 210 and 211, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively; 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211; polynucleotides of SEQ ID NOs: 212 and 213, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively; polynucleotides of SEQ ID NOs: 214 and 215, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215; polynucleotides of SEQ ID NOs: 216 and 217, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively; polynucleotides of SEQ ID NOs: 218 and 219, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 219 and 220, respectively; 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 218 and 219; a polynucleotide of SEQ ID NOs: 218 and 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or a polynucleotide of SEQ ID NOs: 225 and 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively. Any of NO:225 and 226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 130 or SEQ ID NO: 131, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 130 or SEQ ID NO: 131, respectively, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 134 or SEQ ID NO: 135, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 134 or SEQ ID NO: 135. ID NO: 135 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the polynucleotide. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 132 or SEQ ID NO: 133, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 132 or SEQ ID NO: 133, respectively, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 136 or SEQ ID NO: 137, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 136 or SEQ ID NO: 137. NO:137 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 139, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 139, respectively, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 145, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 145. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 142, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 142, respectively, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 148, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 148. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 140, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 140, respectively, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 146, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 146. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 143, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 143, respectively, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 149, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 149. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 150, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 150, respectively, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 152. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO:151, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:151, respectively, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:153, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:153. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 154, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 154, respectively, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 157, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 157. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO:155, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:155, respectively, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:158, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:158. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO:156, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:156, respectively, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:159, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:159. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 160, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 160, respectively, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 161, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 161. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 162, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 162, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 163, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 163. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 164, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 164, respectively, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 165, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 165. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 166, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 166, respectively, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 167, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 167. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO:210, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:210, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:21 1, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:21 1. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO:212, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:212, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:213, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:213. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO:214, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:214, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:215, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:215. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO:216, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:216, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:217, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:217. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO:218, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:218, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:219, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:219. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO:218, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:218, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:226. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO:225, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:225, and (b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:226. In some embodiments, the first polynucleotide encoding the first fusion polypeptide and the second polynucleotide encoding the second fusion polypeptide are located in a single open reading frame. In some embodiments, the first polynucleotide encoding the first fusion polypeptide is located in the first open reading frame, and the second polynucleotide encoding the second fusion polypeptide is located in the second open reading frame. In some embodiments, the first polynucleotide encoding the first fusion polypeptide and the second polynucleotide encoding the second fusion polypeptide are located in a single expression cassette. In some embodiments, the first polynucleotide encoding the first fusion polypeptide is located in the first expression cassette, and the second polynucleotide encoding the second fusion polypeptide is located in the second expression cassette. In some embodiments, the vector is a plasmid vector, a bacterial vector, or a viral vector. In some embodiments, the vector is a viral vector. In some embodiments, the viral vector is a DNA virus or an RNA virus. In some embodiments, the viral vector is replication defective, replication defective, replication attenuated, or replication competent. In some embodiments, the viral vector is from a virus selected from adenovirus, adeno-associated virus, arenavirus, alphavirus, poxvirus, cytomegalovirus, rhabdovirus, vesicular stomatitis virus, flavivirus, Maraba virus, and vaccinia virus. In some embodiments, the viral vector is from a virus from a taxonomic family selected from Adenoviridae, Arenaviridae, Herpesviridae (e.g., cytomegalovirus), Poxviridae (e.g., vaccinia virus, e.g., modified vaccinia virus Ankara (MVA)), Flaviviridae (e.g., yellow fever virus), Rhabdoviridae (e.g., vesiculovirus, e.g., Maraba vesiculovirus), Togaviridae (e.g., alphavirus, e.g., Venezuelan equine encephalitis virus). In some embodiments, the viral vector is an arenavirus vector selected from the group consisting of: lymphocytic choriomeningitis mammalian arenavirus (LCMV), Cali mammalian arenavirus (also known as Pichinde mammalian arenavirus or Pichinde arenavirus), Guanarito virus (GTOV), Junin virus (JUNV), Lassa virus (LASV), Lujo virus (LUJV), Machupo virus (MACV), Sabia virus (SABV), and Whitewater Arroyo virus (WWAV). In some embodiments, the viral vector is an arenavirus vector selected from the group consisting of: lymphocytic choriomeningitis mammalian arenavirus (LCMV) or Cali mammalian arenavirus (also known as Pichinde mammalian arenavirus or Pichinde arenavirus). In some embodiments, the arenavirus vector comprises a two-segment genome. In some embodiments, the arenavirus vector comprises a three-segment genome. In some embodiments, the viral vector is a human adenovirus or a simian adenovirus (e.g., a chimpanzee adenovirus, a gorilla adenovirus, or a rhesus adenovirus). In some embodiments, the viral vector is an adenovirus vector selected from the following: adenovirus serotype 5 (Ad5), adenovirus serotype 26 (Ad26), adenovirus serotype 34 (Ad34), adenovirus serotype 35 (Ad35), adenovirus serotype 48 (Ad48), chimpanzee adenovirus (e.g., ChAd3 (AdC3), ChAd5 (AdC5), ChAd6 (AdC6), ChAd7 (AdC7), ChAd8 (AdC8), ChAd9 (AdC9) , ChAd10(AdC10), ChAd11(AdC11), ChAd17(AdC17), ChAd16(AdC16), ChAd19(AdC19), ChAd20(AdC20), ChAd22(AdC22), ChAd24(AdC24), ChAdY25, ChAd26(AdC26), ChAd28(AdC28), ChAd30 (AdC30), ChAd31(AdC31), Ch Ad37(AdC37), ChAd38(AdC38), ChAd43(AdC43), ChAd44(AdC44), ChAd55(AdC55), ChAd63(AdC63), ChAdV63, ChAd68(AdC68), ChAd73(AdC73), ChAd82(AdC82), ChAd83(AdC83), ChAd143(Ad C143), ChAd144(AdC144), C hAd145 (AdC145), ChAd147 (AdC147)), gorilla adenovirus (e.g., GC44, GC45, GC46), and rhesus monkey adenovirus (e.g., RhAd51, RhAd52, RhAd53, RhAd54, RhAd55, RhAd56, RhAd57, RhAd58, RhAd59, RhAd60, RhAd61, RhAd62, RhAd63, RhAd64, RhAd65, RhAd66).

Also provide host cell, it comprises one or more polynucleotides as described herein, one or more expression cassettes or one or more vectors.In some embodiments, one or more polynucleotides are not integrated into the host cell genome, for example, are free.In some embodiments, one or more polynucleotides are integrated into the host cell genome.In some embodiments, host cell is mammalian cell, for example human cell.In various embodiments, host cell can be in vitro or in vivo.

Immunogenic compositions are also provided. In various embodiments, the immunogenic compositions comprise one or more of a fusion polypeptide or a composite fusion polypeptide as described herein, one or more polynucleotides, or one or more vectors, and a pharmaceutically acceptable carrier. In some embodiments, the immunogenic compositions comprise two or more of a fusion polypeptide or a composite fusion polypeptide as described herein, two or more polynucleotides, two or more vectors. In some embodiments, the one or more polynucleotides are DNA, cDNA, mRNA, or self-replicating RNA. In some embodiments, the immunogenic composition comprises a first fusion polypeptide and a second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, the first polypeptide and the second polypeptide comprising, in order from N-terminus to C-terminus, the following polypeptide fragments optionally bound or linked by one or more linkers: SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17; SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11; SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21; SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17; SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11; SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: NO:25, 23, 15, 21 and 19; SEQ ID NO:20, 6, 4, 18, 16 and 26, and SEQ ID NO:7, 19, 5, 21, 27 and 17; SEQ ID NO:8, 24, 14, 12, 22 and 10, and SEQ ID NO:9, 13, 25, 23, 15 and 11; SEQ ID NO:18, 26, 20, 4, 6 and 16, and SEQ ID NO:7, 21, 17, 5, 27 and 19; SEQ ID NO:22, 24, 12, 14, 8 and 10, and SEQ ID NO:15, 25, 9, 23, 13 and 11; SEQ ID NO:24, 6, 4, 20, 18 and 32, and SEQ ID NO:8, 30, 14, 12, 26 and 10; SEQ ID NO:24, 6, 4, 20, 18 and 32, and SEQ ID NO:7, 21, 5, 25, 33 and 19; SEQ ID NO:24, 6, 4, 20, 18 and 32, and SEQ ID NO:8, 30, 14, 12, 26 and 10; SEQ ID NO:8, 30, 14, 12, 26 and 10, and SEQ ID NO:9, 13, 31, 27, 15 and 11; SEQ ID NO:6, 20, 4, 24, 32 and 18, and SEQ ID NO:8, 12, 30, 26, 14 and 10; SEQ ID NO:7, 21, 5, 25, 33 and 19 and SEQ ID NO:9, 13, 31, 27, 15 and 11; SEQ ID NO:20, 32, 24, 4, 6 and 18, and SEQ ID NO:26, 30, 12, 14, 8 and 10; SEQ ID NO:7, 25, 19, 5, 33 and 21, and SEQ ID NO:15, 31, 9, 27, 13 and 11; SEQ ID NO:24, 6, 16 and 18, and SEQ ID NO:26, 20, 10 and 28; SEQ ID NO:24, 6, 16 and 18, and SEQ ID NO:26, 10, 20 and 28; SEQ ID NO:24, 6, 16 and 18, and SEQ ID NO:7, 25, 17 and 19; SEQ ID NO:7, 19, 17 and 25, and SEQ ID NO:21, 27, 11 and 29; SEQ ID NO:24, 16, 6 and 18, and SEQ ID NO:27, 11, 21 and 29; SEQ ID NO:7, 25, 17 and 19, and SEQ ID NO:11, 27, 21 and 29; SEQ ID NO:7, 25, 17 and 19, and SEQ ID NO:21, 27, 11 and 29; SEQ ID NO:22, 6, 20 and 28, and SEQ ID NO:23, 7, 21 and 29; SEQ ID NO:22, 20, 6 and 28, and SEQ ID NO:7, 21, 23 and 29; SEQ ID NO:26, 10, 20 and 28, and SEQ ID NO:21, 27, 11 and 29; SEQ ID NO:22, 6, 16, 20, 18, 28, 26 and 10; or SEQ ID NO:7, 21, 19, 17, 27, 25, 29 and 11. In some embodiments, the immunogenic composition comprises one or more fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, which fusion polypeptides comprise or consist of the amino acid sequence of any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223 and 227. In some embodiments, the immunogenic composition comprises one or more fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, which fusion polypeptides comprise or consist of the amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223. In some embodiments, the immunogenic composition comprises the following first and second fusion polypeptides, one or more polynucleotides, or one or more vectors or one or more liposome complexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a fusion polypeptide of SEQ ID NOs: 70 and 71, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; a fusion polypeptide of SEQ ID NOs: 72 and 73, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively. 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:76 and 77; a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:78 and 79, respectively; a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:80 and 81, respectively. 82 and 83, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively; a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively. 84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85; a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively; a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively. 88 and 89; a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively; a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively. 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86; a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively. 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87; a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively; a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively. 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 88, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively. 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89; a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively; a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91; a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively; a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively. 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; 94 and 96; a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively; a fusion polypeptide of SEQ ID NOs:220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively; a fusion polypeptide of SEQ ID NOs:220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221; a fusion polypeptide of SEQ ID NOs: 98 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; a fusion polypeptide of SEQ ID NOs: 99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:100 and 101, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:100 and 101. In some embodiments, the immunogenic composition comprises the following first and second fusion polypeptides, one or more polynucleotides, or one or more vectors or one or more liposome complexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides bound or connected in order from N-terminus to C-terminus and optionally through one or more linkers: a fusion polypeptide of SEQ ID NOs: 70 and 71, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; a fusion polypeptide of SEQ ID NOs: 71 and 70, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; 71 and 70, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70; a fusion polypeptide of SEQ ID NOs: 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; a fusion polypeptide of SEQ ID NOs: 73 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72; a fusion polypeptide of SEQ ID NOs: 74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; a fusion polypeptide of SEQ ID NOs: 75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76; a fusion polypeptide of SEQ ID NOs: 78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; a fusion polypeptide of SEQ ID NOs: 79 and 80%, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:81 and 80; a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively; a fusion polypeptide of SEQ ID NOs:83 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 83, respectively. 83 and 82; a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:84 and 85, respectively; a fusion polypeptide of SEQ ID NOs:85 and 84, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:84 and 85, respectively; 85 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 84; a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively; a fusion polypeptide of SEQ ID NOs:87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 88, respectively. 87 and 86; a fusion polypeptide of SEQ ID NOs:87 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:87 and 86; a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:88 and 89, respectively; 89, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 89 and 88; a fusion polypeptide of SEQ ID NOs: 82 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; a fusion polypeptide of SEQ ID NOs: 85 and 82, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 82; a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 86, respectively; a fusion polypeptide of SEQ ID NOs:86 and 82, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 86, respectively; 86 and 82; a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; a fusion polypeptide of SEQ ID NOs:88 and 82, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; 88 and 82; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively; 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 87 and 85; a fusion polypeptide of SEQ ID NOs: 88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; a fusion polypeptide of SEQ ID NOs: 87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 87 and 88; a fusion polypeptide of SEQ ID NOs: 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; 85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 89 and 85; a fusion polypeptide of SEQ ID NOs: 85 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; a fusion polypeptide of SEQ ID NOs: 101 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85; a fusion polypeptide of SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; 91 and 90; a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:92 and 93, respectively; a fusion polypeptide of SEQ ID NOs:93 and 92, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:92 and 93, respectively; 93 and 92; a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively; a fusion polypeptide of SEQ ID NOs:95 and 94, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively; 95 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; 97 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96; a fusion polypeptide of SEQ ID NOs: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; a fusion polypeptide of SEQ ID NOs: 96 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95; a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; a fusion polypeptide of SEQ ID NOs: 221 and 220, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of SEQ ID NOs: 221 and 220; a fusion polypeptide of SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of SEQ ID NOs: 98 and 100, respectively; a fusion polypeptide of SEQ ID NOs: 100 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of SEQ ID NOs: 98; a fusion polypeptide of SEQ ID NOs: 99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; a fusion polypeptide of SEQ ID NOs: 101 and 99, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively. 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99; a fusion polypeptide of SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; a fusion polypeptide of SEQ ID NOs: 99 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98; a fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or a fusion polypeptide of SEQ ID NOs: 101 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. NO: 101 and 100 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, a first and a second viral vector comprising one or more polynucleotides, or a first and a second liposome complex (e.g., LNP), the one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 82 and 83, or a fusion polypeptide with SEQ ID NO: 84, or a fusion polypeptide with SEQ ID NO: 85, or a fusion polypeptide with SEQ ID NO: 86, or a fusion polypeptide with SEQ ID NO: 87, or a fusion polypeptide with SEQ ID NO: 88, or a fusion polypeptide with SEQ ID NO: 89, or a fusion polypeptide with SEQ ID NO: 90, or a fusion polypeptide with SEQ ID NO: 91, NO:82 and 83 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:82 and 83, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO:86 and 87, or a fusion polypeptide with SEQ ID NO:87, respectively. NO: 86 and 87 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO: 86 and 87. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 84 and 85, or a fusion polypeptide with SEQ ID NO: 86 and 87, respectively. NO:84 and 85 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:84 and 85, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:88 and 89, or a fusion polypeptide with SEQ ID NO:89, respectively. NO: 88 and 89 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO: 88 and 89. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 82 and 86, or a fusion polypeptide with SEQ ID NO: 87, or a fusion polypeptide with SEQ ID NO: 88 and 89, respectively. NO:82 and 86 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:82 and 86, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:83 and 87, or a fusion polypeptide with SEQ ID NO:83 and 87, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:83 and 87. In some embodiments, the immunogenic composition comprises a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: NO:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:88 and 87, respectively. In some embodiments, the immunogenic composition comprises a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: NO:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:85 and 87, respectively. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:85 and 87, respectively. NO:84 and 88 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:84 and 88, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:85 and 89, or a fusion polypeptide with SEQ ID NO:87, 88, 89, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of ... NO: 85 and 89 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO: 85 and 89. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 98 and 100, or a fusion polypeptide with SEQ ID NO: 101, or a fusion polypeptide with SEQ ID NO: 102, or a fusion polypeptide with SEQ ID NO: 103, or a fusion polypeptide with SEQ ID NO: 104, or a fusion polypeptide with SEQ ID NO: 105, or a fusion polypeptide with SEQ ID NO: 106, or a fusion polypeptide with SEQ ID NO: 107, or a fusion polypeptide with SEQ ID NO: 108, or a fusion polypeptide with SEQ ID NO: 110, or a fusion polypeptide with SEQ ID NO: 111, or a fusion polypeptide with SEQ ID NO: 112, or a fusion polypeptide with SEQ ID NO: 113, or a fusion polypeptide with SEQ ID NO: 114, or a fusion polypeptide with SEQ ID NO: 115, or a fusion polypeptide with SEQ ID NO: 116, or NO:98 and 100 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:98 and 100, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:85 and 101, or a fusion polypeptide with SEQ ID NO:85 and 101, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:85 and 101. In some embodiments, the immunogenic composition comprises a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide of SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively. In some embodiments, the immunogenic composition comprises a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide of SEQ ID NOs: 92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. In some embodiments, the composition comprises a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: NO:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:96 and 97, respectively. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:96 and 97, respectively. NO:94 and 96 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:94 and 96, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:95 and 97, or a fusion polypeptide with SEQ ID NO:97, respectively. NO: 95 and 97 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO: 95 and 97. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 220 and 221, or a fusion polypeptide with SEQ ID NO: 222, respectively. NO: 220 and 221 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO: 220 and 221, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 95 and 97, or a fusion polypeptide with SEQ ID NO: 97, respectively. NO:95 and 97 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:95 and 97. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:98 and 100, or a fusion polypeptide with SEQ ID NO:99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145 NO:98 and 100 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:98 and 100, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:99 and 101, or a fusion polypeptide with SEQ ID NO: 102, or a fusion polypeptide with SEQ ID NO: 103, or a fusion polypeptide with SEQ ID NO: 104, or a fusion polypeptide with SEQ ID NO: 105, or a fusion polypeptide with SEQ ID NO: 106, or a fusion polypeptide with SEQ ID NO: 107, or a fusion polypeptide with SEQ ID NO: 108, or a fusion polypeptide with SEQ ID NO: 110, or a fusion polypeptide with SEQ ID NO: 111, or a fusion polypeptide with SEQ ID NO: 112, or a fusion polypeptide with SEQ ID NO: 113, or a fusion polypeptide with SEQ ID NO: 114, or a fusion polypeptide with SEQ ID NO: 115, or a fusion polypeptide with SEQ ID NO: 116, or a fusion polypeptide with SEQ ID NO: 117, or a fusion polypeptide with SEQ ID NO: 118, or a fusion polypeptide with SEQ ID NO: 119, or a fusion polypeptide with SEQ ID NO: 121, or a fusion polypeptide with SEQ ID NO: 122, or a fusion polypeptide with SEQ ID NO: 123, or a fusion polypeptide with A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:99 and 101. In some embodiments, the immunogenic composition comprises a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively. In some embodiments, the immunogenic composition comprises a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively. In some embodiments, the immunogenic composition comprises a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. In some embodiments, the immunogenic composition comprises a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively. In some embodiments, the immunogenic composition comprises a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively. In some embodiments, the immunogenic composition comprises a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. In some embodiments, the immunogenic composition comprises a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively. In some embodiments, the immunogenic composition comprises a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the immunogenic composition comprises a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 200, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 200, and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 201, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 201. NO:201 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polypeptides. In some embodiments, the immunogenic composition comprises a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 202, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 202, and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 203, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 204. NO:203 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polypeptide. In some embodiments, the immunogenic composition comprises a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 203, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 203, and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 204, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 205. NO:204 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polypeptide. In some embodiments, the immunogenic composition comprises a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 105, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 105, and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 107, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 107. A polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to NO:107. In some embodiments, the immunogenic composition comprises a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 206, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 206, and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 207, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 208. A polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to NO:207. In some embodiments, the immunogenic composition comprises a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 208, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 208, and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209 or SEQ ID NO: A polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to NO:227. In some embodiments, the immunogenic composition comprises a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 222, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222, and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. A polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to NO:227. In some embodiments, the immunogenic composition comprises a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 222, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222, and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 223, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 223. NO:223 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polypeptide. In some embodiments, the immunogenic composition comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226. In some embodiments, the immunogenic composition comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226. In some embodiments, the immunogenic composition comprises the following first and second polynucleotides, or one or more vectors comprising the following first and second polynucleotides: polynucleotides of SEQ ID NOs: 130 and 132, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively; polynucleotides of SEQ ID NOs: 130 and 134, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively; 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134; a polynucleotide of SEQ ID NOs: 131 and 133, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively; a polynucleotide of SEQ ID NOs: 131 and 135, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135; a polynucleotide of SEQ ID NOs: 132 and 136, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively; a polynucleotide of SEQ ID NOs: 133 and 135, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135; polynucleotides of SEQ ID NOs: 133 and 137, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively; polynucleotides of SEQ ID NOs: 134 and 136, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136; a polynucleotide of SEQ ID NOs: 135 and 137, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively; a polynucleotide of SEQ ID NOs: 138 and 141, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 142, respectively. 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 138 and 141; a polynucleotide of SEQ ID NOs: 138 and 144, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively; a polynucleotide of SEQ ID NOs: 139 and 142, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139 and 143, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142; polynucleotides of SEQ ID NOs: 139 and 145, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; polynucleotides of SEQ ID NOs: 140 and 146, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively; a polynucleotide of SEQ ID NOs: 143 and 149, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149; a polynucleotide of SEQ ID NOs: 145 and 148, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively; a polynucleotide of SEQ ID NOs: 150 and 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152; polynucleotides of SEQ ID NOs: 150 and 155, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively; polynucleotides of SEQ ID NOs: 151 and 153, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153; a polynucleotide of SEQ ID NOs: 151 and 156, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively; a polynucleotide of SEQ ID NOs: 152 and 158, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157; a polynucleotide of SEQ ID NOs: 155 and 158, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; a polynucleotide of SEQ ID NOs: 156 and 159, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159; a polynucleotide of SEQ ID NOs: 160 and 161, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; a polynucleotide of SEQ ID NOs: 162 and 163, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively; a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167; the polynucleotides of SEQ ID NOs: 210 and 211, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively; the polynucleotides of SEQ ID NOs: 212 and 213, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively; a polynucleotide of SEQ ID NOs: 216 and 217, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively. 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 216 and 217; a polynucleotide of SEQ ID NOs: 218 and 219, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively; a polynucleotide of SEQ ID NOs: 218 and 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 218 and 229, respectively; or a polynucleotide of SEQ ID NOs: 225 and 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following first and second polynucleotides: (a) a first vector or a first liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 131 and 135, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively, and (b) a second vector or a second liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 133 and 137, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: Any of NO:133 and 137 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following first and second polynucleotides: (a) a first vector or a first liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 139 and 145, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively, and (b) a second vector or a second liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 142 and 148, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: Any of NO:142 and 148 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following first and second polynucleotides: (a) a first vector or a first liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 140 and 146, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively, and (b) a second vector or a second liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 143 and 149, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: NO: any of 143 and 149 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. In some embodiments, the first and second viral vectors of such immunogenic compositions are lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vectors. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following first and second polynucleotides: (a) a first vector or a first liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 150 and 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively, and (b) a second vector or a second liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: any of ID NOs: 155 and 158. In some embodiments, the first and second viral vectors of such immunogenic compositions are Cali mammalian arenavirus (also known as Pichinde mammalian arenavirus or Pichinde arenavirus) viral vectors. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following first and second polynucleotides: (a) a first vector or a first liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 151 and 153, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively, and (b) a second vector or a second liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 156 and 159, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: Any of NO:156 and 159 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 160, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 160, respectively, and (b) a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 161, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 161, respectively. NO:161 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 162, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 162, respectively, and (b) a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 164, respectively. NO:163 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 164, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 164, respectively, and (b) a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 165, respectively. NO:165 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 166, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 166, respectively, and (b) a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 167, respectively. NO:167 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 210, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 210, and (b) a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 211, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 211. NO:211 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 212, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 212, and (b) a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 213, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 213. NO:213 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 214, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 214, and (b) a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 215, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 215. NO:215 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 216, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 216, and (b) a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 217, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 217. NO:217 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 218, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218, and (b) a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 219, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 219. NO:219 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 218, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218, and (b) a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 226. NO:226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 225, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 225, and (b) a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 226. NO:226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the immunogenic composition comprises a composite fusion polypeptide, a vector comprising a polynucleotide encoding the composite fusion polypeptide, or a liposome complex (e.g., LNP), which composite fusion polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227. In some embodiments, the immunogenic composition comprises a composite fusion polypeptide, a vector comprising a polynucleotide encoding the composite fusion polypeptide, or a liposome complex (e.g., LNP), wherein the composite fusion polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 209, 222, and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223. In some embodiments, the one or more fusion polypeptides do not comprise any polypeptide fragments corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116, and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol, and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2, and 3, respectively. In some embodiments, the one or more fusion polypeptides do not comprise any polypeptide fragment having an amino acid sequence of SEQ ID NOs: 35-47 or a fragment or subsequence thereof, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 35-47 or a fragment or subsequence thereof. In various embodiments of the immunogenic composition, the first and second viral vectors can be lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vectors, Cali mammalian arenavirus (also known as Pichinde mammalian arenavirus or Pichinde arenavirus) viral vectors, or adenovirus vectors, such as chimpanzee adenovirus vectors (ChAd). In some embodiments, the immunogenic composition comprises a single vector comprising one or more polynucleotides encoding the first and second fusion polypeptides. In some embodiments, the immunogenic composition further comprises one or more of an adjuvant, a detergent, a micelle former, and an oil. In some embodiments, the immunogenic composition is formulated for administration via a route selected from: intravenous, intramuscular, intradermal, subcutaneous, intranodal, and mucosal (e.g., buccal, intranasal, rectal, intravaginal). In some embodiments, the immunogenic composition is formulated as a liquid, a suspension, or an emulsion. In some embodiments, the immunogenic composition is lyophilized.

Also provided is a kit, which includes one or more unit doses of one or more fusion polypeptides as described herein, one or more composite fusion polypeptides, one or more polynucleotides, one or more carriers, or one or more immunogenic compositions. In some embodiments, the kit includes two or more fusion polypeptides as described herein, two or more composite fusion polypeptides, two or more polynucleotides, two or more carriers, or two or more immunogenic compositions. In some embodiments, one or more unit doses are in a single container. In some embodiments, one or more unit doses are in two or more separate containers. In some embodiments, the kit includes one or more containers selected from vials, ampoules, and preloaded syringes. In some embodiments, the kit includes one or more containers, which contain an aqueous solution of one or more fusion polypeptides, one or more polynucleotides, or one or more carriers. In some embodiments, one or more unit doses are the same. In some embodiments, one or more unit doses are different. In some embodiments, the kit includes one or more unit doses of one or more viral vectors, and the unit dose is in the range of about 10 ³ to about 10 ¹² viral focus forming units (FFU) or plaque forming units (PFU) or infectious units (IU) or viral particles (vp), for example, about 10 ⁴ to about 10 ⁷ viral FFU or PFU or IU or vp, for example, about 10 ³ to about 10 ⁴ , 10 ⁵ , 10 ⁶ , 10 ⁷ , 10 ⁸ , 10 ⁹ , 10 ¹⁰ , 10 ¹¹ , 10 ¹² , 10 ¹³ , 10 ¹⁴ or 10 ¹⁵ viral FFU or PFU or IU or vp. In some embodiments, the kit includes a first fusion polypeptide and a second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, the first polypeptide and the second polypeptide comprising, in order from N-terminus to C-terminus, the following polypeptide fragments optionally bound or connected by one or more linkers: SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17; SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11; SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21; SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17; SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11; SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: NO:25, 23, 15, 21 and 19; SEQ ID NO:20, 6, 4, 18, 16 and 26, and SEQ ID NO:7, 19, 5, 21, 27 and 17; SEQ ID NO:8, 24, 14, 12, 22 and 10, and SEQ ID NO:9, 13, 25, 23, 15 and 11; SEQ ID NO:18, 26, 20, 4, 6 and 16, and SEQ ID NO:7, 21, 17, 5, 27 and 19; SEQ ID NO:22, 24, 12, 14, 8 and 10, and SEQ ID NO:15, 25, 9, 23, 13 and 11; SEQ ID NO:24, 6, 4, 20, 18 and 32, and SEQ ID NO:8, 30, 14, 12, 26 and 10; SEQ ID NO:24, 6, 4, 20, 18 and 32, and SEQ ID NO:7, 21, 5, 25, 33 and 19; SEQ ID NO:24, 6, 4, 20, 18 and 32, and SEQ ID NO:8, 30, 14, 12, 26 and 10; SEQ ID NO:8, 30, 14, 12, 26 and 10, and SEQ ID NO:9, 13, 31, 27, 15 and 11; SEQ ID NO:6, 20, 4, 24, 32 and 18, and SEQ ID NO:8, 12, 30, 26, 14 and 10; SEQ ID NO:7, 21, 5, 25, 33 and 19 and SEQ ID NO:9, 13, 31, 27, 15 and 11; SEQ ID NO:20, 32, 24, 4, 6 and 18, and SEQ ID NO:26, 30, 12, 14, 8 and 10; SEQ ID NO:7, 25, 19, 5, 33 and 21, and SEQ ID NO:15, 31, 9, 27, 13 and 11; SEQ ID NO:24, 6, 16 and 18, and SEQ ID NO:26, 20, 10 and 28; SEQ ID NO:24, 6, 16 and 18, and SEQ ID NO:26, 10, 20 and 28; SEQ ID NO:24, 6, 16 and 18, and SEQ ID NO:7, 25, 17 and 19; SEQ ID NO:7, 19, 17 and 25, and SEQ ID NO:21, 27, 11 and 29; SEQ ID NO:24, 16, 6 and 18, and SEQ ID NO:27, 11, 21 and 29; SEQ ID NO:7, 25, 17 and 19, and SEQ ID NO:11, 27, 21 and 29; SEQ ID NO:7, 25, 17 and 19, and SEQ ID NO:21, 27, 11 and 29; SEQ ID NO:22, 6, 20 and 28, and SEQ ID NO:23, 7, 21 and 29; SEQ ID NO:22, 20, 6 and 28, and SEQ ID NO:7, 21, 23 and 29; SEQ ID NO:26, 10, 20 and 28, and SEQ ID NO:21, 27, 11 and 29; SEQ ID NO:22, 6, 16, 20, 18, 28, 26 and 10; or SEQ ID NO:7, 21, 19, 17, 27, 25, 29 and 11. In some embodiments, the kit includes one or more fusion polypeptides, one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, or one or more liposome complexes (LNPs), wherein the fusion polypeptides comprise or consist of the amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227. In some embodiments, the kit includes one or more fusion polypeptides, one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, or one or more liposome complexes (LNPs), wherein the fusion polypeptides comprise or consist of the amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223. In some embodiments, the kit includes the following first and second fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a fusion polypeptide of SEQ ID NOs: 70 and 71, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; a fusion polypeptide of SEQ ID NOs: 72 and 73, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively. 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively. 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:76 and 77; a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:78 and 79, respectively; a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:80 and 81, respectively. 82 and 83, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively; a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively. 84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85; a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively; a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively. 88 and 89; a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively; a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively. 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86; a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively. 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87; a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively; a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively. 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 88, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively; 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89; a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively; a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91; a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively; a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively. 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; 94 and 96; a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively; a fusion polypeptide of SEQ ID NOs:220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively; a fusion polypeptide of SEQ ID NOs:220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221; a fusion polypeptide of SEQ ID NOs: 98 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; a fusion polypeptide of SEQ ID NOs: 99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:100 and 101, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:100 and 101. In some embodiments, the kit includes the following first and second fusion polypeptides, one or more vectors or one or more liposome complexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides bound or connected in order from N-terminus to C-terminus and optionally through one or more linkers: a fusion polypeptide of SEQ ID NOs: 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; 71 and 70, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70; a fusion polypeptide of SEQ ID NOs: 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; a fusion polypeptide of SEQ ID NOs: 73 and 72, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72; a fusion polypeptide of SEQ ID NOs: 74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; a fusion polypeptide of SEQ ID NOs: 75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76; a fusion polypeptide of SEQ ID NOs: 78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; a fusion polypeptide of SEQ ID NOs: 79 and 80%, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:81 and 80; a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively; a fusion polypeptide of SEQ ID NOs:83 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 83, respectively. 83 and 82; a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:84 and 85, respectively; a fusion polypeptide of SEQ ID NOs:85 and 84, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:84 and 85, respectively; 85 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 84; a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively; a fusion polypeptide of SEQ ID NOs:87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 88, respectively. 87 and 86; a fusion polypeptide of SEQ ID NOs:87 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:87 and 86; a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:88 and 89, respectively; 89, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88; a fusion polypeptide of SEQ ID NOs: 82 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; a fusion polypeptide of SEQ ID NOs: 85 and 82, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82; a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 86, respectively; a fusion polypeptide of SEQ ID NOs:86 and 82, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 86, respectively; 86 and 82; a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; a fusion polypeptide of SEQ ID NOs:88 and 82, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; 88 and 82; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively; 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 85; a fusion polypeptide of SEQ ID NOs: 88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; a fusion polypeptide of SEQ ID NOs: 87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 87 and 88; a fusion polypeptide of SEQ ID NOs: 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; 85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 89 and 85; a fusion polypeptide of SEQ ID NOs: 85 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; a fusion polypeptide of SEQ ID NOs: 101 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85; a fusion polypeptide of SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; 91 and 90; a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively; a fusion polypeptide of SEQ ID NOs:93 and 92, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:93 and 93, respectively. 93 and 92; a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively; a fusion polypeptide of SEQ ID NOs:95 and 94, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively; 95 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; 97 and 96; a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:94 and 96, respectively; a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:94 and 96, respectively; 96 and 94; a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively; a fusion polypeptide of SEQ ID NOs:97 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:97 and 97, respectively. 97 and 95; a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; a fusion polypeptide of SEQ ID NOs: 221 and 220, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of SEQ ID NOs: 221 and 220; a fusion polypeptide of SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of SEQ ID NOs: 98 and 100, respectively; a fusion polypeptide of SEQ ID NOs: 100 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of SEQ ID NOs: 98; a fusion polypeptide of SEQ ID NOs: 99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; a fusion polypeptide of SEQ ID NOs: 101 and 99, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively. 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99; a fusion polypeptide of SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; a fusion polypeptide of SEQ ID NOs: 99 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98; a fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or a fusion polypeptide of SEQ ID NOs: 101 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:101 and 100. In some embodiments, the kit includes a first, second, third, and fourth viral vectors or liposome complexes (e.g., LNPs) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; NO:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:84 and 85, respectively; (c) a third viral vector or liposome complex (e.g., LNP), comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: comprising a fusion polypeptide of SEQ ID NO:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:84 and 85, respectively; NO:86 and 87 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:86 and 87; and (d) a fourth viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:88 and 89, respectively. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively, and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 83 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:83 and 87. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively, and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 88 and 89, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:88 and 87. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 88, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively, and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 85 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:85 and 87. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: a polynucleotide encoding the following fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 200, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 200, and (b) a second viral vector or liposome complex (e.g., LNP) comprising: a polynucleotide encoding the following fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 201, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 201. NO:201 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: a polynucleotide encoding the following fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 202, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 202, and (b) a second viral vector or liposome complex (e.g., LNP) comprising: a polynucleotide encoding the following fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 203, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 204. NO:203 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: a polynucleotide encoding the following fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 204, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 204, and (b) a second viral vector or liposome complex (e.g., LNP) comprising: a polynucleotide encoding the following fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 205, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 205. NO:205 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: a polynucleotide encoding the following fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 105 or 206, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 105 or 206, respectively, and (b) a second viral vector or liposome complex (e.g., LNP) comprising: a polynucleotide encoding the following fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 107 or 207, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: NO:107 or 207 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: a polynucleotide encoding the following fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 208, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 208, and (b) a second viral vector or liposome complex (e.g., LNP) comprising: a polynucleotide encoding the following fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209. NO:227 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: a polynucleotide encoding the following fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 222, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222, and (b) a second viral vector or liposome complex (e.g., LNP) comprising: a polynucleotide encoding the following fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209 or SEQ ID NO: NO:227 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: a polynucleotide encoding the following fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 222, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222, and (b) a second viral vector or liposome complex (e.g., LNP) comprising: a polynucleotide encoding the following fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 223, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 223. IDNO: 223 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide. In some embodiments, the kit includes a first, second, third, and fourth viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; NO:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:83 and 87, respectively; (c) a third viral vector or liposome complex (e.g., LNP), comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: comprising a fusion polypeptide of SEQ ID NO:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:83 and 87, respectively; NO:84 and 88 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:84 and 88; and (d) a fourth viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:85 and 89, respectively. In some embodiments, the kit includes a first, second, third, and fourth viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; NO:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:83 and 87, respectively; (c) a third viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: comprising a fusion polypeptide of SEQ ID NO:98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:83 and 87, respectively; NO:98 and 100 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:98 and 100; and (d) a fourth viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:85 and 101, respectively. In some embodiments, the kit includes a first, second, third, and fourth viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; NO:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:83 and 87, respectively; (c) a third viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: comprising a fusion polypeptide of SEQ ID NO:98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:83 and 87, respectively; NO:98 and 100 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:98 and 100; and (d) a fourth viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:99 and 101, respectively. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 90 and 91, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively, and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 92 and 93, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:92 and 93. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 94 and 96, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively, and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 95 and 97, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:95 and 97. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively, and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively. NO:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:95 and 97, respectively. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively, and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 96 and 97, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:96 and 97. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: NO:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:99 and 101, respectively. In some embodiments, the kit includes a first, second, third, and fourth viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: NO:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:95 and 97, respectively; (c) a third viral vector or liposome complex (e.g., LNP), comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: comprising a fusion polypeptide of SEQ ID NO:98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:95 and 97, respectively; NO:98 and 100 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:98 and 100; and (d) a fourth viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:99 and 101, respectively. In some embodiments, the kit includes a first, second, third, and fourth viral vectors or liposome complexes (e.g., LNPs) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; NO:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:96 and 97, respectively; (c) a third viral vector or liposome complex (e.g., LNP), comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: comprising a fusion polypeptide of SEQ ID NO:98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:96 and 97, respectively; NO:98 and 99 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:98 and 99; and (d) a fourth viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:100 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:100 and 101, respectively. In various embodiments of the kit, the viral vector is a lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vector, a Cali mammalian arenavirus (also known as Pichinde mammalian arenavirus or Pichinde arenavirus) viral vector, or an adenovirus vector, such as a chimpanzee adenovirus vector (ChAd). In some embodiments, the kit includes a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226. In some embodiments, the kit includes a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NO: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NO: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226. In some embodiments, the kit includes the following first and second polynucleotides, or one or more vectors or one or more liposome complexes (e.g., LNPs) comprising the following first and second polynucleotides: polynucleotides of SEQ ID NOs: 130 and 132, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively; polynucleotides of SEQ ID NOs: 130 and 134, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively; 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134; a polynucleotide of SEQ ID NOs: 131 and 133, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively; a polynucleotide of SEQ ID NOs: 131 and 135, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135; a polynucleotide of SEQ ID NOs: 132 and 136, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively; a polynucleotide of SEQ ID NOs: 133 and 135, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135; polynucleotides of SEQ ID NOs: 133 and 137, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively; polynucleotides of SEQ ID NOs: 134 and 136, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136; a polynucleotide of SEQ ID NOs: 135 and 137, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively; a polynucleotide of SEQ ID NOs: 138 and 141, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 142, respectively. 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 138 and 141; a polynucleotide of SEQ ID NOs: 138 and 144, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively; a polynucleotide of SEQ ID NOs: 139 and 142, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139 and 143, respectively. 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139 and 142; a polynucleotide of SEQ ID NOs: 139 and 145, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; a polynucleotide of SEQ ID NOs: 140 and 146, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively; a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149; a polynucleotide of SEQ ID NOs: 145 and 148, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively; a polynucleotide of SEQ ID NOs: 150 and 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152; polynucleotides of SEQ ID NOs: 150 and 155, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively; polynucleotides of SEQ ID NOs: 151 and 153, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153; a polynucleotide of SEQ ID NOs: 151 and 156, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively; a polynucleotide of SEQ ID NOs: 152 and 158, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, ... 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157; a polynucleotide of SEQ ID NOs: 155 and 158, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; a polynucleotide of SEQ ID NOs: 156 and 159, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159; a polynucleotide of SEQ ID NOs: 160 and 161, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; a polynucleotide of SEQ ID NOs: 162 and 163, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively; a polynucleotide of SEQ ID NOs: 166 and 167, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167; the polynucleotides of SEQ ID NOs: 210 and 211, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively; the polynucleotides of SEQ ID NOs: 212 and 213, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively; a polynucleotide of SEQ ID NOs: 216 and 217, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217; polynucleotides of SEQ ID NOs: 218 and 219, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively; polynucleotides of SEQ ID NOs: 218 and 226, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 229, respectively; or a polynucleotide of SEQ ID NOs: 225 and 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing the following first and second polynucleotides: (a) a first vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 131 and 135, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively, and (b) a second vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 133 and 137, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: Any of NO:133 and 137 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing the following first and second polynucleotides: (a) a first vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 139 and 145, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively, and (b) a second vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 143 and 149, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: Any of NO:139 and 145 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. In some embodiments, the kit includes a first, second, third, and fourth viral vector or liposome complex (e.g., LNP), each vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide: (a) a first viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 131 and 135, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; (b) a second viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 133 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively. any one of SEQ ID NOs: 133 and 137 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; (c) a third viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide, the first and the second polynucleotide comprising SEQ ID NOs: 139 and 145, or respectively identical to SEQ ID NOs: 139 and 145. any one of SEQ ID NOs: 139 and 145 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; and (d) a fourth viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 142 and 148, or being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing the following first and second polynucleotides: (a) a first vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 140 and 146, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively, and (b) a second vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 143 and 149, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: NO: any of 143 and 149 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. In some embodiments, the first and second viral vectors are lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vectors. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing the following first and second polynucleotides: (a) a first vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 150 and 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively, and (b) a second vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: NO: any of 155 and 158 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. In some embodiments, the first and second viral vectors are Cali mammalian arenavirus (also known as Pichinde mammalian arenavirus or Pichinde arenavirus) viral vectors. In some embodiments, the kit includes a first, second, third, and fourth viral vector or liposome complex (e.g., LNP), each vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide: (a) a first viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 140 and 146, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; (b) a second viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 143 and 149, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. any of SEQ ID NOs: 143 and 149 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; (c) a third viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 150 and 152, or respectively identical to SEQ ID NOs: 151 and 152. any of SEQ ID NOs: 150 and 152 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; and (d) a fourth viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or the same as SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. Any of NOs: 155 and 158 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the kit includes a first, second, third, and fourth viral vector or liposome complex (e.g., LNP), each vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide: (a) a first viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 150 and 152, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; (b) a second viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 155 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively. any of SEQ ID NOs: 155 and 158 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; (c) a third viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide, the first and the second polynucleotide comprising SEQ ID NOs: 151 and 153, or respectively identical to SEQ ID NOs: any one of SEQ ID NOs: 151 and 153 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; and (d) a fourth viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 156 and 159, or being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. In various embodiments, one or more of the first, second, third, and fourth vectors are adenoviral vectors. In some embodiments, the kit includes a first and a second viral vector or liposome complex (e.g., LNP) containing the following first and second polynucleotides: (a) a first vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 160 and 161, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively, and (b) a second vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 162 and 163, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively. Any of NO:162 and 163 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. In some embodiments, the kit includes a first and a second viral vector comprising the following first and second polynucleotides: (a) a first vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 164 and 165, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively, and (b) a second vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 166 and 167, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: Any of NO:166 and 167 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. In some embodiments, the kit includes: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 210, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 211. NO:211 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the kit includes: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 212, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 213, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 213. NO:213 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the kit includes: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 214, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 215. NO:215 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the kit includes: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 216, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 217, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 217. NO:217 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the kit includes: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 219, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 219. NO:219 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the kit includes: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 226. NO:226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the kit includes: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 225, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 226. NO:226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the kit includes a composite fusion polypeptide, a vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding the composite fusion polypeptide, which composite fusion polypeptide comprises or consists of: an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the kit includes a composite fusion polypeptide, a vector or a liposome complex (e.g., LNP) comprising a polynucleotide encoding the composite fusion polypeptide, wherein the composite fusion polypeptide comprises or consists of: an amino acid sequence of any one of SEQ ID NOs: 209, 222, and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223. In some embodiments, the one or more fusion polypeptides do not comprise any polypeptide fragments corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116, and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol, and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2, and 3, respectively. In some embodiments, the one or more fusion polypeptides do not comprise any polypeptide fragment having an amino acid sequence of SEQ ID NO:35-47 or a fragment or subsequence thereof, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:35-47 or a fragment or subsequence thereof. In some embodiments, the kit further comprises one or more unit doses of one or more additional therapeutic agents. In some embodiments, the kit comprises one or more agents that activate latent HIV, such as one or more latency reversal agents (LRAs). In some embodiments, the kit includes one or more LRAs selected from the following: one or more toll-like receptor (TLR) agonists or activators, histone deacetylase (HDAC) inhibitors, proteasome inhibitors, protein kinase C (PKC) activators, Smyd2 inhibitors, BET-bromodomain 4 (BRD4) inhibitors, ionomycin, inhibitor of apoptosis protein (IAP) antagonists, and activator mimics of the second mitochondria derived from caspase (SMAC). In some embodiments, the kit includes one or more agonists or activators of one or more Toll-like receptors (TLR). In some embodiments, TLR agonists or activators are selected from TLR2 agonists, TLR3 agonists, TLR4 agonists, TLR5 agonists, TLR7 agonists, TLR8 agonists, and TLR9 agonists. In some embodiments, the TLR7 agonist is selected from GS 9620 (visamod), R848 (resiquimod), DS-0509, LHC-165 and TMX-101 (imiquimod), and/or wherein the TLR8 agonist is selected from GS-9688 (selgantomod), R848 (resiquimod) and NKTR-262 (dual TLR7/TLR8 agonist). In some embodiments, the kit includes one or more interleukin receptor agonists selected from the interleukins of IL-2, IL-7, IL-12 and IL-15. In some embodiments, the kit includes one or more cytokines selected from IL-2, IL-7, IL-12, IL-15 and their variants. In some embodiments, the kit includes one or more innate immune activators. In some embodiments, the one or more innate immune activators include agonists of receptors selected from the following: fms-associated tyrosine kinase 3 (FLT3), interferon gene stimulator (STING) receptor, DExD/H box helicase 58 (DDX58; also known as RIG-I), nucleotide binding oligomerization domain protein 2 (NOD2). In some embodiments, the kit includes an agonist of fms-associated tyrosine kinase 3 (FLT3). In some embodiments, the kit includes one or more antagonists or inhibitors of inhibitory immune checkpoint proteins or receptors and/or one or more activators or agonists of stimulatory immune checkpoint proteins or receptors. In some embodiments, the one or more immune checkpoint proteins or receptors are selected from: CD27, CD70; CD40, CD40LG; CD47, CD48 (SLAMF2), transmembrane and immunoglobulin domain-containing protein 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3); V-set domain-containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunomodulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7H6); HERV-H LTR-associated 2 (HHLA2, B7H7); inducible T cell co-stimulator (ICOS, CD278); inducible T cell co-stimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30L); TNFRSF10A (CD261, DR4, TRAILR1), TNFRSF9 (CD137 ), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5, TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte-associated (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13B (BAFF); TNFRSF18 (GITR), TNFSF18 (GITRL); MHC class I polypeptide-related sequence A (MICA); MHC Class I polypeptide-related sequence B (MICB); CD274 (CD274, PDL1, PD-L1); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155); PVR-related immunoglobulin domain-containing protein (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT ); T cell immunoglobulin and mucin domain-containing protein 4 (TIMD4; TIM4; hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); lymphocyte activation 3 (LAG3, CD223); signal transducer lymphocyte activation molecule family member 1 (SLAMF1, SLAM, CD150); lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6, CD352); SLAM family member 7 (SLAMF7, CD319); UL16 binding protein 1 (ULBP1); UL16 binding protein 2 (ULBP2 ); UL16 binding protein 3 (ULBP3); retinoic acid early transcript 1E (RAET1E; ULBP4); retinoic acid early transcript 1G (RAET1G; ULBP5); retinoic acid early transcript 1L (RAET1L; ULBP6); lymphocyte activation 3 (CD223); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314); killer cell lectin-like receptor C2 (KLRC2, CD159c, N KG2C); killer cell lectin-like receptor C3 (KLRC3, NKG2E); killer cell lectin-like receptor C4 (KLRC4, NKG2F); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor D1 (KLRD1); and SLAM family member 7 (SLAMF7). In some embodiments, the kit includes one or more blockers or inhibitors of one or more T cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the T cell inhibitory immune checkpoint protein or receptor is selected from: CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain-containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunomodulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte-associated (BTLA)); PVR-associated Immunoglobulin domain proteins (PVRIG, CD112R); T-cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activation 3 (LAG3, CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); and killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1). In some embodiments, the kit includes one or more agonists or activators of one or more T cell stimulatory immune checkpoint proteins or receptors. In some embodiments, the T cell stimulatory immune checkpoint proteins or receptors are selected from: CD27, CD70, CD40, CD40LG; inducible T cell co-stimulator (ICOS, CD278); inducible T cell co-stimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). In some embodiments, the kit includes one or more blockers or inhibitors of one or more NK cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the NK cell inhibitory immune checkpoint proteins or receptors are selected from: killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); and killer cell lectin-like receptor D1 (KLRD1, CD94). In some embodiments, the kit includes one or more agonists or activators of one or more NK cell stimulatory immune checkpoint proteins or receptors. In some embodiments, NK cell stimulatory immune checkpoint proteins or receptors are selected from CD16, CD226 (DNAM-1); Killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314); and SLAM family member 7 (SLAMF7). In some embodiments, one or more immune checkpoint inhibitors include protein inhibitors of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, the kit includes antibodies that bind to CTLA4. In some embodiments, the protein or antibody inhibitor of CTLA4 is selected from: ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, C G-0161, ATOR-1144, PBI-5D3H5, FPT-155(CTLA4/PD-L1/CD28), PF-06936308(PD-1/CTLA4), MGD-019(PD-1/CTLA4), KN-046(PD-1/CTLA4), MEDI-5752(CTLA4/PD-1), XmAb-20717 (PD-1/CTLA4) and AK-104(CTLA4/PD-1). In some embodiments, the protein inhibitor of PD-L1 (CD274) or PD-1 (PDCD1) is selected from: pembrolizumab, nivolumab, cemiplimab, pidilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK-301, PF-06801591, BGB-A317 (tislelizumab), elizumab), GLS-010(WBP-3055), AK-103(HX-008), AK-105, CS-1003, HLX-10, MGA-012, BI-754091, AGEN-2034, JS-001(toripalimab), JNJ-63723283, genolimzumab(CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, SHR-1210(camrelizumab), Sym-021, ABBV-181, PD1-PIK, BAT-1306(MSB001 0718C), CX-072, CBT-502, TSR-042 (dostarlimab), MSB-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308 (sintilimab), HLX-20, KL-A167, STI-A1014, STI-A1015 (IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/CTLA4), MGD -013(PD-1/LAG-3), FS-118(LAG-3/PD-L1)MGD-019(PD-1/CTLA4), KN-046(PD-1/CTLA4), MEDI-5752(CTLA4/PD-1), RO-7121661(PD-1/TIM-3), XmAb-20717(PD-1/CTLA4), AK-1 04 (CTLA4/PD-1), M7824 (PD-L1/TGFβ-EC domain), CA-170 (PD-L1/VISTA), CDX-527 (CD27/PD-L1), LY-3415244 (TIM3/PDL1) and INBRX-105 (4-1BB/PDL1). In some embodiments, one or more immune checkpoint inhibitors include small molecule inhibitors of CD274 (PDL1, PD-L1), programmed cell death 1 (PDCD1, PD1, PD-1), or CTLA4. In some embodiments, the small molecule inhibitors of CD274 or PDCD1 are selected from GS-4224, GS-4416, INCB086550, and MAX10181. In some embodiments, the small molecule inhibitors of CTLA4 include BPI-002. In some embodiments, the kit further includes one or more antiviral agents. In some embodiments, the one or more antiviral agents are selected from: HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, and capsid inhibitors.

Also provided are methods for eliciting an immune response to human immunodeficiency virus (HIV) in a subject in need thereof, comprising administering to the subject a fusion polypeptide, a composite fusion polypeptide, a polynucleotide, a carrier, a liposome complex (e.g., LNP) or an immunogenic composition as described herein. Also provided are methods for treating or preventing human immunodeficiency virus (HIV) in a subject in need thereof, comprising administering to the subject a fusion polypeptide, a composite fusion polypeptide, a carrier, a liposome complex (e.g., LNP) or an immunogenic composition as described herein. In some embodiments, the method requires administration of a single vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide. In some embodiments, two or more fusion polypeptides, two or more composite fusion polypeptides, two or more polynucleotides encoding fusion polypeptides, two or more viral expression vectors comprising polynucleotides encoding fusion polypeptides, two or more liposome complexes (e.g., LNP) or two or more immunogenic compositions as described herein are administered to the subject simultaneously or in parallel. In some embodiments, two or more fusion polypeptides, or two or more polynucleotides encoding fusion polypeptides, or two or more viral expression vectors are in the form of a bivalent antigenic composition. In some embodiments, the method requires administering a first fusion polypeptide and a second fusion polypeptide, one or more polynucleotides encoding the first and second fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, or one or more liposome complexes (e.g., LNPs), wherein the first polypeptide and the second polypeptide comprise, in order from N-terminus to C-terminus, the following polypeptide fragments optionally bound or linked by one or more linkers: SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17; SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11; SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21; SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17; SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11; SEQ ID NOs: NO:22, 24, 14, 18 and 20, and SEQ ID NO:25, 23, 15, 21 and 19; SEQ ID NO:20, 6, 4, 18, 16 and 26, and SEQ ID NO:7, 19, 5, 21, 27 and 17; SEQ ID NO:8, 24, 14, 12, 22 and 10, and SEQ ID NO:9, 13, 25, 23, 15 and 11; SEQ ID NO:18, 26, 20, 4, 6 and 16, and SEQ ID NO:7, 21, 17, 5, 27 and 19; SEQ ID NO:22, 24, 12, 14, 8 and 10, and SEQ ID NO:15, 25, 9, 23, 13 and 11; SEQ ID NO:24, 6, 4, 20, 18 and 32, and SEQ ID NO:8, 30, 14, 12, 26 and 10; SEQ ID NO:24, 6, 4, 20, 18 and 32, and SEQ ID NO:7, 21, 5, 25, 33 and 19; SEQ ID NO:24, 6, 4, 20, 18 and 32, and SEQ ID NO:8, 30, 14, 12, 26 and 10; SEQ ID NO:8, 30, 14, 12, 26 and 10, and SEQ ID NO:9, 13, 31, 27, 15 and 11; SEQ ID NO:6, 20, 4, 24, 32 and 18, and SEQ ID NO:8, 12, 30, 26, 14 and 10; SEQ ID NO:7, 21, 5, 25, 33 and 19 and SEQ ID NO:9, 13, 31, 27, 15 and 11; NO:20, 32, 24, 4, 6 and 18, and SEQ ID NO:26, 30, 12, 14, 8 and 10; SEQ ID NO:7, 25, 19, 5, 33 and 21, and SEQ ID NO:15, 31, 9, 27, 13 and 11; SEQ ID NO:24, 6, 16 and 18, and SEQ ID NO:26, 20, 10 and 28; SEQ ID NO:24, 6, 16 and 18, and SEQ ID NO:26, 10, 20 and 28; SEQ ID NO:24, 6, 16 and 18, and SEQ ID NO:7, 25, 17 and 19; SEQ ID NO:7, 19, 17 and 25, and SEQ ID NO:21, 27, 11 and 29; SEQ ID NO:24, 16, 6 and 18, and SEQ ID NO:27, 11, 21 and 29; SEQ ID NO: NO:7, 25, 17 and 19, and SEQ ID NO:11, 27, 21 and 29; SEQ ID NO:7, 25, 17 and 19, and SEQ ID NO:21, 27, 11 and 29; SEQ ID NO:22, 6, 20 and 28, and SEQ ID NO:23, 7, 21 and 29; SEQ ID NO:22, 20, 6 and 28, and SEQ ID NO:7, 21, 23 and 29; SEQ ID NO:26, 10, 20 and 28, and SEQ ID NO:21, 27, 11 and 29; SEQ ID NO:22, 6, 16, 20, 18, 28, 26 and 10; or SEQ ID NO:7, 21, 19, 17, 27, 25, 29 and 11. In some embodiments, the method entails administering one or more fusion polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227. In some embodiments, the method entails administering one or more fusion polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223. In some embodiments, the method entails administering the following first and second fusion polypeptides, one or more polynucleotides, one or more vectors comprising one or more polynucleotides, or one or more liposome complexes (e.g., LNPs), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a fusion polypeptide of SEQ ID NOs: 70 and 71, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; a fusion polypeptide of SEQ ID NOs: 72 and 73, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively. 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively. 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:76 and 77; a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:78 and 79, respectively; a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:80 and 81, respectively. 82 and 83, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively; a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively. 84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85; a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively; a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively. 88 and 89; a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively; a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively. 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86; a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively. 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87; a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively; a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively. 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 88, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively. 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89; a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively; a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91; a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively; a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively. 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; 94 and 96; a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively; a fusion polypeptide of SEQ ID NOs:220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively; a fusion polypeptide of SEQ ID NOs:220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221; a fusion polypeptide of SEQ ID NOs: 98 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; a fusion polypeptide of SEQ ID NOs: 99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively; or a fusion polypeptide of SEQ ID NOs:100 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:100 and 101, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:100 and 101. In some embodiments, the method entails administering the following first and second fusion polypeptides, one or more vectors or one or more liposome complexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides bound or linked, in order from N-terminus to C-terminus and optionally via one or more linkers: a fusion polypeptide of SEQ ID NOs: 70 and 71, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; 71 and 70, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70; a fusion polypeptide of SEQ ID NOs: 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; a fusion polypeptide of SEQ ID NOs: 73 and 72, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72; a fusion polypeptide of SEQ ID NOs: 74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; a fusion polypeptide of SEQ ID NOs: 75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76; a fusion polypeptide of SEQ ID NOs: 78 and 79, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; a fusion polypeptide of SEQ ID NOs: 79 and 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; 80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:81 and 80; a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively; a fusion polypeptide of SEQ ID NOs:83 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 83, respectively. 83 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 82; a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively; a fusion polypeptide of SEQ ID NOs:85 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:8 85 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 84; a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively; a fusion polypeptide of SEQ ID NOs:87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 88, respectively. 87 and 86; a fusion polypeptide of SEQ ID NOs:87 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:87 and 86; a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:88 and 89, respectively; 89, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 89 and 88; a fusion polypeptide of SEQ ID NOs: 82 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; a fusion polypeptide of SEQ ID NOs: 85 and 82, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 82; a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 86, respectively; a fusion polypeptide of SEQ ID NOs:86 and 82, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 86, respectively; 86 and 82; a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; a fusion polypeptide of SEQ ID NOs:88 and 82, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; 88 and 82; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively; 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 87 and 85; a fusion polypeptide of SEQ ID NOs: 88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; a fusion polypeptide of SEQ ID NOs: 87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 88; a fusion polypeptide of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 84, respectively; 85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 89 and 85; a fusion polypeptide of SEQ ID NOs: 85 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; a fusion polypeptide of SEQ ID NOs: 101 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85; a fusion polypeptide of SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; 91 and 90; a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:92 and 93, respectively; a fusion polypeptide of SEQ ID NOs:93 and 92, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:92 and 93, respectively; 93 and 92; a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively; a fusion polypeptide of SEQ ID NOs:95 and 94, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 94, respectively. 95 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; 97 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96; a fusion polypeptide of SEQ ID NOs: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; a fusion polypeptide of SEQ ID NOs: 96 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95; a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; a fusion polypeptide of SEQ ID NOs: 221 and 220, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220; a fusion polypeptide of SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; a fusion polypeptide of SEQ ID NOs: 100 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98; a fusion polypeptide of SEQ ID NOs: 99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; a fusion polypeptide of SEQ ID NOs: 101 and 99, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively. 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99; a fusion polypeptide of SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; a fusion polypeptide of SEQ ID NOs: 99 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98; a fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or a fusion polypeptide of SEQ ID NOs: 101 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:101 and 100. In some embodiments, the method entails administering a first and a second viral vector or a first and a second liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: NO:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:86 and 87, respectively. In some embodiments, the method entails administering a first and a second viral vector or a first and a second liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 88 and 89, respectively. In some embodiments, the method entails administering a first and a second viral vector or a first and a second liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: NO:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:83 and 87, respectively. In some embodiments, the method entails administering a first and a second viral vector or a first and a second liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: NO:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:85 and 87, respectively. In some embodiments, the method entails administering a first and a second viral vector or a first and a second liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively. NO:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:88 and 87, respectively. In some embodiments, the method entails administering a first and a second viral vector or a first and a second liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: NO:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:85 and 89, respectively. In some embodiments, the method entails administering a first and a second viral vector or a first and a second liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: NO:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:96 and 97, respectively. In some embodiments, the method entails administering a first and a second viral vector or a first and a second liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: NO:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:95 and 97, respectively. In some embodiments, the method entails administering a first and a second viral vector or a first and a second liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively. 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the method entails administering a first and a second viral vector or a first and a second liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: NO:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:99 and 101, respectively. In some embodiments, the method entails administering a first and a second viral vector or a first and a second liposome complex (e.g., LNP) containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: NO:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:85 and 101, respectively. In some embodiments, the method entails administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 200 and being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 200, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 201 or being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 201. NO:201 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the method entails administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO:202 and being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:202, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO:203 or being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:203. NO:203 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the method entails administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO:204 and being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:204, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO:205 or being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:205. NO:205 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the method entails administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 105 and being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 105, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 107 or being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 107. NO:107 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the method entails administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO:206 and being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:206, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO:207 or being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:207. NO:207 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the method entails administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO:208 and being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:208, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO:209 or SEQ ID NO:227, or being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:209 or SEQ ID NO:227. IDNO: 227 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the method entails administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO:222 and being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:222, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO:209 or SEQ ID NO:227, or being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:209 or SEQ ID NO:227. IDNO: 227 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the method entails administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO:222 and being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:222, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO:223 or being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:223. NO: 223 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the method requires the administration of a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide of SEQ ID NO: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 90 and 91, respectively. In some embodiments, the method entails administering a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide of SEQ ID NOs: 92 and 93, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. In various embodiments, the first and second viral vectors are lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vectors, Cali mammalian arenavirus (also known as Pichinde mammalian arenavirus or Pichinde arenavirus) viral vectors, or adenovirus vectors, such as chimpanzee adenovirus vectors (ChAd). In some embodiments, the first and second viral vectors or the first and second liposome complexes (e.g., LNPs) are co-administered in parallel. In some embodiments, the method requires administration of the following first and second polynucleotides, or one or more vectors or one or more liposome complexes (e.g., LNPs) comprising the following first and second polynucleotides: polynucleotides of SEQ ID NOs: 130 and 132, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively; polynucleotides of SEQ ID NOs: 130 and 134, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively; 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134; a polynucleotide of SEQ ID NOs: 131 and 133, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively; a polynucleotide of SEQ ID NOs: 131 and 135, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135; a polynucleotide of SEQ ID NOs: 132 and 136, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively; a polynucleotide of SEQ ID NOs: 133 and 135, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135; polynucleotides of SEQ ID NOs: 133 and 137, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively; polynucleotides of SEQ ID NOs: 134 and 136, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136; a polynucleotide of SEQ ID NOs: 135 and 137, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively; a polynucleotide of SEQ ID NOs: 138 and 141, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 142, respectively. 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 138 and 141; a polynucleotide of SEQ ID NOs: 138 and 144, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively; a polynucleotide of SEQ ID NOs: 139 and 142, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139 and 143, respectively. 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139 and 142; polynucleotides of SEQ ID NOs: 139 and 145, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; polynucleotides of SEQ ID NOs: 140 and 146, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively; a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149; a polynucleotide of SEQ ID NOs: 145 and 148, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively; a polynucleotide of SEQ ID NOs: 150 and 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152; polynucleotides of SEQ ID NOs: 150 and 155, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively; polynucleotides of SEQ ID NOs: 151 and 153, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153; a polynucleotide of SEQ ID NOs: 151 and 156, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively; a polynucleotide of SEQ ID NOs: 152 and 158, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, ... 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157; a polynucleotide of SEQ ID NOs: 155 and 158, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; a polynucleotide of SEQ ID NOs: 156 and 159, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159; a polynucleotide of SEQ ID NOs: 160 and 161, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; a polynucleotide of SEQ ID NOs: 162 and 163, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively; a polynucleotide of SEQ ID NOs: 166 and 167, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167; the polynucleotides of SEQ ID NOs: 210 and 211, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively; the polynucleotides of SEQ ID NOs: 212 and 213, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively; a polynucleotide of SEQ ID NOs: 216 and 217, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively. 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217; polynucleotides of SEQ ID NOs: 218 and 219, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively; polynucleotides of SEQ ID NOs: 218 and 226, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 229, respectively; or a polynucleotide of SEQ ID NOs: 225 and 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively. In some embodiments, the method entails administering a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following first and second polynucleotides: (a) a first vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 140 and 146, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively, and (b) a second vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 143 and 149, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: Any of NO:143 and 149 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, wherein the first and second viral vectors are lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vectors. In some embodiments, the method entails administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing the following first and second polynucleotides: (a) a first vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 150 and 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively, and (b) a second vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: Any of NOs: 155 and 158 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, wherein the first and second viral vectors are Cali mammalian arenavirus (also known as Pichinde mammalian arenavirus or Pichinde arenavirus) viral vectors. In some embodiments, the method requires administering a composite fusion polypeptide, a vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding the composite fusion polypeptide, which composite fusion polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the method requires administering a composite fusion polypeptide, a vector or a liposome complex (e.g., LNP) comprising a polynucleotide encoding the composite fusion polypeptide, which composite fusion polypeptide comprises or consists of: an amino acid sequence of any one of SEQ ID NOs: 209, 222, and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223. In some embodiments, the method entails administering a polynucleotide (e.g., in a vector, in a liposome complex (e.g., LNP)) comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226. In some embodiments, the method entails administering a polynucleotide (e.g., in a vector, in a liposome complex (e.g., LNP)) comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence of any one of SEQ ID NOs: any one of NO:139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical nucleic acid sequence. In some embodiments, the method entails administering: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 210, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 211. any one of NO:211 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. In some embodiments, the method entails administering: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 212, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 213, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 213. any one of NO:213 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. In some embodiments, the method entails administering: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 214, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 215. Any of NO:215 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the polynucleotide. In some embodiments, the method entails administering: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 216, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 217, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 217. any one of NO:217 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. In some embodiments, the method entails administering: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 219, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 219. NO:219 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the method entails administering: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 226. NO:226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the method entails administering: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 225, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 226. NO:226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the one or more fusion polypeptides do not comprise any polypeptide fragments corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116, and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol, and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2, and 3, respectively. In some embodiments, the one or more fusion polypeptides do not comprise any polypeptide fragment having the following amino acid sequence: an amino acid sequence of SEQ ID NO: 35-47 or a fragment or subsequence thereof, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 35-47 or a fragment or subsequence thereof. In some embodiments, the subject is infected with HIV-1 virus, suspected of being infected with HIV-1 virus, or at risk of being infected with HIV-1 virus. In some embodiments, the subject is chronically infected with HIV-1. In some embodiments, the subject is acutely infected with HIV-1. In some embodiments, the subject suffers from HIV-1 infection at Fiebig stage IV or earlier, such as Fiebig stage III, Fiebig stage II or Fiebig stage I. In some embodiments, the fusion polypeptide, composite fusion polypeptide, polynucleotide, vector, liposome complex (e.g., LNP) or immunogenic composition is administered via a route selected from: intravenous, intramuscular, intradermal, subcutaneous, intranodal and mucosal (e.g., buccal, intranasal, rectal, vaginal). In some embodiments, the method requires about 10 ³ to about 10 ¹² Virus focus forming units (FFU) or plaque forming units (PFU) or infectious units (IU) or virus particles (vp), for example about 10 ⁴ to about 10 ⁷ Virus FFU or PFU or IU or vp, for example about 10 ³ to about 10 ⁴ , 10 ⁵ , 10 ⁶ , 10 ⁷ , 10 ⁸ , 10 ⁹ , 10 ¹⁰ , 10 ¹¹ , 10 ¹² , 10 ¹³ , 10 ¹⁴ or 10 ¹⁵ In some embodiments, the method includes a primary immunization-boosting scheme, which includes applying a primary immunization composition at a first time point and applying one or more boosting compositions at one or more subsequent time points. In some embodiments, the method includes repeating the primary immunization-boosting scheme once or multiple iterations. In some embodiments, the primary immunization composition and the one or more boosting compositions are administered at intervals of at least 1 week, 2 weeks, 3 weeks or 1 month, for example, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months. In some embodiments, the primary immunization composition and the boosting composition comprise the same immunogenic composition. In some embodiments, the primary immunization composition and the boosting composition comprise different immunogenic compositions. In some embodiments, the primary immunization composition and the boosting composition comprise the same one or more fusion polypeptides and the same viral expression vector. In some embodiments, the primary immunization composition and the boosting composition comprise different fusion polypeptides and/or different viral expression vectors. In some embodiments, these methods include primary immunization with a first viral expression vector and boosting with a second viral expression vector. In some embodiments, the prime-boost regimen comprises: (a) priming with one or more viral expression vectors and boosting with one or more polynucleotides, wherein the one or more polynucleotides comprise DNA, cDNA, mRNA, or self-replicating RNA; (b) priming with one or more polynucleotides, wherein the one or more polynucleotides comprise DNA, cDNA, mRNA, or self-replicating RNA, and boosting with one or more viral expression vectors; (c) priming with one or more viral expression vectors and boosting with one or more viral expression vectors, wherein the one or more viral expression vectors in the priming composition and the one or more viral expression vectors in the boosting composition are from the same, related, or unrelated taxonomic families; (d) priming with one or more replication-defective viral expression vectors and boosting with one or more replication-defective viral expression vectors, wherein the one or more replication-defective viral expression vectors in the priming composition and the one or more replication-defective viral expression vectors in the boosting composition are from the same, related, or unrelated taxonomic families. unrelated taxonomic families; (e) priming with one or more replication-attenuated viral expression vectors and boosting with one or more replication-attenuated viral expression vectors, wherein the one or more replication-attenuated viral expression vectors in the priming composition and the one or more replication-attenuated viral expression vectors in the boosting composition are from the same, related or unrelated taxonomic families; (f) priming with one or more replication-defective viral expression vectors and boosting with one or more replication-attenuated viral expression vectors; (g) priming with one or more replication-attenuated viral expression vectors and boosting with one or more replication-defective viral expression vectors; (h) priming with one or more lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral expression vectors and boosting with one or more picinder mammalian arenavirus viral expression vectors; (i) priming with one or more picinder mammalian arenavirus viral expression vectors and boosting with one or more lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral expression vectors (j) priming with one or more replication-defective mammalian arenavirus viral expression vectors and boosting with one or more replication-defective mammalian lymphocytic choriomeningitis arenavirus (LCMV) viral expression vectors; (k) priming with one or more replication-defective mammalian lymphocytic choriomeningitis arenavirus (LCMV) viral expression vectors and boosting with one or more replication-defective mammalian arenavirus viral expression vectors; (l) priming with one or more arenavirus viral expression vectors and boosting with one or more adenovirus viral expression vectors; (m) priming with one or more adenovirus viral expression vectors and boosting with a boosting composition comprising one or more arenavirus viral expression vectors; (n) priming with one or more adenovirus viral expression vectors and boosting with a boosting composition comprising one or more RNA molecules (e.g., mRNA, self-amplifying or self-replicating RNA); (o) priming with one or more RNA molecules (e.g., mRNA, self-amplifying or self-replicating RNA ) and boosted with a boosting composition comprising one or more adenovirus expression vectors; (p) primed with one or more chimpanzee adenovirus (ChAd) expression vectors and boosted with a boosting composition comprising one or more self-amplifying or self-replicating RNAs (saRNA or samRNA); (q) primed with one or more self-amplifying or self-replicating RNAs (saRNA or samRNA) and boosted with a boosting composition comprising one or more chimpanzee adenovirus (ChAd) expression vectors; (r) primed with one or more poxvirus expression vectors and boosted with one or more arenavirus expression vectors; (s) primed with one or more arenavirus expression vectors and boosted with a boosting composition comprising one or more poxvirus expression vectors; (t) primed with one or more poxvirus expression vectors and boosted with one or more adenovirus expression vectors; or (u) primed with one or more adenovirus expression vectors and boosted with a boosting composition comprising one or more poxvirus expression vectors. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising the following first and second fusion polypeptides, one or more vectors comprising one or more polynucleotides or one or more liposome complexes (e.g., LNPs), wherein the one or more polynucleotides encode the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a fusion polypeptide of SEQ ID NOs: 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; a fusion polypeptide of SEQ ID NOs: 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively. 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:76 and 77; a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:78 and 79, respectively; a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:80 and 81, respectively. 82 and 83, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively; a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively. 84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85; a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively; a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively. 88 and 89; a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively; a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively. 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86; a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively. 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87; a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively; a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively. 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 88, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively; 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89; a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively; a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91; a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively; a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively. 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively; 94 and 96; a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively; a fusion polypeptide of SEQ ID NOs:220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively; a fusion polypeptide of SEQ ID NOs:220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221; a fusion polypeptide of SEQ ID NOs: 98 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; a fusion polypeptide of SEQ ID NOs: 99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively; or a fusion polypeptide of SEQ ID NOs:100 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:100 and 101, respectively. NO: 100 and 101 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 100 and 101; and (2) boosted with an immunogenic composition comprising a first fusion polypeptide and a second fusion polypeptide, one or more vectors or one or more liposome complexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally bound or linked by one or more linkers: SEQ ID NO: 70 and 71, or SEQ ID NO: 72, or SEQ ID NO: 73, or SEQ ID NO: 74, or SEQ ID NO: 75, or SEQ ID NO: 76, or SEQ ID NO: 77, or SEQ ID NO: 78, or SEQ ID NO: 79, or SEQ ID NO: 80, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 100 and 101, or 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:72 and 73, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively. 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 74 and 75; a fusion polypeptide of SEQ ID NOs: 76 and 77, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; a fusion polypeptide of SEQ ID NOs: 78 and 79, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively. 80 and 81, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; a fusion polypeptide of SEQ ID NOs: 82 and 83, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively. 82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively. 86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87; a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively; a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively. 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85; a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively; a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively. 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88; a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively; a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively. 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87; a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively; a fusion polypeptide of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 88, respectively. 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 88; a fusion polypeptide of SEQ ID NOs:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively; a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively. 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 101; a fusion polypeptide of SEQ ID NOs: 90 and 91, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; a fusion polypeptide of SEQ ID NOs: 92 and 93, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively. 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97; a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 96, respectively; a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively. 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100; a fusion polypeptide of SEQ ID NOs:99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 101, respectively; a fusion polypeptide of SEQ ID NOs:98 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 101, respectively; or a fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising the following first and second fusion polypeptides, one or more vectors comprising one or more polynucleotides, one or more liposome complexes (e.g., LNPs), wherein the one or more polynucleotides encode the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a fusion polypeptide of SEQ ID NOs: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; (b) a fusion polypeptide of SEQ ID NOs: 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97; (c) a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 96, respectively; (d) a fusion polypeptide of SEQ ID NOs:220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: NO: 220 and 221 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO: 220 and 221; and/or (e) a fusion polypeptide of SEQ ID NO: 95 and 97, or a fusion polypeptide of SEQ ID NO: 97, or a fusion polypeptide of SEQ ID NO: 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, NO:95 and 97 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:95 and 97; and (2) boosted with an immunogenic composition comprising the first fusion polypeptide and the second fusion polypeptide, one or more vectors or one or more liposome complexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and the second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a fusion polypeptide of SEQ ID NO:98 and 99, or a fusion polypeptide of SEQ ID NO:99, or a fusion polypeptide of SEQ ID NO:91, or a fusion polypeptide of SEQ ID NO:92, or a fusion polypeptide of SEQ ID NO:93, or a fusion polypeptide of SEQ ID NO:94, or a fusion polypeptide of SEQ ID NO:95 and 97, respectively. 98 and 99; (b) a fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; (c) a fusion polypeptide of SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NOS:98 and 100; and/or (d) a fusion polypeptide of SEQ ID NOS:99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOS:99 and 101, respectively. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP), wherein the first and the second viral vector or the first and the second liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or a liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively, or one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: NO: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 220 and 221, respectively; and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: comprising a fusion polypeptide of SEQ ID NO: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 220 and 221, respectively; NO:95 and 97 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97; and (2) boosting with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP), wherein the first and the second viral vector or the first and the second liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first viral vector or a liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NOs:98 and 100, or a fusion polypeptide with SEQ ID NOs: 101 and 102, respectively; NO:98 and 100 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:98 and 100; and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:99 and 101, respectively. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO: 82 and 85, or a fusion polypeptide comprising SEQ ID NO: 83 and 84, respectively; NO:82 and 85 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:82 and 85; and (2) boosted with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO:87 and 88, or a fusion polypeptide with SEQ ID NO:89, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:89, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:81 and 90, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:87 and 88. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively. NO: 87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 87 and 88, respectively. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO: 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 87 and 88, respectively. NO:82 and 88 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:82 and 88; and (2) boosted with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO:85 and 87, or a fusion polypeptide with SEQ ID NO:87, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:85 and 87. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, comprising a fusion polypeptide of SEQ ID NOs: 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, comprising SEQ ID NOs: 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. NO:94 and 95 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:94 and 95; and (2) boosted with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO:96 and 97, or a fusion polypeptide with SEQ ID NO:97, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:96 and 97. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively. NO:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:96 and 97, respectively.

In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO: 94 and 96, or a fusion polypeptide comprising SEQ ID NO: 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175 NO:94 and 96 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:94 and 96; and (2) boosted with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO:95 and 97, or a fusion polypeptide with SEQ ID NO:97, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 220 and 221, or a fusion polypeptide of SEQ ID NOs: 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275 NO: 220 and 221 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO: 220 and 221; and (2) boosted with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO: 95 and 97, or a fusion polypeptide with SEQ ID NO: 97, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:95 and 97. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 94 and 96, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: NO:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:95 and 97, respectively. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) and a second viral vector or liposome complex (e.g., LNP), the first viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:95 and 97, respectively. ID NO: 220 and 221 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of the above-mentioned fusion polypeptides; the second viral vector or liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO: 95 and 97, or a fusion polypeptide comprising SEQ ID NO: 97, or a fusion polypeptide comprising SEQ ID NO: 98, or a fusion polypeptide comprising SEQ ID NO: 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide comprising SEQ ID NOs: 95 and 97, respectively. NO:94 and 95 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:94 and 95; and (2) boosted with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO:98 and 99, or a fusion polypeptide with SEQ ID NO:99, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NOs:98 and 99. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 105, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 105, respectively; and (2) boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 109, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 109, respectively. NO:109 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the composite fusion polypeptide. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 105 or 206, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 105 or 206, respectively; and (2) boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 105 or 206. NO:107 or 207, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:107 or 207. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 105, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 105, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 107, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 107, respectively. NO:107 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 206, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 206, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 207, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 208, respectively. NO:207 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 208, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 208, respectively; and (2) boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 228, respectively. NO:209 or SEQ ID NO:227 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 222, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222, respectively; and (2) boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222, respectively. NO:209 or SEQ ID NO:227 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the composite fusion polypeptide. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 222, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222, respectively; and (2) boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 223, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 223, respectively. NO:223 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the composite fusion polypeptide. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 208, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 208, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209, respectively. NO:227 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 222, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227, respectively. NO:227 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 222, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 223, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 223, respectively. NO:223 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO: 96 and 97, or a fusion polypeptide comprising SEQ ID NO: 97, or a fusion polypeptide comprising SEQ ID NO: 98, or a fusion polypeptide comprising SEQ ID NO: 99, or a fusion polypeptide comprising SEQ ID NO: 100, or a fusion polypeptide comprising SEQ ID NO: 101, or a fusion polypeptide comprising SEQ ID NO: 102, or a fusion polypeptide comprising SEQ ID NO: 103, or a fusion polypeptide comprising SEQ ID NO: 104, or a fusion polypeptide comprising SEQ ID NO: 105, or a fusion polypeptide comprising SEQ ID NO: 106, or a fusion polypeptide comprising SEQ ID NO: 107, or a fusion polypeptide comprising SEQ ID NO: 108, or a fusion polypeptide comprising SEQ ID NO: 109, or a fusion polypeptide comprising SEQ ID NO: 110, or a fusion polypeptide comprising SEQ ID NO: 111, or a fusion polypeptide comprising SEQ ID NO: 112, or a fusion polypeptide comprising SEQ ID NO: 113, or a fusion polypeptide comprising SEQ ID NO: 114, or a fusion polypeptide comprising SEQ ID NO: 115, or a fusion polypeptide comprising SEQ ID NO: 116, or a fusion polypeptide comprising SEQ ID NO: 117, or a fusion polypeptide comprising SEQ ID NO: 118, or a fusion polypeptide comprising SEQ ID NO: 119 ... NO:96 and 97 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:96 and 97; and (2) boosted with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO: 100 and 101, or a fusion polypeptide with SEQ ID NO: 102, or a fusion polypeptide with SEQ ID NO: 103, or a fusion polypeptide with SEQ ID NO: 104, or a fusion polypeptide with SEQ ID NO: 105, or a fusion polypeptide with SEQ ID NO: 106, or a fusion polypeptide with SEQ ID NO: 107, or a fusion polypeptide with SEQ ID NO: 108, or a fusion polypeptide with SEQ ID NO: 110, or a fusion polypeptide with SEQ ID NO: 111, or a fusion polypeptide with SEQ ID NO: 112, or a fusion polypeptide with SEQ ID NO: 113, or a fusion polypeptide with SEQ ID NO: 114, or a fusion polypeptide with SEQ ID NO: 115, or a fusion polypeptide with SEQ ID NO: 116, or a fusion polypeptide with SEQ ID NO: 117, or a fusion polypeptide with SEQ ID NO: 118, or a fusion polypeptide with SEQ ID NO: 119, or a fusion polypeptide with SEQ ID NO: 121, or a fusion polypeptide with SEQ ID NO: 122, or a fusion polypeptide with SEQ ID NO: 123, or a fusion polypeptide with A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:100 and 101. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 107, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 107, respectively; and (2) boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 111, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 111, respectively. NO:111 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the composite fusion polypeptide. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 200, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 200, respectively; and (2) boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 201, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 201, respectively. NO:201 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the composite fusion polypeptide. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 200, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 200; and a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 201, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 201. NO:201 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 202, or a composite fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 202; and (2) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 203, or a composite fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 204. NO:203 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the composite fusion polypeptide. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 202, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 202; and a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 203, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 204. NO:203 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 204, or a composite fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 204; and (2) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 205, or a composite fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 205. NO:205 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the composite fusion polypeptide. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 204, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 204; and a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 205, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 205. NO:205 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP), wherein the first and the second viral vector or the first and the second liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector or a liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NO:82 and 83, or a fusion polypeptide comprising SEQ ID NO:84, or a fusion polypeptide comprising SEQ ID NO:85, or a fusion polypeptide comprising SEQ ID NO:86, or a fusion polypeptide comprising SEQ ID NO:87, or a fusion polypeptide comprising SEQ ID NO:88, or a fusion polypeptide comprising SEQ ID NO:89, or a fusion polypeptide comprising SEQ ID NO:90, or a fusion polypeptide comprising SEQ ID NO:91, or a fusion polypeptide comprising SEQ ID NO:92, or a fusion polypeptide comprising SEQ ID NO:93, or a fusion polypeptide comprising SEQ ID NO:94, or a fusion polypeptide comprising SEQ ID NO:95, or a fusion polypeptide comprising SEQ ID NO:96, or a fusion polypeptide comprising SEQ ID NO:97, or a fusion polypeptide comprising SEQ ID NO:98, or a fusion polypeptide comprising SEQ ID NO:99, or a fusion polypeptide comprising SEQ ID NO:100, or a fusion polypeptide comprising SEQ ID NO:82 and 83 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:82 and 83; and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:86 and 87, or a fusion polypeptide comprising SEQ ID NO:87, or a fusion polypeptide comprising SEQ ID NO:88, or a fusion polypeptide comprising SEQ ID NO:89, or a fusion polypeptide comprising SEQ ID NO:90, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:91, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 86 and 87 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87; and (2) boosting with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP), wherein the first and the second viral vector or the first and the second liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first viral vector or a liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NOs: 84 and 85, or a fusion polypeptide comprising SEQ ID NOs: 86 and 87 ... NO:84 and 85 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:84 and 85; and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:88 and 89, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:88 and 89, respectively. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP), wherein the first and the second viral vector or the first and the second liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first fusion polypeptide and the second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first viral vector or a liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and the second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 82 and 86, or a fusion polypeptide comprising SEQ ID NO: 83 and 84, respectively; NO:82 and 86 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:82 and 86; and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:83 and 87, or a fusion polypeptide comprising SEQ ID NO:84 or SEQ ID NO:85, or a fusion polypeptide comprising SEQ ID NO:86, or a fusion polypeptide comprising SEQ ID NO:87, or a fusion polypeptide comprising SEQ ID NO:88, or a fusion polypeptide comprising SEQ ID NO:89, or a fusion polypeptide comprising SEQ ID NO:90, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:91, NO:83 and 87 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87; and (2) boosting with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP), wherein the first and the second viral vector or the first and the second liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs:84 and 88, or a fusion polypeptide comprising SEQ ID NOs:85 and 89, respectively; NO:84 and 88 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:84 and 88; and (b) a second viral vector comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:85 and 89, respectively. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP), wherein the first and the second viral vector or the first and the second liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first fusion polypeptide and the second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first viral vector or a liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and the second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 82 and 86, or a fusion polypeptide comprising SEQ ID NO: 83 and 84, respectively; NO:82 and 86 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:82 and 86; and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:83 and 87, or a fusion polypeptide comprising SEQ ID NO:84 or SEQ ID NO:85, or a fusion polypeptide comprising SEQ ID NO:86, or a fusion polypeptide comprising SEQ ID NO:87, or a fusion polypeptide comprising SEQ ID NO:88, or a fusion polypeptide comprising SEQ ID NO:89, or a fusion polypeptide comprising SEQ ID NO:90, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:91, NO:83 and 87 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of SEQ ID NOs:83 and 87; and (2) boosting with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP), wherein the first and the second viral vector or the first and the second liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first viral vector or a liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NOs:98 and 100, or a fusion polypeptide with SEQ ID NOs:101 and 102, respectively; NO:98 and 100 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:98 and 100; and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:99 and 101, respectively. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP), wherein the first and the second viral vector or the first and the second liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first fusion polypeptide and the second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first viral vector or a liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and the second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 82 and 86, or a fusion polypeptide comprising SEQ ID NO: 83 and 84, respectively; NO:82 and 86 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:82 and 86; and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:83 and 87, or a fusion polypeptide comprising SEQ ID NO:84 or SEQ ID NO:85, or a fusion polypeptide comprising SEQ ID NO:86, or a fusion polypeptide comprising SEQ ID NO:87, or a fusion polypeptide comprising SEQ ID NO:88, or a fusion polypeptide comprising SEQ ID NO:89, or a fusion polypeptide comprising SEQ ID NO:90, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:91, NO:83 and 87 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of SEQ ID NOs:83 and 87; and (2) boosting with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP), wherein the first and the second viral vector or the first and the second liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first viral vector or a liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NOs:98 and 100, or a fusion polypeptide with SEQ ID NOs:101 and 102, respectively; NO:98 and 100 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:98 and 100; and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:85 and 101, respectively. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP), wherein the first and the second viral vector or the first and the second liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first fusion polypeptide and the second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first viral vector or a liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and the second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 98 and 100, or a fusion polypeptide with SEQ ID NO: 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, NO:98 and 100 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of; and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:99 and 101, or a fusion polypeptide comprising SEQ ID NO:91 or 102, respectively. 99 and 101 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101; and (2) boosting with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP), wherein the first and the second viral vector or the first and the second liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first viral vector or a liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide comprising SEQ ID NOs: 83 and 87, respectively; NO:82 and 86 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:82 and 86; and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:83 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:83 and 87, respectively. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP), wherein the first and the second viral vector or the first and the second liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first fusion polypeptide and the second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first viral vector or a liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and the second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 98 and 100, or a fusion polypeptide with SEQ ID NO: 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, NO:98 and 100 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:98 and 100; and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:85 and 101, or a fusion polypeptide comprising SEQ ID NO:87 and 102, respectively. NO: 85 and 101 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101; and (2) boosting with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP), wherein the first and the second viral vector or the first and the second liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: (a) a first viral vector or a liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide comprising SEQ ID NOs: 83 and 87, respectively; NO:82 and 86 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:82 and 86; and (b) a second viral vector or liposome complex (e.g., LNP) comprising: one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:83 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:83 and 87, respectively. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally bound or linked via one or more linkers: fusion polypeptides of SEQ ID NOs: 90 and 91, or fusion polypeptides of SEQ ID NOs: 91 and 92, respectively; NO:90 and 91 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:90 and 91; and (2) boosted with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: SEQ ID NO:92 and 93, or SEQ ID NO:94, or SEQ ID NO:95, or SEQ ID NO:96, or SEQ ID NO:97, or SEQ ID NO:98, or SEQ ID NO:99, or SEQ ID NO:100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:92 and 93. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following polynucleotides: (a) a first viral vector or a liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 131 and 135, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; and (b) a second viral vector or a liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 133 and 137, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: any of SEQ ID NOs: 133 and 137 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; and (2) boosted with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following polynucleotides: (a) a first viral vector or a liposome complex (e.g., LNP) comprising a first and a second polynucleotide, the first and the second polynucleotide comprising SEQ ID NOs: 139 and 145, or a polynucleotide identical to SEQ ID NOs: 139 and 145, respectively. any one of SEQ ID NOs: 139 and 145 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; and (b) a second viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 142 and 148, or being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following polynucleotides: (a) a first viral vector or a liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 140 and 146, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; and (b) a second viral vector or a liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 143 and 149, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: any of NOs: 143 and 149 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; and (2) boosted with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following polynucleotides: (a) a first viral vector or a liposome complex (e.g., LNP) comprising a first and a second polynucleotide, the first and the second polynucleotide comprising SEQ ID NOs: 150 and 152, or SEQ ID NOs: 151 and 152, respectively. any of SEQ ID NOs: 150 and 152 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; and (b) a second viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or the same as SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. Any of NOs: 155 and 158 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following polynucleotides: (a) a first viral vector or a liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 150 and 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and (b) a second viral vector or a liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 158 and 159. NO: 155 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 154 and 157 or SEQ ID NO: 155 and 158, respectively; and (2) boosting with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following polynucleotides: (a) a first viral vector or a liposome complex (e.g., LNP) comprising a first and a second polynucleotide, the first and the second polynucleotide comprising SEQ ID NO: 140 and 146, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 154 and 157 or SEQ ID NO: 155 and 158, respectively; any one of SEQ ID NOs: 140 and 146 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; and (b) a second viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 143 and 149, or being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following polynucleotides: (a) a first viral vector or a liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 150 and 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and (b) a second viral vector or a liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 155 and 158, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: any of NOs: 155 and 158 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; and (2) boosted with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following polynucleotides: (a) a first viral vector or a liposome complex (e.g., LNP) comprising a first and a second polynucleotide, the first and the second polynucleotide comprising SEQ ID NOs: 151 and 153, or SEQ ID NOs: 154 and 155, respectively. any one of SEQ ID NOs: 151 and 153 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; and (b) a second viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 156 and 159, or being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following polynucleotides: (a) a first viral vector or a liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 150 and 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and (b) a second viral vector or a liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 155 and 158, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: any of NOs: 155 and 158 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; and (2) boosted with an immunogenic composition comprising a first and a second viral vector or a first and a second liposome complex (e.g., LNP) comprising the following polynucleotides: (a) a first viral vector or a liposome complex (e.g., LNP) comprising a first and a second polynucleotide, the first and the second polynucleotide comprising SEQ ID NOs: 139 and 145, or a polynucleotide identical to SEQ ID NOs: 139 and 145, respectively. any one of SEQ ID NOs: 139 and 145 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; and (b) a second viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 142 and 148, or being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising a polynucleotide comprising SEQ ID NOs: 160 and 161, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; and (2) boosting with an immunogenic composition comprising a second viral vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs: 162 and 163, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively. Any of NO:162 and 163 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the prime-boost regimen comprises: (1) priming with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 164 and 165, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively; and (2) boosting with an immunogenic composition comprising a second viral vector or liposome complex (e.g., LNP) comprising a first and second polynucleotide comprising SEQ ID NOs: 166 and 167, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively. Any of NO: 166 and 167 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the viral vector in the priming composition is a lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vector, and the viral vector in the boosting composition is a Cali mammalian arenavirus (also known as Pichinde mammalian arenavirus or Pichinde arenavirus) viral vector. In various embodiments, the viral vector in the priming composition is a Cali mammalian arenavirus viral vector (also known as Pichinde mammalian arenavirus or Pichinde arenavirus), and the viral vector in the boosting composition is a lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vector. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 210; and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 211. NO:211 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 212; and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 213, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 214. ID NO: 213 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotide. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 214; and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 215. NO:215 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 216; and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 217, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 217. NO:217 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218; and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 219, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 219. NO:219 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218; and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 227. NO:226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides. In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 225; and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 227. NO:226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. In some embodiments, the viral vector in the initial immunization composition and the viral vector in the booster composition are adenoviral vectors, such as chimpanzee adenovirus vectors (ChAd). In some embodiments, the viral vector in the initial immunization composition and the viral vector in the booster composition are replication-deficient. In some embodiments, the viral vector in the initial immunization composition and the viral vector in the booster composition are replication-attenuated. In some embodiments, the subject has not received antiretroviral therapy (ART), or ART is interrupted before administering one or more compositions. In some embodiments, ART is interrupted after one or more administrations of the composition. In some embodiments, these methods require administration of one or more additional therapeutic agents, such as two, three, four or more additional therapeutic agents, to the subject. In some embodiments, these methods require co-administration of one or more agents that activate latent HIV, such as one or more latency reversal agents (LRAs). In some embodiments, one or more LRAs are selected from: agonists or activators of one or more toll-like receptors (TLRs), histone deacetylase (HDAC) inhibitors, proteasome inhibitors, protein kinase C (PKC) activators, Smyd2 inhibitors, BET-bromodomain 4 (BRD4) inhibitors, ionomycin, inhibitor of apoptosis protein (IAP) antagonists, and activator mimics of the second mitochondria derived from caspase (SMAC). In some embodiments, these methods require co-administration of one or more agonists or activators of one or more Toll-like receptors (TLRs). In some embodiments, TLR agonists or activators are selected from TLR2 agonists, TLR3 agonists, TLR4 agonists, TLR5 agonists, TLR7 agonists, TLR8 agonists, and TLR9 agonists. In some embodiments, the TLR7 agonist is selected from GS 9620 (visamod), R848 (resiquimod), DS-0509, LHC-165 and TMX-101 (imiquimod), and/or wherein the TLR8 agonist is selected from GS-9688 (sergantomod), R848 (resiquimod) and NKTR-262 (dual TLR7/TLR8 agonist). In some embodiments, these methods require co-administration of one or more interleukin receptor agonists selected from interleukins selected from IL-2, IL-7, IL-12 and IL-15. In some embodiments, these methods require co-administration of one or more cytokines selected from IL-2, IL-7, IL-12, IL-15 and variants thereof. In some embodiments, these methods require co-administration of one or more innate immune activators. In some embodiments, the one or more innate immune activators include agonists of receptors selected from the following: fms-associated tyrosine kinase 3 (FLT3), interferon gene stimulator (STING) receptor, DExD/H box helicase 58 (DDX58; also known as RIG-I), nucleotide binding oligomerization domain protein 2 (NOD2). In some embodiments, the method requires co-administration of an agonist of fms-associated tyrosine kinase 3 (FLT3). In some embodiments, the method requires co-administration of one or more antagonists or inhibitors of inhibitory immune checkpoint proteins or receptors and/or one or more activators or agonists of stimulatory immune checkpoint proteins or receptors. In some embodiments, the one or more immune checkpoint proteins or receptors are selected from: CD27, CD70; CD40, CD40LG; CD47, CD48 (SLAMF2), transmembrane and immunoglobulin domain-containing protein 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3); V-set domain-containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunomodulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7H6); HERV-H LTR-associated 2 (HHLA2, B7H7); inducible T cell co-stimulator (ICOS, CD278); inducible T cell co-stimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30L); TNFRSF10A (CD261, DR4, TRAILR1), TNFRSF9 (CD137 ), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5, TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte-associated (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13B (BAFF); TNFRSF18 (GITR), TNFSF18 (GITRL); MHC class I polypeptide-related sequence A (MICA); MHC Class I polypeptide-related sequence B (MICB); CD274 (CD274, PDL1, PD-L1); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155); PVR-related immunoglobulin domain-containing protein (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT ); T cell immunoglobulin and mucin domain-containing protein 4 (TIMD4; TIM4; hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); lymphocyte activation 3 (LAG3, CD223); signal transducer lymphocyte activation molecule family member 1 (SLAMF1, SLAM, CD150); lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6, CD352); SLAM family member 7 (SLAMF7, CD319); UL16 binding protein 1 (ULBP1); UL16 binding protein 2 (ULBP2 ); UL16 binding protein 3 (ULBP3); retinoic acid early transcript 1E (RAET1E; ULBP4); retinoic acid early transcript 1G (RAET1G; ULBP5); retinoic acid early transcript 1L (RAET1L; ULBP6); lymphocyte activation 3 (CD223); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314); killer cell lectin-like receptor C2 (KLRC2, CD159c, N KG2C); killer cell lectin-like receptor C3 (KLRC3, NKG2E); killer cell lectin-like receptor C4 (KLRC4, NKG2F); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor D1 (KLRD1); and SLAM family member 7 (SLAMF7). In some embodiments, the method requires co-administration of one or more blockers or inhibitors of one or more T cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the T cell inhibitory immune checkpoint protein or receptor is selected from: CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain-containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunomodulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte-associated (BTLA)); PVR-associated Immunoglobulin domain proteins (PVRIG, CD112R); T-cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activation 3 (LAG3, CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); and killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1). In some embodiments, the method requires co-administration of one or more agonists or activators of one or more T cell stimulatory immune checkpoint proteins or receptors. In some embodiments, the T cell stimulatory immune checkpoint proteins or receptors are selected from: CD27, CD70, CD40, CD40LG; inducible T cell co-stimulator (ICOS, CD278); inducible T cell co-stimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). In some embodiments, the method requires co-administration of one or more blockers or inhibitors of one or more NK cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the NK cell inhibitory immune checkpoint proteins or receptors are selected from: killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); and killer cell lectin-like receptor D1 (KLRD1, CD94). In some embodiments, the method requires co-administration of one or more agonists or activators of one or more NK cell stimulatory immune checkpoint proteins or receptors. In some embodiments, NK cell stimulatory immune checkpoint proteins or receptors are selected from CD16, CD226 (DNAM-1); killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314); and SLAM family member 7 (SLAMF7). In some embodiments, one or more immune checkpoint inhibitors include protein inhibitors of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, these methods require co-administration of antibodies that bind to CTLA4. In some embodiments, the protein or antibody inhibitor of CTLA4 is selected from: ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, C G-0161, ATOR-1144, PBI-5D3H5, FPT-155(CTLA4/PD-L1/CD28), PF-06936308(PD-1/CTLA4), MGD-019(PD-1/CTLA4), KN-046(PD-1/CTLA4), MEDI-5752(CTLA4/PD-1), XmAb-20717 (PD-1/CTLA4) and AK-104(CTLA4/PD-1). In some embodiments, the protein inhibitor of PD-L1 (CD274) or PD-1 (PDCD1) is selected from: pembrolizumab, nivolumab, cemiplimab, pidilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK-301, PF-06801591, BGB-A317 (tislelizumab), elizumab), GLS-010(WBP-3055), AK-103(HX-008), AK-105, CS-1003, HLX-10, MGA-012, BI-754091, AGEN-2034, JS-001(toripalimab), JNJ-63723283, genolimzumab(CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, SHR-1210(camrelizumab), Sym-021, ABBV-181, PD1-PIK, BAT-1306(MSB001 0718C), CX-072, CBT-502, TSR-042 (dostarlimab), MSB-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308 (sintilimab), HLX-20, KL-A167, STI-A1014, STI-A1015 (IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/CTLA4), MGD -013(PD-1/LAG-3), FS-118(LAG-3/PD-L1)MGD-019(PD-1/CTLA4), KN-046(PD-1/CTLA4), MEDI-5752(CTLA4/PD-1), RO-7121661(PD-1/TIM-3), XmAb-20717(PD-1/CTLA4), AK-1 04 (CTLA4/PD-1), M7824 (PD-L1/TGFβ-EC domain), CA-170 (PD-L1/VISTA), CDX-527 (CD27/PD-L1), LY-3415244 (TIM3/PDL1) and INBRX-105 (4-1BB/PDL1). In some embodiments, one or more immune checkpoint inhibitors include small molecule inhibitors of CD274 (PDL1, PD-L1), programmed cell death 1 (PDCD1, PD1, PD-1), or CTLA4. In some embodiments, small molecule inhibitors of CD274 or PDCD1 are selected from GS-4224, GS-4416, INCB086550, and MAX10181. In some embodiments, small molecule inhibitors of CTLA4 include BPI-002. In some embodiments, the method further includes administering one or more antiviral agents to the subject. In some embodiments, the one or more antiviral agents are selected from: HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, and capsid inhibitors. In some embodiments, these methods further include administering one or more anti-HIV antibodies or antigen-binding fragments thereof to the subject. In some embodiments, the one or more anti-HIV antibodies or antigen-binding fragments thereof bind to HIV gp120. In some embodiments, the anti-HIV antibody or antigen-binding fragment thereof comprises a broadly neutralizing antibody. In some embodiments, one or more anti-HIV antibodies or antigen-binding fragments thereof that bind, inhibit and/or neutralize HIV compete with or comprise the VH and VL variable domains of broadly neutralizing antibodies (bNAbs) against HIV. In some embodiments, one or more anti-HIV antibodies or antigen-binding fragments thereof that bind, inhibit and/or neutralize HIV bind to an epitope or region of gp120 selected from the following: (i) the third variable loop (V3) and/or a high mannose patch containing the N332 oligomannosaccharide glycan; (ii) the CD4 binding site (CD4bs); (iii) the second variable loop (V2) and/or the Env trimer vertex; (iv) the gp120/gp41 interface; or (v) the silent face of gp120. In some embodiments, the antibody or antigen-binding fragment thereof that binds, inhibits and/or neutralizes HIV binds to an epitope or region of gp120 in the third variable loop (V3) and/or the high mannose patch comprising the N332 oligomannose glycan, and competes with or comprises the VH and VL regions of an antibody selected from the group consisting of GS-9722, PGT-121, PGT-121.414, PGT-122, PGT-123, PGT-124, PGT-125, PGT-126, PGT-128, PGT-130, PGT-133, PGT-134, PG T-135, PGT-136, PGT-137, PGT-138, PGT-139, 10-1074, 10-1074-J, GS-2872, VRC24, 2G12, BG18, 354BG8, 354BG18, 354BG42, 354BG33, 354BG129, 354BG188, 354BG41 1. 354BG426, DH270.1, DH270.6, PGDM12, VRC41.01, PGDM21, PCDN-33A, BF520.1 and VRC29.03. In some embodiments, the antibody or antigen-binding fragment thereof binds to an epitope or region of gp120 in the CD4 binding site (CD4bs) and competes with or comprises the VH and VL regions of an antibody selected from b12, F105, VRC01, VRC07, VRC07-523, VRC03, VRC06, VRC06b01VRC08, VRC0801, NIH 45-46, GS-9723, GS-5423, 3BNC117, 3BNC60, VRC-PG04, PGV04; CH103, 44-VRC13.01, 1NC9, 12A12, N6, N49-P7, NC-Cow1, IOMA, CH235 and CH235.12, N49P6, N49P7, N49P11, N49P9 and N60P25. In some embodiments, the antibody or antigen-binding fragment thereof that binds to, inhibits and/or neutralizes HIV binds to an epitope or region of gp120 in the second variable loop (V2) and/or the apex of the Env trimer, and competes with or comprises the VH and VL regions of an antibody selected from the group consisting of PG9, PG16, PGC14, PGG14, PGT-142, PGT-143, PGT-144, PGT-145, CHO1, CH59, PGDM1400, CAP256, CAP256-VRC26.08, CAP256-VRC26.09, CAP256-VRC26.25, PCT64-24E, and VRC38.01. In some embodiments, the antibody or antigen-binding fragment thereof binds to an epitope or region of gp120 in the gp120/gp41 interface and competes with or comprises the VH and VL regions of an antibody selected from the group consisting of PGT-151, CAP248-2B, 35O22, 8ANC195, ACS202, VRC34, and VRC34.01. In some embodiments, the antibody or antigen-binding fragment thereof that binds, inhibits, and/or neutralizes HIV binds to an epitope or region of the silent face of gp120 and competes with or comprises the VH and VL regions of an antibody selected from the group consisting of VRC-PG05 and SF12. In some embodiments, the antibody or antigen-binding fragment thereof that binds, inhibits, and/or neutralizes HIV binds to an epitope or region of gp41 in the membrane proximal region (MPER). In some embodiments, the antibody or antigen-binding fragment thereof that binds, inhibits and/or neutralizes HIV binds to an epitope or region of gp41 in the membrane proximal region (MPER) and competes with or comprises the VH and VL regions of an antibody selected from the group consisting of 10E8, 10E8v4, 10E8-5R-100cF, 4E10, DH511.11P, 2F5, 7b2, and LN01. In some embodiments, the antibody or antigen-binding fragment thereof that binds, inhibits and/or neutralizes HIV binds to an epitope or region of the gp41 fusion peptide and competes with or comprises the VH and VL regions of an antibody selected from the group consisting of VRC34 and ACS202. In some embodiments of these methods, after one or more administrations of one or more fusion polypeptides, composite fusion polypeptides, polynucleotides, carriers, liposome complexes (e.g., LNPs), or immunogenic compositions, optionally in combination with one or more additional therapeutic agents, the subject does not exhibit symptoms of HIV or AIDS for at least 3 months, at least 6 months, at least 1 year, at least 2 years, at least 3 years, or longer without antiretroviral therapy (ART). In some embodiments of these methods, after one or more administrations of one or more fusion polypeptides, composite fusion polypeptides, polynucleotides, carriers, liposome complexes (e.g., LNPs), or immunogenic compositions, optionally in combination with one or more additional therapeutic agents, the subject has less than 500 (e.g., less than 400, less than 300, less than 200, less than 100, less than 50) viral load copies/ml blood for at least 3 months, at least 6 months, at least 1 year, at least 2 years, at least 3 years, or longer without antiretroviral therapy (ART).

Also provided is a method for designing a fusion polypeptide capable of eliciting an immune response against one or more viral target antigens, the method comprising: (a) computer identification of one or more sequence conserved regions in a population of polypeptide sequences encoded by viral genes, the population being derived from a population of inter-patient viruses; (b) computer identification of the two most common polypeptide sequences from the one or more conserved regions identified in step a), and generating multivalent polypeptide fragments from these conserved regions; and (c) arranging these polypeptide fragments to reduce or avoid the generation of harmful epitopes at the junctions between the polypeptide fragments. In some embodiments, step (c) comprises reducing or eliminating the junction 9-mers that bind to a specific HLA allele with a predicted IC50 value of less than about 1000 nM or a percentile rank within the top 5% in the population of polypeptide fragments. Also provided is a method for designing a fusion polypeptide capable of eliciting an immune response against one or more viral target antigens, the method comprising: (a) computer identification of one or more sequence conserved regions in a first polypeptide sequence population encoded by a viral gene, the first population being derived from an inter-patient viral population; (b) optionally, computer identification of the two most common polypeptide sequences from the one or more conserved regions identified in step a); and (c) arranging the retained polypeptide fragments into one or more continuous fusion polypeptides so that the connecting portion connecting the polypeptide fragments avoids or reduces the generation of epitopes that can bind to human MHC class I or human MHC class II molecules or have a percentile rank within the top 5% of the polypeptide fragment population, for example, with a predicted binding affinity IC50 value of less than about 1000 nM. In some embodiments, step (c) comprises reducing or eliminating viral polypeptide 9-mers having at least 55% (5 of 9 amino acid residues), such as at least 65% (6 of 9 amino acid residues), such as at least 75% (7 of 9 amino acid residues), such as at least 85% (8 of 9 amino acid residues) amino acid sequence identity with human proteins. In some embodiments, the multivalent polypeptide fragment is a bivalent polypeptide fragment. In some embodiments, the fusion polypeptide design method further includes the step of identifying variant subsequences within one or more sequence conserved regions in a patient population of polypeptide sequences encoded by viral genes using deep sequencing data, for example. In some embodiments, the fusion polypeptide design method further includes the step of identifying the conserved regions of polypeptides encoded by viral genes, so that at least 70% of the variant subsequences within one or more sequence conserved regions in the patient population are within the bivalent polypeptide fragment. In some embodiments, the fusion polypeptide design method further includes the step of shortening the length of the fusion polypeptide, for example, by at least 10%, 15%, 20%, 25%, 30% or more, retaining a polypeptide fragment subsequence containing (i) computer-predicted and (ii) in vitro-confirmed epitopes. Also provided is a method for producing a multivalent antigen, the method comprising constructing a set of multivalent amino acid sequences within a structurally conserved region of a population of viral proteome sequences by a method comprising the following steps: (a) aligning the population of viral proteome sequences; (b) for each sequence in the alignment, generating a set of 9 amino acid subsequences ("9-mers") starting from the N-terminal amino acid, each subsequence overlapping the previous subsequence by eight amino acids, such that each sequence of length 1 in the alignment contains (1-8) 9-mers; (c) calculating the number of amino acid sequences in each sequence in the alignment from position (c)(1) wherein the frequency is calculated as the number of times the unique 9-mer occurs at position i in the alignment divided by the total number of sequences in the alignment; (d) calculating the polyvalent conservation at each position by adding the proportion of sequences in the alignment that contain any of the two or more most common unique 9-mers; (e) generating an alignment of conserved regions by extracting sequences in the alignment that have polyvalent conservation greater than 80% or greater than 90%; and (f) determining the polyvalent conservation of the conserved regions. The frequency of each unique 9-mer pair at each position in the alignment; (g) connecting the 9-mer pairs at adjacent positions in the alignment of the conserved region that share an overlap of eight amino acids; (h) generating a directed acyclic graph in which each 9-mer pair is a node, edges between adjacent nodes are formed by connecting 9-mer pairs in adjacent positions, the weight of each edge equal to the frequency of the downstream 9-mer pair, (h)(1) adding the source node and connecting it to all nodes at the first position, (h)(2) adding the sink node and connecting it to all nodes at the last position, and (h)(3) connecting all The weight is negated; (i) finding the best path from the source node to the sink node in the directed acyclic graph, wherein the best path is defined by the sum of the frequencies of all 9-mer pairs in the directed acyclic graph; (j) if two or more 9-mers at adjacent positions in the best bivalent 9-mer path share an overlap of eight amino acids, a multivalent antigen is constructed by connecting them, thereby generating two or more sequences of connected 9-mers, which together form a multivalent antigen; and (k) optionally, rearranging the polypeptide fragments to reduce or avoid the generation of harmful epitopes at the junctions between the polypeptide fragments. In some embodiments, the multivalent conservation is bivalent conservation, and wherein the multivalent antigen is a bivalent antigen. In some embodiments, in step (a), the conserved regions are further defined by performing one or more of the following steps: (i) removing fragments of less than 35 amino acids in length (e.g., 9 amino acids to 10, 15, 20, 25, 30 or 35 amino acids in length); (ii) removing fragments determined to have less than 90% multivalent (e.g., bivalent) conservation; (iii) removing fragments determined to be weakly immunogenic or non-immunogenic (e.g., as demonstrated in vitro or in vivo); and/or (iv) including additional fragments determined to be immunogenic (e.g., as demonstrated in vitro or in vivo). In some embodiments, the step of rearranging the peptide fragments to reduce or avoid the generation of harmful epitopes is performed by a method comprising one or more of a computer HLA binding analysis and a human proteome cross-recognition analysis. In some embodiments, the fusion polypeptide design method further comprises the step of inserting a linker sequence between one or more adjacent fragments. In some embodiments, the fusion polypeptide design method further comprises improving the multivalent (e.g., bivalent) antigen generated in step (h) by removing connected 9-mers that bind to a specific HLA allele with a predicted IC50 value of less than about 1000 nM or a percentile rank within the top 5% of the polypeptide fragment population. In some embodiments, the method further comprises improving the multivalent (e.g., bivalent) antigen generated in step (h) by removing 9-mers that have at least 55% (5 of 9 amino acid residues), such as at least 65% (6 of 9 amino acid residues), such as at least 75% (7 of 9 amino acid residues), such as at least 85% (8 of 9 amino acid residues) amino acid sequence identity with human peptides or residues facing the same T cell receptor (TCR) as human proteins. In some embodiments, the fusion polypeptide design method further comprises the step of rearranging the polypeptide fragments to reduce or avoid the generation of harmful epitopes at the junctions between the polypeptide fragments. In some embodiments, the step of rearranging the peptide fragments to reduce or avoid the generation of harmful epitopes is performed by a method comprising one or more of a computer HLA binding analysis and a human proteome cross-recognition analysis. In some embodiments, the fusion polypeptide design method further includes, for example, using deep sequencing data to identify variant subsequences within one or more sequence conserved regions in a patient population of a polypeptide sequence encoded by a viral gene. In some embodiments, the fusion polypeptide design method further includes identifying a conserved region of a polypeptide encoded by a viral gene, so that at least 70% of the variant subsequences within one or more sequence conserved regions in a patient population are within a bivalent polypeptide fragment. In some embodiments, the fusion polypeptide design method further includes shortening the length of the fusion polypeptide, for example, by at least 10%, 15%, 20%, 25%, 30% or more, retaining a step of a polypeptide fragment subsequence containing (i) computer prediction and (ii) in vitro confirmed epitopes. With regard to the fusion polypeptide design method, in some embodiments, the one or more viral target antigens are from mammalian viruses, such as human viruses. In some embodiments, the one or more viral target antigens are from a virus selected from the group consisting of human immunodeficiency virus (HIV), hepatitis B virus (HBV), human papillomavirus (HPV), herpes simplex virus (HSV), Ebola virus, Zika virus, and chikungunya virus. In some embodiments, the inter-patient viral population is from a patient population that has not received antiretroviral therapy (ART). In some embodiments, the inter-patient viral population is from a patient population that has received antiretroviral therapy (ART). Also provided is a fusion polypeptide prepared according to the fusion polypeptide design method described herein, wherein the fusion polypeptide triggers an immune response of a mammal, such as a human, to the virus.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG1 shows a six-step workflow for designing fusion polypeptides to elicit an antiviral response.

FIG2 shows a representative method of a population-based vaccine construction approach.

FIG3 illustrates the steps of a conservative walking analysis (CWA) algorithm as described herein.

Figures 4A to 4B. Figure 4A shows how "bivalent conservation" can be determined based on the prevalence of the two most common 9-mers among all considered viral sequences in a population. Figure 4A discloses the sequences corresponding to patients 1 to 10 as SEQ ID NOs 168-169, 169-170, 169, 169, 171-172, and 172-173, respectively, in order of appearance. Figure 4A also discloses "QNLQGQMVH" as SEQ ID NO: 174, "QNIQGQMVH" as SEQ ID NO: 175, and "PNIQGQMVH" as SEQ ID NO: 176. Figure 4B shows how conserved regions can be identified based on the distribution of "bivalent conservation" in 9-mer positions. HIV-1 Gag p24 is used as a representative protein.

Figures 5A to 5C. Figure 5A shows unique 9-mers extracted from aligned natural sequences. Figure 5A discloses SEQ ID NOs: 177-183, respectively, in column order. Figure 5B shows a directed acyclic graph constructed based on 9-mer pair nodes and their connections. Figure 5B discloses "GIIIIIIII" as SEQ ID NO: 180, "AIIIIIIII" as SEQ ID NO: 181, "IIIIIIIIK" as SEQ ID NO: 182, "IIIIIIIIH" as SEQ ID NO: 183 and "IIIIIIIIR" as SEQ ID NO: 184. Figure 5C shows how to connect the 9-mers in the connected 9-mer pairs. When there are two options for connection, the final connection is determined by the prevalence of each connection in the naturally occurring sequence. Figure 5C discloses "GIIIIIIII" as SEQ ID NO:180, "AIIIIIIII" as SEQ ID NO:181, "IIIIIIIIK" as SEQ ID NO:182 and "IIIIIIIIH" as SEQ ID NO:183.

Figure 6 shows the results of human proteome cross-recognition analysis. Figure 6 discloses SEQ ID NOs: 185-188 in column order.

Figure 7 illustrates how polypeptide fragment alignment analysis can reduce or eliminate the potential presentation of deleterious or undesirable epitopes in junction regions.

Figure 8 provides a schematic diagram of a viral vector containing a fusion protein (e.g., SEQ ID NO: 94-101) of immunogen version 1. The fusion polypeptide of immunogen version 1 has twelve conserved regions within HIV-1 Gag, Pol, and Nef ranging in length from 516 to 527 amino acids, which have been rearranged to reduce or minimize overall ligation reactions. A total of four vectors enable a bivalent, heterologous prime/boost vaccine regimen.

Figure 9 provides a flow chart showing the basic method of the method for designing fusion proteins (e.g., SEQ ID NOs: 82-89) of immunogen version 2. A set of 9-mers are selected from the conserved regions and combined to form the fusion polypeptides of immunogen version 2, a subset of immunogen version 1. The sequences and gene regions included in immunogen version 2 are provided in Table E.

Figures 10A to 10D show regions encoding HIV proteins Pol (A-B), Gag (C) and Nef (D) that were selected for immunogen version 2 by combining deep sequencing data and immunogenicity data. Solid horizontal black line = intra-patient conservation (assessed by covering 9-mer variants within patients with bivalent vaccines). Gray horizontal line = inter-patient conservation. Solid vertical black bar = LANL response. White vertical bar = ELISpot response. Horizontal bar (diagonal strip) = region maintained in immunogen version 2.

Figure 11 provides a schematic diagram of a viral vector containing a fusion protein (e.g., SEQ ID NO: 82-89) of immunogen version 2. The fusion polypeptide of immunogen version 2 has eight conserved regions within HIV-1 Gag, Pol and Nef ranging in length from 351 to 365 amino acids, which have been rearranged to reduce or minimize overall ligation reactions. A total of four vectors enable a bivalent, heterologous prime/boost vaccine regimen.

Figures 12A-12B demonstrate that as the size of the fusion polypeptide of immunogen version 1 decreases with the size of the fusion polypeptide of immunogen version 2, the median response remains stable. 12A. The ability of the fusion polypeptide of immunogen version 1 to induce a T cell response was tested in vitro on a total of 93 donor PBMCs. The dotted line represents the median number of responses identified. Immunogen version 1 detected an immune response in 73 of the 93 participants (78.49%). 12B. Computer assessment of the ability of the fusion polypeptide of immunogen 2 to induce a T cell response in the same participants. The dotted line represents the median number of responses identified. Immunogen version 2 detected an immune response in 71 of the 93 participants (76.34%).

Figure 13 provides a flow chart showing the basic method of the method for designing fusion proteins (e.g., SEQ ID NOs: 90-93) of immunogen version 3. A set of 9-mers are selected from the conserved regions and combined to form the fusion polypeptides of immunogen version 3, a subset of immunogen version 1. The sequences and gene regions included in immunogen version 3 are provided in Table E.

Figures 14A to 14D show regions encoding HIV proteins Pol (A-B), Gag (C) and Nef (D) that were selected for immunogen version 3 by combining deep sequencing data and immunogenicity data. Solid horizontal black line = intra-patient conservation (assessed by covering 9-mer variants within patients with bivalent vaccine). Gray horizontal line = inter-patient conservation. Solid vertical black bar = LANL response. Gray vertical bar = ELISpot response. Horizontal open column = region maintained in improved immunogen.

Figure 15 provides a schematic diagram of a viral vector containing a fusion protein of immunogen version 3 (e.g., SEQ ID NO: 90-93). Schematic diagram of immunogen version 3 construct. The fusion polypeptide of immunogen version 3 has four conserved regions within HIV-1 Gag, Pol and Nef with lengths ranging from 391 to 394 amino acids, which have been rearranged to minimize overall ligation reactions. A total of two vectors enable a bivalent, heterologous prime/boost vaccine regimen.

FIG. 16 shows polypeptide fragments encoded by the HIV-1 Gag gene used in the fusion polypeptide constructs described herein. The Gag HIV-1 HXB2 reference polypeptide (SEQ ID NO: 1) sequence is underlined. Amino acid residues corresponding to residues 54-146 and 370-500 of the Gag HIV-1 HXB2 reference polypeptide and subsequences and fragments thereof are not included in the polypeptide fragments described herein. FIG. 16 discloses SEQ ID NOs 1 and 4-7, respectively, in the order of appearance.

Figure 17A to Figure 17C show the polypeptide fragments encoded by HIV-1Pol gene used in the fusion polypeptide construct described herein.Pol HIV-1 HXB2 reference polypeptide (SEQ ID NO:2) sequence is underlined.Amino acid residues corresponding to Pol HIV-1HXB2 reference polypeptide residues 1-55, 118-128, 321-366, 432-541, 607-682, 709-746, 828-839 and 921-931 and their subsequences and fragments are not included in the polypeptide fragments described herein.Figure 17A to Figure 17C disclose SEQ ID NO 2, 8-21, 24-25, 189, 23 and 26-27 respectively in the order of appearance.

Figure 18 shows the polypeptide fragments encoded by the HIV-1 Nef gene used in the fusion polypeptide constructs described herein. The Nef HIV-1 HXB2 reference polypeptide (SEQ ID NO:3) sequence with tryptophan (W) at position 124 is underlined. The amino acid residues corresponding to Nef HIV-1 HXB2 reference polypeptide residues 1-63, 100-116 and 149-206 and their subsequences and fragments are not included in the polypeptide fragments described herein. Figure 18 discloses SEQ ID NO3, 30-31, 28-29 and 32-33 in the order of appearance, respectively.

Figure 19 shows a schematic diagram of a composite fusion polypeptide containing HIV-1 immunogen version 1 polypeptide sequences (e.g., SEQ ID NOs: 105, 107, 109, 111, and 206-209). The composite fusion polypeptide depicted has 12 conserved regions within HIV-1 Gag, Pol, and Nef, which have been rearranged to minimize overall ligation reactions. All four vectors are used to transduce monocyte-derived dendritic cells (moDCs) in CD8+ T cell primary immunization assays and are co-labeled as "post-vaccination" in assays corresponding to these polypeptide sequences. Figure 19 discloses "AAA" as SEQ ID NO: 48 and discloses "AAY" as SEQ ID NO: 49.

Figures 20A to 20B. Ad5 vectors expressing composite fusion polypeptides of SEQ ID NO: 105, 107, 109 or 111 were used to transduce moDC to assess transgene expression and transduction efficiency. Expression efficiency was assessed by Gag p24 ELISA (N = 2) (Figure 20A). The y-axis represents the concentration of Gag p24 (pg/ml) detected in moDC lysates on day 3 after transduction with an Ad5 vector (■) expressing a composite fusion polypeptide of SEQ ID NO: 105, 107, 109 or 111 or an empty vector control (▲) at a multiplicity of infection (MOI) of 500. Figure 20B shows representative moDC transduction efficiency on day 3 after transduction with an Ad5 viral vector expressing GFP at an MOI of 500 in N = 36 human donors. The proportion of cells expressing GFP obtained by flow cytometry is shown on the y-axis. The x-axis represents vaccine immunogen constructs of the conserved regions of SEQ ID NO: 105, 107, 109 and 111 (■) or empty vector control (▲) or untransduced (·) at a multiplicity of infection (MOI) of 500. Transduction efficiency was determined by flow cytometry assessment of the percentage of GFP expression of transduced moDCs (N=36). The amino acid sequences are provided in Table F.

Figure 21 shows a schematic diagram of a fusion polypeptide containing HIV-1 immunogen version 2 fusion polypeptide (SEQ ID NO: 82-89). The composite fusion polypeptide depicted has 12 conserved regions within HIV-1 Gag, Pol and Nef that have been rearranged to minimize overall ligation reactions. All eight vectors were used to transduce moDC in a CD8+ T cell priming assay and were collectively labeled "post-vaccination" in assays using these sequences. Figure 21 discloses "AAA" as SEQ ID NO: 48, "QEE" as SEQ ID NO: 51, "KILQEE" as SEQ ID NO: 198 and "AAQEE" as SEQ ID NO: 199.

Figure 22A to Figure 22B. Ad5 vectors expressing composite fusion polypeptides of SEQ ID NO: 82-89 were used to transduce moDC to assess transgene expression and transduction efficiency. Expression efficiency was assessed by Gag p24 ELISA (N = 2) (Figure 22A). The y-axis represents the concentration of Gag p24 (pg/ml) detected in moDC lysates on the 3rd day after transduction with an Ad5 vector (■) expressing a composite fusion polypeptide of SEQ ID NO: 82-89 or an empty vector control (▲) at a multiplicity of infection (MOI) of 500. Figure 22B shows a representative moDC transduction efficiency on the 3rd day after transduction with an MOI of 500 using an Ad5 viral vector expressing GFP in N = 3 human donors. The proportion of cells expressing GFP obtained by flow cytometry is shown on the y-axis. The x-axis represents vaccine immunogen constructs of the conserved regions of SEQ ID NOs: 82-89 (■) or empty vector control (▲) or untransduced (·) at a multiplicity of infection (MOI) of 500. The amino acid sequences are provided in Table E.

Figure 23 shows a schematic diagram of fusion polypeptides containing HIV-1 immunogen version 3 fusion polypeptides (SEQ ID NOs: 90-93). All four vectors were used to transduce moDCs in a CD8+ T cell priming assay and are collectively labeled "post-vaccination" in assays using these sequences. Figure 23 discloses "QEE" as SEQ ID NO: 51, "AAQEE" as SEQ ID NO: 199 and "AAY" as SEQ ID NO: 49.

Figure 24A to Figure 24B. Ad5 vectors expressing composite fusion polypeptides of SEQ ID NO: 90-93 were used to transduce moDC to evaluate the expression and transduction efficiency of the transgene. The expression efficiency was evaluated by Gag p24 ELISA (N = 2) (Figure 24A). The y-axis represents the concentration of Gag p24 (pg / ml) detected in moDC lysates on the third day after transduction with an Ad5 vector (■) expressing a composite fusion polypeptide of SEQ ID NO: 82-89 or an empty vector control (▲) at an infection multiplicity (MOI) of 500. Figure 24B shows the representative moDC transduction efficiency on the third day after transduction with an Ad5 viral vector expressing GFP at an MOI of 500 in N = 3 human donors. The proportion of cells expressing GFP obtained by flow cytometry is shown on the y-axis. The x-axis represents vaccine immunogen constructs of the conserved regions of SEQ ID NO: 90-93 (■) or empty vector control (▲) or untransduced (·) at a multiplicity of infection (MOI) of 500. The amino acid sequences are provided in Table E.

Figure 25 shows a schematic diagram of fusion polypeptides containing HIV-1 immunogen version 1 fusion polypeptide sequences. The fusion polypeptides of SEQ ID NOs:94 and 95 represent bivalent sequences within HIV-1 Gag, Pol, and Nef; SEQ ID NOs:96 and 97 represent bivalent sequences within HIV-1 Pol and Nef. The fusion polypeptides of SEQ ID NOs:94-97 can be combined to form a prime sequence. The fusion polypeptides of SEQ ID NOs:98 and 99 represent bivalent sequences within HIV-1 Gag, Pol, and Nef. The fusion polypeptides of SEQ ID NOs:100 and 101 represent bivalent sequences within HIV-1 Pol and Nef. The fusion polypeptides of SEQ ID NOs:98-101 can be combined to form a boost sequence that can be used after priming with the fusion polypeptides of SEQ ID NOs:94-97. The bivalent sequence was designed to cover >80% of the inter-patient diversity in viral sequences, and the gene segments used to generate the polypeptide fusion constructs were rearranged to minimize the generation of de novo epitopes reactive with human proteins and to minimize the enhancement of ligation reactions in the prime boost sequence. Figure 25 discloses "AAA" as SEQ ID NO:48 and "AAY" as SEQ ID NO:49.

Figure 26 shows the immunization scheme in Balb/c mice. Mice were immunized intramuscularly (IM) with 1×10 ⁹ PFU of Ad5 vector expressing HIV-1 fusion polypeptide sequence in the right and left quadriceps as indicated. Splenocytes were collected on day 16 after immunization and responses to HIV Gag, Pol and Nef antigens were measured by IFN-γ ELISpot assay.

Figures 27A to 27B show the results of immunogenicity testing in Balb/c mice by IFN-γ ELISpot with peptides stimulated with any of the following: HIV-1 Gag (i and ii), Nef (vii and viii) (Figure 27A), Pol (Protease/RT) (iii and iv) or Pol (Integrase) (v and vi) (Figure 27B) peptides. The fusion polypeptide of SEQ ID NO: 94-95 (Seq 94, Seq 95) was used as a bivalent priming sequence. The fusion polypeptide of SEQ ID NO: 98-99 (Seq 98, Seq 99) was used as a bivalent boosting sequence. The Y-axis represents the size of the IFN-γ response to stimulation with a specific peptide pool, expressed as the number of spot-forming colonies (SFC) per ¹⁰⁶ splenocytes. Peptide-specific values were obtained by subtracting controls without peptide stimulation to exclude nonspecific responses. The X-axis represents the individual vaccine constructs used for in vivo priming to study their peptide-specific responses. All vectors were immunogenic, inducing robust responses to HIV-1 Gag responses, weaker but detectable responses to Pol proteins (protease, RT, and integrase). No responses to HIV-Nef were detected in this model, which may be due to the previously described immunodominant pattern of HIV-1 Gag epitopes in Balb/c mice and reflects the lack of Nef epitopes that can be presented in Balb/c mice.

Figure 28 shows the results of immunogenicity testing in Balb/c mice by IFN-γ ELISpot with peptides stimulated with any of the following: HIV-1 Pol (protease and RT) (i and ii), Pol (integrase) (iii and iv) or Nef (v and vi) peptides. The fusion polypeptides of SEQ ID NO: 96-97 (Seq 96, Seq 97) were used as bivalent priming sequences. The fusion polypeptides of SEQ ID NO: 100-101 (Seq 100, Seq 101) were used as bivalent boosting sequences. The Y-axis represents the size of the IFN-γ response to stimulation with a specific peptide pool, expressed as the number of spot-forming colonies (SFC) per 10 ⁶ splenocytes. Peptide-specific values were obtained by subtracting controls without peptide stimulation to exclude nonspecific responses. The X-axis represents individual vaccine constructs used for in vivo priming to study their peptide-specific responses. All vectors were immunogenic, inducing robust responses to HIV-1Pol (particularly protease and RT peptides), weaker responses to integrase peptides that could be detected. No responses to HIV-Nef were detected in this model, which may be due to the previously described immunodominance pattern of HIV-1 Gag epitopes in Balb/c mice and reflects the lack of Nef epitopes that can be presented in Balb/c mice.

Figure 29 shows a representative immunization scheme in Balb/c mice. As shown, mice were immunized intramuscularly (IM) in the right and left quadriceps with Ad5 vectors expressing HIV-1 sequences at 1×10 ⁹ PFU. The immunogenicity of the individual vectors (i) was tested as a single dose to prime the response, with spleens harvested on day 16 for analysis. The combined vectors (ii) were tested according to a homologous vector prime-boost scheme, with boosting on day 29 and spleens harvested on day 36 for analysis. Responses to Gag, Pol and Nef antigens were determined by IFN-γ ELISpot assay and ICS/flow cytometry.

Figures 30A-30B show the immunogenicity evaluated by immunization with either a single Ad5 vector alone (A) or a homologous Ad5 vector prime-boost combination (B). Seq 94-F2A-95 (tPA-SEQ ID NO: 105) and Seq 98-F2A-99 (tPA-SEQ ID NO: 109) were used as prime-boost pairs. The immunogenicity of the vectors was tested in Balb/c mice by IFN-γ ELISpot with peptides stimulated with either: HIV-1 Gag, (i) and (ii); Pol (Protease/RT, (iii) and (iv); Pol (Integrase, (v) and (vi); or Nef (vii and viii) peptides. The Y-axis represents the magnitude of the IFN-γ response to stimulation with a specific peptide pool, expressed as the number of spot-forming colonies (SFC) per ¹⁰⁶ splenocytes. Peptide-specific values were obtained by subtracting the control without peptide stimulation to exclude nonspecific responses. The X-axis represents the individual vaccine constructs used for in vivo priming to study their peptide-specific responses. All vectors were immunogenic, inducing robust responses to HIV-1 Gag responses, weaker but detectable responses to Pol proteins (Protease, RT and Integrase). No responses to HIV-Nef were detected in this model, which may be due to the previously described HIV-1 in Balb/c mice. The immunodominant pattern of the Gag epitope reflects the lack of Nef epitopes that can be presented in Balb/c mice. The response was enhanced by homologous boosting with an Ad5 vector expressing a booster sequence.

Figures 31A-31B show the immunogenicity evaluated by immunization with either a single Ad5 vector prime alone or a homologous Ad5 vector prime-boost combination. Seq 96-F2A-97 (tPA-SEQ ID NO: 107) and Seq100-F2A-101 (tPA-SEQ ID NO: 111) were used as the prime-boost pair. The immunogenicity of the vectors was tested in Balb/c mice by IFN-γ ELISpot with peptides stimulated with either: HIV-1 Pol (protease/RT, (i) and (ii); Pol (integrase, (iii) and (iv); or Nef (v and vi) peptides. The Y-axis represents the magnitude of the IFN-γ response to stimulation with a particular peptide pool, expressed as the number of spot-forming colonies (SFC) per ¹⁰⁶ splenocytes. Peptide-specific values were obtained by subtracting controls without peptide stimulation to exclude nonspecific responses. The X-axis represents the individual vaccine constructs used for in vivo priming to study their peptide-specific responses. All vectors were immunogenic, inducing robust responses to HIV-1 Pol (particularly protease and RT peptides), and detectable weaker responses to integrase peptides. The responses observed for protease and RT were weaker than those previously observed for Seq 96 and Seq 96 when not combined. 97. However, the immunogenic response was enhanced when Seq96-F2A-97 and Seq100-F2A-101 were administered sequentially. No response to HIV-Nef was detected in this model, which may be due to the previously described immunodominant pattern of HIV-1 Gag epitopes in Balb/c mice and reflects the lack of Nef epitopes that can be presented in Balb/c mice.

Figures 32A to 32C show HIV-1 Gag immunogenicity by intracellular cytokine staining (ICS) after vaccination with a single vector Seq 94-F2A-95 (tPA-SEQ ID NO: 105) or Seq98-F2A-99 (tPA-SEQ ID NO: 109) and homologous priming-boosting. The Y axis represents the proportion of CD8+ (Figure 32A i, ii and Figure 32C iii) or CD4+ (Figure 32Biv, v and Figure 32C vi) T cells that express HIV-Gag-specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α (as a single cytokine or a combination of cytokines), as shown on the X axis. HIV-Gag-specific values are obtained by subtracting controls without peptide stimulation to exclude nonspecific responses. Strong CD4+ and CD8+ T cell responses were generated in response to vaccination, confirming the most robust multifunctionality in CD8+ T cells. Homologous prime-boost enhances the polyfunctionality of CD8+ T cell responses.

Figures 33A to 33C show HIV-1Pol (protease and RT) immunogenicity by ICS after vaccination with single vectors Seq 94-F2A-95 (tPA-SEQ ID NO: 105) or Seq98-F2A-99 (tPA-SEQ ID NO: 109) and homologous priming-boosting. The Y axis represents the proportion of CD8+ (Figure 33A i, ii and Figure 33C iii) or CD4+ (Figure 33B iv, v and Figure 33C vi) T cells that express HIV-Pol (protease and RT) specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α (as individual cytokines or combinations of cytokines), as shown on the X axis. HIV-Pol (protease and RT) specific values were obtained by subtracting controls without peptide stimulation to exclude nonspecific responses. CD4+ and CD8+ T cell responses were generated in response to vaccination. These responses are weaker than Gag responses and tend to be monofunctional, with limited enhancement.

Figures 34A to 34C show HIV-1Pol (integrase) immunogenicity by ICS after vaccination with a single vector Seq 94-F2A-95 (tPA-SEQ ID NO: 105) or Seq98-F2A-99 (tPA-SEQ ID NO: 109) and homologous priming-boosting. The Y axis represents the proportion of CD8+ (Figure 34A i, ii and Figure 34C iii) or CD4+ (Figure 34B iv, v and Figure 34Cvi) T cells that express HIV-Pol (integrase) specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α (as individual cytokines or combinations of cytokines), as shown on the X axis. HIV-Pol (integrase) specific values are obtained by subtracting controls without peptide stimulation to exclude nonspecific responses. CD4+ and CD8+ T cell responses were generated in response to vaccination. These responses are weaker than Gag responses and tend to be monofunctional, with limited enhancement.

Figures 35A to 35C show HIV-1 Nef immunogenicity by ICS after vaccination with a single vector Seq 94-F2A-95 (tPA-SEQ ID NO: 105) or Seq98-F2A-99 (tPA-SEQ ID NO: 109) and homologous priming-boosting. The Y axis represents the proportion of CD8+ (Figure 35A i, ii and Figure 35C iii) or CD4+ (Figure 35B iv, v and Figure 35C vi) T cells that express HIV-Nef-specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α (as a combination of individual cytokines or cytokines), as shown on the X axis. HIV-1 Nef-specific values were obtained by subtracting controls without peptide stimulation to exclude nonspecific responses. Very low proportions of CD4+ and CD8+ T cell responses were generated in response to vaccination. These responses are weaker than Gag responses and tend to be monofunctional, with limited enhancement.

Figures 36A to 36C show HIV-1Pol (protease and RT) immunogenicity by ICS after vaccination with single vectors Seq 96-F2A-97 (tPA-SEQ ID NO: 107) and Seq100-F2A-101 (tPA-SEQ ID NO: 111) and homologous vector priming-boosting. The Y axis represents the proportion of CD8+ (Figure 36A i, ii and Figure 36C iii) or CD4+ (Figure 36Biv, v and Figure 36C vi) T cells that express HIV-Pol (protease and RT) specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α (as individual cytokines or combinations of cytokines), as shown on the X axis. HIV-1Pol (protease and RT) specific values were obtained by subtracting controls without peptide stimulation to exclude nonspecific responses. CD4+ and CD8+ responses were generated in response to vaccination. Seq 100-F2A-101 (tPA-SEQ ID NO: 111) showed strong immunogenicity with multifunctionality (production of ≥ 2 cytokines). Homologous vector prime-boost with vector expressing fusion polypeptide enhanced CD4+ and CD8+ T cell responses.

Figures 37A to 37C show HIV-1Pol (integrase) immunogenicity by ICS after vaccination with single vectors Seq 96-F2A-97 (tPA-SEQ ID NO: 107) and Seq100-F2A-101 (tPA-SEQ ID NO: 111) and homologous vector priming-boosting. The Y axis represents the proportion of CD8+ (Figure 37A i, ii and Figure 37C iii) or CD4+ (Figure 37B iv, v and Figure 37C vi) T cells that express HIV-Pol (integrase) specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α (as individual cytokines or combinations of cytokines), as shown on the X axis. HIV-1Pol (integrase) specific values are obtained by subtracting controls without peptide stimulation to exclude nonspecific responses. CD4+ and CD8+ responses were generated in response to vaccination. Seq 100-F2A-101 (tPA-SEQ ID NO: 111) showed strong immunogenicity with multifunctionality (production of ≥ 2 cytokines). Homologous vector prime-boost with vector expressing fusion polypeptide enhanced CD4+ and CD8+ T cell responses.

Figures 38A to 38C show HIV-1 Nef immunogenicity by ICS after vaccination with single vectors Seq 96-F2A-97 (tPA-SEQ ID NO: 107) and Seq100-F2A-101 (tPA-SEQ ID NO: 111) and homologous vector priming-boosting. The Y axis represents the proportion of CD8+ (Figure 38A i, ii and Figure 38C iii) or CD4+ (Figure 38B iv, v and Figure 38Cvi) T cells, which express HIV-Nef-specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α (as a combination of individual cytokines or cytokines), as shown on the X axis. HIV-1 Nef-specific values are obtained by subtracting controls without peptide stimulation to exclude nonspecific responses. Low levels of CD4+ and CD8+ T cell responses were generated in response to vaccination, and more responses were observed in CD4 T cells. Seq 100-F2A-101 (tPA-SEQ ID NO: 111) demonstrated and induced major monokine production. Homologous vector prime-boost with vector expressing fusion polypeptide enhanced CD4+ and CD8+ T cell responses.

Figure 39 provides a schematic diagram of the protocol established for the moDC-T cell priming assays used to test the immunogenicity of all conserved region vaccine constructs followed by individual epitope mapping using a 384-well ELISpot assay.

Figure 40 provides a summary of the breadth of responses in ex vivo analysis of PBMCs from N = 93 participants after in vitro priming with moDC. The heat map represents the breadth of T cell responses to Gag, Pol and Nef conserved antigens after in vitro priming with Ad5-empty vector MOI 500 (before vaccine) or Ad5 viral vectors expressing SEQ ID NO: 105, 107, 109 and 111 (MOI = 500, respectively). Each matching row in the heat map represents a response from a single participant, and the breadth of the response is classified as 0, 1-3, 4-6, 7-9, 10-12 or 13-16. As described in detail in Example 9, a positive ELISpot response is defined as >3 times the background level.

Figure 41 shows characterization of the breadth of immune responses targeting HIV-1 Gag, Pol, and Nef antigens following priming with moDC transduced with Ad5 viral vectors expressing either empty vector (pre-vaccine) or conserved region vaccines (SEQ ID NOs: 105, 107, 109, and 111, each at MOI=500 (post-vaccine)) in N=93 participants. Also listed are the fractions of participants that exhibited responses to ≥3 or 0 epitopes in each antigen following in vitro priming with the vaccine immunogen sequences. Positive ELISpot responses were defined as >3 times background levels. Each point represents one donor. Wilcoxon matched pairs signed rank test ****p<0.0001.

Figure 42 shows the breadth of responses to Gag (·), Pol (▲) and Nef (▼), defined as the number of newly recognized peptides assessed by IFN-γ ELISpot assay (excluding pre-existing baseline responses) at day 10 after co-culturing PBMCs with autologous moDCs transduced with Ad5 vaccine vectors expressing conserved region constructs (SEQ ID NOs: 105, 107, 109 and 111, each at MOI = 500). Each point represents one donor. The median with interquartile range is shown.

Figure 43A to Figure 43B show the results of in vitro HIV-1 virus inhibition assay staining for Gag-p24 in target cells. Autologous CD4+ T cells were infected in vitro with HIV-1BaL, cultured alone, or cultured for 3 days in the presence of CFSE-labeled CD8+ T cells primed with vaccine or empty vector, and analyzed for infection using flow cytometry. Representative flow cytometry diagrams illustrate the gating strategy for CD4+ T cells (HIV-1 Gag+ cells with downregulated surface CD4 expression) infected with Gag p24+ in target cells (CFSE-CD8- cells).

Figures 44A to 44B show the fraction of HIV-1 Gag+CD4-T cells remaining after 3 days of co-culture with enriched CD8+ T cells, which were obtained after primary immunization with vaccines (SEQ ID NO: 105, 107, 109 and 111 or empty vector control, each with MOI = 500), where N = 51 participants were standardized to infect cultured CD4+ T cells in the absence of CD8+ T cells. Depending on cell availability, each condition was completed in technical replicates or triplicates. The correlation between residual Gag+ cell % (Figure 44A) and total response breadth, Gag response breadth and Pol response breadth (Figure 44B) is also shown. Correlation was assessed by a two-sided Spearman rank correlation test without Bonferroni adjustment.

Figures 45A-45B show the breadth of responses to Gag, Pol and Nef assessed by IFN-γ ELISpot assay at day 10 after co-culturing PBMCs with autologous moDCs transduced with Ad5 vaccine vectors expressing conserved region constructs SEQ ID NOs: 82-89 (Figure 45A) and SEQ ID NOs: 90-93 (Figure 45B), each at MOI = 500. Each point represents one donor. The median with interquartile range is shown.

Figure 46 provides a schematic diagram of the prime-boost immunization scheme with arenavirus vectors in non-human primates (NHPs). Healthy rhesus macaques from India were immunized with arenavirus vectors by the intramuscular (IM) route. Vectors expressing Gag and Env (TT2 (replication-attenuated Pichinde virus) and TT1 (replication-attenuated LCMV)) were administered to the left quadriceps, while vectors expressing Pol (TT2 and TT1) were administered to the right quadriceps. The doses administered were as follows: 1×10 ⁶ replication-competent viral particles (RCV) of TT2 Gag, Env, and Pol1/Pol2 vectors, 4×10 ⁶ RCVs of TT1 Gag, Env, and 2×10 ⁶ RCVs of TT1 Pol1/Pol2. In the placebo group, NHPs were administered a placebo buffer solution consisting of 10 mM HEPES, 150 mM NaCl, 20 mM glycine, and 0.1% rhesus serum albumin. Responses to Gag, Env and Pol antigens were measured by IFN-γ ELISpot assay.

FIG. 47A-B. 47A. Time course of total responses to Gag, Env and Pol assessed by IFN-γ ELISpot of PBMCs isolated from NHP peripheral blood at two four-week intervals after the first vaccine dose up to week 32. Median values with interquartile ranges are shown. 47B. NHP responses in FIG. 47A were classified as moderate or high responders based on the magnitude of the peak IFN-γ-ELISpot response below or above 1000 SFU/10 ⁶ PBMCs, respectively. Each line represents one animal that received the arenavirus vaccine vector. Peak responses after each immunization remained constant in subsequent boosts.

Figures 48A to 48D show the magnitude of the total response (A) to Gag (B), Env (C) and Pol (D) assessed by IFN-γ ELISpot of PBMCs isolated from peripheral blood of NHPs two weeks after vaccine doses 1, 2, 3 and 4. The threshold for positive responses is indicated by dashed lines and is set to the observation of at least 50 SFU/10 ⁶ PBMCs for Gag, Env and Pol, and 150 SFU/10 ⁶ PBMCs for total SIV-specific responses. Each symbol represents one NHP. The median with interquartile range is shown. After four doses of heterologous vaccine, positive responses to Gag, Env and Pol were observed in at least 21 of 24 NHPs (response rate greater than or equal to 87.5%). The magnitude of the Gag and Pol responses observed after dose 2 (TT1) and dose 3 (TT2) remained stable in each subsequent vaccine boost.

Figure 49A to Figure 49D show the total SIV (A), Gag (B), Env (C) and Pol (D) specific IFN-γ response breadth 2 weeks after vaccine booster dose 2 (triangle), dose 3 (square) and dose 4 (diamond). Statistical analysis was performed by Wilcoxon paired signed rank test. Data are expressed as median ± interquartile range (IQR).

Figure 50A to Figure 50C show the time course of plasma SIV viral load in (A) week 0-40 after attack; (B) peak viral load in week 2 after attack; (C) set point viral load measured in week 10-40 after attack. The placebo group is shown as a solid triangle, and the TT2/TT1 vaccine group is shown as a solid circle. Data are expressed as median ± SEM. By Mann-Whitney t test, *p<0.05 and **p<0.01 in B and C. Median viral load (VL) is shown above each group in Figure B and Figure C.

Figure 51 shows immunoblot analysis of replication attenuated arenavirus vectors. Transgenic expression of Gag/Nef/Pol fusion polypeptides from raw materials (p1) of replication attenuated LCMV and replication attenuated PICV vectors was determined by immunoblot staining for Gag epitope p24 (mAb anti-HIV1 p24; Abeam). Whole cell lysates from three biological replicates (1, 2, 3) were analyzed. TT1 = replication attenuated LCMV; TT2 = replication attenuated PICV. GNP = Gag/Nef/Pol; PN = Pol/Nef. TT1-HIV-GNP1/PN1 (SEQ ID NOs: 98 and 100); TT1-HIV-GNP2/PN2 (SEQ ID NOs: 99 and 101); TT2-HIV-GNP1/PN1 (SEQ ID NOs: 82 and 86); TT2-HIV-GNP2/PN2 (SEQ ID NOs: 83 and 87).

Figure 52 shows immunoblot analysis of replication attenuated arenavirus vectors. Transgenic expression of Gag/Nef/Pol from raw material (p1) of replication attenuated LCMV and replication attenuated PICV HIV Immunogen 1 vectors was determined by immunoblot staining for Gag epitope p24 (mAb anti-HIV1 p24; Abeam). Whole cell lysates from three biological replicates (1, 2, 3) were analyzed. TT1 = replication attenuated LCMV; TT2 = replication attenuated PICV. GNP = Gag/Nef/Pol; PN = Pol/Nef.

Figure 53 shows transgene stability analysis for TT1-HIV-GNP1/PN1 (a transgene encoding a fusion polypeptide of SEQ ID NO: 98 and 100). Transgene PCR results for 4 biological replicates (1-4) and the indicated passage levels are shown. The last passage showing ≥50% full-length transgene was visually assessed.

Figure 54 shows transgene stability analysis of TT1-HIV-GNP2/PN2 (a transgene encoding a fusion polypeptide of SEQ ID NO: 99 and 101). Transgene PCR results for 3 biological replicates (1-3) and the indicated passage levels are shown. The last passage showing ≥50% full-length transgene was visually assessed.

Figure 55 shows transgene stability analysis for TT2-HIV-GNP1/PN1 (with transgenes encoding fusion polypeptides SEQ ID NOs: 94 and 95). Transgene PCR results for 3 biological replicates (1-3) and the indicated passage levels are shown. The last passage showing ≥50% full-length transgene was visually assessed.

Figure 56 shows transgene stability analysis of TT2-HIV-GNP2/PN2 (with transgenes encoding fusion polypeptides SEQ ID NOs: 95 and 97). Transgene PCR results for 3 biological replicates (1-3) and the indicated passage levels are shown. Passages were interrupted at passage level 4. The (approximately) last passage showing ≥50% full-length transgene was visually assessed.

Figure 57 shows immunoblot analysis of replication attenuated arenavirus vectors. Transgenic expression of Gag/Pol from raw materials (P1) and BDS equivalent passages (P4) of replication attenuated LCMV and replication attenuated PICV HIV Immunogen 2 vectors was determined by immunoblot staining for the Gag epitope p24 (mAb anti-HIV1 p24; Abeam). Whole cell lysates of biological replicates (1, 2, 3, 4 of TT1-HIV(C2)-GP1/PN1; 1, 2 of TT1-HIV(C2)-GP2/PN2) or representative samples (TT2-HIV(C2)-GP1/PN1 and TT2-HIV(C2)-GP2/PN2) were analyzed. TT1 = replication attenuated LCMV; TT2 = replication attenuated PICV. GP = Gag/Pol; PN = Pol/Nef. Control = Positive (+) control represents cell lysates infected with TT1-HIV immunogen 2 or TT2-HIV immunogen 2; negative (-) control represents uninfected cells.

Figure 58 shows the transgenic stability analysis of TT1-HIV (C2) -GP1 / PN1. A represents the transgenic PCR results of 5 biological replicates (1-5) and the passage levels shown. The expected sizes of the full-length PCR products are 1359bp (LCMV-GP1 NP fragment) and 1366bp (LCMV-PN1 GP fragment) respectively. Visually evaluate the last passage showing ≥ 50% full-length transgenic.

Figure 59 shows the transgenic stability analysis of TT1-HIV (C2) -GNP2 / PN2. A represents the transgenic PCR results of 4 biological replicates (1-4) and the level of passage shown. The expected size of the full-length PCR product is 1344bp (LCMV-GP2 NP fragment) and 1364bp (LCMV-PN2 GP fragment) respectively. Visually evaluate the last passage showing ≥ 50% full-length transgenic.

Figure 60 shows the transgenic stability analysis of TT2-HIV (C2) -GP1/PN1. A represents the transgenic PCR results of 4 biological replicates (1-3 and 9) and the level of passage shown. The expected size of the full-length PCR product is 1456bp (PICV-GP1 NP fragment) and 1496bp (PICV-PN1GP fragment) respectively. Visually evaluate the last passage showing ≥50% full-length transgenic.

Figure 61 shows the transgenic stability analysis of TT2-HIV (C2) -GP2/PN2. Shown are the transgenic PCR results for 3 biological replicates (1-3) and the level of passage shown. The expected size of the full-length PCR product is 1450bp (PICV-GP2 NP fragment) and 1505bp (PICV-PN2 GP fragment) respectively. The passage is interrupted at level 6 of passage. Visually evaluate the (approximately) last passage showing ≥50% full-length transgenic.

Figure 62 shows a schematic diagram of a non-human primate study evaluating the combination of the attenuated PICV/LCMV arenavirus primary-boost regimen and the combination of immunomodulators in the TT2/TT1 vaccine replication. Each group has 13 rhesus monkeys. The vaccine refers to the alternating administration of TT2 (solid circles) and TT1 (open circles). After the vaccine is administered, the checkpoint inhibitor αPD1 antibody (triangle) and αCTLA4 antibody (square) are immediately administered. FLT3L-Fc FLT3 agonist (black line) is administered one week before each vaccine dose.

Figure 63 shows the overall response kinetics to Gag, Env and Pol assessed by IFN-γ ELISpot of PBMCs isolated from NHP peripheral blood at two-week intervals after the first vaccine dose until week 16. Median values with interquartile ranges are shown. Statistical analysis was performed by two-way ANOVA with repeated measures and Dunnett's post-test. *p<0.05, **p<0.01, ***p<0.001 for comparison of the combination group to vaccine alone.

Figure 64A to Figure 64D show the (A) total SIV, (B) Gag, (C) Env and (D) Pol-specific IFN-γ response breadth 2 weeks after the last vaccine dose of PBMC. Vector (Vx) is grouped in circles only, Vx+αPD1 is grouped in triangles, Vx+αCTLA4 is grouped in squares, and Vx+Flt3L is grouped in diamonds. Statistical analysis was performed by Kruskal-Wallis test and Dunn's post-test. Data are expressed as median ± IQR. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

DETAILED DESCRIPTION

1. Introduction

This article describes an antiviral vaccine immunodesign method that incorporates intra-patient diversity by using deep sequence data to assess viral quasispecies and determine the level of intra-individual viral diversity. We developed an algorithm that takes into account inter-patient and intra-patient viral diversity in the design of vaccine immunogens and the immunogenicity of vaccine sequences. Understanding host viral diversity and antigen processing and presentation as well as T cell priming not only ensures that vaccine immunogens produce a large number of antigen-specific T cells, but also ensures that antigen-specific T cells with cytotoxic activity are produced. In the design of antiviral vaccine immunogens, we combined the calculated computer analysis of viral sequences and binding specificity with in vitro experimental immunology. We established an in vitro vaccine test model that enables us to identify conserved regions that produce the strongest responses in a large population. This method enables us to identify new epitopes that have not been previously recognized within conserved regions. This immunogenicity data enables the development of highly conserved, highly immunogenic vaccine immunogens that can be delivered to a large population.

Provided herein are fusion polypeptides and related compositions (including immunogenic compositions and pharmaceutical compositions) comprising multiple polypeptides or peptide fragments, as well as methods for preparing fusion polypeptides and methods of using them to induce an immunogenic response to human immunodeficiency virus (HIV-1) in a subject in need thereof. As used herein, an "immunogen" is a substance that induces an immune response or is capable of inducing an immune response, such as an antigen. Also provided are polynucleotides encoding the fusion polypeptides described herein, and vectors comprising the polynucleotides.

Provided herein are fusion polypeptides designed to induce antiviral immune responses. Vaccine constructs described herein are designed to provide mathematically determined improved coverage of predicted T cell epitopes ("PTEs") using the most highly conserved predicted epitopes within a viral proteome sequence source set. As an example of a method for designing an antiviral immunogen, a fusion polypeptide encoded by at least two of the HIV-1 genes gag, pol, and nef is used. Fusion polypeptides and methods described herein retain both the positional information of PTEs in the sequence source set and the bivalent sequence set to improve the coverage of conservative PTEs. Therefore, described herein are multivalent (e.g., bivalent) vaccine constructs that advantageously improve or increase highly conservative PTEs that are most likely to be highly similar to conserved epitopes in naturally occurring sequences in proteins expressed by viral species in patient populations and in individual patients, because both retain positional information. In addition, using only highly conserved PTE sequences in HIV-1 species between patient populations reduces the possibility of escape mutants, because highly conserved sequences are more likely to contribute to viral structure and function.

Also provided is a computational method for designing antiviral vaccine immunogens for highly variable viruses (such as HIV-1).Antiviral immunogens can be designed to provide coverage for a group of individuals with a set of defined HLA alleles or for a wide range of population coverage at the individual level.In the vaccine immunogen design method described herein, we define a computational method for using a large number of population sequences (e.g., from public databases and internally developed databases) to target the conserved regions within the vaccine sequence.In addition, using individual patient deep sequence data, we define the sequence variability of each potential T cell epitope in the conserved region.In addition, we identify the region that can be used as the actual epitope based on the possibility of a group of HLA alleles presented by individual hosts.The possibility of combining with the host HLA defined by the publicly available and internally developed database is used to develop a deep learning model that simulates the peptide combination of each allele.This can be combined with the in-computer, published and/or experimental in vitro T cell elicitation data that can define the potential impact of antigen variants in regulating TCR recognition or identify peptides as escape variants.This data is used to design a group of peptide immunogens containing epitopes and related epitope variants. The epitope sequences are linked in series or serially (either directly fused or linked via a linker sequence) into a single fusion polypeptide. The peptide fragments are linked in a computationally determined order from N-terminus to C-terminus, which reduces or eliminates the generation of linked epitopes that may mimic human self-antigens and have adverse effects (e.g., eliciting autoimmune or tolerogenic responses).

Unlike similar graphic-based vaccine design methods, the methods described herein use only adjacent PTEs that are also adjacent in the natural sequence to construct connected PTE fragments. In addition, the method of the present invention first constructs a bivalent construct consisting of two matching polypeptides to improve or increase the coverage of each PTE position in the viral proteome. The bivalent construct itself can be used as a vaccine, such as the constructs described in Examples 1 and 2 below. The bivalent construct designed by analyzing population-based sequences (e.g., diversity between patients) identifies population-based conserved sequences that may contribute to viral structure.

The methods described herein may begin with identifying bivalent sequences of conserved regions using a process referred to herein as "conservation analysis" or "conservation algorithm." These methods may also include the step of constructing a bivalent vaccine construct having maximum epitope coverage while retaining positional information of PTEs from natural sequences using a process referred to herein as "conservation walking algorithm" or "CWA."

2. Fusion polypeptides that can be used to promote immune responses to human immunodeficiency virus-1 (HIV-1)

Provided herein are fusion polypeptides comprising multiple polypeptides or peptide fragments encoded by one or more HIV-1 genes. A "fragment" of a fusion polypeptide as described herein is a continuous sequence of at least 25 amino acids relative to a reference sequence (e.g., HIV-1 HXB2 reference sequences of Gag, Pol and Nef polypeptides, provided herein as SEQ ID NO: 1-3, respectively). Polypeptides as described herein are "fusion" polypeptides because they are assembled from the connection or series polypeptides or peptide fragments of two or more HIV-1 proteins (e.g., at least Pol and Nef). With respect to HIV-1 protein reference sequences, polypeptides or peptide fragments may correspond to discontinuous sequences of the same HIV-1 protein or different HIV-1 proteins. Typically, fusion polypeptides are non-naturally occurring and may be synthetic or recombinantly produced.

In various embodiments, the immunogenic polypeptides or fusion polypeptides described herein and/or polynucleotides encoding such polypeptides are provided in an isolated form. This means that the purity of the polypeptide or polynucleotide is generally at least 50% by weight of interfering proteins, cells and other contaminants produced by its production or purification, but does not exclude the possibility of combining the medicament with an excess of pharmaceutically acceptable carriers or other vehicles intended to promote its use. As described herein, when applied to polypeptides or polynucleotides, the term "isolated" means that the polypeptide or polynucleotide is substantially free of cellular components associated with it in the natural state. It can be, for example, in a homogeneous state and can be in a dry state or in an aqueous solution. Purity and homogeneity can be determined using known methods, such as analytical chemistry techniques, such as polyacrylamide gel electrophoresis, column chromatography, thin layer chromatography or high performance liquid chromatography (HPLC) analysis. Proteins that are the main species present in the preparation are substantially purified. "Isolated" or "purified" polypeptides or polynucleotides are substantially free of other cell materials or culture media when produced by recombinant technology, or substantially free of chemical precursors or other chemicals when chemically synthesized. In various embodiments, the purified polypeptide and/or polynucleotide is at least 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% (w/w), isolated, purified or free of interfering proteins and contaminants from production or purification. Typically, the immunogenic polypeptide or fusion polypeptide described herein and/or the polynucleotide encoding such polypeptide is the main macromolecular species remaining after purification.

a. Peptide fragments

With regard to HIV-1 genes encoding polypeptide fragments for assembling the fusion polypeptides described herein, in various embodiments, the fusion polypeptide comprises multiple polypeptide fragments of one or more HIV-1 proteins encoded by one or more (e.g., two or more, three or more) human immunodeficiency virus-1 (HIV-1) genes selected from Gag, Pol and Nef. In some embodiments, the multiple polypeptide fragments consist only of polypeptide fragments encoded by HIV-1 genes pol and nef, for example, polypeptide fragments encoded by HIV-1 genes gag, env, tat, rev, vpr, vif and vpu are not included. In some embodiments, the multiple polypeptide fragments consist only of polypeptide fragments encoded by HIV-1 genes gag, pol and nef, for example, polypeptide fragments encoded by HIV-1 genes env, tat, rev, vpr, vif and vpu are not included.

With respect to the number of polypeptide fragments assembled, linked, connected or concatenated into a single fusion polypeptide, in various embodiments, the fusion polypeptide is composed of at least 4 and at most 6 polypeptide fragments (e.g., 4, 5 or 6 polypeptide fragments). Depending on the circumstances, the polypeptide fragments can be arranged in the same or different order as the naturally occurring protein. In various embodiments, the fusion polypeptide comprises 1 to 4 Pol polypeptide fragments, 1 to 2 Nef polypeptide fragments and optionally 1 to 3 Gag polypeptide fragments.

With respect to the polypeptide region encoded by the HIV-1 gene selected as the polypeptide fragment included in the fusion polypeptide, in various embodiments, the polypeptide fragment is derived from a conserved region in a population of viral proteome sequences. In some embodiments, the conserved region is greater than 80% in HIV-1 species, for example, greater than 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%, for example, as determined in a population of patients. As used herein, a conserved region in a polypeptide encoded by an HIV-1 gene refers to the percentage of sequences in a population of sequences containing the same amino acid fragment or subsequence (e.g., a fragment or 9-mer of 9 amino acids in length) as the most common amino acid fragment or subsequence in a predetermined amino acid fragment or subsequence position, wherein the amino acid fragment or subsequence position is determined relative to a reference sequence (e.g., HIV-1 HXB2 polypeptide sequence, e.g., SEQ ID NO: 1-3). The start and end positions of the HIV polypeptides identified herein are relative to the HIV-1 HXB2 reference polypeptide, GenBank Accession No. K03455 (ncbi.nlm.nih.gov/nuccore/K03455), provided herein as SEQ ID NOs: 1-3 and identified in Table A. As used herein, the numbering of a given amino acid polymer or nucleic acid polymer "corresponds to," "corresponds to," or "relative to" the numbering of a selected or reference amino acid polymer or nucleic acid polymer when the position of any given polymer component (e.g., amino acid, nucleotide, also collectively referred to as "residue") is designated by reference to the same or equivalent position in a selected amino acid or nucleic acid polymer (e.g., based on an optimal alignment or consensus sequence), rather than by the actual numerical position of the component in the given polymer. In various embodiments, the conserved region is conserved between one or more of the HIV-1 evolutionary branches within group M (e.g., one or more of the HIV-1 evolutionary branches A-K, such as one or more of the evolutionary branches A, B, C, D and G) (e.g., between HIV-1 group M evolutionary branch B and its recombinant form (e.g., CRF01_AE)).

In some embodiments, the plurality of polypeptide fragments comprises at least 4 polypeptide fragments, such as at least 4, 5, 6, or more polypeptide fragments selected from SEQ ID NOs: 4-33, such as the polypeptide fragments identified in Table B.

In various embodiments, the fusion polypeptide comprises two, three, four, five, six or more polypeptide fragments comprising or consisting of amino acid residues corresponding to Gag 1-53, Gag 147-369, Pol56-117, Pol 129-320, Pol 367-431, Pol 542-606, Pol 586-606, Pol 683-708, Pol 747-827, Pol 840-909, Pol 840-920, Pol 932-1003, Nef 64-76, Nef 64-99 or Nef 117-148, wherein the Gag, Pol and Nef amino acid position numbers correspond to the HIV-1 HXB2 reference sequence set forth in SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the fusion polypeptide comprises two, three, four, five, six or more polypeptide fragments selected from SEQ ID NOs: 4-33.

In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide fragments, wherein the amino acid position numbers of Gag, Pol, and Nef correspond to SEQ ID NOs: 1, 2, and 3, respectively:

a) amino acid residues corresponding to Gag 1-53, Gag 147-369, Pol 683-708, and Nef 117-148;

b) amino acid residues corresponding to: Pol 56-117, Pol 129-320, Pol 367-431, and Nef 64-99;

c) amino acid residues corresponding to Pol 542-606, Pol 747-827, Pol 840-920, Pol 932-1003, and Nef 64-99;

d) amino acid residues corresponding to Gag 1-53, Gag 147-369, Pol 683-708, Pol 747-827, Pol 840-920, and Nef 117-148;

e) amino acid residues corresponding to Pol 56-117, Pol 129-320, Pol367-431, Pol 542-606, Pol 932-1003, and Nef 64-99;

f) amino acid residues corresponding to Gag 147-369, Pol 586-606, Pol 683-708, and Pol840-920;

g) amino acid residues corresponding to Pol 129-320, Pol 747-827, Pol 932-1003, and Nef64-76; or

h) Amino acid residues corresponding to: Gag: 147-369, Pol 747-827, Pol 840-909 and Nef 64-76.

In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide fragments:

a) SEQ ID NOs: 4, 6, 18 and 32, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 4, 6, 18 and 32, respectively;

b) SEQ ID NOs: 5, 7, 19 and 33, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 5, 7, 19 and 33, respectively;

c) SEQ ID NOs: 8, 10, 12 and 30, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 10, 12 and 30, respectively;

d) SEQ ID NOs: 9, 11, 13 and 31, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 11, 13 and 31, respectively;

e) SEQ ID NOs: 14, 20, 24, 26 and 30, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 14, 20, 24, 26 and 30, respectively;

f) SEQ ID NOs: 15, 21, 25, 27 and 31, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 21, 25, 27 and 31, respectively;

g) SEQ ID NO:4, 6, 18, 20, 24 and 32, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:4, 6, 18, 20, 24 and 32, respectively;

h) SEQ ID NO:5, 7, 19, 21, 25 and 33, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:5, 7, 19, 21, 25 and 33, respectively;

i) SEQ ID NOs: 8, 10, 12, 14, 26 and 30, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 10, 12, 14, 26 and 30, respectively;

j) SEQ ID NO:9, 11, 13, 15, 27 and 31, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:9, 11, 13, 15, 27 and 31, respectively;

k) SEQ ID NOs: 6, 16, 18 and 24, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 16, 18 and 24, respectively;

l) SEQ ID NOs:7, 17, 19 and 25, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs:7, 17, 19 and 25, respectively;

m) SEQ ID NOs: 10, 20, 26 and 28, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 10, 20, 26 and 28, respectively;

n) SEQ ID NOs: 11, 21, 27 and 29, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 21, 27 and 29, respectively;

o) SEQ ID NOs: 6, 20, 22 and 28, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 20, 22 and 28, respectively;

p) SEQ ID NOs: 7, 21, 23 and 29, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 23 and 29, respectively;

q) SEQ ID NOs: 6, 16, 18 and 24, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 16, 18 and 24, respectively;

r) SEQ ID NOs:7, 17, 19 and 25, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs:7, 17, 19 and 25, respectively;

s) SEQ ID NOs: 10, 20, 26 and 28, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 10, 20, 26 and 28, respectively; or

t) SEQ ID NOs: 11, 21, 27 and 29, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 21, 27 and 29, respectively.

Modifications can be made in the structures of fusion polypeptides described herein and polynucleotides encoding such fusion polypeptides, and these modifications still obtain functional molecules encoding variants or derivative polypeptides with desired (e.g., immunogenic) characteristics. When it is desired to change the amino acid sequence of a polypeptide to produce an equivalent or even improved variant or part of a fusion polypeptide described herein, those skilled in the art will typically change one or more of the codons encoding the DNA sequence.

For example, certain amino acids can be substituted for other amino acids in the protein structure without significantly losing its ability to bind to other polypeptides (e.g., antigens) or cells. Since it is the binding ability and properties of a protein that define the biological functional activity of the protein, certain amino acid sequence substitutions can be made in the protein sequence, and of course in its underlying DNA coding sequence, but obtain a protein with similar properties. It is therefore contemplated that various changes can be made in the polypeptide sequences of the disclosed fusion polypeptides or the corresponding DNA sequences encoding such fusion polypeptides without significantly losing their biological utility or activity.

In many cases, polypeptide variants will contain one or more conservative substitutions. A "conservative substitution" is one in which an amino acid is substituted for another amino acid with similar properties, such that one skilled in the art of peptide chemistry would expect that the secondary structure and hydrophilicity of the polypeptide would remain essentially unchanged.

When comparing polynucleotide and polypeptide sequences, two sequences are considered "identical" if the sequence of nucleotides or amino acids in the two sequences is the same when aligned for maximum correspondence as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. As used herein, a "comparison window" refers to a segment of at least about 20 consecutive positions (usually 30 to about 75, 40 to about 50) in which the sequence can be compared to a reference sequence having the same number of consecutive positions after the two sequences have been optimally aligned.

Optimal alignment of sequences for comparison can be performed using the Megalign program in the Lasergene bioinformatics software package (DNASTAR, Inc., Madison, WI) using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins-Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC, Vol. 5, Supplement 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenes, pp. 626-645; Methods in Enzymology, Vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) CABIOS 5:151-153; Myers, E.W. and Muller W. (1988) CABIOS 4:11-17; Robinson, E.D. (1971) Comb. Theor 77:105; Santou, N. Nes, M. (1987) Mol. Biol. Evol. 4:406-425; Sneath, P. H. A. and Sokal, R. R. (1973) Numerical Taxonomy-the Principles and Practice of Numerical Taxonomy, Freeman Press, San Francisco, CA; Wilbur, W. J. and Lipman, D. J. (1983) ) Proc. Natl. Acad., Sci. USA 80:726-730.

Alternatively, optimal alignment of sequences for comparison can be performed by the local identity algorithm (Smith and Waterman (1981) Add. APL. Math 2:482), the identity alignment algorithm (Needleman and Wunsch (1970) J. Mol. Biol. 48:443), the similarity search method (Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444), computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or inspection.

An example of an algorithm suitable for determining sequence identity and sequence similarity percentages is the BLAST and BLAST 2.0 methods, which are described in Altschul et al. (1977) Nucl. Acids Res. 25: 3389-3402 and Altschul et al. (1990) J. Mol. Biol. 215: 403-410, respectively. BLAST and BLAST 2.0 can be used, for example, with the parameters described herein to determine the sequence identity percentages of the polynucleotides and polypeptides described herein. Software for performing BLAST analysis is publicly available through the National Center for Biotechnology Information (blast.ncbi.nlm.nih.gov/Blast.cgi).

In an illustrative example, for nucleotide sequences, the cumulative score can be calculated using the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatched residues; always < 0). Extension of the word hits in each direction stops when: the cumulative alignment score drops by the amount X from its maximum achieved value; the cumulative score becomes zero or lower due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses a word length (W) of 11 and an expectation (E) of 10 as defaults, and a BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89: 10915) alignment, (B) of 50, an expectation (E) of 10, M = 5, N = -4, and a comparison of both chains.

For amino acid sequences, a scoring matrix can be used to calculate the cumulative score. Extension of the word hits in each direction stops when: the cumulative alignment score drops by the amount X from its maximum achieved value; the cumulative score goes to zero or lower due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.

In one method, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences within a comparison window of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may contain 20% or less (usually 5% to 15%, or 10% to 12%) additions or deletions (i.e., gaps) compared to the reference sequence (not comprising additions or deletions) for the optimal alignment of the two sequences. The percentage is calculated by determining the number of positions where the same nucleic acid base or amino acid residue occurs in the two sequences to generate the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e., the window size) and multiplying the result by 100 to generate the percentage of sequence identity.

As used herein, the term polypeptide "variant" is a polypeptide that generally differs from a polypeptide specifically disclosed herein in one or more substitutions, deletions, additions and/or insertions. Such variants may be naturally occurring or may be generated synthetically, for example, by modifying one or more of the above-described polypeptide sequences described herein and evaluating one or more biological activities of the polypeptide as described herein and/or using any of a variety of techniques well known in the art. The term "variant" may also refer to any naturally occurring or engineered molecule comprising one or more nucleotide or amino acid mutations.

In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide fragments, in order from N-terminus to C-terminus, optionally bound or linked by one or more linkers:

a) SEQ ID NOs: 6, 4, 18 and 32, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 4, 18 and 32, respectively;

b) SEQ ID NOs: 7, 5, 33 and 19, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 5, 33 and 19, respectively;

c) SEQ ID NOs: 12, 30, 8 and 10, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 12, 30, 8 and 10, respectively;

d) SEQ ID NOs: 9, 31, 13 and 11, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 31, 13 and 11, respectively;

e) SEQ ID NOs: 14, 26, 20, 30 and 24, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 14, 26, 20, 30 and 24, respectively;

f) SEQ ID NOs: 15, 31, 21, 27 and 25, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 31, 21, 27 and 25, respectively;

g) SEQ ID NOs:32, 18, 4 and 6, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs:32, 18, 4 and 6, respectively;

h) SEQ ID NOs: 7, 33, 5 and 19, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 33, 5 and 19, respectively;

i) SEQ ID NOs: 8, 30, 12 and 10, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 30, 12 and 10, respectively;

j) SEQ ID NOs: 13, 31, 9 and 11, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 13, 31, 9 and 11, respectively;

k) SEQ ID NOs: 26, 30, 14, 20, and 24, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 26, 30, 14, 20, and 24, respectively;

l) SEQ ID NOs:31, 27, 15, 25 and 21, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs:31, 27, 15, 25 and 21, respectively;

m) SEQ ID NOs: 24, 6, 4, 20, 18 and 32, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 4, 20, 18 and 32, respectively;

n) SEQ ID NOs: 6, 20, 4, 24, 32 and 18, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 20, 4, 24, 32 and 18, respectively;

o) SEQ ID NOs: 7, 21, 5, 25, 33 and 19, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 5, 25, 33 and 19, respectively;

p) SEQ ID NOs: 8, 30, 14, 12, 26 and 10, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 30, 14, 12, 26 and 10, respectively;

q) SEQ ID NOs: 8, 12, 30, 26, 14 and 10, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 12, 30, 26, 14 and 10, respectively;

r) SEQ ID NO:9, 13, 31, 27, 15 and 11, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:9, 13, 31, 27, 15 and 11, respectively;

s) SEQ ID NOs: 20, 32, 24, 4, 6, and 18, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 20, 32, 24, 4, 6, and 18, respectively;

t) SEQ ID NOs:7, 25, 19, 5, 33 and 21, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs:7, 25, 19, 5, 33 and 21, respectively;

u) SEQ ID NOs: 26, 30, 12, 14, 8 and 10, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 30, 12, 14, 8 and 10, respectively;

v) SEQ ID NOs: 15, 31, 9, 27, 13 and 11, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 31, 9, 27, 13 and 11, respectively;

w) SEQ ID NOs: 24, 6, 16 and 18, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 16 and 18, respectively;

x) SEQ ID NOs: 7, 19, 17 and 25, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 19, 17 and 25, respectively;

y) SEQ ID NOs: 24, 16, 6 and 18, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 16, 6 and 18, respectively;

z) SEQ ID NOs:7, 25, 17 and 19, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs:7, 25, 17 and 19, respectively;

aa) SEQ ID NOs: 26, 20, 10 and 28, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 20, 10 and 28, respectively;

bb) SEQ ID NOs: 21, 27, 11 and 29, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 21, 27, 11 and 29, respectively;

cc) SEQ ID NOs: 26, 10, 20 and 28, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 10, 20 and 28, respectively;

dd) SEQ ID NOs: 11, 27, 21 and 29, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 27, 21 and 29, respectively;

ee) SEQ ID NOs: 22, 6, 20 and 28, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 22, 6, 20 and 28, respectively;

ff) SEQ ID NOs: 23, 7, 21 and 29, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 23, 7, 21 and 29, respectively;

gg) SEQ ID NOs: 22, 20, 6 and 28, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 22, 20, 6 and 28, respectively; or

hh) SEQ ID NOs: 7, 21, 23 and 29, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 23 and 29, respectively.

Typically, the fusion polypeptide does not comprise any polypeptide fragment corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef1-63, Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. Typically, the fusion polypeptide does not comprise any polypeptide fragment having an amino acid sequence of SEQ ID NOs: 35-47, or a fragment or subsequence thereof, provided in Table C, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or a fragment or subsequence thereof.

With regard to the range of lengths of individual polypeptides or peptide fragments, in various embodiments, each polypeptide fragment is at least 25 amino acids in length and up to about 230 amino acids in length, e.g., at least 25 amino acids in length and up to 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, or 230 amino acids in length.

With respect to the length of the full-length fusion polypeptide, in various embodiments, in some embodiments, the full length of the fusion polypeptide comprises at least about 330 amino acids and at most about 550 amino acids in length, e.g., at least about 330 amino acids and at most about 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, or 550 amino acids in length. In some embodiments, the full length of the fusion polypeptide is no longer than 550 amino acids in length, e.g., no longer than 545, 540, 535, 530, 525, 520, 515, 510, 505, 500, 495, 490, 485, 480, 475, 470, 465, 460, 455, 450, 445, 440, 435, 430, 425, 420, 415, 410, 405, 400, 390, 385, 380, 375, 370, 365, 360, 355, 350, 345, 340, 335, or 330 amino acids in length. In various embodiments, in the absence of a signal or leader sequence, the full length of the fusion polypeptide comprises at least about 330 amino acids and at most about 505 amino acids in length, e.g., at least about 330 amino acids and at most about 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, or 505 amino acids in length. In various embodiments, in the absence of a signal or leader sequence, the full length of the fusion polypeptide is no longer than 505 amino acids in length, e.g., no longer than 505, 500, 495, 490, 485, 480, 475, 470, 465, 460, 455, 450, 445, 440, 435, 430, 425, 420, 415, 410, 405, 400, 390, 385, 380, 375, 370, 365, 360, 355, 350, 345, 340, 335, or 330 amino acids in length. In various embodiments, in the absence of a signal or leader sequence, the full length of the fusion polypeptide comprises at least about 350 amino acids and at most about 550 amino acids in length, e.g., at least about 350 amino acids and at most about 355, 360, 365, 370, 375, 380, 385, 390, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, or 550 amino acids in length. In various embodiments, in the absence of a signal or leader sequence, the total length of the fusion polypeptide is no longer than 550 amino acids in length, e.g., no longer than 545, 540, 535, 530, 525, 520, 515, 510, 505, 500, 495, 490, 485, 480, 475, 470, 465, 460, 455, 450, 445, 440, 435, 430, 425, 420, 415, 410, 405, 400, 390, 385, 380, 375, 370, 365, 360, 355 or 350 amino acids. The inclusion of a signal or leader sequence is described in more detail below.

Generally, fusion polypeptides are immunogenic because they can cause, for example, an immune response to HIV-1 in the human body. In some embodiments, for example, fusion polypeptides as described herein optionally combined with one or more additional therapeutic agents can cause protection or effective immune responses to HIV-1 in the human body, for example, can prevent HIV-1 infection in uninfected individuals or in a therapeutic environment, can cause sufficient to induce immune-mediated control of HIV-1 or eradicate the immune response of HIV-1 in infected individuals. The immunogenicity of fusion polypeptides can be assessed and demonstrated in vitro and in vivo assays as described herein. For example, the immunogenicity of fusion polypeptides can be demonstrated by in vitro assays (including CD4+ and/or CD8+ T cell activation (for example, including cytokine expression and target killing assays) or proliferation assays). T cells can be activated by exposure to antigen presenting cells (APCs) (for example dendritic cells, for example monocyte-derived dendritic cells) transfected with polynucleotides encoding fusion polypeptides. Such assays are known in the art and described herein. The immunogenicity of the fusion polypeptide can also be demonstrated in an in vivo animal model, for example, by administering, for example, a transgenic of one or more human HLA molecules (available from Jackson Laboratories or Taconic) to mice (e.g., BALB/c or BL6) or non-human primates, and assessing CD4+ and/or CD8+ T cell activation (e.g., including serum cytokine levels) or proliferation. In various embodiments, one, two, three or more of each polypeptide fragment comprises or consists of one or more predicted T cell epitopes, for example as determined by calculation or experiment. In some embodiments, the fusion polypeptide comprises one or more polypeptide fragments that are bound to or presented by one or more human HLA class I and/or class II alleles (e.g., 1, 2, 3, 4, 5, or 6 alleles), for example, within a single subject or between multiple subjects.

Tandem peptide fragments

As the case may be, one or more polypeptide fragments may be directly adjacent to or fused to adjacent fragments, or may be bound, connected or linked to adjacent fragments by one or more peptide linkers. In various embodiments, one or more peptide linkers are selected from one or more of the following: for example, polyalanine linkers, polyglycine linkers, cleavable linkers, flexible linkers, rigid linkers, Nef linker sequences, and combinations thereof within a linker or within a full-length fusion polypeptide. Exemplary fusion protein linkers that can be used to connect one or more polypeptide fragments in the fusion polypeptide of the present invention are described, for example, in Chen et al., Adv Drug Deliv Rev. (2013) 65 (10): 1357–1369. In some embodiments, the polyalanine linker comprises 2 or 3 consecutive alanine residues, such as AA, AAA (SEQ ID NO: 48), AAY (SEQ ID NO: 49), or AAX, or is composed of these consecutive alanine residues, wherein X is any amino acid (e.g., A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, Y) (SEQ ID NO: 50). In some embodiments, a polyglycine linker is used, such as GGS (SEQ ID NO: 57), GSG (SEQ ID NO: 58), or GGGS (SEQ ID NO: 59). In some embodiments, the cleavable linker is selected from a 2A cleavable peptide. Exemplary 2A cleavable peptides that can be used to link one or more polypeptide fragments in the fusion polypeptide of the present invention are described, for example, in Donnelly et al., J. Gen. Virol (2001), 82, 1027–1041 and Chng et al., mAbs (2015) 7: 2, 403-412. Exemplary cleavable peptides that can be used to link one or more polypeptide fragments include, but are not limited to, 2A cleavable sequences (e.g., foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine teschovirus-1 (P2A), and lycopodiella virus (T2A)) and furin recognition/cleavage sequences (e.g., RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), RRKR (SEQ ID NO: 62)). In certain embodiments, furin recognition/cleavage sequences (e.g., RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), RRKR (SEQ ID NO: 62)) are combined or fused with 2A cleavable peptides (e.g., foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine teschovirus-1 (P2A), and lycopodiella virus (T2A)) in a single linker. See, e.g., Chng et al., mAbs (2015) 7: 2, 403-412. In various embodiments, the 2A cleavable linker comprises or consists of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical to ATNFSLLKQAGDVEENPGP (SEQ ID NO:63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO:64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO:65), QCTNYALLKLAGDVESNPGP (SEQ ID NO:66), or EGRGSLLTCGDVEENPGP (SEQ ID NO:67). In some embodiments, the cleavable linker comprises or consists of an amino acid sequence selected from RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and RRKR (SEQ ID NO: 62). REKR (SEQ ID NO: 61) is a naturally occurring cleavable linker in HIV and SIV envelope glycoprotein precursors (Bahbouhi et al., Biochem. J. (2002) 366, 863-872). Exemplary linkers that can be used to link or connect one or more polypeptide fragments in a fusion polypeptide are provided in Table D.

Exemplary fusion polypeptides designed and assembled according to the methods described herein without a signal sequence are provided in Table E. Table E discloses "AAA" as SEQ ID NO:48, "LIK" as SEQ ID NO:53, "AAY" as SEQ ID NO:49, "SEG" as SEQ ID NO:55, "QEE" as SEQ ID NO:51, "KIL" as SEQ ID NO:52 and "PPV" as SEQ ID NO:54.

In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223, and 227. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223. In some embodiments, the fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 82, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 82. In some embodiments, the fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 83, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 83. In some embodiments, the fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 85, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 85. In some embodiments, the fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 86, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 86. In some embodiments, the fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 87, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 87. In some embodiments, the fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 98, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 98. In some embodiments, the fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 99, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 99. In some embodiments, the fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 100, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 100. In some embodiments, the fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 101, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 101. In some embodiments, the fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 209, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209. In some embodiments, the fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 222, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222. In some embodiments, the fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 223. In some embodiments, the fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 227. Optionally or as needed, the fusion polypeptide may have an N-terminal methionine residue.

Composite fusion peptide

In various embodiments, a composite fusion polypeptide comprising two or more fusion polypeptides as described herein is provided. Such composite fusion polypeptides can be delivered in viral vectors, which can express polypeptides having at least about 750 amino acids in length, for example, at least about 800, 850, 900, 950, 1000, 1050, 1100 amino acids in length or longer. Depending on the circumstances, two or more fusion polypeptides can be directly fused, or combined or connected by one or more joints. In some embodiments, a composite fusion polypeptide is provided, which at least comprises a first fusion polypeptide and a second fusion polypeptide as described herein, and the first and second fusion polypeptides are optionally combined or connected by one or more joints as described herein (e.g., a cleavable joint, such as a 2A cleavable peptide joint).

In various embodiments, the first fusion polypeptide and the second fusion polypeptide in the composite fusion polypeptide comprise the same polypeptide fragment, such as the same amino acid residue position range. In some embodiments, the first fusion polypeptide and the second fusion polypeptide in the composite fusion polypeptide are bivalent. For example, in some embodiments, the first fusion polypeptide and the second fusion polypeptide comprise or consist of the following polypeptide fragments, wherein the Gag, Pol, and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2, and 3, respectively:

a) amino acid residues corresponding to Gag 1-53, Gag 147-369, Pol 683-708, and Nef 117-148;

b) amino acid residues corresponding to: Pol 56-117, Pol 129-320, Pol 367-431, and Nef 64-99;

c) amino acid residues corresponding to Pol 542-606, Pol 747-827, Pol 840-920, Pol 932-1003, and Nef 64-99;

d) amino acid residues corresponding to Gag 1-53, Gag 147-369, Pol 683-708, Pol 747-827, Pol 840-920, and Nef 117-148;

e) amino acid residues corresponding to Pol 56-117, Pol 129-320, Pol 367-431, Pol 542-606, Pol 932-1003, and Nef 64-99;

f) amino acid residues corresponding to Gag 147-369, Pol 586-606, Pol 683-708, and Pol840-920;

g) amino acid residues corresponding to Pol 129-320, Pol 747-827, Pol 932-1003, and Nef64-76; or

h) Amino acid residues corresponding to: Gag: 147-369, Pol 747-827, Pol 840-909 and Nef 64-76.

In various embodiments, the first fusion polypeptide and the second fusion polypeptide in the composite fusion polypeptide comprise different polypeptide fragments, such as the same amino acid residue position range. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are bivalent. For example, in some embodiments, the composite fusion polypeptide (including the first fusion polypeptide and the second fusion polypeptide) comprises or consists of the following polypeptide fragments, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively:

a) amino acid residues corresponding to Gag 147-369, Pol 129-320, Pol 586-606, Pol 683-708, Pol 747-827, Pol 840-920, Pol 932-1003, and Nef 64-76; or

b)Gag 1-53, Gag 147-369, Pol 56-117, Pol 129-320, Pol 367-431, Pol 542-606, Pol 683-708, Pol 747-827, Pol 840-920, Pol 932- 1003, Nef 64-99 and Nef 117-148.

In some embodiments, the composite fusion polypeptide comprises the following polypeptide fragments in order from N-terminus to C-terminus, optionally bound or linked by one or more linkers:

a) SEQ ID NOs: 6, 4, 16 and 26 and SEQ ID NOs: 7, 5, 27 and 17, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 4, 16 and 26 and SEQ ID NOs: 7, 5, 27 and 17, respectively;

b) SEQ ID NOs: 12, 24, 8 and 10 and SEQ ID NOs: 9, 25, 13 and 11, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 12, 24, 8 and 10 and SEQ ID NOs: 9, 25, 13 and 11, respectively;

c) SEQ ID NOs: 14, 22, 18, 24 and 20 and SEQ ID NOs: 15, 25, 19, 23 and 21, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 14, 22, 18, 24 and 20 and SEQ ID NOs: 15, 25, 19, 23 and 21, respectively;

d) SEQ ID NOs: 26, 16, 4 and 6 and SEQ ID NOs: 7, 27, 5 and 17, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 16, 4 and 6 and SEQ ID NOs: 7, 27, 5 and 17, respectively;

e) SEQ ID NOs: 8, 24, 12 and 10 and SEQ ID NOs: 13, 25, 9 and 11, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 24, 12 and 10 and SEQ ID NOs: 13, 25, 9 and 11, respectively;

f) SEQ ID NOs: 24, 6, 16 and 18 and SEQ ID NOs: 7, 25, 17 and 19, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 16 and 18 and SEQ ID NOs: 7, 25, 17 and 19, respectively;

g) SEQ ID NOs: 26, 10, 20 and 28 and SEQ ID NOs: 21, 27, 11 and 29, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 10, 20 and 28 and SEQ ID NOs: 21, 27, 11 and 29, respectively;

h) SEQ ID NOs: 24, 6, 16 and 18 and SEQ ID NOs: 26, 10, 20 and 28, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 16 and 18 and SEQ ID NOs: 26, 10, 20 and 28, respectively;

i) SEQ ID NOs:7, 25, 17 and 19 and SEQ ID NOs:21, 27, 11 and 29, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs:7, 25, 17 and 19 and SEQ ID NOs:21, 27, 11 and 29, respectively;

j) SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26 and 10, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26 and 10, respectively;

k) SEQ ID NO:7, 21, 19, 17, 27, 25, 29 and 11, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:7, 21, 19, 17, 27, 25, 29 and 11, respectively;

l) SEQ ID NOs:22, 24, 14, 18 and 20 and SEQ ID NOs:25, 23, 15, 21 and 19, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs:22, 24, 14, 18 and 20 and SEQ ID NOs:25, 23, 15, 21 and 19, respectively;

m) SEQ ID NOs: 20, 6, 4, 18, 16 and 26 and SEQ ID NOs: 7, 19, 5, 21, 27 and 17, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 20, 6, 4, 18, 16 and 26 and SEQ ID NOs: 7, 19, 5, 21, 27 and 17, respectively;

n) SEQ ID NOs: 8, 24, 14, 12, 22 and 10 and SEQ ID NOs: 9, 13, 25, 23, 15 and 11, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 24, 14, 12, 22 and 10 and SEQ ID NOs: 9, 13, 25, 23, 15 and 11, respectively;

o) SEQ ID NOs: 18, 26, 20, 4, 6 and 16 and SEQ ID NOs: 7, 21, 17, 5, 27 and 19, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 18, 26, 20, 4, 6 and 16, SEQ ID NOs: 7, 21, 17, 5, 27 and 19, respectively;

p) SEQ ID NOs: 24, 6, 4, 20, 18 and 32 and SEQ ID NOs: 7, 21, 5, 25, 33 and 19, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 4, 20, 18 and 32, SEQ ID NOs: 7, 21, 5, 25, 33 and 19, respectively;

q) SEQ ID NO:6, 20, 4, 24, 32, 18 and SEQ ID NO:8, 12, 30, 26, 14 and 10, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:6, 20, 4, 24, 32, 18 and SEQ ID NO:8, 12, 30, 26, 14 and 10, respectively;

r) SEQ ID NOs: 8, 30, 14, 12, 26 and 10 and SEQ ID NOs: 9, 13, 31, 27, 15 and 11, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 30, 14, 12, 26 and 10, SEQ ID NOs: 9, 13, 31, 27, 15 and 11, respectively;

s) SEQ ID NOs: 24, 6, 4, 20, 18 and 32 and SEQ ID NOs: 8, 30, 14, 12, 26 and 10, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 4, 20, 18 and 32 and SEQ ID NOs: 8, 30, 14, 12, 26 and 10, respectively;

t) SEQ ID NO:6, 20, 4, 24, 32, 18 and SEQ ID NO:8, 12, 30, 26, 14 and 10, or a sequence fragment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:6, 20, 4, 24, 32, 18 and SEQ ID NO:8, 12, 30, 26, 14 and 10, respectively; or

u) SEQ ID NOs:7, 21, 5, 25, 33 and 19 and SEQ ID NOs:9, 13, 31, 27, 15 and 11, or sequence fragments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs:7, 21, 5, 25, 33 and 19 and SEQ ID NOs:9, 13, 31, 27, 15 and 11, respectively.

In various embodiments, the composite fusion polypeptide comprises or consists of the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a fusion polypeptide of SEQ ID NOs:70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:70 and 71, respectively;

a fusion polypeptide of SEQ ID NOs:72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:72 and 73, respectively;

· A fusion polypeptide of SEQ ID NOs:74 and 75, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%, 152%, 153%, 154%, 155%, 156%, 157%, 158%, 159%, 160%, 161%, 162%, 163%, 164%, 165%, 166%, 167%, 168%, 169%,

98% or 99% identical fusion polypeptides;

· a fusion polypeptide of SEQ ID NOs:76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively;

a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:78 and 79, respectively;

a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:80 and 81, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively;

a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:90 and 91, respectively;

a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively;

a fusion polypeptide of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 96, respectively;

a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively;

a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 100, respectively;

· a fusion polypeptide of SEQ ID NOs:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 101, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively; or

· A fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively.

In various embodiments, the composite fusion polypeptide comprises or consists of the following first fusion polypeptide and the second fusion polypeptide, optionally bound or linked by one or more linkers, in order from N-terminus to C-terminus:

a fusion polypeptide of SEQ ID NOs:70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:70 and 71, respectively;

a fusion polypeptide of SEQ ID NOs:71 and 70, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:71 and 70, respectively;

a fusion polypeptide of SEQ ID NOs:72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:72 and 73, respectively;

a fusion polypeptide of SEQ ID NOs:73 and 72, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:73 and 72, respectively;

a fusion polypeptide of SEQ ID NOs:74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively;

a fusion polypeptide of SEQ ID NOs:75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:75 and 74, respectively;

a fusion polypeptide of SEQ ID NOs:76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively;

a fusion polypeptide of SEQ ID NOs:77 and 76, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:77 and 76, respectively;

a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:78 and 79, respectively;

a fusion polypeptide of SEQ ID NOs:79 and 78, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:79 and 78, respectively;

a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:80 and 81, respectively;

a fusion polypeptide of SEQ ID NOs:81 and 80, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:81 and 80, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively;

a fusion polypeptide of SEQ ID NOs:83 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 84, respectively;

a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 86, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:89 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:89 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively;

a fusion polypeptide of SEQ ID NOs:86 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 83, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 84, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 84, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:89 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:89 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively;

a fusion polypeptide of SEQ ID NOs: 101 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:90 and 91, respectively;

a fusion polypeptide of SEQ ID NOs:91 and 90, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:91 and 90, respectively;

a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively;

a fusion polypeptide of SEQ ID NOs:93 and 92, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:93 and 92, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively;

a fusion polypeptide of SEQ ID NOs:95 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 94, respectively;

a fusion polypeptide of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively;

a fusion polypeptide of SEQ ID NOs:97 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:97 and 96, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 96, respectively;

a fusion polypeptide of SEQ ID NOs:96 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 94, respectively;

a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively;

a fusion polypeptide of SEQ ID NOs:97 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:97 and 95, respectively;

a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;

a fusion polypeptide of SEQ ID NOs: 221 and 220, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 100, respectively;

a fusion polypeptide of SEQ ID NOs: 100 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively;

· a fusion polypeptide of SEQ ID NOs:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 101, respectively;

a fusion polypeptide of SEQ ID NOs: 101 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively;

a fusion polypeptide of SEQ ID NOs:99 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 98, respectively;

a fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or

· A fusion polypeptide of SEQ ID NOs: 101 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively.

In some embodiments of the composite fusion polypeptide, the first fusion polypeptide and the second fusion polypeptide are bound or connected by a cleavable linker. In various embodiments, the first fusion polypeptide and the second fusion polypeptide are bound or connected by a cleavable linker selected from the following items: 2A cleavable peptides (e.g., foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine Teschovirus-1 (P2A) and T. punctatus virus (T2A)), furin protease recognition/cleavage sequences (e.g., RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), RRKR (SEQ ID NO: 62)) and combinations, derivatives or variants thereof. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are bound or connected by a furin protease recognition/cleavage site selected from the following items: RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and RRKR (SEQ ID NO: 62). In some embodiments, the first fusion polypeptide and the second fusion polypeptide are bound or linked by a 2A cleavable peptide comprising or consisting of the amino acid sequence of ATNFSLLKQAGDVEENPGP (SEQ ID NO:63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO:64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO:65), QCTNYALLKLAGDVESNPGP (SEQ ID NO:66), or EGRGSLLTCGDVEENPGP (SEQ ID NO:67). NO:66) or EGRGSLLTCGDVEENPGP (SEQ ID NO:67) is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical to an amino acid sequence.

Exemplary composite fusion polypeptides designed and assembled according to the methods described herein without a signal sequence are provided in Table F. Table F discloses "AAA" as SEQ ID NO:48, "LIK" as SEQ ID NO:53, "AAY" as SEQ ID NO:49, "SEG" as SEQ ID NO:55, "QEE" as SEQ ID NO:51, "RAKR" as SEQ ID NO:60 and "PPV" as SEQ ID NO:54.

In some embodiments, the composite fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227. In some embodiments, the composite fusion polypeptide comprises or consists of: an amino acid sequence of any one of SEQ ID NOs: 209, 222, and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223. In some embodiments, the composite fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 209, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209. In some embodiments, the composite fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 222, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222. In some embodiments, the composite fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 223. In some embodiments, the composite fusion polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 227. Optionally or where desired, the composite fusion polypeptide may have an N-terminal methionine residue.

Signal or leader sequence

In various embodiments, fusion polypeptide and/or composite fusion polypeptide include signal sequence or signal peptide, for example, to guide fusion polypeptide or composite fusion polypeptide to be transported to proteasome or lysosomal compartment in cell. In various embodiments, fusion polypeptide or composite fusion polypeptide include signal sequence at N-terminal and/or C-terminal. In some embodiments, fusion polypeptide composite fusion polypeptide includes N-terminal signal peptide or leader sequence. In various embodiments, signal peptide or leader sequence are from the source protein selected from serum protein, cytokine, chemokine, chaperone, unchanged protein and the protein that protein is directed to lysosomal compartment. In some embodiments, the signal peptide or leader sequence is from a source protein selected from the group consisting of colony stimulating factor 2 (CSF2, GM-CSF), tissue plasminogen activator (PLAT, t-PA), C-C motif chemokine ligand 7 (CCL7, MCP-3), C-X-C motif chemokine ligand 10 (CXCL10, IP-10), catenin beta 1 (CTNNB1), CD74 (p33; DHLAG; HLADG; Ia-GAMMA, invariant chain), serum albumin (ALB), polyubiquitin B/C (UBB/UBC), calreticulin (CALR), vesicular stomatitis virus G protein (VSV-G), lysosomal associated membrane protein 1 (LAMP-1), and lysosomal associated membrane protein 2 (LAMP-2). In certain embodiments, the fusion polypeptide includes N-terminal and C-terminal signal sequences from LAMP-1, e.g., SEQ ID NOs: 125 and 126, respectively. In various embodiments, the signal peptide or leader sequence is selected from the amino acid sequence of any one of SEQ ID NOs: 115-126, or a nucleic acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 115-126. Exemplary signal sequences that can be used in fusion polypeptides and composite fusion polypeptides of the invention are provided in Table G.

3. Polynucleotides encoding fusion polypeptides or composite fusion polypeptides

Provided are polynucleotides encoding fusion polypeptides or composite fusion polypeptides as described herein, vectors comprising such polynucleotides, and host cells (e.g., human cells, mammalian cells, yeast cells, plant cells, insect cells, bacterial cells (e.g., E. coli)) comprising such polynucleotides or expression vectors. Provided herein are polynucleotides comprising a nucleotide sequence encoding any one of the fusion polypeptides or composite fusion polypeptides provided herein, and expression cassettes and vectors comprising such polynucleotide sequences, e.g., expression vectors for effective expression in host cells (e.g., mammalian cells). In various embodiments, the polynucleotides are DNA, cDNA, mRNA, self-amplifying RNA (SAM), self-replicating RNA, or self-amplifying replicon RNA (RepRNA). In some embodiments, the polynucleotides include alphavirus self-replicating or self-amplifying replicon RNA (RepRNA). Self-replicating RNA and self-amplifying replicon RNA as vaccine delivery modes are described in, for example, Ballesteros-Briones et al., Curr Opin Virol. (2020) 44:145-153; Bloom et al., Gene Ther. (2020) 22:1-13; Lundstrom, Int. J. Mol. Sci. (2020) 21:5130; Moyo et al., Mol Ther Methods Clin Dev. (2018) 12:32-46; Tews et al., Methods Mol Biol. (2017) 1499:15-35; Démoulins et al., Methods Mol Biol. (2017) 1499:37-75; Englezou et al., Mol Ther Nucleic Acids. (2018) 12: 118-134; McCollough et al., Vaccines (Basel). (2014) 2(4): 735-54; and McCollough et al., Mol Ther Nucleic Acids. (2014) 3: e173.

The terms "polynucleotide" and "nucleic acid molecule" refer interchangeably to polymeric forms of nucleotides, and include sense and antisense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers described above. As used herein, the term "nucleic acid molecule" is interchangeable with the term "polynucleotide". In some embodiments, nucleotides refer to modified forms of ribonucleotides, deoxyribonucleotides, or any type of nucleotides, and combinations thereof. The term also includes, but is not limited to, DNA in single-stranded and double-stranded forms. In addition, polynucleotides, such as cDNA or mRNA, may include one or both of naturally occurring and modified nucleotides linked together by naturally occurring and/or non-naturally occurring nucleotide bonds. As will be readily appreciated by those skilled in the art, nucleic acid molecules may be chemically or biochemically modified, or may contain non-natural or derived nucleotide bases. Such modifications include, for example, labeling, methylation, substitution of one or more of the naturally occurring nucleotides with analogs, internucleotide modifications such as uncharged bonds (e.g., methylphosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged bonds (e.g., phosphorothioates, phosphorodithioates, etc.), side chain moieties (e.g., polypeptides), intercalators (e.g., acridine, psoralens, etc.), chelators, alkylates, and modified bonds (e.g., α-anomeric nucleic acids, etc.). The above terms are also intended to include any topological conformation, including single-stranded conformation, double-stranded conformation, partially double-stranded conformation, triple-stranded conformation, hairpin conformation, circular conformation, and padlock conformation. Unless otherwise indicated, reference to a nucleic acid sequence encompasses its complementary sequence. Therefore, reference to a nucleic acid molecule with a specific sequence should be understood to encompass its complementary chain and its complementary sequence. The term also includes codon preference polynucleotides for improving expression in a desired viral expression vector or host cell.

As used herein, "substitution" means that one or more amino acids or nucleotides are replaced by different amino acids or nucleotides, respectively.

An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in a cell that normally contains the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location. An "isolated nucleic acid" encoding a polypeptide fragment or a fusion polypeptide or a composite fusion polypeptide refers to one or more nucleic acid molecules encoding such a polypeptide fragment or a fusion polypeptide or a composite fusion polypeptide, including such nucleic acid molecules in a single vector or separate vectors, and such nucleic acid molecules present at one or more locations in a host cell.

As used herein, the term polynucleotide "variant" is a polynucleotide that typically differs from a polynucleotide specifically disclosed herein in one or more substitutions, deletions, additions and/or insertions. Such variants may be naturally occurring or may be generated synthetically, for example, by modifying one or more of the polynucleotide sequences described herein and evaluating one or more biological activities of the encoded polypeptide as described herein and/or using any of a variety of techniques well known in the art.

In some embodiments, the nucleic acid molecule has a codon preference to enhance expression in a desired host cell (e.g., a human cell, a mammalian cell, a yeast cell, a plant cell, an insect cell, or a bacterial cell, such as an E. coli cell). Therefore, a polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein is provided, wherein the polynucleotide has a codon preference, comprises a replacement heterologous signal sequence, and/or eliminates an mRNA instability element. Methods for generating codon-biased nucleic acids can be performed by adjusting the methods described in the following documents: for example, U.S. Patent Nos. 5,965,726; 6,174,666; 6,291,664; 6,414,132; and 6,794,498. Preferred codon usage for expressing a fusion polypeptide or a composite fusion polypeptide comprising an HIV-1 polypeptide fragment from a desired viral expression vector and/or in a desired host cell is provided, for example, at kazusa.or.jp/codon/ and genscript.com/tools/codon-frequency-table.

In some embodiments, the polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein has a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence selected from SEQ ID NOs: 130-167, 210-219, and 225-226 provided in Table H. In some embodiments, the polynucleotide encoding a fusion polypeptide or composite fusion polypeptide as described herein has a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence selected from SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226 provided in Table H. Table H discloses "AAA" as SEQ ID NO:48, "LIK" as SEQ ID NO:53, "AAY" as SEQ ID NO:49, "SEG" as SEQ ID NO:55, "QEE" as SEQ ID NO:51, "RAKR" as SEQ ID NO:60, "KIL" as SEQ ID NO:52, and "PPV" as SEQ ID NO:54. In some embodiments, a polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein has a nucleic acid sequence of SEQ ID NO:139, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO:139. In some embodiments, the polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein has a nucleic acid sequence of SEQ ID NO: 142, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 142. In some embodiments, the polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein has a nucleic acid sequence of SEQ ID NO: 145, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 145. In some embodiments, the polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein has a nucleic acid sequence of SEQ ID NO: 148, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 148. In some embodiments, the polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein has a nucleic acid sequence of SEQ ID NO: 150, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 150. In some embodiments, the polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein has a nucleic acid sequence of SEQ ID NO: 152, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 152. In some embodiments, the polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein has a nucleic acid sequence of SEQ ID NO: 155, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 155. In some embodiments, the polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein has a nucleic acid sequence of SEQ ID NO: 158, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 158. In some embodiments, the polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein has a nucleic acid sequence of SEQ ID NO: 225, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO: 225. In some embodiments, the polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein has a nucleic acid sequence of SEQ ID NO:226, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to SEQ ID NO:226.

As appropriate, in certain embodiments, the 3' end of the polynucleotide encoding the fusion polypeptide or composite fusion polypeptide described herein comprises one or more tandem stop codons, such as two or more tandem TAG ("amber"), TAA ("ochre"), or TGA ("opal" or "umber") stop codons. The multiple tandem stop codons may be the same or different.

As the case may be, in certain embodiments, the 3' end of the polynucleotide encoding the fusion polypeptide or composite fusion polypeptide described herein does not contain a poly A sequence. As the case may be, in certain embodiments, the 3' end of the polynucleotide encoding the fusion polypeptide or composite fusion polypeptide described herein contains a poly A sequence.

An expression cassette is also provided, comprising a polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein, which is operably connected to one or more regulatory sequences, for example, a promoter. In some embodiments, the polynucleotide is operably connected to a constitutive promoter or an inducible promoter and is under its control. In some embodiments, the promoter is selected from the major immediate early promoter of cytomegalovirus (CMV), a CMV enhancer fused to a chicken β-actin promoter (CAG), human elongation factor-1α (HEF-1α), mouse cytomegalovirus (mouse CMV), Chinese hamster elongation factor-1α (CHEF-1α) and phosphoglycerate kinase (PGK). In some embodiments, the promoter is a natural promoter of a viral expression vector, for example, an arenavirus vector promoter, an adenovirus vector promoter, etc.

Also provided are methods for preparing fusion polypeptides or composite fusion polypeptides, pharmaceutical compositions, immunogenic compositions, or vaccine compositions comprising them. In some specific implementations, these methods include constructing fusion polypeptides or composite fusion polypeptides using peptide synthesis. In some embodiments, the method includes constructing polynucleotides encoding each of the polypeptides of the bivalent antigen using synthetic or recombinant DNA technology and expressing the polypeptides from expression vectors. In some embodiments, the method may also include inserting the polynucleotides into one or more vectors and expressing the encoded polypeptides in cells.

4. Vectors and Host Cells

Also provided are vectors comprising one or more polynucleotides encoding one or more of the fusion polypeptides or composite fusion polypeptides described herein, or or an expression cassette comprising such polynucleotides. The vector may be of any type, such as a recombinant vector, such as an expression vector. The vector includes, but is not limited to, plasmids, cosmids, bacterial artificial chromosomes (BACs) and yeast artificial chromosomes (YACs) and vectors derived from bacteriophages or plants or animals (including humans) viruses. The vector may include a replication origin recognized by the proposed host cell, and with respect to expression vectors, includes a promoter and other regulatory regions recognized by the host cell. In other embodiments, the vector includes one or more polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides disclosed herein, and the polynucleotides are operably connected to a promoter and optionally other regulatory elements. Certain vectors are capable of autonomous replication in the host into which they are introduced (for example, a vector with a bacterial replication origin can replicate in bacteria). Other vectors may be integrated into the host's genome when introduced into the host, thereby replicating with the host genome. The vector includes, but is not limited to, those suitable for recombinant production of fusion polypeptides and/or composite fusion polypeptides disclosed herein.

As used herein, the term "vector" refers to a nucleic acid molecule that is capable of propagating another nucleic acid connected thereto. The term includes vectors that are self-replicating nucleic acid structures and vectors that are integrated into the genome of a host cell into which the vector has been introduced. Some vectors are suitable for delivering nucleic acid molecules or polynucleotides of the present application. Certain vectors are capable of directing the expression of nucleic acids that are effectively connected thereto. Such vectors are referred to herein as expression vectors.

The term "operably linked" refers to two or more nucleic acid sequence elements that are typically physically linked and in a functional relationship with each other. For example, a promoter is operably linked to a coding sequence if it is capable of initiating or regulating the transcription or expression of the coding sequence, in which case the coding sequence is understood to be "under the control of the promoter."

The selection of the vector depends on the subsequent recombination procedure and the host used. The introduction of the vector into the host cell can be achieved by calcium phosphate transfection, DEAE-dextran-mediated transfection, lipofectamine transfection, electroporation, viral infection or via administration to the subject as described herein. The vector can replicate autonomously or can replicate together with the chromosome into which they are integrated. In certain embodiments, the vector contains one or more selection markers. The selection of the marker can depend on the host cell selected. These include but are not limited to kanamycin, neomycin, puromycin, hygromycin, zeocin, thymidine kinase gene (HSV-TK) from herpes simplex virus and dihydrofolate reductase gene (dhfr) from mouse. The present invention also encompasses vectors comprising one or more nucleic acid molecules encoding fusion polypeptides or composite fusion polypeptides described herein, which are operably connected to one or more nucleic acid molecules encoding proteins or peptides that can be used to separate immunogenic polypeptides. These proteins or peptides include but are not limited to glutathione-S-transferase, maltose binding protein, metal-binding polyhistidine, green fluorescent protein, luciferase and beta-galactosidase.

In various embodiments, the vector comprises one or more polynucleotides encoding one or more fusion polypeptides comprising or consisting of the amino acid sequence of any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223, and 227. In various embodiments, the vector comprises one or more polynucleotides encoding one or more fusion polypeptides comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223.

In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:82, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:82. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:83, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:83. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:85, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:85. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:86, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:86. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 87, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 87. In various embodiments, the vector comprising a polynucleotide encoding one or more of the aforementioned fusion polypeptides is Cali mammalian arenavirus (also known as Pichinde mammalian arenavirus or Pichinde arenavirus).

In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:85, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:85. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:98, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:98. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:99, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:99. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:100, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:100. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 101, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 101. In various embodiments, the vector comprising a polynucleotide encoding one or more of the foregoing fusion polypeptides is a lymphocytic choriomeningitis mammalian arenavirus (LCMV).

In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:209, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:209. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:222, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:222. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:223. In various embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:227.

In various embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a fusion polypeptide of SEQ ID NOs:70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:70 and 71, respectively;

a fusion polypeptide of SEQ ID NOs:72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:72 and 73, respectively;

a fusion polypeptide of SEQ ID NOs:74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively;

· a fusion polypeptide of SEQ ID NOs:76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively;

a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:78 and 79, respectively;

a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:80 and 81, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively;

a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:90 and 91, respectively;

a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively;

a fusion polypeptide of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 96, respectively;

a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively;

a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 100, respectively;

a fusion polypeptide of SEQ ID NOs:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 101, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively; or

a fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively;

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:84 and 85, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:82 and 85, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:84 and 88, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:90 and 91, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 96, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively.

In various embodiments, the vector comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively.

In various embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 105 or 206, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105 or 206.

In various embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 107 or 207, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107 or 207.

In various embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:109, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:109.

In various embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:111, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:111.

In various embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:200, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:200.

In various embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:201, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:201.

In various embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:202, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:202.

In various embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:203, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:203.

In various embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:204, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:204.

In various embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:205, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:205.

In various embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:208, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:208.

In various embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:209, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:209.

In various embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:222, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:222.

In various embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:223, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:223.

In various embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:227, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:227.

In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein, which has a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence selected from SEQ ID NOs: 130-167, 210-219 and 225-226. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein, which has a nucleic acid sequence of any one of SEQ ID NO: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or 100% identical to a nucleic acid sequence selected from SEQ ID NO: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226.

In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein, the polynucleotide having a nucleic acid sequence of SEQ ID NO: 139, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical or 100% identical to the nucleic acid sequence of SEQ ID NO: 139. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein, the polynucleotide having a nucleic acid sequence of SEQ ID NO: 142, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical or 100% identical to the nucleic acid sequence of SEQ ID NO: 142. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein, the polynucleotide having a nucleic acid sequence of SEQ ID NO: 145, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical or 100% identical to the nucleic acid sequence of SEQ ID NO: 145. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein, the polynucleotide having a nucleic acid sequence of SEQ ID NO: 148, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical or 100% identical to the nucleic acid sequence of SEQ ID NO: 148. In various embodiments, the vector comprising one or more of the foregoing polynucleotides is a lymphocytic choriomeningitis mammalian arenavirus (LCMV).

In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein, the polynucleotide having a nucleic acid sequence of SEQ ID NO: 150, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical, or 100% identical to the nucleic acid sequence of SEQ ID NO: 150. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein, the polynucleotide having a nucleic acid sequence of SEQ ID NO: 152, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical, or 100% identical to the nucleic acid sequence of SEQ ID NO: 152. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein, the polynucleotide having a nucleic acid sequence of SEQ ID NO: 155, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical or 100% identical to the nucleic acid sequence of SEQ ID NO: 155. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein, the polynucleotide having a nucleic acid sequence of SEQ ID NO: 158, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical or 100% identical to the nucleic acid sequence of SEQ ID NO: 158. In various embodiments, the vector comprising one or more of the aforementioned polynucleotides is a Cali mammalian arenavirus (also known as Pichinde mammalian arenavirus or Pichinde arenavirus).

In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein, the polynucleotide having a nucleic acid sequence of SEQ ID NO: 225, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical or 100% identical to the nucleic acid sequence of SEQ ID NO: 225. In some embodiments, the vector comprises a polynucleotide encoding a fusion polypeptide or a composite fusion polypeptide as described herein, the polynucleotide having a nucleic acid sequence of SEQ ID NO: 226, or a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical or 100% identical to the nucleic acid sequence of SEQ ID NO: 226.

In various embodiments, the vector comprises the following first and second polynucleotides:

· a polynucleotide of SEQ ID NOs: 130 and 132, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively;

· a polynucleotide of SEQ ID NOs: 130 and 134, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively;

· a polynucleotide of SEQ ID NOs: 131 and 133, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively;

· a polynucleotide of SEQ ID NOs: 131 and 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively;

· a polynucleotide of SEQ ID NOs: 132 and 136, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively;

· a polynucleotide of SEQ ID NOs: 133 and 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively;

· a polynucleotide of SEQ ID NOs: 133 and 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively;

· a polynucleotide of SEQ ID NOs: 134 and 136, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively;

· a polynucleotide of SEQ ID NOs: 135 and 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively;

· a polynucleotide of SEQ ID NOs: 138 and 141, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively;

· a polynucleotide of SEQ ID NOs: 138 and 144, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively;

· a polynucleotide of SEQ ID NOs: 139 and 142, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively;

· a polynucleotide of SEQ ID NOs: 139 and 145, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively;

· a polynucleotide of SEQ ID NOs: 140 and 146, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively;

· a polynucleotide of SEQ ID NOs: 142 and 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively;

· a polynucleotide of SEQ ID NOs: 143 and 149, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively;

· a polynucleotide of SEQ ID NOs: 145 and 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively;

· a polynucleotide of SEQ ID NOs: 150 and 152, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively;

· a polynucleotide of SEQ ID NOs: 150 and 155, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively;

· a polynucleotide of SEQ ID NOs: 151 and 153, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively;

· a polynucleotide of SEQ ID NOs: 151 and 156, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively;

· a polynucleotide of SEQ ID NOs: 152 and 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively;

· a polynucleotide of SEQ ID NOs: 153 and 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively;

· a polynucleotide of SEQ ID NOs: 154 and 157, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively;

· a polynucleotide of SEQ ID NOs: 155 and 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively;

· a polynucleotide of SEQ ID NOs: 156 and 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively;

· a polynucleotide of SEQ ID NOs: 160 and 161, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively;

· a polynucleotide of SEQ ID NOs: 162 and 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively;

· a polynucleotide of SEQ ID NOs: 164 and 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively;

· a polynucleotide of SEQ ID NOs: 166 and 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively;

· a polynucleotide of SEQ ID NOs: 210 and 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively;

· a polynucleotide of SEQ ID NOs: 212 and 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively;

· a polynucleotide of SEQ ID NOs: 214 and 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively;

· a polynucleotide of SEQ ID NOs: 216 and 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively;

· a polynucleotide of SEQ ID NOs: 218 and 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively;

a polynucleotide of SEQ ID NOs: 218 and 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or

· a polynucleotide of SEQ ID NOs: 225 and 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively;

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 130 or SEQ ID NO: 131, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 130 or SEQ ID NO: 131, respectively, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 134 or SEQ ID NO: 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 134 or SEQ ID NO: 135, respectively.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 132 or SEQ ID NO: 133, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 132 or SEQ ID NO: 133, respectively, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 136 or SEQ ID NO: 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 136 or SEQ ID NO: 137, respectively.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 139, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 139, respectively, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 145, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 145.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 140, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 140, respectively, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 146, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 146.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 142, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 142, respectively, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 148, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 148.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 143, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 143, respectively, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 149, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 149.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 150, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 150, respectively, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 152.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 151, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 151, respectively, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 153, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 153.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 154, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 154, respectively, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 157, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 157.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 155, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 155, respectively, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 158, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 158.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 156, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 156, respectively, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 159, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 159.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 160, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 160, respectively, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 161, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 161.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 162, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 162, respectively, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 163, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 163.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 164, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 164, respectively, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 165, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 165.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 166, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 166, respectively, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO: 167, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 167.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:211, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:211.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO:212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:212, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:213, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:213.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO:214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:214, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:215, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:215.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO:216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:216, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:217, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:217.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO:218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:218, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:219, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:219.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO:218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:218, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:226.

In various embodiments, the vector comprises the following first and second polynucleotides:

a) a first polynucleotide comprising: a polynucleotide of SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225, and

b) a second polynucleotide comprising: a polynucleotide of SEQ ID NO:226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:226.

In various embodiments, the vector comprises a polynucleotide comprising SEQ ID NO:225, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:225.

In various embodiments, the vector comprises a polynucleotide comprising: a polynucleotide of SEQ ID NO:226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:226.

In other embodiments, the vector used is pcDNA ^™ 3.1+ (ThermoFisher, MA).

In some embodiments, the vector is a viral vector. Depending on the circumstances, the viral vector can be a DNA virus or an RNA virus, including a self-replicating RNA virus. Self-replicating RNA viruses include alphaviruses, and are described, for example, in Lundstrom, Molecules. (2018) 23 (12). pii: E3310 (PMID: 30551668); and Ljungberg et al., Expert Rev Vaccines. (2015) 14 (2): 177-94). Additional alphaviruses used as viral vectors are described, for example, in WO 2020/097393 and WO 2018/208856. In various embodiments, the viral vector is from a virus selected from the group consisting of adenovirus, adeno-associated virus, arenavirus, alphavirus, self-replicating alphavirus, poxvirus, cytomegalovirus, rhabdovirus, vesicular stomatitis virus, flavivirus, Maraba virus, and vaccinia virus. In some embodiments, the viral vector is from a virus family selected from the group consisting of Adenoviridae (e.g., adenovirus, adeno-associated virus), Arenaviridae (e.g., lymphocytic choriomeningitis mammalian arenavirus, Cali mammalian arenavirus (also known as Pichinde mammalian arenavirus), Poxviridae (e.g., vaccinia virus), Herpesviridae (e.g., cytomegalovirus, herpes virus, e.g., HSV-1), Parvoviridae (e.g., Parvovirus H1), Poxviridae (e.g., vaccinia virus, e.g., modified vaccinia virus Ankara (MVA)), Flaviviridae (e.g., yellow fever virus), Reovirus (e.g., Reovirus), Picornaviridae (e.g., Coxsackievirus, Seneca Valley Virus, Poliovirus), Paramyxoviridae (e.g., measles virus, Newcastle disease virus, Virus) (NDV)), Rhabdoviridae (e.g., vesiculoviruses, including Maraba vesiculovirus and vesicular stomatitis virus (VSV)), Togaviridae (e.g., alphaviruses, e.g., Venezuelan equine encephalitis virus, e.g., self-replicating alphaviruses; Sindbis virus), Enteroviridae (e.g., Echovirus). Exemplary modified vaccinia virus vectors for expressing fusion polypeptides and/or composite fusion polypeptides of the present invention are described, e.g., in WO 2019/134049.

In some embodiments, the viral expression vector is an arenavirus vector selected from the group consisting of lymphocytic choriomeningitis mammalian arenavirus (LCMV) (NCBI: txid11623), Cali mammalian arenavirus (also known as Pichinde mammalian arenavirus or Pichinde virus) (NCBI: txid2169993), Guanarito virus (GTOV) (NCBI: txid45219), Argentine mammalian arenavirus (also known as Junin virus (JUNV)) (NCBI: txid2169993), and Argentine mammalian arenavirus (also known as Junin virus (JUNV)). txid2169991), Lassa virus (LASV) (NCBI: txid11620), Luyo virus (LUJV) (NCBI: txid649188), Machupo virus (MACV) (NCBI: txid11628), Brazilian mammalian arenavirus (also known as Sabia virus (SABV)) (NCBI: txid2169992) and Whitewater Arroyo virus (WWAV) (NCBI: txid46919). In some embodiments, the viral expression vector is an arenavirus vector selected from the following: lymphocytic choriomeningitis mammalian arenavirus (LCMV) or Cali mammalian arenavirus (also known as Pichinde mammalian arenavirus or Pichinde arenavirus). Exemplary arenavirus vectors that can be used as delivery and expression vehicles for the fusion polypeptides described herein are described in, e.g., WO 2009/083210, WO 2015/183895, WO 2016/075250, WO 2017/198726, and U.S. Pat. No. 9,943,585.

In some embodiments, the viral expression vector is an adenoviral vector, e.g., from a human adenovirus or a simian adenovirus (e.g., a chimpanzee adenovirus, a gorilla adenovirus, or a rhesus monkey adenovirus). In some embodiments, the adenoviral vector is selected from a serotype 5 adenovirus (Ad5), a serotype 26 adenovirus (Ad26), a serotype 34 adenovirus (Ad34), a serotype 35 adenovirus (Ad35), a serotype 48 adenovirus (Ad48), a chimpanzee adenovirus (e.g., ChAd3 (AdC3), ChAd5 (AdC5), ChAd6 (AdC6), ChAd7 (AdC7), ChAd8 (AdC8), ChAd9 (AdC9), ChAd10 (AdC10), ChAd11(AdC11), ChAd17(AdC17), ChAd16(AdC16), ChAd19(AdC19), ChAd20(AdC20), ChAd22(AdC22), ChAd24(AdC24), ChAdY25, ChAd26(AdC26), ChAd28(AdC28), ChAd30(AdC30) ,ChAd31(AdC31),ChAd37( AdC37), ChAd38(AdC38), ChAd43(AdC43), ChAd44(AdC44), ChAd55(AdC55), ChAd63(AdC63), ChAdV63, ChAd68(AdC68), ChAd73(AdC73), ChAd82(AdC82), ChAd83(AdC83), ChAd143(AdC14 3), ChAd144 (AdC144), ChAd 145 (AdC145), ChAd147 (AdC147)), gorilla adenovirus (e.g., GC44, GC45, GC46), and rhesus macaque adenovirus (e.g., RhAd51, RhAd52, RhAd53, RhAd54, RhAd55, RhAd56, RhAd57, RhAd58, RhAd59, RhAd60, RhAd61, RhAd62, RhAd63, RhAd64, RhAd65, RhAd66). Exemplary chimpanzee, gorilla and macaque adenovirus vectors that can be used as delivery and expression vehicles for the fusion polypeptides and/or composite fusion polypeptides described herein are described, for example, in the following documents: WO 2019/076880; WO 2019/076877; Andrabi et al., (2019) Cell Reports 27:2426-2441; Guo et al., Hum Vaccin Immunother. (2018) 14(7):1679-1685; Abbink et al., J Virol. (2015) 89(3):1512-22; Abbink et al., J Virol. (2018) 92(6).pii:e01924-17, and in WO 2020/243719A1 and WO 2018/098362A1.

In various embodiments, the viral expression vector is unable to replicate (ie, replication-defective or replication-deficient), eg, has reduced or attenuated replication capacity compared to a wild-type viral vector (ie, replication-attenuated), or is replication-competent.

Also provided is a host cell comprising one or more polynucleotides encoding one or more of the fusion polypeptides or composite fusion polypeptides described herein or one or more vectors expressing the fusion polypeptides or composite fusion polypeptides. Any of a variety of host cells can be used. In one embodiment, the host cell is a prokaryotic cell, such as Escherichia coli. In another embodiment, the host cell is a eukaryotic cell, such as a yeast cell, a plant cell, an insect cell, a mammalian cell, such as a cell line based on Chinese hamster ovary (CHO) or CHO-derived (e.g., CHO-S, CHO DG44, ExpiCHO ^™ , ZFN-modified GS-/- CHO cell lines, CHO-K1, CHO-K1a), COS cells, BHK cells, NSO cells or Bowes melanoma cells. Examples of human host cells are, inter alia, HeLa, 911, AT1080, A549 and HEK293 (e.g., HEK293E, HEK293F, HEK293H, HEK293T, Expi293 ^™ ). In addition, the fusion polypeptide and/or complex fusion polypeptide can be expressed in yeast cells such as Pichia pastoris (see, e.g., Powers et al., J Immunol Methods. 251: 123-35 (2001)), Hanseula or Saccharomyces.

The terms "host cell", "host cell line" and "host cell culture" are used interchangeably to refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells", including primary transformed cells and progeny derived therefrom, without regard to the number of passages. Progeny may not be completely identical to the parent cell in terms of nucleic acid content, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected in the initially transformed cell are included herein.

As the case may be, the host cell can be stably or transiently transfected with one or more polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides as described herein. As the case may be, the host cell can be infected with one or more vectors expressing one or more fusion polypeptides or composite fusion polypeptides as described herein. In some embodiments, the host cell can express one or more replication attenuated or replication-capable vectors of one or more fusion polypeptides or composite fusion polypeptides as described herein or can propagate the vector. Exemplary cells suitable for being infected by viral vectors and/or propagating viral vectors include but are not limited to BHK-21, A549, Vero and HEK293 (e.g., HEK293E, HEK293F, HEK293H, HEK293T, Expi293 ^TM ) cells. In certain embodiments, the host cell expresses Coxsackie virus and adenovirus receptor (CAR), such as MDCK, Caco-2 or Calu-3 host cells. In certain embodiments, the polynucleotides are integrated into the genome of the host cell.

5. Pharmaceutical compositions/immunogenic compositions

Provided are pharmaceutical compositions or immunogenic compositions, comprising one or more of a fusion polypeptide or a composite fusion polypeptide as described herein, or polynucleotides encoding one or more of a fusion polypeptide or a composite fusion polypeptide as described herein, or a viral expression vector comprising one or more such polynucleotides, and a pharmaceutically acceptable diluent, carrier or excipient. Typically, the pharmaceutical compositions described herein are immunogenic. In certain embodiments, the pharmaceutical composition comprises a therapeutically effective amount of one or more fusion polypeptides or composite fusion polypeptides, or one or more polynucleotides encoding a fusion polypeptide or a composite fusion polypeptide, or one or more viral expression vectors containing one or more polynucleotides encoding a fusion polypeptide or a composite fusion polypeptide.

Various pharmaceutically acceptable diluents, carriers, and excipients, as well as techniques for preparing and using pharmaceutical compositions or immunogenic compositions will be known to those of skill in the art in light of the present disclosure. Exemplary pharmaceutical compositions and pharmaceutically acceptable diluents, carriers and excipients are also described, for example, in the following literature: Loyd V. Allen Jr (ed.), "Remington: The Science and Practice of Pharmacy," 22nd edition, 2012, Pharmaceutical Press; Brunton, Knollman and Hilal-Dandan, "Goodman and Gilman's The Pharmacological Basis of Therapeutics," 13th edition, 2017, McGraw-Hill Education/Medical; McNally and Hastedt (eds.), "Protein Formulation and Delivery," 2nd edition, 2007, CRC Press; Banga, "Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems," 3rd edition, 2015, CRC Press; Lars Hovgaard, Frokjaer and van de Weert (eds.), "Pharmaceutical Formulation Development of Peptides and Proteins," 2nd edition, 2012, CRC Press Press; Carpenter and Manning (Editors), "Rational Design of Stable Protein Formulations: Theory and Practice," 2002, Springer (Pharmaceutical Biotechnology (Book 13)); Meyer (Editor), "Therapeutic Protein Drug Products: Practical Approaches to Formulation in the Laboratory, Manufacturing, and the Clinic," 2012, Woodhead Publishing.

In certain embodiments, polynucleotides or carriers are formulated into lipid complexes, for example, lipid nanoparticles (LNPs). As used herein, "lipoplexes" refer to cationic liposomes as non-viral (synthetic) lipid carriers of one or more polynucleotides (e.g., RNA, DNA). For example, in some embodiments in which fusion polypeptides and/or composite fusion polypeptides are expressed by self-replicating or self-amplifying RNA molecules, self-replicating or self-amplifying RNAs can be formulated into LNPs. As used herein, the term "lipid nanoparticles" refers to one or more spherical nanoparticles of a solid lipid core matrix with an average diameter between about 10 nanometers and about 1000 nanometers and including a lipophilic molecule that can dissolve. In certain embodiments, the lipid core is stabilized by a surfactant (e.g., an emulsifier) and may include one or more of the following items: triglycerides (e.g., tristearin), diglycerides (e.g., glyceryl behenate), monoglycerides (e.g., glyceryl monostearate), fatty acids (e.g., stearic acid), steroids (e.g., cholesterol) and waxes (e.g., cetyl palmitate), including combinations thereof. Lipid nanoparticles are described, for example, in Petrilli et al., Curr Pharm Biotechnol. 15:847-55, 2014; and U.S. Pat. Nos. 6,217,912, 6,881,421, 7,402,573, 7,404,969, 7,550,441, 7,727,969, 8,003,621, 8,691,750, 8,871,509, 9,017,726, 9,173,853, 9,220,779, 9,227,917, and 9,278,130, each of which is incorporated by reference in its entirety. In one embodiment, a self-replicating or self-amplifying RNA (saRNA) molecule encoding one or more of the fusion polypeptides or composite fusion polypeptides described herein is formulated or condensed into a polyethyleneimine (PEI)-complex delivery vehicle, e.g., as described in Moyo et al., Mol Ther Methods Clin Dev. (2018) 12:32-46; Blakney et al., Gene Therapy (2019) 26:363-372; Démoulins et al., Nanomedicine. (2016) Apr; 12(3):711-722 and Démoulins et al., J Control Release. (2017) 266:256-271, which may be a nanoparticle.

In embodiments where the fusion polypeptide or composite fusion polypeptide is expressed by a viral expression vector, the viral expression vector can be formulated for a desired route of administration, e.g., as an isotonic pharmaceutically acceptable aqueous solution for intravenous, intramuscular, subcutaneous, or intranodal administration. In some embodiments, the viral expression vector can be formulated for mucosal (e.g., buccal or intrarectal) delivery. Exemplary formulations of viral expression vectors that can be used in the pharmaceutical compositions and methods described herein are described, for example, in the following literature: Manfredsson and Benskey, eds., "Viral Vectors for Gene Therapy: Methods and Protocols (Methods in Molecular Biology)," 2019, Book 1937 in Methods in Molecular Biology Series, Humana Press; WO 2017/013169 (formulation of Adenoviral vectors in an aqueous mixture or freeze dried composition in the presence of amorphous sugar and low salt concentration); and Kumru et al., J Pharm Sci. (2018) November; 107(11): 2764-3374 (aqueous formulations buffered in Tris and containing proline, lactose, and mannitol as stabilizing additives). The formulation of arenavirus vectors is described, for example, in WO 2009/083210, WO 2016/075250, and WO 2017/198726. In certain embodiments, the viral expression vector is delivered via microneedle-mediated delivery, for example, as described in Zaric et al., Expert Opin Drug Deliv. (2017) October; 14(10): 1177-1187. Intranodal delivery of mRNA vaccines is described, for example, in Jong et al., Vaccines (Basel). (2019) 7(4): 209; Leal et al., AIDS. (2018) 32(17): 2533-2545; Jong et al., Trials. (2019) 20(1): 361; and Joe et al., J Transl Med. (2019) 17(1): 242.

In some embodiments, each carrier, diluent or excipient is "acceptable" in the sense that it is compatible with the pharmaceutical composition/immunogenic composition and the other ingredients and is not injurious to the subject. Typically, a pharmaceutically acceptable carrier is an aqueous pH buffer. Some examples of materials that can be used as pharmaceutically acceptable carriers, diluents or excipients include: water; buffers, e.g., buffers with a pKa in the range of about 6.0 to about 8.0, e.g., physiologically acceptable buffers, e.g., selected from phosphate, carbonate, bicarbonate, citrate, maleate, glycine-glycine, HEPES, HEPPSO, HEPPS, imidazole, BICINE, TRICINE, Tris and BIS-Tris; sugars, such as lactose, trehalose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethyl cellulose and cellulose acetate; powdered Tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository wax; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Hank's solution, Ringer's solution; ethanol; phosphate buffer solution; amino acids (e.g., charged amino acids, including but not limited to aspartic acid, asparagine, glutamic acid, glutamine, histidine, arginine, lysine); and other nontoxic compatible substances used in pharmaceutical preparations. Wetting agents, emulsifiers and lubricants (such as sodium lauryl sulfate and magnesium stearate) as well as coloring agents, release agents, coating agents, sweeteners, flavoring agents and fragrances, preservatives and antioxidants may also be present in the composition.

In one particular formulation, an arenavirus vector described herein (e.g., LCMV or a Pichin's mammalian arenavirus vector (PICV)) is formulated in an isotonic aqueous solution comprising a biocompatible buffer (e.g., HEPES and NaCl) at a neutral or near-neutral pH and a pKa in the range of about 6.0 to about 8.0, and a nonionic surfactant (e.g., F68 (also known as Poloxamer 188). In one particular formulation, the arenavirus vector described herein (e.g., LCMV or Pichinde mammalian arenavirus vector) is formulated in an isotonic aqueous solution comprising HEPES buffer at pH 7.4, NaCl and F68 (also known as Poloxamer 188). Schleiss et al. (Clin Vaccine Immunol. 2017 Jan 5; 24(1): e00300-16) describe the formulation of LCMV vectors in a diluent of 25 mM HEPES, 150 mM NaCl, 0.01% PLURONIC F68 at pH 7.4, which can be used to formulate the arenavirus vectors described herein. Sorbitol was added to a final concentration of 10% before freezing below -60°C.

The preparation and delivery method of the pharmaceutical composition or immunogenic composition will generally be adjusted according to the site and disease to be treated. Exemplary preparations include, but are not limited to, those suitable for parenteral administration (e.g., intravenous, intraarterial, intramuscular, subcutaneous or intranodal administration), including preparations encapsulated in micelles, liposomes or drug release capsules (incorporated in an active agent designed for slow release in a biocompatible coating); ingestible preparations; preparations for topical use, such as creams, ointments and gels; and other preparations, such as inhalants, aerosols and sprays. In some embodiments, the pharmaceutical composition or immunogenic composition is formulated for parenteral (e.g., intravenous, subcutaneous, intranodal or oral) administration. In some embodiments, the pharmaceutical composition or immunogenic composition is formulated for mucosal (e.g., buccal, rectal and/or intravaginal) administration. In some embodiments, for intrarectal administration, the pharmaceutical composition or immunogenic composition may be formulated as a suppository or enema. In some embodiments, for intravaginal administration, the pharmaceutical composition or immunogenic composition may be formulated as a vaginal suppository.

In certain embodiments, the pharmaceutical composition/immunogenic composition is sterile. In certain embodiments, the pharmaceutical composition or immunogenic composition has a pH in the range of 4.5 to 8.5, 4.5 to 6.5, 6.5 to 8.5, or a pH of about 5.0, about 5.5, about 6.0, about 6.5, about 7.0, about 7.5, about 8.0, or about 8.5. In one embodiment, the pharmaceutical composition/immunogenic composition has an osmotic capacity in the range of 240mOsmol/L to 260mOsmol/L or 250mOsmol/L to 330mOsmol/L. In certain embodiments, the pharmaceutical composition/immunogenic composition is isotonic or nearly isotonic.

In some embodiments, the pharmaceutical composition or immunogenic composition is a liquid or solid. In some embodiments, the pharmaceutical composition or immunogenic composition comprises an aqueous solution. In some embodiments, the pharmaceutical composition or immunogenic composition is lyophilized or is a frozen liquid.

In some embodiments, the pharmaceutical composition or immunogenic composition further comprises one or more additional therapeutic agents, such as a second therapeutic agent, or a second therapeutic agent and a third therapeutic agent, for use in combination therapy as described herein.

In certain embodiments, pharmaceutical composition or immunogenic composition also include adjuvant.Exemplary adjuvants that can be co-formulated or co-administered with fusion polypeptide as described herein or composite fusion polypeptide, polynucleotides encoding such fusion polypeptide or composite fusion polypeptide and carriers expressing such fusion polypeptide or composite fusion polypeptide include but are not limited to cytokines, chemokines, immune co-stimulatory molecules, toll-like receptor agonists, activator mimics derived from the second mitochondria of caspase (SMAC) or inhibitors (such as immune checkpoint inhibitors) of immunosuppressive pathways, as described herein, and described in Li et al., Curr Issues Mol Biol. (2017) 22: 17-40. Other adjuvants that can be co-formulated or co-administered with the fusion polypeptides or composite fusion polypeptides described herein, polynucleotides encoding such fusion polypeptides or composite fusion polypeptides, and vectors expressing such fusion polypeptides or composite fusion polypeptides include, but are not limited to, mineral salts (e.g., aluminum salts (e.g., alum), calcium phosphate, incomplete Freund's adjuvant), lipid particles (e.g., MF59, cochleate, virus-like particles), microparticles (e.g., virosomes, polylactic acid (PLA), poly[lactide-co-glycolide] (PLG)), immunopotentiators (e.g., dsRNA:Poly(I:C), P oly-IC: LC, monophosphoryl lipid A (MPL), LPS, flagellin, imidazoline quinoline: imiquimod (R837), resiquimod (848), CpG oligodeoxynucleotide (ODN), muramyl dipeptide (MDP), saponin (QS-21) and mucosal adjuvants (e.g., cholera toxin (CT), heat-labile enterotoxin (LTK3 and LTR72), chitosan). Adjuvants that can be co-formulated or co-administered with the fusion polypeptides described herein, polynucleotides encoding such fusion polypeptides, and vectors expressing such fusion polypeptides are described in Apostólico et al., J Immunol Res. (2016) 2016: 1459394.

In some embodiments, the pharmaceutical composition or immunogenic composition comprises two or more fusion polypeptides and/or composite fusion polypeptides, two or more polynucleotides encoding such fusion polypeptides and/or composite fusion polypeptides, or two or more vectors expressing such fusion polypeptides and/or composite fusion polypeptides. In various embodiments, the pharmaceutical composition or immunogenic composition comprises a bivalent first fusion polypeptide and a second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding a bivalent first and second fusion polypeptide. In some embodiments, the pharmaceutical composition or immunogenic composition comprises a first fusion polypeptide and a second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, and the first and second polypeptides comprise the following polypeptide fragments optionally bound or connected by one or more linkers in order from N-terminus to C-terminus:

SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17;

SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11;

SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21;

SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17;

SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11;

SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 15, 21 and 19;

SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17;

SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ ID NOs: 9, 13, 25, 23, 15 and 11;

SEQ ID NOs: 18, 26, 20, 4, 6 and 16, and SEQ ID NOs: 7, 21, 17, 5, 27 and 19;

SEQ ID NOs: 22, 24, 12, 14, 8 and 10, and SEQ ID NOs: 15, 25, 9, 23, 13 and 11;

SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10;

SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 7, 21, 5, 25, 33 and 19;

SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10;

SEQ ID NOs: 8, 30, 14, 12, 26 and 10, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11;

SEQ ID NOs: 6, 20, 4, 24, 32 and 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10;

SEQ ID NOs: 7, 21, 5, 25, 33 and 19, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11;

SEQ ID NOs: 20, 32, 24, 4, 6 and 18, and SEQ ID NOs: 26, 30, 12, 14, 8 and 10;

SEQ ID NOs: 7, 25, 19, 5, 33 and 21, and SEQ ID NOs: 15, 31, 9, 27, 13 and 11;

SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 20, 10 and 28;

SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28;

SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19;

SEQ ID NOs: 7, 19, 17 and 25, and SEQ ID NOs: 21, 27, 11 and 29;

SEQ ID NOs: 24, 16, 6 and 18, and SEQ ID NOs: 27, 11, 21 and 29;

SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 11, 27, 21 and 29;

SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29;

SEQ ID NOs: 22, 6, 20 and 28, and SEQ ID NOs: 23, 7, 21 and 29;

SEQ ID NOs: 22, 20, 6 and 28, and SEQ ID NOs: 7, 21, 23 and 29;

SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29;

SEQ ID NO: 22, 6, 16, 20, 18, 28, 26 and 10; or

· SEQ ID NO: 7, 21, 19, 17, 27, 25, 29 and 11.

In some embodiments, the pharmaceutical composition or immunogenic composition comprises one or more (e.g., two or more) fusion polypeptides, or one or more (e.g., two or more) vectors comprising one or more polynucleotides encoding one or more (e.g., two or more) fusion polypeptides, which fusion polypeptides comprise or consist of the amino acid sequence of any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223, and 227. In some embodiments, the pharmaceutical composition or immunogenic composition comprises one or more (e.g., two or more) fusion polypeptides, or one or more (e.g., two or more) vectors comprising one or more polynucleotides encoding one or more (e.g., two or more) fusion polypeptides, which fusion polypeptides comprise or consist of the amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223.

In some embodiments, a pharmaceutical composition or immunogenic composition comprises the following first and second fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked via one or more linkers:

a fusion polypeptide of SEQ ID NOs:70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:70 and 71, respectively;

a fusion polypeptide of SEQ ID NOs:72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:72 and 73, respectively;

a fusion polypeptide of SEQ ID NOs:74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively;

· a fusion polypeptide of SEQ ID NOs:76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively;

a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:78 and 79, respectively;

a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:80 and 81, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively;

a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:90 and 91, respectively;

· A fusion polypeptide of SEQ ID NOs:92 and 93, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 1

98% or 99% identical fusion polypeptides;

a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively;

a fusion polypeptide of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 96, respectively;

a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively;

a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 100, respectively;

a fusion polypeptide of SEQ ID NOs:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 101, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively; or

· A fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively.

In some embodiments, the pharmaceutical composition or immunogenic composition comprises a composite fusion polypeptide or a vector comprising a polynucleotide encoding a composite fusion polypeptide, which composite fusion polypeptide comprises or consists of: an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the pharmaceutical composition or immunogenic composition comprises a composite fusion polypeptide or a vector comprising a polynucleotide encoding a composite fusion polypeptide, which composite fusion polypeptide comprises or consists of: an amino acid sequence of any one of SEQ ID NOs: 209, 222 and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 209, 222 and 223. In some embodiments, the pharmaceutical composition or immunogenic composition comprises a composite fusion polypeptide or a vector comprising a polynucleotide encoding a composite fusion polypeptide, which composite fusion polypeptide comprises or consists of: an amino acid sequence of SEQ ID NO:209, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:209. In some embodiments, the pharmaceutical composition or immunogenic composition comprises a composite fusion polypeptide or a vector comprising a polynucleotide encoding a composite fusion polypeptide, which composite fusion polypeptide comprises or consists of: an amino acid sequence of SEQ ID NO:222, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:222. In some embodiments, the pharmaceutical composition or immunogenic composition comprises a composite fusion polypeptide or a vector comprising a polynucleotide encoding a composite fusion polypeptide, which composite fusion polypeptide comprises or consists of: the amino acid sequence of SEQ ID NO:223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:223. In some embodiments, the pharmaceutical composition or immunogenic composition comprises a composite fusion polypeptide or a vector comprising a polynucleotide encoding a composite fusion polypeptide, which composite fusion polypeptide comprises or consists of: an amino acid sequence of SEQ ID NO:227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:227.

In some embodiments, the pharmaceutical composition or immunogenic composition comprises the following first and second fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides in order from N-terminus to C-terminus, optionally bound or linked by one or more linkers:

a fusion polypeptide of SEQ ID NOs:70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:70 and 71, respectively;

a fusion polypeptide of SEQ ID NOs:71 and 70, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:71 and 70, respectively;

a fusion polypeptide of SEQ ID NOs:72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:72 and 73, respectively;

a fusion polypeptide of SEQ ID NOs:73 and 72, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:73 and 72, respectively;

a fusion polypeptide of SEQ ID NOs:74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively;

a fusion polypeptide of SEQ ID NOs:75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:75 and 74, respectively;

a fusion polypeptide of SEQ ID NOs:76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively;

a fusion polypeptide of SEQ ID NOs:77 and 76, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:77 and 76, respectively;

a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:78 and 79, respectively;

a fusion polypeptide of SEQ ID NOs:79 and 78, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:79 and 78, respectively;

a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:80 and 81, respectively;

a fusion polypeptide of SEQ ID NOs:81 and 80, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:81 and 80, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively;

a fusion polypeptide of SEQ ID NOs:83 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 84, respectively;

a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 86, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:89 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:89 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively;

a fusion polypeptide of SEQ ID NOs:86 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 83, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 84, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 84, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:89 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:89 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively;

a fusion polypeptide of SEQ ID NOs: 101 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:90 and 91, respectively;

a fusion polypeptide of SEQ ID NOs:91 and 90, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:91 and 90, respectively;

a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively;

a fusion polypeptide of SEQ ID NOs:93 and 92, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:93 and 92, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively;

a fusion polypeptide of SEQ ID NOs:95 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 94, respectively;

a fusion polypeptide of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively;

a fusion polypeptide of SEQ ID NOs:97 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:97 and 96, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 96, respectively;

a fusion polypeptide of SEQ ID NOs:96 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 94, respectively;

a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively;

a fusion polypeptide of SEQ ID NOs:97 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:97 and 95, respectively;

a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;

a fusion polypeptide of SEQ ID NOs: 221 and 220, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 100, respectively;

a fusion polypeptide of SEQ ID NOs: 100 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively;

a fusion polypeptide of SEQ ID NOs:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 101, respectively;

a fusion polypeptide of SEQ ID NOs: 101 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively;

a fusion polypeptide of SEQ ID NOs:99 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 98, respectively;

a fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or

· A fusion polypeptide of SEQ ID NOs: 101 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 105 or 206, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105 or 206.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 107 or 207, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107 or 207.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 109, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 109.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:111, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:111.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:200, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:200.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:201, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:201.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:202, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:202.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:203, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:203.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:204, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:204.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:205, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:205.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:208, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:208.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:209, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:209.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:222, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:222.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:223, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:223.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:227, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:227.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or liposome complex (e.g., LNP) and a second viral vector or liposome complex (e.g., LNP), wherein the first viral vector or liposome complex (e.g., LNP) comprises a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 200 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 200, and the second viral vector or liposome complex (e.g., LNP) comprises a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 201 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 202. NO:201 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polypeptides.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 202 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 202, and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 203 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 204. NO:203 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polypeptide.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 204 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 204, and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 205 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 206. NO:205 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polypeptide.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 105 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 105, and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 107 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 108. A polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to NO:107.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 206 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 206, and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 207 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 208. A polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to NO:207.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 208 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 208, and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209 or SEQ ID NO: A polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to NO:227.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 222 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222, and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. A polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to NO:227.

In various embodiments, the immunogenic composition or pharmaceutical composition comprises a first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising a polypeptide comprising SEQ ID NO: 222 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222, and a second viral vector or liposome complex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising a polypeptide comprising SEQ ID NO: 223 or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 224. NO:223 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polypeptide.

In some embodiments, the pharmaceutical composition or immunogenic composition comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226. In some embodiments, the pharmaceutical composition or immunogenic composition comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226.

In some embodiments, the pharmaceutical composition or immunogenic composition comprises the following first polynucleotide and second polynucleotide, or one or more vectors comprising the following first polynucleotide and second polynucleotide, the first and second polynucleotides respectively comprising or consisting of:

· a polynucleotide of SEQ ID NOs: 130 and 132, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively;

· a polynucleotide of SEQ ID NOs: 130 and 134, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively;

· a polynucleotide of SEQ ID NOs: 131 and 133, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively;

· a polynucleotide of SEQ ID NOs: 131 and 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively;

· a polynucleotide of SEQ ID NOs: 132 and 136, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively;

· a polynucleotide of SEQ ID NOs: 133 and 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively;

· a polynucleotide of SEQ ID NOs: 133 and 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively;

· a polynucleotide of SEQ ID NOs: 134 and 136, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively;

· a polynucleotide of SEQ ID NOs: 135 and 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively;

· a polynucleotide of SEQ ID NOs: 138 and 141, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively;

· a polynucleotide of SEQ ID NOs: 138 and 144, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively;

· a polynucleotide of SEQ ID NOs: 139 and 142, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively;

· a polynucleotide of SEQ ID NOs: 139 and 145, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively;

· a polynucleotide of SEQ ID NOs: 140 and 146, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively;

· a polynucleotide of SEQ ID NOs: 142 and 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively;

· a polynucleotide of SEQ ID NOs: 143 and 149, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively;

· a polynucleotide of SEQ ID NOs: 145 and 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively;

· a polynucleotide of SEQ ID NOs: 150 and 152, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively;

· a polynucleotide of SEQ ID NOs: 150 and 155, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively;

· a polynucleotide of SEQ ID NOs: 151 and 153, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively;

· a polynucleotide of SEQ ID NOs: 151 and 156, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively;

· a polynucleotide of SEQ ID NOs: 152 and 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively;

· a polynucleotide of SEQ ID NOs: 153 and 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively;

· a polynucleotide of SEQ ID NOs: 154 and 157, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively;

· a polynucleotide of SEQ ID NOs: 155 and 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively;

· a polynucleotide of SEQ ID NOs: 156 and 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively;

· a polynucleotide of SEQ ID NOs: 160 and 161, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively;

· a polynucleotide of SEQ ID NOs: 162 and 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively;

· a polynucleotide of SEQ ID NOs: 164 and 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively;

· a polynucleotide of SEQ ID NOs: 166 and 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively;

· a polynucleotide of SEQ ID NOs: 210 and 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively;

· a polynucleotide of SEQ ID NOs: 212 and 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively;

· a polynucleotide of SEQ ID NOs: 214 and 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively;

· a polynucleotide of SEQ ID NOs: 216 and 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively;

· a polynucleotide of SEQ ID NOs: 218 and 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively;

a polynucleotide of SEQ ID NOs: 218 and 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or

· A polynucleotide of SEQ ID NOs: 225 and 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a first and a second polynucleotide of SEQ ID NOs: 131 and 135, or a first and a second polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; and

b) a second viral vector comprising: a first and a second polynucleotide of SEQ ID NOs: 133 and 137, or a first and a second polynucleotide that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a first and a second polynucleotide of SEQ ID NOs: 139 and 145, or a first and a second polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; and

b) a second viral vector comprising: a first and a second polynucleotide of SEQ ID NOs: 142 and 148, or a first and a second polynucleotide that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a first and a second polynucleotide of SEQ ID NOs: 140 and 146, or a first and a second polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; and

b) a second viral vector comprising: a first and a second polynucleotide of SEQ ID NOs: 143 and 149, or a first and a second polynucleotide that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a first and a second polynucleotide of SEQ ID NOs: 150 and 152, or a first and a second polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and

b) a second viral vector comprising: a first and a second polynucleotide of SEQ ID NOs: 154 and 157, or a first and a second polynucleotide that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a first and a second polynucleotide of SEQ ID NOs: 150 and 152, or a first and a second polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and

b) a second viral vector comprising: a first and a second polynucleotide of SEQ ID NOs: 155 and 158, or a first and a second polynucleotide that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a first and a second polynucleotide of SEQ ID NOs: 151 and 153, or a first and a second polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; and

b) a second viral vector comprising: a first and a second polynucleotide of SEQ ID NOs: 156 and 159, or a first and a second polynucleotide that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a polynucleotide of SEQ ID NO: 160, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 160, respectively; and

b) a second viral vector comprising: a polynucleotide of SEQ ID NO: 161, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 161, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a polynucleotide of SEQ ID NO: 162, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 162, respectively; and

b) a second viral vector comprising: a polynucleotide of SEQ ID NO: 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 163, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a polynucleotide of SEQ ID NO: 164, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 164, respectively; and

b) a second viral vector comprising: a polynucleotide of SEQ ID NO: 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 165, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a polynucleotide of SEQ ID NO: 166, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 166, respectively; and

b) a second viral vector comprising: a polynucleotide of SEQ ID NO: 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 167, respectively.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a polynucleotide of SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210; and

b) a second viral vector comprising: a polynucleotide of SEQ ID NO:211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:211.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a polynucleotide of SEQ ID NO: 212, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212; and

b) a second viral vector comprising: a polynucleotide of SEQ ID NO:213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:213.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a polynucleotide of SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214; and

b) a second viral vector comprising: a polynucleotide of SEQ ID NO:215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:215.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a polynucleotide of SEQ ID NO: 216, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216; and

b) a second viral vector comprising: a polynucleotide of SEQ ID NO:217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:217.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a polynucleotide of SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218; and

b) a second viral vector comprising: a polynucleotide of SEQ ID NO:219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:219.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a polynucleotide of SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218; and

b) a second viral vector comprising: a polynucleotide of SEQ ID NO:226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:226.

In various embodiments, the immunogenic or pharmaceutical composition comprises a first and a second viral vector comprising one or more polynucleotides:

a) a first viral vector comprising: a polynucleotide of SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225; and

b) a second viral vector comprising: a polynucleotide of SEQ ID NO:226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:226.

In various embodiments of the pharmaceutical composition or immunogenic composition, the one or more fusion polypeptides do not comprise any polypeptide fragments corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116 and Nef149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In various embodiments of the pharmaceutical composition or immunogenic composition, the one or more fusion polypeptides do not comprise any polypeptide fragment having an amino acid sequence of SEQ ID NOs: 35-47 or a fragment or subsequence thereof, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47 or a fragment or subsequence thereof.

6. Treatment Methods

Also provided is a method for treating or preventing HIV infection or related diseases or disorders in a subject (e.g., a human subject) in need thereof, the method comprising providing an effective amount of one or more fusion polypeptides or composite fusion polypeptides as described herein or one or more polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides as described herein or expressing one or more fusion polypeptides or composite fusion polypeptides as described herein to a subject in need thereof. As used herein, the term "subject" refers to a mammal. The mammal can be any mammal, such as a human, non-human primate, rodent (e.g., mouse, rat, guinea pig), dog, cat, or domestic animal (such as a cow, horse, goat, camel, sheep, or pig). The term "patient" refers to a human subject. As used herein, the term "effective amount" refers to the amount of therapy to achieve the desired preventive or therapeutic effect in the context of administering therapy to a subject. The polynucleotide may be present in a vector (e.g., a viral vector as described herein). In some embodiments, the related disease or disorder is caused by HIV infection. In other embodiments, it is acquired immunodeficiency syndrome (AIDS). In certain embodiments, the subject is a mammal infected by HIV of virological inhibition, and in other embodiments, the subject is a mammal infected by HIV of treatment naive type or a subject infected by HIV of treatment without virological inhibition. In certain embodiments, the treatment naive type subject has a viral load between <50 copies/mL and 10 ⁸ copies/ml. In certain embodiments, the subject of virological inhibition has a viral load of <50 copies/ml. In another embodiment, the subject is a mammal, such as a person. In certain embodiments, the subject has been diagnosed with HIV (such as HIV-1 or HIV-2) infection or associated disease or disorder (such as AIDS), or is considered to be in the risk of HIV (such as HIV-1 or HIV-2) infection or associated disease or disorder (such as AIDS). Subjects in the risk of HIV related diseases or disorders include patients who have been exposed to HIV in some other way or have been exposed to HIV with infected people. The use of preventive agents can occur before the characteristic symptoms of HIV related diseases or disorders are manifested, so that preventive diseases or disorders or alternatively delay their progress.

In some embodiments, the subject is chronically infected with HIV-1. In some embodiments, the subject is acutely infected with HIV-1, for example, with Fiebig IV stage or earlier, such as Fiebig III stage, Fiebig II stage or Fiebig I stage HIV-1 infection. In some embodiments, the subject does not receive antiretroviral therapy (ART), or ART is interrupted before applying one or more compositions. In some embodiments, ART is interrupted after one or more administrations of the composition. In some embodiments, ART is administered simultaneously with one or more fusion polypeptides or composite fusion polypeptides as described herein or one or more polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides as described herein or one or more carriers expressing one or more fusion polypeptides or composite fusion polypeptides as described herein.

Also provided is a method for preventing or inhibiting the increase in the amount of HIV virus titer, virus replication, virus proliferation or HIV virus DNA, HIV proviral DNA or HIV virus protein in a subject (e.g., a human subject). In one embodiment, the method requires providing a certain amount of one or more fusion polypeptides or composite fusion polypeptides as described herein or encoding one or more fusion polypeptides or composite fusion polypeptides as described herein or one or more polynucleotides or expressing one or more fusion polypeptides or composite fusion polypeptides as described herein to a subject in need thereof to effectively prevent HIV titer increase, virus replication, or a certain amount of one or more HIV strains or isolates in the subject. In certain embodiments, the method also includes measuring the amount of HIV virus or proviral DNA or protein at one or more time points (e.g., before or after providing one or more fusion polypeptides or composite fusion polypeptides as described herein or encoding one or more fusion polypeptides or composite fusion polypeptides as described herein or expressing one or more fusion polypeptides or composite fusion polypeptides as described herein) to a subject in need thereof. Methods and biomarkers for determining the amount of HIV viral or proviral DNA or protein in a subject are known and available in the art and are described, for example, in Siliciano, J.D. et al., Curr Opin. HIV AIDS, 5(6):491-7 (2010); and Rouzioux, C. et al., Curr Opin HIV AIDS, 8(3):170-5 (2013).

In some embodiments, one or more fusion polypeptides or composite fusion polypeptides or composite fusion polypeptides as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides as described herein, or one or more vectors expressing one or more fusion polypeptides or composite fusion polypeptides as described herein can be used, for example, in methods of inhibiting certain viruses (such as the HIV isolates described herein), prophylactically inhibiting or preventing infection by certain viruses (such as the HIV isolates described herein), detecting certain viruses (such as the HIV isolates described herein) in samples, inhibiting certain viruses (such as the HIV isolates described herein), or diagnosing certain viruses (such as the HIV isolates described herein).

For in vivo treatment of mammalian subjects (e.g., humans), a pharmaceutical composition may be administered or provided to a subject, the pharmaceutical composition comprising one or more fusion polypeptides or composite fusion polypeptides as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides as described herein, or one or more vectors expressing one or more fusion polypeptides or composite fusion polypeptides as described herein. When used in in vivo therapy, one or more fusion polypeptides or composite fusion polypeptides as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides as described herein, or one or more vectors expressing one or more fusion polypeptides or composite fusion polypeptides as described herein are typically administered or provided to a patient in a therapeutically effective amount (i.e., the amount of viral load and/or viral reservoirs that eliminate or reduce the patient). One or more fusion polypeptides or composite fusion polypeptides as described herein or one or more polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides as described herein or one or more vectors expressing one or more fusion polypeptides or composite fusion polypeptides as described herein are administered or provided to mammalian subjects (e.g., humans) according to known methods, such as, but not limited to, intravenous administration (e.g., push injection) or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intranodal, intraarticular, intrasynovial, intrathecal, oral, topical or inhalation routes. One or more fusion polypeptides or composite fusion polypeptides as described herein or one or more polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides as described herein or one or more vectors expressing one or more fusion polypeptides or composite fusion polypeptides as described herein can be administered parenterally (where possible) or intravenously at the target cell site. In one embodiment, administration of one or more fusion polypeptides or composite fusion polypeptides as described herein or one or more polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides as described herein or one or more vectors expressing one or more fusion polypeptides or composite fusion polypeptides as described herein to a subject is performed via an intravenous route. In another embodiment, administration to a subject of one or more fusion polypeptides or composite fusion polypeptides as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides as described herein, or one or more vectors expressing one or more fusion polypeptides or composite fusion polypeptides as described herein is performed via a subcutaneous route. In additional embodiments, the pharmaceutical composition of the present disclosure is administered systemically, parenterally, or topically (e.g., via mucosal, including buccal, rectal, and/or vaginal routes) to a subject.

In certain embodiments, the present disclosure provides a method for treating HIV infection, the method comprising administering to a human subject in need thereof a therapeutically effective amount of one or more fusion polypeptides or composite fusion polypeptides as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides as described herein, or one or more vectors expressing one or more fusion polypeptides or composite fusion polypeptides as described herein. In some embodiments, the present disclosure provides a method for preventing HIV infection, the method comprising administering to a human subject in need thereof a therapeutically effective amount of one or more fusion polypeptides or composite fusion polypeptides as described herein, or one or more polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides as described herein, or one or more vectors expressing one or more fusion polypeptides or composite fusion polypeptides as described herein.

In various embodiments, the method requires administration of a first and a second bivalent fusion polypeptide, or a first and a second polynucleotide encoding a first and a second fusion polypeptide, respectively (e.g., a first and a second expression cassette, a first and a second open reading frame), or a single viral expression vector comprising a first and a second polynucleotide encoding a first and a second fusion polypeptide, respectively (e.g., a first and a second expression cassette, a first and a second open reading frame), wherein the first and the second fusion polypeptide are bivalent fusion polypeptides. In certain embodiments, the single viral expression vector has a two-segment genome. In certain embodiments, the single viral expression vector has a three-segment genome. In various embodiments, the method requires administration of a single composite fusion polypeptide, or a single polynucleotide encoding the composite fusion polypeptide (e.g., a single expression cassette, a single open reading frame), or a single viral expression vector comprising a polynucleotide encoding the composite fusion polypeptide, wherein the composite fusion polypeptide comprises a bivalent fusion polypeptide.

In some embodiments, the methods entail administering to a subject: a first fusion polypeptide and a second fusion polypeptide or one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, the first and second polypeptides comprising, in order from N-terminus to C-terminus, the following polypeptide fragments optionally bound or linked by one or more linkers:

SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17;

SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11;

SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21;

SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17;

SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11;

SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 15, 21 and 19;

SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17;

SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ ID NOs: 9, 13, 25, 23, 15 and 11;

SEQ ID NOs: 18, 26, 20, 4, 6 and 16, and SEQ ID NOs: 7, 21, 17, 5, 27 and 19;

SEQ ID NOs: 22, 24, 12, 14, 8 and 10, and SEQ ID NOs: 15, 25, 9, 23, 13 and 11;

SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10;

SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 7, 21, 5, 25, 33 and 19;

SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10;

SEQ ID NOs: 8, 30, 14, 12, 26 and 10, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11;

SEQ ID NOs: 7, 21, 5, 25, 33 and 19, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11;

SEQ ID NOs: 20, 32, 24, 4, 6 and 18, and SEQ ID NOs: 26, 30, 12, 14, 8 and 10;

SEQ ID NOs: 6, 20, 4, 24, 32 and 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10;

SEQ ID NOs: 7, 25, 19, 5, 33 and 21, and SEQ ID NOs: 15, 31, 9, 27, 13 and 11;

SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 20, 10 and 28;

SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28;

SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19;

SEQ ID NOs: 7, 19, 17 and 25, and SEQ ID NOs: 21, 27, 11 and 29;

SEQ ID NOs: 24, 16, 6 and 18, and SEQ ID NOs: 27, 11, 21 and 29;

SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 11, 27, 21 and 29;

SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29;

SEQ ID NOs: 22, 6, 20 and 28, and SEQ ID NOs: 23, 7, 21 and 29;

SEQ ID NOs: 22, 20, 6 and 28, and SEQ ID NOs: 7, 21, 23 and 29;

SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29;

SEQ ID NO: 22, 6, 16, 20, 18, 28, 26 and 10; or

· SEQ ID NO: 7, 21, 19, 17, 27, 25, 29 and 11.

In some embodiments, the methods entail administering to a subject: one or more fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223, and 227. In some embodiments, the methods entail administering to a subject: one or more fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223.

In some embodiments, the methods entail administering to a subject: the following first and second fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a fusion polypeptide of SEQ ID NOs:70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:70 and 71, respectively;

a fusion polypeptide of SEQ ID NOs:72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:72 and 73, respectively;

a fusion polypeptide of SEQ ID NOs:74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively;

a fusion polypeptide of SEQ ID NOs:76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively;

a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:78 and 79, respectively;

a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:80 and 81, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively;

a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:90 and 91, respectively;

a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively;

a fusion polypeptide of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 96, respectively;

a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively;

a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 100, respectively;

a fusion polypeptide of SEQ ID NOs:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 101, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively; or

· A fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively.

In some embodiments, the methods entail administering to a subject a first and a second viral vector containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 83, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 82 and 83, respectively, and (b) a second viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 86 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:86 and 87.

In some embodiments, the methods entail administering to a subject a first and a second viral vector containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 84 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 84 and 85, respectively, and (b) a second viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 88 and 89, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:88 and 89.

In some embodiments, the methods entail administering to a subject a first and a second viral vector containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 82 and 86, respectively, and (b) a second viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 83 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:83 and 87.

In some embodiments, the methods entail administering to a subject a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 88, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 82 and 88, respectively, and (b) a second viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 85 and 87, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:85 and 87.

In some embodiments, the methods entail administering to a subject a first and a second viral vector containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 82 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 82 and 85, respectively, and (b) a second viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 87 and 88, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:87 and 88.

In some embodiments, the methods entail administering to a subject a first and a second viral vector containing one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 84 and 88, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 84 and 88, respectively, and (b) a second viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 85 and 89, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:85 and 89.

In some embodiments, the methods entail administering to a subject a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 94 and 96, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 94 and 96, respectively, and (b) a second viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 95 and 97, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:95 and 97.

In some embodiments, the methods entail administering to a subject a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 220 and 221, respectively, and (b) a second viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 95 and 97, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:95 and 97.

In some embodiments, the methods entail administering to a subject a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 94 and 95, respectively, and (b) a second viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 96 and 97, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:96 and 97.

In some embodiments, the methods entail administering to a subject a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 98 and 100, respectively, and (b) a second viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 99 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:99 and 101.

In some embodiments, the methods entail administering to a subject a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 98 and 100, respectively, and (b) a second viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 85 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:85 and 101.

In some embodiments, the methods entail administering to a subject a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: (a) a first viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 98 and 99, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 98 and 99, respectively, and (b) a second viral vector comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 100 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 101 and 102, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO:100 and 101.

In some embodiments, the methods entail administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding the following first fusion polypeptide: comprising SEQ ID NO: 200, being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 200, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding the following second fusion polypeptide: comprising SEQ ID NO: 201, being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 202. NO:201 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical.

In some embodiments, the methods entail administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding the following first fusion polypeptide: comprising SEQ ID NO: 202, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 202, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding the following second fusion polypeptide: comprising SEQ ID NO: 203, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 204. NO:203 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical.

In some embodiments, the methods entail administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 204 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 204, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 205 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 205. NO:205 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical.

In some embodiments, the methods entail administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding the following first fusion polypeptide: comprising SEQ ID NO: 105, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 105, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding the following second fusion polypeptide: comprising SEQ ID NO: 107, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 108. NO:107 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical.

In some embodiments, the methods entail administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding the following first fusion polypeptide: comprising SEQ ID NO:206, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:206, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding the following second fusion polypeptide: comprising SEQ ID NO:207, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:208. NO:207 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical.

In some embodiments, the methods entail administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 208 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 208, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or is identical to SEQ ID NO: 209 or SEQ ID NO: 228. NO:227 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical.

In some embodiments, the methods entail administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 222 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or is identical to SEQ ID NO: 209 or SEQ ID NO: 228. NO:227 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical.

In some embodiments, the methods entail administering first and second viral vectors or first and second liposome complexes (e.g., LNPs) containing first and second polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide: (a) a first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising a polynucleotide encoding the following first fusion polypeptide: comprising SEQ ID NO: 222, being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222, and (b) a second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising a polynucleotide encoding the following second fusion polypeptide: comprising SEQ ID NO: 223, being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 223. NO:223 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical.

In some embodiments, the methods entail administering to a subject a viral vector containing one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively.

In some embodiments, the methods entail administering to a subject a viral vector containing one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively.

In some embodiments, the methods entail administering to a subject: the following first and second fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding, in order from N-terminus to C-terminus, the following first and second fusion polypeptides optionally bound or linked by one or more linkers:

a fusion polypeptide of SEQ ID NOs:70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:70 and 71, respectively;

a fusion polypeptide of SEQ ID NOs:71 and 70, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:71 and 70, respectively;

a fusion polypeptide of SEQ ID NOs:72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:72 and 73, respectively;

a fusion polypeptide of SEQ ID NOs:73 and 72, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:73 and 72, respectively;

a fusion polypeptide of SEQ ID NOs:74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively;

a fusion polypeptide of SEQ ID NOs:75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:75 and 74, respectively;

a fusion polypeptide of SEQ ID NOs:76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively;

a fusion polypeptide of SEQ ID NOs:77 and 76, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:77 and 76, respectively;

a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:78 and 79, respectively;

a fusion polypeptide of SEQ ID NOs:79 and 78, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:79 and 78, respectively;

a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:80 and 81, respectively;

a fusion polypeptide of SEQ ID NOs:81 and 80, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:81 and 80, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively;

a fusion polypeptide of SEQ ID NOs:83 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 84, respectively;

a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 86, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:89 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:89 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively;

a fusion polypeptide of SEQ ID NOs:86 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 83, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 84, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 84, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:89 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:89 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively;

a fusion polypeptide of SEQ ID NOs: 101 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:90 and 91, respectively;

a fusion polypeptide of SEQ ID NOs:91 and 90, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:91 and 90, respectively;

a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively;

a fusion polypeptide of SEQ ID NOs:93 and 92, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:93 and 92, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively;

a fusion polypeptide of SEQ ID NOs:95 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 94, respectively;

a fusion polypeptide of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively;

a fusion polypeptide of SEQ ID NOs:97 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:97 and 96, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 96, respectively;

a fusion polypeptide of SEQ ID NOs:96 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 94, respectively;

a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively;

a fusion polypeptide of SEQ ID NOs:97 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:97 and 95, respectively;

a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;

a fusion polypeptide of SEQ ID NOs: 221 and 220, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 100, respectively;

a fusion polypeptide of SEQ ID NOs: 100 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively;

a fusion polypeptide of SEQ ID NOs:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 101, respectively;

a fusion polypeptide of SEQ ID NOs: 101 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively;

a fusion polypeptide of SEQ ID NOs:99 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 98, respectively;

a fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or

· A fusion polypeptide of SEQ ID NOs: 101 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively.

In some embodiments, the methods entail administering to a subject a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226. In some embodiments, the methods entail administering to a subject a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226.

In some embodiments, the methods entail administering to a subject: the following first and second polynucleotides, or one or more vectors comprising or consisting of the following first and second polynucleotides:

· a polynucleotide of SEQ ID NOs: 130 and 132, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively;

· a polynucleotide of SEQ ID NOs: 130 and 134, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively;

· a polynucleotide of SEQ ID NOs: 131 and 133, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively;

· a polynucleotide of SEQ ID NOs: 131 and 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively;

· a polynucleotide of SEQ ID NOs: 132 and 136, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively;

· a polynucleotide of SEQ ID NOs: 133 and 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively;

· a polynucleotide of SEQ ID NOs: 133 and 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively;

· a polynucleotide of SEQ ID NOs: 134 and 136, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively;

· a polynucleotide of SEQ ID NOs: 135 and 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively;

· a polynucleotide of SEQ ID NOs: 138 and 141, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively;

· a polynucleotide of SEQ ID NOs: 138 and 144, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively;

· a polynucleotide of SEQ ID NOs: 139 and 142, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively;

· a polynucleotide of SEQ ID NOs: 139 and 145, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively;

· a polynucleotide of SEQ ID NOs: 140 and 146, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively;

· a polynucleotide of SEQ ID NOs: 142 and 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively;

· a polynucleotide of SEQ ID NOs: 143 and 149, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively;

· a polynucleotide of SEQ ID NOs: 145 and 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively;

· a polynucleotide of SEQ ID NOs: 150 and 152, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively;

· a polynucleotide of SEQ ID NOs: 150 and 155, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively;

· a polynucleotide of SEQ ID NOs: 151 and 153, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively;

· a polynucleotide of SEQ ID NOs: 151 and 156, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively;

· a polynucleotide of SEQ ID NOs: 152 and 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively;

· a polynucleotide of SEQ ID NOs: 153 and 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively;

· a polynucleotide of SEQ ID NOs: 154 and 157, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively;

· a polynucleotide of SEQ ID NOs: 155 and 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively;

· a polynucleotide of SEQ ID NOs: 156 and 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively;

· a polynucleotide of SEQ ID NOs: 160 and 161, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively;

· a polynucleotide of SEQ ID NOs: 162 and 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively;

· a polynucleotide of SEQ ID NOs: 164 and 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively;

· a polynucleotide of SEQ ID NOs: 166 and 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively;

· a polynucleotide of SEQ ID NOs: 210 and 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively;

· a polynucleotide of SEQ ID NOs: 212 and 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively;

· a polynucleotide of SEQ ID NOs: 214 and 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively;

· a polynucleotide of SEQ ID NOs: 216 and 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively;

· a polynucleotide of SEQ ID NOs: 218 and 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively;

a polynucleotide of SEQ ID NOs: 218 and 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or

· A polynucleotide of SEQ ID NOs: 225 and 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively.

In some embodiments, the method entails administering: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 210, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 211. any one of NO:211 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides.

In some embodiments, the method entails administering: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 212, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 213, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 213. any one of NO:213 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides.

In some embodiments, the method entails administering: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 214, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 215. Any of NO:215 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the polynucleotide.

In some embodiments, the method entails administering: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 216, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 217, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 217. any one of NO:217 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides.

In some embodiments, the method entails administering: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 219, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 219. any one of NO:219 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides.

In some embodiments, the method entails administering: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 226. any one of NO:226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides.

In some embodiments, the method entails administering: (a) a first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 225, and (b) a second carrier or liposome complex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 226. any one of NO:226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides.

In some embodiments, the methods require administering to a subject: a composite fusion polypeptide or a vector comprising a polynucleotide encoding a composite fusion polypeptide, the composite fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227. In some embodiments, the methods require administering to a subject: a composite fusion polypeptide or a vector comprising a polynucleotide encoding a composite fusion polypeptide, the composite fusion polypeptide comprising or consisting of: an amino acid sequence of any one of SEQ ID NOs: 209, 222, and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223.

In various embodiments of these methods, the one or more fusion polypeptides do not comprise any polypeptide fragments corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116, and Nef 149-206, or fragments or subsequences thereof, wherein Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2, and 3, respectively. In various embodiments of these methods, the one or more fusion polypeptides do not comprise any polypeptide fragment having an amino acid sequence of SEQ ID NOs:35-47, or a fragment or subsequence thereof, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:35-47, or a fragment or subsequence thereof.

In some embodiments, these methods require administration of one or more viral expression vectors expressing one or more fusion polypeptides. In various embodiments, these methods require administration of about 10 ³ to about 10 ¹² viral focus forming units (FFU) or plaque forming units (PFU) or infectious units (IU) or viral particles (vp) per administration, such as about 10 ⁴ to about 10 ⁷ viral FFU or PFU or IU or vp, such as about 10 ³ to about 10 ⁴ , 10 ⁵ , 10 ⁶ , 10 ⁷ , 10 ⁸ , 10 ⁹ , 10 ¹⁰ , 10 ¹¹ , 10 ¹² , 10 ¹³ , 10 ¹⁴ or 10 ¹⁵ viral FFU or PFU or IU or vp.

In various embodiments, these methods implement a primary immunization-boosting scheme, which includes applying a primary immunization composition at a first time point and applying one or more boosting compositions at one or more subsequent time points. Typically, in a primary immunization-boosting scheme, primary immunization compositions and boosting compositions are applied sequentially. Exemplary primary immunization-boosting schemes include primary immunization-boosting-primary immunization-boosting and primary immunization-boosting-boosting-boosting. In some embodiments, the primary immunization composition and one or more boosting compositions are administered at intervals of at least 1 week, 2 weeks, 3 weeks or 1 month, for example, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months. In some embodiments, the primary immunization composition and the boosting composition comprise the same immunogenic composition. In some embodiments, the primary immunization composition and the boosting composition comprise different immunogenic compositions. In some embodiments, the primary immunization composition and the boosting composition comprise the same one or more fusion polypeptides and the same viral expression vector. In some embodiments, the primary immunization composition and the boosting composition comprise different fusion polypeptides and the same viral expression vector. In some embodiments, the primary immunization composition and the boosting composition comprise the same fusion polypeptide and different viral expression vectors. In some embodiments, these methods require priming with a first viral expression vector and boosting with a second viral expression vector. Depending on the circumstances, the prime-boost regimen can be repeated one or more iterations.

In various embodiments, the prime-boost regimen includes:

Prime with one or more viral expression vectors and boost with one or more polynucleotides, wherein the one or more polynucleotides comprise DNA, cDNA, mRNA or self-replicating RNA;

priming with one or more polynucleotides, wherein the one or more polynucleotides comprise DNA, cDNA, mRNA, self-amplifying or self-replicating RNA, and boosting with one or more viral expression vectors;

priming with one or more viral expression vectors and boosting with one or more viral expression vectors, wherein the one or more viral expression vectors in the priming composition and the one or more viral expression vectors in the boosting composition are from the same, related or unrelated taxonomic families;

priming with one or more replication-defective viral expression vectors and boosting with one or more replication-defective viral expression vectors, wherein the one or more replication-defective viral expression vectors in the priming composition and the one or more replication-defective viral expression vectors in the boosting composition are from the same, related or unrelated taxonomic families;

priming with one or more replication-attenuated viral expression vectors and boosting with one or more replication-attenuated viral expression vectors, wherein the one or more replication-attenuated viral expression vectors in the priming composition and the one or more replication-attenuated viral expression vectors in the boosting composition are from the same, related or unrelated taxonomic families;

Prime with one or more replication-defective viral expression vectors and boost with one or more replication-attenuated viral expression vectors;

Prime with one or more replication-attenuated viral expression vectors and boost with one or more replication-defective viral expression vectors;

· priming with one or more lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral expression vectors and boosting with one or more picinder mammalian arenavirus viral expression vectors;

· priming with one or more picinder mammalian arenavirus viral expression vectors and boosting with one or more lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral expression vectors;

· priming with one or more replication-defective picinder mammalian arenavirus viral expression vectors and boosting with one or more replication-defective lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral expression vectors;

· priming with one or more replication-defective lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral expression vectors and boosting with one or more replication-defective picinder mammalian arenavirus viral expression vectors;

Prime with one or more arenavirus expression vectors and boost with one or more adenovirus expression vectors;

priming with one or more adenovirus expression vectors and boosting with a boosting composition comprising one or more arenavirus expression vectors;

priming with one or more adenoviral viral expression vectors and boosting with a boosting composition comprising one or more RNA molecules (e.g., mRNA, self-amplifying or self-replicating RNA);

Prime with one or more RNA molecules (e.g., mRNA, self-amplifying or self-replicating RNA) and boost with a boosting composition comprising one or more adenoviral viral expression vectors;

Prime with one or more chimpanzee adenovirus (ChAd) expression vectors and boost with a boosting composition comprising one or more self-amplifying or self-replicating RNAs (saRNA or samRNA);

Prime with one or more self-amplifying or self-replicating RNAs (saRNA or samRNA) and boost with a boosting composition comprising one or more chimpanzee adenovirus (ChAd) expression vectors;

Prime with one or more poxvirus (e.g., vaccinia) viral expression vectors and boost with one or more arenavirus viral expression vectors;

priming with one or more arenavirus viral expression vectors and boosting with a boosting composition comprising one or more poxvirus (e.g., vaccinia) viral expression vectors;

Prime with one or more poxvirus (e.g., vaccinia) viral expression vectors and boost with one or more adenovirus viral expression vectors; or

priming with one or more adenovirus viral expression vectors and boosting with a boosting composition comprising one or more poxvirus (e.g., vaccinia) viral expression vectors;

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising the following first and second fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked via one or more linkers:

a fusion polypeptide of SEQ ID NOs:70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:70 and 71, respectively;

a fusion polypeptide of SEQ ID NOs:72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:72 and 73, respectively;

a fusion polypeptide of SEQ ID NOs:74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively;

a fusion polypeptide of SEQ ID NOs:76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively;

a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:78 and 79, respectively;

a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:80 and 81, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively;

a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:90 and 91, respectively;

a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively;

a fusion polypeptide of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 96, respectively;

a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively;

a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 100, respectively;

a fusion polypeptide of SEQ ID NOs:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 101, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively; or

100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; and 2) boosting with an immunogenic composition comprising the following first and second fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a fusion polypeptide of SEQ ID NOs:70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:70 and 71, respectively;

a fusion polypeptide of SEQ ID NOs:72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:72 and 73, respectively;

a fusion polypeptide of SEQ ID NOs:74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively;

a fusion polypeptide of SEQ ID NOs:76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively;

a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:78 and 79, respectively;

a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:80 and 81, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively;

a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:90 and 91, respectively;

a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively;

a fusion polypeptide of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 96, respectively;

a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively;

a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 100, respectively;

a fusion polypeptide of SEQ ID NOs:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 101, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively; or

a fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively;

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising the following first and second fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked via one or more linkers:

a) a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively;

b) a fusion polypeptide of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively;

c) a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 96, respectively;

d) a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; and/or

e) a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively; and

2) boosting with an immunogenic composition comprising the following first and second fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked via one or more linkers:

a) a fusion polypeptide of SEQ ID NOs:98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively;

b) a fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively;

c) a fusion polypeptide of SEQ ID NOs:98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 100, respectively; and/or

d) a fusion polypeptide of SEQ ID NOs:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 101, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked via one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; and

2) boosting with an immunogenic composition comprising a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; and/or

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked via one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; and

2) boosting with an immunogenic composition comprising a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; and/or

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked via one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; and

2) boosting with an immunogenic composition comprising a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and/or

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In various embodiments of the method, the priming vector is a Cali mammalian arenavirus (also known as a Pichinde mammalian arenavirus or a Pichinde arenavirus), and the boosting vector is a lymphocytic choriomeningitis mammalian arenavirus (LCMV). In various embodiments of the method, the priming vector and the boosting vector are replication attenuated or replication competent.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked via one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; and

2) boosting with an immunogenic composition comprising a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and/or

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 85 and 101, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. In various embodiments of the method, the priming vector is a Cali mammalian arenavirus (also known as a Pichinde mammalian arenavirus or a Pichinde arenavirus), and the boosting vector is a lymphocytic choriomeningitis mammalian arenavirus (LCMV). In various embodiments of the method, the priming vector and the boosting vector are replication attenuated or replication competent.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked via one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; and

2) boosting with an immunogenic composition comprising a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and/or

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. In various embodiments of the method, the priming vector is a lymphocytic choriomeningitis mammalian arenavirus (LCMV) and the boosting vector is a Cali mammalian arenavirus (also known as a Pichinde mammalian arenavirus or a Pichinde arenavirus). In various embodiments of the method, the priming vector and the boosting vector are replication attenuated or replication competent.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked via one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; and

2) boosting with an immunogenic composition comprising a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and/or

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. In various embodiments of the method, the priming vector is a lymphocytic choriomeningitis mammalian arenavirus (LCMV) and the boosting vector is a Cali mammalian arenavirus (also known as a Pichinde mammalian arenavirus or a Pichinde arenavirus). In various embodiments of the method, the priming vector and the boosting vector are replication attenuated or replication competent.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked via one or more linkers:

a) a first viral vector, comprising: one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 94 and 96, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; or one or more polynucleotides encoding the following first and second fusion polypeptides: a fusion polypeptide comprising SEQ ID NOs: 220 and 221, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 222, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NOs: 220 and 221; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; and

2) boosting with an immunogenic composition comprising a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and/or

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first and a second fusion polypeptide of SEQ ID NOs: 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; and

2) boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: SEQ ID NOs: 87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, comprising a fusion polypeptide of SEQ ID NOs: 82 and 85, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, comprising SEQ ID NOs: NO:87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:87 and 88, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first and a second fusion polypeptide of SEQ ID NOs: 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; and

2) boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 82 and 88, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 82 and 88, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively. NO:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:85 and 87, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first and a second fusion polypeptide of SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; and

2) boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first and a second fusion polypeptide of SEQ ID NOs: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; and

2) boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively. NO:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:96 and 97, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first and a second fusion polypeptide of SEQ ID NOs: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; and

2) boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first and a second fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; and

2) boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 94 and 96, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: NO:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:95 and 97, respectively.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) and a second viral vector or liposome complex (e.g., LNP), wherein the first viral vector or liposome complex (e.g., LNP) comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO: 220 and 221, or a fusion polypeptide with SEQ ID NO: 221, respectively. NO: 220 and 221 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of NO: 220 and 221; the second viral vector or liposome complex (e.g., LNP) comprises one or more polynucleotides, the one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally bound or connected by one or more linkers: a fusion polypeptide comprising SEQ ID NO: 95 and 97, or SEQ ID NO: 97, respectively. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of NO:95 and 97.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first and a second fusion polypeptide of SEQ ID NOs: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; and

2) boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers, of SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 105, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105; and

2) boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 109, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 109.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 105 or 206, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105 or 206; and

2) boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 107 or 207, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107 or 207.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 105, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 105, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 107, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 107, respectively. NO:107 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 206, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 206, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 207, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 208, respectively. NO:207 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 208, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 208; and

2) boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:209 or SEQ ID NO:227, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:209 or SEQ ID NO:227, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 222, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222; and

2) boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:209 or SEQ ID NO:227, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:209 or SEQ ID NO:227, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 222, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222; and

2) boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:223, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:223.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 208, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 208, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209, respectively. NO:227 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide. In various embodiments of the method, the priming composition comprises one or more ChAd vectors and the boosting composition comprises one or more self-amplifying mRNA molecules, for example, similar to the priming-boosting scheme described in NCT04776317 and WO 2021/236854 for SARS-CoV2 vaccines, WO 2021/203104 for infectious disease vaccines, and WO 2020/243719.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 222, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227, respectively. NO:227 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide. In various embodiments of the method, the priming composition comprises one or more ChAd vectors and the boosting composition comprises one or more self-amplifying mRNA molecules, for example, similar to the priming-boosting scheme described in NCT04776317 and WO 2021/236854 for SARS-CoV2 vaccines, WO 2021/203104 for infectious disease vaccines, and WO 2020/243719.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 222, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 223, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 223, respectively. NO:223 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide. In various embodiments of the method, the priming composition comprises one or more ChAd vectors and the boosting composition comprises one or more self-amplifying mRNA molecules, for example, similar to the priming-boosting scheme described in NCT04776317 and WO 2021/236854 for SARS-CoV2 vaccines, WO 2021/203104 for infectious disease vaccines, and WO 2020/243719.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first and a second fusion polypeptide of SEQ ID NOs: 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; and

2) boosting with an immunogenic composition comprising a viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally bound or linked by one or more linkers: a fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 107, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107; and

2) boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:111, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:111.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 200, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 200; and

2) boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:201, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:201.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 202, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 202; and

2) boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:203, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:203.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO: 204, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 204; and

2) boosting with an immunogenic composition comprising a viral vector comprising a polynucleotide encoding a composite fusion polypeptide comprising SEQ ID NO:205, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:205.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 204, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 204, respectively; and a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NO: 205, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 205, respectively. NO:205 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the fusion polypeptide.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a first and a second viral vector, the first and the second viral vector comprising the following polynucleotides:

a) a first viral vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 131 and 135, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; and

b) a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 133 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively. And

2) boosting with an immunogenic composition comprising a first and a second viral vector comprising the following polynucleotides:

a) a first viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 139 and 145, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; and

b) a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 142 and 148, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a first and a second viral vector, the first and the second viral vector comprising the following polynucleotides:

a) a first viral vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 139 and 145, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; and

b) a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 142 and 148, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. And

2) boosting with an immunogenic composition comprising a first and a second viral vector comprising the following polynucleotides:

a) a first viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 131 and 135, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; and

b) a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 133 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a first and a second viral vector, the first and the second viral vector comprising the following polynucleotides:

a) a first viral vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 140 and 146, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; and

b) a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 143 and 149, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. And

2) boosting with an immunogenic composition comprising a first and a second viral vector comprising the following polynucleotides:

a) a first viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 150 and 152, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and

b) a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. In various embodiments of the method, the priming vector is a Cali mammalian arenavirus (also known as a Pichinde mammalian arenavirus or a Pichinde arenavirus), and the boosting vector is a lymphocytic choriomeningitis mammalian arenavirus (LCMV). In various embodiments of the method, the priming vector and the boosting vector are replication attenuated or replication competent.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a first and a second viral vector, the first and the second viral vector comprising the following polynucleotides:

a) a first viral vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 150 and 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and

b) a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively; and

2) boosting with an immunogenic composition comprising a first and a second viral vector comprising the following polynucleotides:

a) a first viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 140 and 146, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; and

b) a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 143 and 149, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. In various embodiments of the method, the priming vector is a Cali mammalian arenavirus (also known as a Pichinde mammalian arenavirus or a Pichinde arenavirus), and the boosting vector is a lymphocytic choriomeningitis mammalian arenavirus (LCMV). In various embodiments of the method, the priming vector and the boosting vector are replication attenuated or replication competent.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a first and a second viral vector, the first and the second viral vector comprising the following polynucleotides:

a) a first viral vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 150 and 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and

b) a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 155 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively. And

2) boosting with an immunogenic composition comprising a first and a second viral vector comprising the following polynucleotides:

a) a first viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 151 and 153, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; and

b) a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 156 and 159, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a first and a second viral vector, the first and the second viral vector comprising the following polynucleotides:

a) a first viral vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 150 and 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and

b) a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 155 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively. And

2) boosting with an immunogenic composition comprising a first and a second viral vector comprising the following polynucleotides:

a) a first viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 139 and 145, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; and

b) a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 142 and 148, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. In various embodiments of the method, the priming vector is a Cali mammalian arenavirus (also known as a Pichinde mammalian arenavirus or a Pichinde arenavirus), and the boosting vector is a lymphocytic choriomeningitis mammalian arenavirus (LCMV). In various embodiments of the method, the priming vector and the boosting vector are replication attenuated or replication competent.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a first viral vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 160 and 161, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; and

2) boosting with an immunogenic composition comprising a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 162 and 163, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively.

In some embodiments, the prime-boost regimen comprises:

1) priming with an immunogenic composition comprising a first viral vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 164 and 165, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively; and

2) boosting with an immunogenic composition comprising a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 166 and 167, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 210; and a second viral vector comprising a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 211. NO:211 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides.

In some embodiments, the prime-boost regimen comprises: priming and boosting with an immunogenic composition comprising a first viral vector comprising the following first polynucleotide: a polynucleotide comprising SEQ ID NO: 212, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 212; and a second viral vector comprising the following second polynucleotide: a polynucleotide comprising SEQ ID NO: 213, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 213. NO:213 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 214; and a second viral vector comprising a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 215. NO:215 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 216; and a second viral vector comprising a second polynucleotide comprising SEQ ID NO: 217, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 217. NO:217 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218; and a second viral vector comprising a second polynucleotide comprising SEQ ID NO: 219, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 219. NO:219 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to polynucleotides.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218; and a second viral vector comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 226. NO:226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotide. In various embodiments of the method, the priming composition comprises one or more ChAd vectors and the boosting composition comprises one or more self-amplifying mRNA molecules, for example, similar to the priming-boosting scheme described in NCT04776317 and WO 2021/236854 for SARS-CoV2 vaccines, WO 2021/203104 for infectious disease vaccines, and WO 2020/243719.

In some embodiments, the prime-boost regimen comprises priming and boosting with an immunogenic composition comprising a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 225; and a second viral vector comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 226. NO:226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotide. In various embodiments of the method, the priming composition comprises one or more ChAd vectors and the boosting composition comprises one or more self-amplifying mRNA molecules, for example, similar to the priming-boosting scheme described in NCT04776317 and WO 2021/236854 for SARS-CoV2 vaccines, WO 2021/203104 for infectious disease vaccines, and WO 2020/243719.

In some embodiments, after one or more administrations of one or more fusion polypeptides as described herein, or one or more polynucleotides encoding one or more fusion polypeptides as described herein, or one or more vectors expressing one or more fusion polypeptides as described herein, optionally with one or more additional therapeutic agents as described herein, the subject does not show symptoms of HIV or AIDS for at least 3 months, at least 6 months, at least 1 year, at least 2 years, at least 3 years, or longer without antiretroviral therapy (ART). In some embodiments, after one or more administrations of one or more fusion polypeptides as described herein, or one or more polynucleotides encoding one or more fusion polypeptides as described herein, or one or more vectors expressing one or more fusion polypeptides as described herein, optionally with one or more additional therapeutic agents as described herein, the subject has a viral load of less than 500 (e.g., less than 400, less than 300, less than 200, less than 100, less than 50) copies/ml of blood for at least 3 months, at least 6 months, at least 1 year, at least 2 years, at least 3 years, or longer without antiretroviral therapy (ART).

7. Combination therapy

In certain embodiments, methods for treating or preventing HIV infection in a person suffering from or at risk of HIV infection are provided, comprising administering to the person a therapeutically effective amount of one or more fusion polypeptides as disclosed herein, or a polynucleotide encoding such a fusion polypeptide, or a vector expressing such a fusion polypeptide, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, one or two, or one to three) additional therapeutic agents. In one embodiment, a method for treating HIV infection in a person suffering from or at risk of HIV infection is provided, comprising administering to the person a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, one or two, or one to three) additional therapeutic agents.

In various embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, or vectors expressing such fusion polypeptides, and a pharmaceutically acceptable carrier, diluent, or excipient are administered in combination with one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents.

In certain embodiments, a method for treating HIV infection is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, one or two, or one to three) additional therapeutic agents suitable for treating HIV infection.

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, or vectors expressing such fusion polypeptides are co-formulated with one, two, three, four or more additional therapeutic agents and a pharmaceutically acceptable carrier. In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, or vectors expressing such fusion polypeptides, or pharmaceutically acceptable salts thereof, are combined with two additional therapeutic agents. As appropriate, one, two, three, four or more additional therapeutic agents may be different therapeutic agents selected from the same class of therapeutic agents, and/or they may be selected from different classes of therapeutic agents.

Administration of HIV combination therapy

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, or vectors expressing such fusion polypeptides are administered together with one or more additional therapeutic agents. Co-administration of a compound disclosed herein with one or more additional therapeutic agents generally refers to simultaneous, parallel, or sequential administration of a compound disclosed herein and one or more additional therapeutic agents, such that a therapeutically effective amount of the compound disclosed herein and one or more additional therapeutic agents are present in the patient's body. When administered sequentially, the combination may be administered in two or more administrations.

Co-administration includes administering a unit dosage of one or more fusion polypeptides as disclosed herein, or a polynucleotide encoding a liposome complex (e.g., LNP) comprising such a polynucleotide, or a vector expressing such a fusion polypeptide, before or after administering a unit dosage of one or more additional therapeutic agents. For example, one or more fusion polypeptides as disclosed herein, or a polynucleotide encoding such a fusion polypeptide, a liposome complex (e.g., LNP) comprising such a polynucleotide, or a vector expressing such a fusion polypeptide may be administered within seconds, minutes, or hours after administering one or more additional therapeutic agents. In some embodiments, a unit dose of one or more fusion polypeptides as disclosed herein, or a polynucleotide encoding such a fusion polypeptide, or a vector expressing such a fusion polypeptide is administered first, and then a unit dose of one or more additional therapeutic agents is administered within seconds or minutes. Alternatively, a unit dose of one or more additional therapeutic agents is administered first, and then a unit dose of one or more fusion polypeptides as disclosed herein, or a polynucleotide encoding such a fusion polypeptide, or a vector expressing such a fusion polypeptide is administered within seconds or minutes. In other embodiments, a unit dose of one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides is first administered, followed by a unit dose of one or more additional therapeutic agents after a few hours (e.g., 1-12 hours). In other embodiments, a unit dose of one or more additional therapeutic agents is first administered, followed by a unit dose of one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, or vectors expressing such fusion polypeptides after a few hours (e.g., 1-12 hours). In some embodiments, one or more additional therapeutic agents are not co-administered, but are administered separately as part of a combined treatment regimen. In such methods, a unit dose of one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides, and one or more additional therapeutic agents can be administered at longer time intervals (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 days or longer time intervals).

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, or vectors expressing such fusion polypeptides, are combined or co-administered with one or more additional therapeutic agents in a single dosage form for simultaneous or concurrent administration to a patient, e.g., as an aqueous formulation for intravenous, intramuscular, intradermal, intranodal, or subcutaneous administration. In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, or vectors expressing such fusion polypeptides, are combined with one or more additional therapeutic agents in a single dosage form for simultaneous or concurrent administration to a patient, e.g., as a rectal suppository.

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides may be co-formulated or co-administered with one or more other compounds for treating HIV. In certain embodiments, co-formulation or co-administration may include another active agent for treating HIV, such as anti-HIV antibodies (e.g., HIV bNAbs), bispecific antibodies and "antibody-like" therapeutic proteins, toll-like receptor (TLR) agonists (e.g., agonists of TLR7, TLR8, and/or TLR9), immune checkpoint inhibitors, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV capsid inhibitors, nucleocapsid protein 7 (NCp7) inhibitors, HIV Tat or Rev inhibitors, inhibitors of Tat-TAR-P-TEFb, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversal agents, immune-based therapies, PI3K inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, Nef inhibitors, latency reversal agents, HIV vaccines, cytokines, immune checkpoint inhibitors, FLT3 agonists, bispecific antibodies that recruit T cells and NK cells, chimeric T cell receptors targeting HIV antigens, pharmacokinetic enhancers and other drugs for the treatment of HIV and their combinations.

In some embodiments, the one or more additional therapeutic agents are selected from dolutegravir, cabotegravir, islatravir, darunavir, bicagavir, esxavirine, rilpivirine, and lenacapasvir, and combinations thereof.

In certain embodiments, one or more active agents are suitable for daily administration, weekly administration, monthly administration, once every 3 months, once every 4 months, once every two years, or once a year, as appropriate.

In some embodiments, one or more fusion polypeptides or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides as disclosed herein and one or more additional therapeutic agents can be anti-HIV agents. In some cases, the additional therapeutic agent can be an HIV protease inhibitor, a non-nucleoside or non-nucleotide inhibitor of HIV reverse transcriptase, a nucleoside or nucleotide inhibitor of HIV reverse transcriptase, an HIV integrase inhibitor, an HIV non-catalytic site (or allosteric) integrase inhibitor, an HIV entry inhibitor, an HIV maturation inhibitor, an HIV capsid inhibitor, a nucleocapsid protein 7 (NCp7) inhibitor, an HIV Tat or Rev inhibitor, an inhibitor of Tat-TAR-P-TEFb, an immunomodulator, an immunotherapeutic agent, an antibody-drug conjugate, a gene modifier, a gene editor (such as CRISPR/Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALEN), a cell therapy (such as chimeric antigen receptor T cell CAR-T and engineered T cell receptor TCR-T, autologous T cell therapy, engineered B cells, NK cells), a latency reversal agent, an immune-based therapy, a phosphatidylinositol 3-kinase (PI3K) inhibitor, HIV antibodies, bispecific antibodies and "antibody-like" therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitors, fatty acid synthase inhibitors, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infection factor inhibitors, HIV-1 Nef modulators, TNFα ligand inhibitors, HIV Nef inhibitors, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain-containing protein 1 modulators, HIV ribonuclease H inhibitors, interferon (IFN) antagonists, defensin modulators, CD3 antagonists, CDK-4 inhibitors, CDK-6 inhibitors, CDK-9 inhibitors, cytochrome P450 3 inhibitors, CXCR4 modulators, dendritic ICAM-3 grabbing non-integrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, complement factor H regulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin-dependent kinase inhibitors, HPK1 (MAP4K1) inhibitors, proprotein convertase PC9 stimulators, ATP-dependent RNA helicase DDX3X inhibitors, reverse transcriptase initiation complex inhibitors, G6PD and NADH oxidase inhibitors, mTOR complex 1 inhibitors, mTOR complex 2 inhibitors, P-glycoprotein regulators, RNA polymerase regulators, TAT protein inhibitors, prolyl endopeptidase inhibitors, phospholipase A2 inhibitors, pharmacokinetic enhancers, HIV gene therapy, HIV vaccines, anti-HIV peptides and combinations thereof.

In some embodiments, the additional therapeutic agent is selected from combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversal agents, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies and bispecific antibodies and "antibody-like" therapeutic proteins, and combinations thereof.

Combination drugs

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with HIV combination drugs. Examples of combination drugs that can be used with the agents of the present disclosure include (efavirenz, tenofovir disoproxil fumarate, and emtricitabine); ( ; rilpivirine, tenofovir disoproxil fumarate, and emtricitabine); (elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine); (tenofovir disoproxil fumarate and emtricitabine; TDF+FTC); (tenofovir alafenamide and emtricitabine); (tenofovir alafenamide, emtricitabine, and rilpivirine); (tenofovir alafenamide, emtricitabine, cobicistat and elvitegravir); darunavir, tenofovir alafenamide hemifumarate, emtricitabine and cobicistat; efavirenz, lamivudine and tenofovir disoproxil fumarate; lamivudine and tenofovir disoproxil fumarate; tenofovir and lamivudine; tenofovir alafenamide and emtricitabine; tenofovir alafenamide hemifumarate and emtricitabine; tenofovir alafenamide hemifumarate, emtricitabine and rilpivirine; tenofovir alafenamide hemifumarate, emtricitabine, cobicistat and elvitegravir; tenofovir analogs; (zidovudine and lamivudine; AZT+3TC); ( ; abacavir sulfate and lamivudine; ABC+3TC); ( ; lopinavir and ritonavir); (dolutegravir, abacavir, and lamivudine); (Bicagevir + Emtricitabine + Tenofovir Alafenamide), (Dolutegravir + Lamivudine), (abacavir sulfate, zidovudine and lamivudine; ABC+AZT+3TC); atazanavir and cobicistat; atazanavir sulfate and cobicistat; atazanavir sulfate and ritonavir; darunavir and cobicistat; dolutegravir and rilpivirine; dolutegravir and rilpivirine hydrochloride; dolutegravir, abacavir sulfate and lamivudine; lamivudine, nevirapine and zidovudine; raltegravir and lamivudine; doravirine, lamivudine and tenofovir disoproxil fumarate; doravirine, lamivudine and tenofovir disoproxil fumarate; dolutegravir + lamivudine, lamivudine + abacavir + zidovudine, lamivudine + abacavir, lamivudine + tenofovir disoproxil fumarate, raltegravir and lamivudine Tenofovir + lamivudine + zidovudine + nevirapine, lopinavir + ritonavir, lopinavir + ritonavir + abacavir + lamivudine, lopinavir + ritonavir + zidovudine + lamivudine, tenofovir + lamivudine, and tenofovir disoproxil fumarate + emtricitabine + rilpivirine hydrochloride, lopinavir, ritonavir, zidovudine, lopinavir + ritonavir + abacavir + lamivudine, lamivudine, cabotegravir + rilpivirine, 3-BNC117 + aboveta, Elpida (essavirin, VM-1500) and VM-1500A, lenacapvir + islatravir (oral, injection) and dual-targeted HIV-1 reverse transcriptase/nucleocapsid protein 7 inhibitors.

Examples of other drugs for treating HIV that can be combined with one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides include, but are not limited to, aspernigerin C, acemannan, alisporivir, BanLec, deferiprone, Gamimune, metenkefalin, naltrexone, Prolastin, REP 9. RPI-MN, VSSP, H1viral, SB-728-T, 1,5-dicaffeoylquinic acid, rHIV7-shl-TAR-CCR5RZ, AAV-eCD4-Ig gene therapy, MazF gene therapy, BlockAide, bevirimab derivatives, ABBV-382, ABX-464, AG-1105, APH-0812, APH0202, bryostatin-1, bryostatin analogs, BG-HIV, BIT-225, BRII-732, BRII-778, CYT-107, CS-TATI-1, fluoro- β-D-arabinose nucleic acid (FANA) modified antisense oligonucleotides, FX-101, Grefsen, GSK-3739937, GSK-3739937 (long-acting), HGTV-43, HPH-116, HS-10234, hydroxychloroquine, IMB-10035, IMO-3100, IND-02, JL-18008, LADAVRU, MK-1376, MK-2048, MK-4250, MK-8507, MK-8558, MK-8591, Islatravir, NOV-205, OB-002H, ODE-Bn-TF V, PA-1050040 (PA-040), PC-707, PGN-007, QF-036, S-648414, SCY-635, SB-9200, SCB-719, TR-452, TEV-90110, TEV-90112, TEV-90111, TEV-90113, RN-18, DIACC-1010, Fasnall, Immuglo, 2-CLIPS peptide, HRF-4467, thrombospondin analog, TBL-1004HI, VG-1177, xl-081, AVI-CO-0 04, rfhSP-D, [18F]-MC-225, URMC-099-C, RES-529, Verdinexor, IMC-M113V, IML-106, antiviral Fc conjugate (AVC), WP-1096, WP-1097, Gammora, ISR-CO48, ISR-48, ISR-49, MK-8527, cannabinoids, ENOB-HV-32, HiviCide-I, T-1144, VIR-576, nipamovir, Covimro and ABBV-1882.

HIV protease inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with HIV protease inhibitors. Examples of HIV protease inhibitors that may be co-administered or combined include amprenavir, atazanavir, brecanavir, darunavir, fosamprenavir, fosamprenavir calcium, indinavir, indinavir sulfate, lopinavir, nelfinavir, nelfinavir mesylate, ritonavir, saquinavir, saquinavir mesylate, tipranavir, ASC-09+ritonavir, AEBL-2, DG-17, GS-1156, TMB-657 (PPL-100), T-169, BL-008, MK-8122, TMB-607, GRL-02031, and TMC-310911. Additional examples of HIV protease inhibitors are described in, for example, U.S. Pat. No. 10,294,234 and U.S. Patent Publication Nos. US2020030327 and US2019210978.

HIV Gag protein inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with HIV Gag protein inhibitors. Examples of HIV Gag protein inhibitors that can be combined or co-administered include, but are not limited to, HRF-10071.

HIV RNase H Inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with an HIV RNase H inhibitor. Examples of HIV RNase H inhibitors that can be combined or co-administered include, but are not limited to, NSC-727447.

HIV Nef inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with HIV Nef inhibitors. Examples of HIV Nef inhibitors that can be combined or co-administered include, but are not limited to, FP-1.

HIV reverse transcriptase inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a non-nucleoside or non-nucleotide inhibitor. Examples of HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase that can be combined or co-administered include dapivirine, delavirdine, delavirdine mesylate, doravirine, efavirenz, etravirine, lentinan, nevirapine, rilpivirine, ACC-007, ACC-008, AIC-292, F-18, KM-023, PC-1005, M1-TFV, M2-TFV, VM-1500A-LAI, PF-3450074, essavirine (extended release oral, HIV infection), doravirine + islatravir (fixed dose combination/oral tablet formulation, HIV-1 infection), essavirine (long-acting injectable nanosuspension, HIV infection) and essavirine (VM-1500).

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with HIV nucleoside or nucleotide inhibitors. Examples of HIV nucleoside or nucleotide inhibitors of reverse transcriptase that can be combined or co-administered include adefovir, adefovir dipivoxil, azvudine, emtricitabine, tenofovir, tenofovir alafenamide, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, and VIDEX (didanosine, ddl), abacavir, abacavir sulfate, alovudine, aritibactam, sinavudine, didanosine, efavirenz, fostavirin, CMX-157, dapivirine, doravirine, etravirine, OCR-5753, tenofovir disoproxil orotate, fostavirin, lamivudine, phosphinothricin, stavudine, zalcitabine, zidovudine, rovafovir-etafoetide (GS-9131), GS-9148, MK-8504, MK-8591, MK-858, VM-2500, and KP-1461.

HIV integrase inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with HIV integrase inhibitors. Examples of HIV integrase inhibitors that can be combined or co-administered include, but are not limited to, elvitegravir, elvitegravir (extended release microcapsules), curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrosine kinase inhibitors, derivatives of tyrosine kinase inhibitors, quercetin, derivatives of quercetin, raltegravir, pegylated raltegravir, dolutegravir, JTK-351, bicagvir, AVX-15567 , cabotegravir (long-acting injectable), diketoquinoline-4-1 derivatives, integrase-LEDGF inhibitors, ledgins, M-522, M-532, MK-0536, NSC-310217, NSC-371056, NSC-48240, NSC-642710, NSC-699171, NSC-699172, NSC-699173, NSC-699174, distilbenesulphonic acid, T169, STP-0404, VM-3500, XVIR-110, ACC-017 and cabotegravir.

In certain embodiments, one or more fusion polypeptides as disclosed herein or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with HIV non-catalytic sites or allosteric integrase inhibitors (NCINIs). Examples of HIV non-catalytic sites or allosteric integrase inhibitors (NCINIs) that can be combined or co-administered include CX-05045, CX-05168, and CX-14442. Other examples of HIV capsid inhibitors include, but are not limited to, those described in the following patents: U.S. Patent Publication Nos. US2014221356 and US2016016973.

HIV virus infectious factor inhibitor

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with HIV viral infectivity factor inhibitors. Examples of HIV viral infectivity factor inhibitors include, but are not limited to, 2-amino-N-(2-methoxyphenyl)-6-((4-nitrophenyl)thio)benzamide derivatives and Irino-L.

HIV entry inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with HIV entry inhibitors. Examples of HIV entry (fusion) inhibitors that can be combined or co-administered include, but are not limited to, AAR-501, LBT-5001, seneviroxetine, CCR5 inhibitors, gp41 inhibitors, CD4 attachment inhibitors, gp120 inhibitors, gp160 inhibitors, and CXCR4 inhibitors.

In certain embodiments, one or more fusion polypeptides as disclosed herein or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a CCR5 inhibitor. Examples of CCR5 inhibitors that may be combined or co-administered include, but are not limited to, apuvirol, vicovirol, maraviroc, maraviroc (long-acting injectable nanoemulsion), sennevirol, lerolizumab (PRO-140), adatasvir (RAP-101), nifevirol (TD-0232), anti-GP120/CD4 or CCR5 bispecific antibodies, B-07, MB-66, polypeptide C25P, TD-0680, selavirol, and vMIP (Haimipu).

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a gp41 inhibitor. Examples of gp41 inhibitors that may be combined or co-administered include, but are not limited to, Abuvirtide, Enfuvirtide, Grefsen (gp41/gp120/gp160 inhibitor), BMS-986197, Enfuvirtide bioimprovers, Enfuvirtide biosimilars, HIV-1 fusion inhibitors (P26-Bapc), ITV-1, ITV-2, ITV-3, ITV-4, CPT-31, Cl3hmAb, lipuvirtide, PIE-12 trimer, and Sifuvirtide.

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a CD4 attachment inhibitor. Examples of CD4 attachment inhibitors that can be combined or co-administered include ibalizumab and CADA analogs.

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a gp120 inhibitor. Examples of gp120 inhibitors that can be combined or co-administered include, but are not limited to, anti-HIV microbicides, Radha-108 (receptol) 3B3-PE38, BMS818251, BanLec, bentonite-based nanomedicines, fostemsavir tromethamine, IQP-0831, VVX-004, and BMS-663068.

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a gp160 inhibitor. Examples of gp160 inhibitors that can be combined or co-administered include, but are not limited to, fangchinoline.

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a CXCR4 inhibitor. Examples of CXCR4 inhibitors that can be combined or co-administered include plerixafor, ALT-1188, N15 peptide, and vMIP (Haimipu).

Maturation inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with HIV maturation inhibitors. Examples of HIV maturation inhibitors that can be combined or co-administered include BMS-955176, GSK-3640254, and GSK-2838232.

Latency reversal agents

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with latency reversal agents (LRAs). Examples of latency reversal agents include, but are not limited to, toll-like receptor (TLR) agonists (including TLR7 agonists, such as GS-9620 (visamod), TLR8 agonists such as GS-9688 (sergantomod), and TLR9 agonists such as lefemod (MGN-1703)), histone deacetylase (HDAC) inhibitors, proteasome inhibitors (such as velcade), protein kinase C (PKC) activators, Smyd2 inhibitors, BET-bromodomain 4 (BRD4) inhibitors (such as ZL-0580, apaberon), ionomycin, IAP antagonists (apoptotic protein In some embodiments, the present invention relates to activators of PKC, such as succinate, succinate-1, succinate-2, succinate-3, succinate-4, succinate-5, succinate-6, succinate-7, succinate-8, succinate-9, succinate-10, succinate-11, succinate-12, succinate-13, succinate-14, succinate-15, succinate-16, succinate-17, succinate-18, succinate-19, succinate-20, succinate-21, succinate-22, succinate-23, succinate-24, succinate-30, succinate-31, succinate-32, succinate-33, succinate-34, succinate-35, succinate-36, succinate-37, succinate-38, succinate-39, succinate-40, succinate-50, succinate-60, succinate-71, succinate-80, succinate-19, succinate-21, succinate-31, succinate-32, succinate-33, succinate-15, succinate-160, succinate-170, succinate-23, succinate-39, succinate-40, succinate-50, succinate-18, succinate-23, succinate-35, succinate-19, succinate-23, succinate-36, succinate-19, succinate-23, succinate-37, succinate-19, succinate-2 Additional examples of TLR8 agonists include, but are not limited to, those described in U.S. Pat. No. US2017/071944.

Histone deacetylase (HDAC) inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with an inhibitor of histone deacetylase 1, histone deacetylase 9 (HDAC9, HD7, HD7b, HD9, HDAC, HDAC7, HDAC7B, HDAC9B, HDAC9FL, HDRP, MITR; Gene ID: 9734). Examples of HDAC inhibitors include, but are not limited to, abexinostat, ACY-241, AR-42, BEBT-908, belinostat, CKD-581, CS-055 (HBI-8000), CT-101, CUDC-907 (fimepinostat), entinostat, givinostat, mocetinostat, panobinostat, pracinostat, quisinostat (JNJ-26481585), resminostat, ricolinostat, romidepsin, SHP-141, TMB-ADC, valproic acid (VAL-001), vorinostat, tinostamustine, remetinostat, and entinostat.

Capsid inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a capsid inhibitor. Examples of capsid inhibitors that may be combined or co-administered include, but are not limited to, capsid polymerization inhibitors or capsid destruction compounds, HIV nucleocapsid p7 (NCp7) inhibitors (such as azodicarbonamide), HIV p24 capsid protein inhibitors, lenacapvir (GS-6207), GS-CA1, AVI-621, AVI-101, AVI-201, AVI-301, and AVI-CAN1-15 series, PF-3450074, HIV-1 capsid inhibitors (HIV-1 infection, Shandong University), and compounds described in (WO 2019/087016 (GSK)). Other examples of capsid inhibitors include, but are not limited to, those described in the following patents: U.S. Patent Publication Nos. US2018051005, US2016108030.

Long-term HIV treatment

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with HIV long-acting treatments. Examples of long-acting regimens that can be combined or co-administered include, but are not limited to, cabotegravir, rilpivirine, any integrase LA, VM-1500LAI, maraviroc (LAI), tenofovir implant, isclatravir implant, doravirine, raltegravir, and long-acting dulutegravir.

HIV long-acting treatments covered in addition include anti-HIV broadly neutralizing antibodies (bNAbs) described herein, which have amino acid substitutions with extended serum half-life in the Fc region. Fc region amino acid substitutions that increase the half-life of antibodies have been described. For example, "YTE mutants" (methionine to tyrosine substitutions at position 252, serine to threonine substitutions at position 254, and threonine to glutamic acid substitutions at position 256 (EU numbering)) show a half-life (Dall'Acqua et al., J Biol Chem, 281: 23514-24 (2006) relative to the wild-type version of the same antibody; Robbie et al., Antimicrob Agents Chemotherap., 57 (12): 6147-6153 (2013)). See also, for example, U.S. Patent No. 7,658,921. In another example, M428L and N434S (EU numbering; "LS") substitutions can increase the pharmacokinetic half-life of bNAbs. In other embodiments, the bNAbs described herein comprise T250Q and M428L (EU numbering) mutations. In other embodiments, the bNAbs described herein comprise H433K and N434F (EU numbering) mutations. Exemplary bNAbs with extended serum half-life that can be combined or co-administered with one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides include 3BNC117-LS, 10-1074-LS, 10-1074-LS-J, GS-5423, and GS-2872.

Cytochrome P450 3 inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a cytochrome P450 3 inhibitor. Examples of cytochrome P450 3 inhibitors include, but are not limited to, those described in U.S. Pat. No. 7,939,553.

RNA polymerase inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with RNA polymerase inhibitors. Examples of RNA polymerase modulators include, but are not limited to, those described in U.S. Pat. Nos. 10,065,958 and 8,008,264.

Immune checkpoint modulators

In various embodiments, one or more fusion polypeptides as disclosed herein or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with one or more blockers or inhibitors of inhibitory immune checkpoint proteins or receptors and/or with one or more stimulators, activators, or agonists of one or more stimulatory immune checkpoint proteins or receptors. Blocking or inhibition of inhibitory immune checkpoints can positively regulate T cell or NK cell activation and prevent immune escape of infected cells. Activation or stimulation of stimulating immune checkpoints can enhance the effect of immune checkpoint inhibitors in infectious treatments. In various embodiments, immune checkpoint proteins or receptors regulate T cell responses (e.g., Xu et al., J Exp Clin Cancer Res. (2018) 37: 110). In various embodiments, the immune checkpoint protein or receptor modulates NK cell responses (e.g., as reviewed in Davis et al., Semin Immunol. (2017) 31:64–75; and Chiossone et al., Nat Rev Immunol. (2018) 18(11):671-688).

Examples of immune checkpoint proteins or receptors include, but are not limited to, CD27 (NCBI gene ID: 939), CD70 (NCBI gene ID: 970), CD40 (NCBI gene ID: 958), CD40LG (NCBI gene ID: 959), CD47 (NCBI gene ID: 961), CD48 (SLAMF2; NCBI gene ID: 962), transmembrane and immunoglobulin domain-containing protein 2 (TMIGD2, CD28H; NCBI gene ID: 126259), CD84 (LY9B, SLAMF5; NCBI gene ID: 8832), CD96 (NCBI gene ID: 10225), CD160 (NCBI gene ID: 11126), MS 4A1 (CD20; NCBI gene ID: 931), CD244 (SLAMF4; NCBI gene ID: 51744); CD276 (B7H3; NCBI gene ID: 80381); V-set domain-containing T cell activation inhibitor 1 (VTCN1, B7H4; NCBI gene ID: 79679); V-set immunomodulatory receptor (VSIR, B7H5, VISTA; NCBI gene ID: 64115); immunoglobulin superfamily member 11 (IGSF11, VSIG3; NCBI gene ID: 152404); natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7H6; NCBI gene ID: 374383); HERV-H LTR-related 2 (HHLA2, B7H7; NCBI Gene ID: 11148); inducible T cell co-stimulator (ICOS, CD278; NCBI Gene ID: 29851); inducible T cell co-stimulator ligand (ICOSLG, B7H2; NCBI Gene ID: 23308); TNF receptor superfamily member 4 (TNFRSF4, OX40; NCBI Gene ID: 7293); TNF superfamily member 4 (TNFSF4, OX40L; NCBI Gene ID: 7292); TNFRSF8 (CD30; NCBI Gene ID: 943), TNFSF8 (CD30L; NCBI Gene ID: 944); TNFRSF10A (CD261, DR4, TRAILR1; NCBI Gene ID: 8797), TNFRSF9 (CD137; NCBI Gene ID: 3604), TNFSF9 (CD137L; NCBI Gene ID: 8744); TNFRSF10B (CD262, DR5, TRAILR2; NCBI Gene ID: 8795), TNFRSF10 (TRAIL; NCBI Gene ID: 8743); TNFRSF14 (HVEM, CD270; NCBI Gene ID: 8764), TNFSF14 (HVEML; NCBI Gene ID: 8740); CD272 (B and T lymphocyte-associated (BTLA); NCBI Gene ID: 151888); TNFRSF17 (BCMA, CD269; NCBI Gene ID: 608), TNFSF13B (BAFF; NCBI Gene ID: 10673); TNFRSF18 (GITR; NCBI Gene ID: 8784), TNFSF18 (GITRL; NCBI Gene ID: 8995); MHC Class I polypeptide-related sequence A (MICA; NCBI Gene ID: 100507436); MHC class I polypeptide-related sequence B (MICB; NCBI Gene ID: 4277); CD274 (CD274, PDL1, PD-L1; NCBI Gene ID: 29126); programmed cell death 1 (PDCD1, PD1, PD-1; CD279; NCBI Gene ID: 5133); cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152; NCBI Gene ID: 1493); CD80 (B7-1; NCBI Gene ID: 941), CD28 (NCBI Gene ID: 940); nectin cell adhesion molecule 2 (NECTIN2, CD112; NCBI Gene ID: 5819); CD226 (DNAM-1; NCBI Gene ID: 10666); poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155; NCBI Gene ID: 5817); PVR-related immunoglobulin domain-containing protein (PVRIG, CD112R; NCBI Gene ID: 79037); T cell with Ig and ITIM domains cellular immune receptor (TIGIT; NCBI gene ID: 201633); T cell immunoglobulin and mucin domain-containing 4 (TIMD4; TIM4; NCBI gene ID: 91937); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3; NCBI gene ID: 84868); galectin 9 (LGALS9; NCBI gene ID: 3965); lymphocyte activation 3 (LAG3, CD223; NCBI gene ID: 3902); signal transduction lymphocytes Cell activation molecule family member 1 (SLAMF1, SLAM, CD150; NCBI gene ID: 6504); Lymphocyte antigen 9 (LY9, CD229, SLAMF3; NCBI gene ID: 4063); SLAM family member 6 (SLAMF6, CD352; NCBI gene ID: 114836); SLAM family member 7 (SLAMF7, CD319; NCBI gene ID: 57823); UL16 binding protein 1 (ULBP1; NCBI gene ID: 80329); UL16 binding protein 2 (ULBP2; NCBI Gene ID: 80328); UL16 binding protein 3 (ULBP3; NCBI Gene ID: 79465); retinoic acid early transcript 1E (RAET1E; ULBP4; NCBI Gene ID: 135250); retinoic acid early transcript 1G (RAET1G; ULBP5; NCBI Gene ID: 353091); retinoic acid early transcript 1L (RAET1L; ULBP6; NCBI Gene ID: 154 064); killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A; NCBI gene ID: 3821); killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314; NCBI gene ID: 22914); killer cell lectin-like receptor C2 (KLRC2, CD159c, NKG2C; NCBI gene ID: 3822); killer cell lectin-like receptor C3 (KLRC3, NKG2E; NCBI gene ID: 3823); killer cell Lectin-like receptor C4 (KLRC4, NKG2F; NCBI Gene ID: 8302); Killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1; NCBI Gene ID: 3802); Killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2; NCBI Gene ID: 3803); Killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3; NCBI Gene ID: 3804); Cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1, KIR, CD158E1; NCBI Gene ID: 3811) (e.g., lirelumab (IPH2102/BMS-986015), IPH-4102); killer cell lectin-like receptor D1 (KLRD1; NCBI Gene ID: 3824), and mitogen-activated protein kinase kinase kinase kinase kinase 1 (MAP4K1, also known as hematopoietic progenitor kinase 1 (HPK1); NCBI Gene ID: 11184).

In various embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with one or more blockers or inhibitors of one or more T cell inhibitory immune checkpoint proteins or receptors. Exemplary T cell inhibitory immune checkpoint proteins or receptors include, but are not limited to, CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain-containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunomodulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte-associated (BTLA)); PVR-associated immune globin domain proteins (PVRIG, CD112R); T-cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activation 3 (LAG3, CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); and killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1). Lirelumab is an exemplary antibody that binds to and blocks the KIR2DL1/2L3 receptor. In various embodiments, the fusion polypeptides, polynucleotides, vectors, LNPs, immunogenic compositions and/or pharmaceutical compositions described herein are combined with one or more agonists or activators of one or more T cell stimulatory immune checkpoint proteins or receptors. Exemplary T cell stimulatory immune checkpoint proteins or receptors include, but are not limited to, CD27, CD70; CD40, CD40LG; inducible T cell co-stimulator (ICOS, CD278); inducible T cell co-stimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); CD244 (2B4, SLAMF4), poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). See, e.g., Xu et al., J Exp Clin Cancer Res. (2018) 37:110.

In various embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with one or more blockers or inhibitors of one or more NK cell inhibitory immune checkpoint proteins or receptors. Exemplary NK cell inhibitory immune checkpoint proteins or receptors include, but are not limited to, killer cell immunoglobulin-like receptor, three Ig domains and a long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin-like receptor, two Ig domains and a long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains and a long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains and a long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin-like receptor, three Ig domains and a long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A) (e.g., monalizumab (IPH2201)); and killer cell lectin-like receptor D1 (KLRD1, CD94). In various embodiments, the agent as described herein is combined with one or more agonists or activators of one or more NK cell stimulatory immune checkpoint proteins or receptors. Exemplary NK cell stimulatory immune checkpoint proteins or receptors include but are not limited to CD16, CD226 (DNAM-1); CD244 (2B4, SLAMF4); Killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314); SLAM family member 7 (SLAMF7). See, for example, Davis et al., Semin Immunol. (2017) 31: 64–75; Fang et al., Semin Immunol. (2017) 31: 37-54; and Chiossone et al., Nat Rev Immunol. (2018) 18 (11): 671-688.

In some embodiments, one or more immune checkpoint inhibitors include protein (e.g., antibody or fragment thereof or antibody mimetic) inhibitors of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, one or more immune checkpoint inhibitors include organic small molecule inhibitors of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, the small molecule inhibitors of CD274 or PDCD1 are selected from GS-4224, GS-4416, INCB086550 and MAX10181. In some embodiments, the small molecule inhibitors of CTLA4 include BPI-002.

Examples of CTLA4 inhibitors that can be co-administered include, but are not limited to, ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, CG-0161, ATO R-1144, PBI-5D3H5, BPI-002, and the multispecific inhibitors FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/CTLA4), MGD-019 (PD-1/CTLA4), KN-046 (PD-1/CTLA4), MEDI-5752 (CTLA4/PD-1), XmAb-20717 (PD-1/CTLA4), and AK-104 (CTLA4/PD-1).

Examples of PD-L1 (CD274) or PD-1 (PDCD1) inhibitors that may be co-administered include, but are not limited to, pembrolizumab, nivolumab, simumab, pidilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK-301, PF-06801591, BGB-A317 (tislelizumab), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, HLX-10, MGA-012, BI-754091, AGEN-2034, JS-001 (toripalizumab), JNJ-63723283, genol monoclonal antibody (CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, SHR-1210 (camrelizumab), Sym-021, ABBV-181 (buglilimab), PD1-PIK, BAT-1306 (MSB0010718C), CX-072, CBT-502, TSR-042 (dotarizumab), MSB-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP- 3155, KN-035, IBI-308 (sintilimab), HLX-20, KL-A167, STI-A1014, STI-A1015 (IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, GS-4224, GS-4416, INCB086550, MAX10181, and multispecific inhibitors FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/CTLA4), MGD-013 (PD-1/LAG-3), FS-118 (LAG-3/PD -L1)MGD-019(PD-1/CTLA4), KN-046(PD-1/CTLA4), MEDI-5752(CTLA4/PD-1), RO-7121661(PD-1/TIM-3), XmAb-20717(PD-1/CTLA4), AK-104(CTLA4/PD-1), M7824(PD-L1/TGFβ -EC domain), CA-170 (PD-L1/VISTA), CDX-527 (CD27/PD-L1), LY-3415244 (TIM3/PDL1) and INBRX-105 (4-1BB/PDL1).

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined with anti-TIGIT antibodies (such as etigilimab, BMS-986207, tiragolumab (also known as MTIG-7192A; RG-6058; RO 7092284), vibriolimab (MK-7684), AGEN1307, AGEN1327, AGEN1777, COM-902, IBI-939, AB154, SGN-TGT, MG1131, and EOS884448 (EOS-448).

TNF receptor superfamily (TNFRSF) member agonists or activators

In various embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with one or more agonists of one or more TNF receptor superfamily (TNFRSF) members, such as agonists of one or more of the following TNF receptor superfamily members: TNFRSF1A (NCBI Gene ID: 7132), TNFRSF1B (NCBI Gene ID: 7133), TNFRSF4 (OX40, CD134; NCBI Gene ID: 72 93), TNFRSF5 (CD40; NCBI gene ID: 958), TNFRSF6 (FAS, NCBI gene ID: 355), TNFRSF7 (CD27, NCBI gene ID: 939), TNFRSF8 (CD30, NCBI gene ID: 943), TNFRSF9 (4-1BB, CD137, NCBI gene ID: 3604), TNFRSF10A (CD261, DR4, TRAILR1, NCBI gene ID: 8797), TNFRSF10B (CD262, DR5, TRAILR2, NCBI gene ID: 8797), I gene ID: 8795), TNFRSF10C (CD263, TRAILR3, NCBI gene ID: 8794), TNFRSF10D (CD264, TRAILR4, NCBI gene ID: 8793), TNFRSF11A (CD265, RANK, NCBI gene ID: 8792), TNFRSF11B (NCBI gene ID: 4982), TNFRSF12A (CD266, NCBI gene ID: 51330), TNFRSF13B (CD267, NCBI gene ID: 23495), TNFRS F13C (CD268, NCBI gene ID: 115650), TNFRSF16 (NGFR, CD271, NCBI gene ID: 4804), TNFRSF17 (BCMA, CD269, NCBI gene ID: 608), TNFRSF18 (GITR, CD357, NCBI gene ID: 8784), TNFRSF19 (NCBI gene ID: 55504), TNFRSF21 (CD358, DR6, NCBI gene ID: 27242) and TNFRSF25 (DR3, NCBI gene ID: 8718).

Exemplary anti-TNFRSF4 (OX40) antibodies that may be co-administered include, but are not limited to, MEDI6469, MEDI6383, MEDI0562 (tavolizumab), MOXR0916, PF-04518600, RG-7888, GSK-3174998, INCAGN1949, BMS-986178, GBR-8383, ABBV-368, and those described in WO2016179517, WO2017096179, WO2017096182, WO2017096281, and WO2018089628.

Exemplary anti-TNFRSF5 (CD40) antibodies that may be co-administered include, but are not limited to, RG7876, SEA-CD40, APX-005M, and ABBV-428.

In some embodiments, the anti-TNFRSF7 (CD27) antibody varilutumab (CDX-1127) is co-administered.

Exemplary anti-TNFRSF9 (4-1BB, CD137) antibodies that may be co-administered include, but are not limited to, usurelumab, utolumab (PF-05082566), AGEN2373, and ADG-106.

Exemplary anti-TNFRSF18 (GITR) antibodies that can be co-administered include, but are not limited to, MEDI1873, FPA-154, INCAGN-1876, TRX-518, BMS-986156, MK-1248, GWN-323, and those described in WO2017096179, WO2017096276, WO2017096189, and WO2018089628. In some embodiments, antibodies or fragments thereof that co-target TNFRSF4 (OX40) and TNFRSF18 (GITR) are co-administered. Such antibodies are described, for example, in WO2017096179 and WO2018089628.

Bispecific and trispecific natural killer (NK) cell engagers

In various embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a bispecific NK cell engager (BiKE) or a trispecific NK cell engager (TriKE) (e.g., without Fc) or a bispecific antibody (e.g., with Fc) against: NK cell activating receptors (e.g., CD16A), C-type lectin receptors (CD94/NK KG2C, NKG2D, NKG2E/H and NKG2F), natural cytotoxicity receptors (NKp30, NKp44 and NKp46), killer cell C-type lectin-like receptors (NKp65, NKp80), Fc receptor FcγR (which mediates antibody-dependent cellular cytotoxicity), SLAM family receptors (e.g., 2B4, SLAM6 and SLAM7), killer cell immunoglobulin-like receptors (KIR) (KIR-2DS and KIR-3DS), DNAM-1 and CD137 (4-1BB). Depending on the circumstances, the anti-CD16 binding bispecific molecule may or may not have Fc. Exemplary bispecific NK cell engagers that can be co-administered target CD16 and one or more HIV-associated antigens as described herein. BiKE and TriKE are described, for example, in Felices et al., Methods Mol Biol. (2016) 1441: 333–346; Fang et al., Semin Immunol. (2017) 31: 37-54. Examples of trispecific NK cell engagers (TRiKE) include OXS-3550, HIV-TriKE, and CD16-IL-15-B7H3 TriKe.

Indoleamine-pyrrole-2,3-dioxygenase (IDO1) inhibitors

In various embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined with inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1; NCBI gene ID: 3620). Examples of IDO1 inhibitors include, but are not limited to, BLV-0801, icadolstat, F-001287, GBV-1012, GBV-1028, GDC-0919, indomod, NKTR-218, NLG-919-based vaccines, PF-06840003, pyranonaphthoquinone derivatives (SN-35837), resminostat, SBLK-200802, BMS-986205, and shIDO-ST, EOS-200271, KHK-2455, LY-3381916.

Toll-like receptor (TLR) agonists

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with an agonist of a toll-like receptor (TLR), such as an agonist of TLR1 (NCBI Gene ID: 7096), TLR2 (NCBI Gene ID: 7097), TLR3 (NCBI Gene ID: 7098), TLR4 (NCBI Gene ID: 7099), TLR5 (NCBI Gene ID: 7100), TLR6 (NCBI Gene ID: 10333), TLR7 (NCBI Gene ID: 51284), TLR8 (NCBI Gene ID: 51311), TLR9 (NCBI Gene ID: 54106), and/or TLR10 (NCBI Gene ID: 81793). Exemplary TLR7 agonists that can be co-administered include, but are not limited to, AL-034, DSP-0509, GS-9620 (visamod), visamod analogs, LHC-165, TMX-101 (imiquimod), GSK-2245035, resiquimod, DSR-6434, DSP-3025, IMO-4200, MCT-465, MEDI-9197, 3M-051, SB-9922, 3M-052, Limtop, TMX-30X, TMX-202, RG-7863, RG-7854, RG-7795, and US20100143301 (Gilead Sciences), US20110098248 (Gilead Sciences), and US20090047249 (Gilead Sciences). Sciences)、US20140045849(Janssen)、US20140073642(Janssen)、WO2014/056953(Janssen)、WO2014/076221(Janssen)、WO2014/128189(Janssen)、US20140350031(Janssen)、WO2014/023813(Janssen)、US20080234251(Array Biopharma)、US20080306050(Array Biopharma)、US20100029585(VentirxPharma)、US20110092485(Ventirx Pharma)、US20110118235(Ventirx Pharma)、US20120082658(Ventirx Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira Therapeutics) and US20130251673 (Novira Therapeutics). TLR7/TLR8 agonists that can be co-administered are NKTR-262, teramod and BDB-001. Exemplary TLR8 agonists that can be co-administered include, but are not limited to, E-6887, IMO-4200, IMO-8400, IMO-9200, MCT-465, MEDI-9197, motolimod, resiquimod, GS-9688 (sergantomod), VTX-1463, VTX-763, 3M-051, 3M-052, and US20140045849 (Janss en), US20140073642(Janssen), WO2014/056953(Janssen), WO2014/076221(Janssen), WO2014/128189(Janssen), US20140350031(Janssen), WO2014/023813(Janssen), US2008023425 1(Array Biopharma), US20080306050 (ArrayBiopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira Therapeutics) and US20130251673 (Novira Therapeutics). Example TLR9 agonists that can be co-administered include, but are not limited to, AST-008 (cavrotolimod), cobitolimod, CMP-001, IMO-2055, IMO-2125, S-540956, litenimod, MGN-1601, BB-001, BB-006, IMO-3100, IMO-8400, IR-103, IMO-9200, agatolimod, DIMS-9054, DV-1079, DV-1179, AZD-1419, lefitolimod (MGN-1703), CYT-003, CYT-003-QbG10, tilsotolimod, and PUL-042. Examples of TLR3 agonists include retamod, polyICLC, 、Apoxxim、 , IPH-33, MCT-465, MCT-475 and ND-1.1. Examples of TLR4 agonists include G-100 and GSK-1795091.

CDK inhibitors or antagonists

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a CDK inhibitor or antagonist. In some embodiments, the agents described herein are combined with an inhibitor or antagonist of CDK. In some embodiments, the CDK inhibitor or antagonist is selected from VS2-370.

STING agonists, RIG-I and NOD2 modulators

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a stimulator of interferon genes (STING) receptor (also known as interferon response stimulator cGAMP interactor 1 (STING1); transmembrane protein 173 (TMEM173); NCBI gene ID: 340061) agonist. In some embodiments, the STING receptor agonist or activator is selected from ADU-S100 (MIW-815), SB-11285, MK-1454, SR-8291, STING agonist (latent HIV), 5,6-dimethylxanthone-4-acetic acid (DMXAA), cyclic GAMP (cGAMP), and cyclic diAMP. In some embodiments, the agents described herein are combined with a RIG-I modulator (such as RGT-100) or a NOD2 modulator (such as SB-9200 and IR-103).

In some embodiments, the additional therapeutic agent is an agonist of DExD/H-box helicase 58 (DDX58; also known as RIG-I, RIG1, RIGI, RLR-1, SGMRT2; NCBI Gene ID: 23586). Exemplary RIG-I agonists include inarigivir soproxil (SB-9200; GS-9992); SB-40, SB-44, ORI-7246, ORI-9350, ORI-7537, ORI-9020, ORI-9198, ORI-7170, RGT-100, and KIN1148, as described in Hemann et al., J Immunol May 1, 2016, 196 (1 Supplement) 76.1. Additional RIG-I agonists are described in, for example, Elion et al., Cancer Res. (2018) 78(21): 6183-6195; and Liu et al., J Virol. (2016) 90(20): 9406-19. RIG-I agonists are commercially available, for example, from Invivogen (invivogen.com). In some embodiments, the agents described herein are combined with nucleotide binding oligomerization domain-containing protein 2 (NOD2; NCBI gene ID: 64127) agonists such as sonagivir (SB-9200; GS-9992) and IR-103.

LAG-3 and TIM-3 inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with anti-TIM-3 such as TSR-022, LY-3321367, MBG-453, INCAGN-2390.

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with an anti-LAG-3 (lymphocyte activation) antibody such as relalizumab (ONO-4482), LAG-525, MK-4280, REGN-3767, INCAGN2385.

Interleukin or cytokine receptor agonists

In certain embodiments, one or more fusion polypeptides as disclosed herein or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with interleukin receptor agonists such as IL-2, IL-7, IL-15, IL-10, IL-12 receptor agonists. Examples of IL-2 receptor agonists that can be co-administered include Proleukin (albeukin, IL-2); BC-IL (Cel-Sci), PEGylated IL-2 (e.g., NKTR-214); modified variants of IL-2 (e.g., THOR-707, Fc-IL-2 fusion proteins), bepei aldesleukin, AIC-284, ALKS-4230, CUI-101, Neo-2/15. Examples of IL-15 receptor agonists that can be co-administered include, but are not limited to, ALT-803, NKTR-255 and hetIL-15, interleukin-15/Fc fusion protein, AM-0015, NIZ-985, SO-C101, IL-15 (pegylated 11-15), P-22339, and IL-15-PD-1 fusion protein N-809. Examples of IL-7 receptor agonists that can be co-administered include CYT-107.

Examples of additional immune-based therapies that can be combined or co-administered include interferon alpha; interferon alpha-2b; interferon alpha-n3; pegylated interferon alpha; interferon gamma; fms-related tyrosine kinase 3 (FLT3) agonists (e.g., GS-3583, CDX-301); gepon; nomofuron, pegylated interferon alpha-2a, pegylated interferon alpha-2b, RPI-MN. In various embodiments, an fms-related tyrosine kinase 3 (FLT3) agonist (e.g., GS-3583, CDX-301) is administered at a first time point, and one or more fusion polypeptides or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are administered at a time point at least 6, 7, 8, 9, 10 days (e.g., 1 week) after the first time point.

In some embodiments, one or more fusion polypeptides as disclosed herein or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNP) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with fms-related tyrosine kinase 3 (FLT3) agonists (e.g., GS-3583, CDX-301). Exemplary FLT3 agonists that can be co-administered are described in, for example, WO 2020/263830A1. In various embodiments, co-administration of FLT3 agonists increases vaccine-induced T cell responses compared to administration of one or more fusion polypeptides or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNP) comprising such polynucleotides, or vectors expressing such fusion polypeptides in the absence of FLT3 agonists.

Phosphatidylinositol 3-kinase (PI3K) inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a PI3K inhibitor. Examples of PI3K inhibitors that may be combined or co-administered include idelalisib, alpelisib, buparlisib, CAI orotate, copanlisib, duvelisib, gedatolisib, neratinib, panulisib, perifosine, pictilisib, pilaralisib, puroquitinib mesylate, regoratinib, regoratinib sodium, sonolisib, taselixib, sib), AMG-319, AZD-8186, BAY-1082439, CLR-1401, CLR-457, CUDC-907, DS-7423, EN-3342, GSK-2126458, GSK-2269577, GSK-2636771, INCB-040093, LY-3023414, MLN -1117, PQR-309, RG-7666, RP-6530, RV-1729, SAR-245409, SAR-260301, SF-1126, TGR-1202, UCB-5857, VS-5584, XL-765 and ZSTK-474.

Diacylglycerol kinase inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with inhibitors of diacylglycerol kinase (DGK) (e.g., diacylglycerol kinase α (DGKα) and diacylglycerol kinase ζ (DGKζ). Examples of DGK inhibitors that may be combined or co-administered include, but are not limited to, ritanserin and the DGK inhibitors described in WO2020006016 and WO2020006018.

Alpha-4/beta-7 antagonists

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with an alpha-4/beta-7 antagonist. Examples of integrin alpha-4/beta-7 antagonists that can be combined or co-administered include PTG-100, TRK-170, abrilumab, etrolizumab, carotegrast methyl, and vedolizumab.

HPK1/MAP4K1 inhibitors

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with an inhibitor of mitogen-activated protein kinase kinase kinase kinase kinase kinase 1 (MAP4K1; also known as hematopoietic progenitor kinase 1 (HPK1); NCBI Gene ID: 11184). Examples of HPK1 inhibitors include, but are not limited to, ZYF-0272 and ZYF-0057.

HIV-targeted antibodies

Examples of HIV antibodies, bispecific antibodies, and "antibody-like" therapeutic proteins that can be combined or co-administered include Fab derivatives, bNAbs (broadly neutralizing HIV-1 antibodies), TMB-360, TMB-370, and those targeting HIV gp120 or gp41, antibody recruitment molecules targeting HIV, anti-CD63 monoclonal antibodies, anti-GB virus C antibodies, anti-GP120/CD4, gp120 bispecific monoclonal antibodies, CCR5 bispecific antibodies, anti-Nef single domain antibodies, anti-Rev antibodies, camelid-derived anti-CD18 antibodies, camelid-derived anti-ICAM-1 antibodies, DCVax-001, gp140 targeting antibodies, gp41-based HIV therapeutic antibodies, human recombinant mAbs, ibalizumab, ibalizumab (second generation), Immuglo, MB-66, clone 3 human monoclonal antibodies targeting KLIC (HIV infection). As described herein, various bNAbs can be used.

In certain embodiments, the co-administered antibody or its antigen-binding fragment or antigen-binding molecule is or is derived from a human neutralizing antibody (e.g., monoclonal antibody) targeting HIV-1. "Neutralizing antibodies" are antibodies that can neutralize HIV's ability to cause and/or maintain infection in a host and/or target cell in vitro. The present disclosure provides neutralizing monoclonal human antibodies, wherein the antibody recognizes an antigen from HIV, such as a gp120 polypeptide. In certain embodiments, "neutralizing antibodies" can inhibit entry of HIV-1 viruses (e.g., SF162 and/or JR-CSF), with a neutralization index >1.5 or >2.0 (Kostrikis LG et al., J. Virol., 70 (1): 445--458 (1996)).

In some embodiments, the co-administered antibody or antigen-binding fragment thereof or antigen-binding molecule is or is derived from a broadly neutralizing antibody (e.g., a monoclonal antibody) targeting HIV-1. The so-called "broadly neutralizing antibody" means an antibody that neutralizes more than one HIV-1 virus species (from different clades and different strains within clades) in a neutralization assay. Broadly neutralizing antibodies can neutralize at least 2, 3, 4, 5, 6, 7, 8, 9 or more different strains of HIV-1, which belong to the same or different clades. Exemplary broadly neutralizing antibodies (bNAbs) that can be co-administered as additional therapeutic agents in combination therapy are described, for example, in 8,673,307, 9,493,549, 9,783,594 and WO 2012/154312, WO 2012/158948, WO 2013/086533, WO 2013/142324, WO 2014/063059, WO 2014/089152, WO 2015/048462, WO 2015/103549, WO 2015/117008, WO 2016/014484, WO 2016/154003, WO 2016/196975, WO 2016/149710, WO 2017/096221, WO The invention is described in WO 2017/133639, WO 2017/133640, the entire contents of which are hereby incorporated by reference for all purposes. Exemplary bNAbs that can be co-administered include, but are not limited to, 12A12, 12A21, NIH45-46, bANC131, 8ANC134, IB2530, INC9, 8ANC195, 8ANC196, 10-259, 10-303, 10-410, 10-847, 10-996, 10-1074, 10-1074-LS, 10-1074-LS-J, 10-1121, 10-1130, 10-1146, 10-1341, 10-1369, 10-1074GM, PGT-121, PGT-121.414, GS-9721, GS-9722, and GS-2872. Additional examples include those described in Sajadi et al., Cell. (2018) 173(7):1783-1795; Sajadi et al., J Infect Dis. (2016) 213(1):156-64; Klein et al., Nature, 492(7427):118-22 (2012); Horwitz et al., Proc Natl Acad Sci U S A, 110(41):16538-43 (2013); Scheid et al., Science, 333:1633-1637 (2011); Scheid et al., Nature, 458:636-640 (2009); Eroshkin et al., Nucleic Acids Res., 42(Database Special):D1 133-9 (2014); Mascola et al., Immunol Rev., 254(l):225-44(2013), such as 2F5, 4E10, M66.6, CAP206-CH12, 10E81 (all of which bind to the MPER of gp41); PG9, PG16, CH01-04 (all of which bind to the V1V2-glycan), 2G12 (which binds to the external domain glycan); b12, HJ16, CH130-149, V RC01-03, VRC-PG04, 04b, VRC-CH30-34, 3BNC62, 3BNC89, 3BNC91, 3BNC95, 3BNC104, 3BNC117, 3BNC176, 8ANC131, GS-9723, GS-5423 (all of which bind to the CD4 binding site), which are hereby incorporated by reference in their entirety for all purposes.

In some embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a broadly neutralizing antibody (bNAb) that binds to an epitope or region of gp120 selected from: (i) the third variable loop (V3) and/or the high mannose patch comprising the N332 oligomannose glycan; (ii) the second variable loop (V2) and/or the Env trimer apex; (iii) the CD4 binding site (CD4bs); (iv) the gp120/gp41 interface; or (v) the silent face of gp120. The aforementioned epitopes or regions of gp120 to which broadly neutralizing antibodies bind are described in, e.g., McCoy, , Retrovirology (2018) 15:70; Sok and Burton, Nat Immunol. 2018 19(11):1179-1188; Possas et al., Expert Opin Ther Pat. 2018 Jul;28(7):551-560; and Stephenson and Barouch, Curr HIV/AIDS Rep (2016) 13:31–37, which are hereby incorporated by reference in their entirety for all purposes.

In some embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a broadly neutralizing antibody (bNAb) that binds to an epitope or region of gp120 in the third variable loop (V3) and/or the high mannose patch comprising the N332 oligomannose glycan, and competes with or comprises the VH and VL regions of an antibody selected from the group consisting of GS-9722, PGT-121.60, PGT-121.66, PGT-121, PGT-121.414, PGT-122, PGT-123, PG-124, PGT-125, PGT-126, PGT-127, PGT-128, PGT-129, PGT-130, PGT-131, PGT-132, PGT-133, PGT-134, PGT-135, PGT-136, PGT-137, PGT-138, PGT-139, PGT-140, PGT-141, PGT-142, PGT-143, PGT-144, PGT-145, PGT-146, PGT-147, PGT-148, PGT-149, PGT-150, PGT-151, PGT-152, PGT-153, PGT-154, PGT-155, PGT-156, PGT-157, PGT-158, PGT-159, T-124, PGT-125, PGT-126, PGT-128, PGT-130, PGT-133, PGT-134, PGT-135, PGT-136, PGT-137, PGT-138, PGT-139, 10-1074, VRC24, 2G12, BG18, 354BG8, 354BG18, 354BG 42. 354BG33, 354BG129, 354BG188, 354BG411, 354BG426, DH270.1, DH270.6, PGDM12, VRC41.01, PGDM21, PCDN-33A, BF520.1 and VRC29.03. Additional broadly neutralizing antibodies that bind to gp120 in the third variable loop (V3) comprising N332 oligomannose glycans and/or high mannose plaques and can be used as secondary antibodies or antigen-binding fragments thereof are described in, e.g., WO 2012/030904, WO 2014/063059, WO 2016/149698, WO 2017/106346, WO 2018/075564, WO 2018/125813, and WO 2018/237148, which are hereby incorporated by reference in their entirety for all purposes.

In some embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a broadly neutralizing antibody (bNAb) that binds to an epitope or region of gp120 in the CD4 binding site (CD4bs) and competes with or comprises the CDRs and/or VH and VL regions of an antibody selected from the group consisting of b12, F105, VRC01, VRC07, VRC0 7-523, VRC03, VRC06, VRC06b01, VRC08, VRC0801, NIH45-46, GS-9723, GS-5423, 3BNC117, 3BNC60, VRC-PG04, PGV04, CH103, 44-VRC13.01, 1NC9, 12A12, N6, N49-P7, NC-Cow1, IOMA, CH235 and CH235.12, N49P6, N49P7, N49P11, N49P9, and N60P25. Other broadly neutralizing antibodies that bind to the gp120 CD4 binding site (CD4bs) and can be used as secondary antibodies or antigen-binding fragments thereof are described in, e.g., WO 2012/154312, WO 2012/158948, WO 2013/090644, WO 2013/192589, WO 2018/125813, which are hereby incorporated by reference in their entirety for all purposes.

In some embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a broadly neutralizing antibody (bNAb) that binds to an epitope or region of gp120 in the second variable loop (V2) and/or the apex of the Env trimer and competes with or comprises the VH and VL regions of an antibody selected from the group consisting of PG9, PG16, PGC14, PGG14, PGT-142, PGT-143, PGT-144, PGT-145, CHO1, CH59, PGDM1400, CAP256, CAP256-VRC26.08, CAP256-VRC26.09, CAP256-VRC26.25, PCT64-24E, and VRC38.01. Additional broadly neutralizing antibodies that bind to gp120 in the second variable loop (V2) and/or the Env trimer apex and can be used as a secondary antibody or antigen-binding fragment thereof are described in, for example, WO 2010/107939, WO 2012/030904, WO 2018/075564, and WO 2018/125813, which are hereby incorporated by reference in their entirety for all purposes.

In some embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a broadly neutralizing antibody (bNAb) that binds to an epitope or region of gp120 in the gp120/gp41 interface and competes with or comprises the VH and VL regions of an antibody selected from the group consisting of PGT-151, CAP248-2B, 35022, 8ANC195, ACS202, VRC34, and VRC34.01. Additional broadly neutralizing antibodies that bind to gp120 in the gp120/gp41 interface and can be used as secondary antibodies or antigen-binding fragments thereof are described, for example, in WO 2011/038290, WO 2012/030904, and WO 2017/079479, which are hereby incorporated by reference in their entirety for all purposes.

In some embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a broadly neutralizing antibody (bNAb) that binds to an epitope or region of the silent face of gp120 and competes with or comprises the VH and VL regions of an antibody selected from VRC-PG05 and SF12. See, e.g., Schoofs et al., "Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope," Immunity (2019) May 14. pii:S1074-7613(19)30194-3 (PMID 31126879).

In some embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a broadly neutralizing antibody (bNAb) that binds to an epitope or region of gp41 in the membrane proximal region (MPER). Additional broadly neutralizing antibodies that bind to gp41 in the MPER and can be used as secondary antibodies or antigen-binding fragments thereof are described, for example, in WO 2011/034582, WO 2011/038290, WO 2011/046623, and WO 2013/070776, which are hereby incorporated by reference herein in their entirety for all purposes.

In some embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a broadly neutralizing antibody (bNAb) that binds to an epitope or region of gp41 in the membrane proximal region (MPER) and competes with or comprises the VH and VL regions of an antibody selected from the group consisting of: 10E8, 10E8v4, 10E8-5R-100cF, 4E10, DH511.11P, 2F5, 7b2, and LN01.

In some embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined or co-administered with a broadly neutralizing antibody (bNAb) that binds to an epitope or region of the gp41 fusion peptide and competes with or comprises the VH and VL regions of an antibody selected from VRC34 and ACS202.

Examples of additional antibodies that can be co-administered include bavituximab, UB-421, BF520.1, BiIA-SG, CHO1, CH59, C2F5, C4E10, C2F5+C2G12+C4E10, CAP256V2LS, 3BNC117, 3BNC117-LS, 3BNC60, DH270.1, DH270.6, D1D2, 10-1074-LS, Cl3hmAb, GS-9722 (epavirumab), PGT-121.414, PGT-121.60, PGT-121.66, PGT-121.70 2. PGT-123, PGT-124, PGT-125, PGT-126, PGT-151, PGT-130, PGT-133, PGT-134, PGT-135, PGT-128, PGT-136, PGT-137, PGT-138, PGT-139, MDX010 (ipilimumab), DH511, DH511-2, N6, N6LS, N49P6, N49P7, N49P7.1, N49P9, N49P11, N60P1.1, N60P25.1, N60P2.1, N60P31.1, N60P22, NIH 45--46, PGC14, PGG14, PGT-142, PGT-143, PGT-144, PGDM1400, PGDM12, PGDM21, PCDN-33A, 2Dm2m, 4Dm2m, 6Dm2m, PGDM1400, MDX010 (ipilimumab), VRC01, VRC-01-LS, A32, 7B2, 10E8, VRC-07-523, VRC07-523LS, VRC24, VRC41.01, 10E8VLS, 3810109, 10E8v4, IMC-HIV, iMabm36, eCD4-Ig, IOMA, CAP256-VRC26.25, DRVIA7, VRC-HIVMAB080-00-AB, VR C-HIVMAB060-00-AB, P2G12, VRC07, 354BG8, 354BG18, 354BG42, 354BG33, 354BG129, 354BG188, 354BG411, 354BG426, VRC29.03, CAP256, CAP256-VRC26.08, CAP256-VRC2 6.09, CAP256-VRC26.25, PCT64-24E and VRC38.01, PGT-151, CAP248-2B, 35O22, ACS202, VRC34 and VRC34.01, 10E8, 10E8v4, 10E8-5R-100cF, 4E10, DH511.11P, 2F5, 7b2 and LN01.

Examples of HIV bispecific and trispecific antibodies include MGD014, B12BiTe, BiIA-SG, TMB-bispecific, SAR-441236, VRC-01/PGDM-1400/10E8v4, 10E8.4/iMab, 10E8v4/PGT121-VRC01.

In some embodiments, bNAbs can be expressed in vivo in patients. Examples of bNAbs delivered in vivo include AAV8-VRC07, mRNA encoding the anti-HIV antibody VRC01, and engineered B cells encoding 3BNC117 (Hartweger et al., J. Exp. Med. 2019, 1301).

Pharmacokinetic enhancers

In certain embodiments, one or more fusion polypeptides as disclosed herein or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined with a pharmacokinetic enhancer. Examples of pharmacokinetic enhancers that can be combined or co-administered include cobicistat and ritonavir.

Additional therapeutic agents

Examples of additional therapeutic agents that can be combined with one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides include WO 2004/096286 (Gilead Sciences), WO 2006/015261 (Gilead Sciences), WO 2006/110157 (Gilead Sciences), WO 2012/003497 (Gilead Sciences), WO 2012/003498 (Gilead Sciences), WO 2012/145728 (Gilead Sciences), WO 2013/006738 (Gilead Sciences), WO 2013/159064 (Gilead Sciences), WO 2014/100323 (Gilead Sciences), US 2013/0165489 (University of Pennsylvania), US 2013/0165489 (University of Pennsylvania), US Compounds disclosed in 2014/0221378 (Japan Tobacco), US 2014/0221380 (Japan Tobacco), WO 2009/062285 (Boehringer Ingelheim), WO 2010/130034 (Boehringer Ingelheim), WO 2013/006792 (Pharma Resources), US 20140221356 (Gilead Sciences), US 20100143301 (Gilead Sciences) and WO 2013/091096 (Boehringer Ingelheim).

HIV vaccine

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined with HIV vaccines. Examples of HIV vaccines that can be combined or co-administered include peptide vaccines, recombinant subunit protein vaccines, live vector vaccines, DNA vaccines, HIV MAG vaccines, DNA vaccines, CD4-derived peptide vaccines, vaccine combinations, adenovirus vector vaccines (adenovirus vectors such as Ad5, Ad26 or Ad35), simian adenovirus (chimpanzee, gorilla, rhesus monkey i.e. rhAd), adeno-associated virus vector vaccines, chimpanzee adenovirus vaccines (e.g., ChAdOX1, ChAd68, ChAd3, ChAd63, ChAd83, ChAd155, ChAd157, Pan5, Pan6, Pan7, Pan9), coxsackievirus-based vaccines, enterovirus-based vaccines, gorilla adenovirus vaccines, lentiviral vector-based vaccines, arenavirus vaccines (such as LCMV, Pichinde), bi- or tripartite-segmented arenavirus-based vaccines, trimer-based vaccines. HIV-1 vaccine, measles virus-based vaccine, flavivirus vector-based vaccine, tobacco mosaic virus vector-based vaccine, varicella-zoster virus-based vaccine, human parainfluenza virus 3 (PIV3)-based vaccine, poxvirus-based vaccine (modified vaccinia virus Ankara (MVA)), orthopoxvirus-derived NYVAC and fowlpox virus-derived ALVAC (canarypox virus) strain); fowlpox virus-based vaccine, rhabdovirus-based vaccine, such as VSV and Maraba virus; recombinant human CMV (rhCMV)-based vaccine, alphavirus-based vaccine, such as Semliki Forest virus, Venezuelan equine encephalitis virus and Sindbis virus; (see Lauer, Clinical and Vaccine Immunology, 2017, DOI: 10.1128/CVI.00298-16); LNP-formulated mRNA-based therapeutic vaccine; LNP-formulated self-replicating RNA/self-amplifying RNA vaccine.

Examples of HIV vaccines that can be co-administered include, but are not limited to, AAVLP-HIV vaccine, AE-298p, anti-CD40.Env-gp140 vaccine, Ad4-EnvC150, BG505 SOSIP.664gp140 adjuvant vaccine, BG505 SOSIP.GT1.1gp140 adjuvant vaccine, ChAdOx1.tHIVconsv1 vaccine, CMV-MVA triple vaccine, ChAdOx1.HTI, Chimigen HIV vaccine, ConM SOSIP.v7gp140, ALVAC HIV (vCP1521), AIDSVAX B/E (gp120), monomeric gp120 HIV-1C subtype vaccine, MPER-656 liposomal subunit vaccine, Remune, ITV-1, Contre Vir, Ad5-ENVA-48, DCVax-001 (CDX-2401), Vacc-4x, Vacc-C5, VAC-3S, multi-stage DNA recombinant adenovirus-5 (rAd5), rAd5 gag-pol envA/B/C vaccine, Pennvax-G, Pennvax-GP, Pennvax-G/MVA-CMDR, HIV-TriMix-mRNA vaccine, HIV-LAMP-vax, Ad35, Ad35-GRIN, NAcGM3/VSSP ISA-51, poly-ICLC adjuvant vaccine, TatImmune, GTU-multiHIV (FIT-06), ChAdV63.HIVconsv, gp140[delta]V2.TV1+MF-59, rVSVIN HIV-1 gag vaccine, SeV-EnvF, SeV-Gag vaccine, AT-20, DNK-4, ad35-Grin/ENV, TBC-M4, HIVAX, HIVAX-2, HIV vaccine based on N123-VRC-34.01 induced antigen, NYVAC-HIV-PT1, NYVAC-HIV-PT4, DNA-HIV-PT123, rAAV1-PG9DP, GOVX-B11, GOVX-B21, GOVX-C55, TVI-HIV-1, Ad-4 (Ad4-env Clade C+Ad4-mGag), Paxvax, EN41-UGR7C, EN41-FPA2, ENOB-HV-11, ENOB-HV-12, PreVaxTat, AE-H, MYM-V101, CombiHIVvac, ADVAX, MYM-V201, MVA-CMDR, MagaVax, DNA-Ad5 gag/pol/nef/nev (HVTN505), MVATG-17401, ETV-01, CDX-1401, DNA expressing SCaVII and Sev vector vaccine, rcAD26.MOS1.HIV-Env, Ad26.Mod.HIV vaccine, Ad26.Mod.HIV+MVA mosaic vaccine+gp140, AGS-004, AVX-101, AVX-201, PEP-6409, SAV-001, ThV-01, TL-01, TUTI-16, VGX-3300, VIR-1111, IHV-001 and virus-like particle vaccines (such as pseudovirion vaccines), CombiVICHvac, LFn-p24 B/C fusion vaccine, GTU-based DNA vaccine, HIV gag/pol/nef/env DNA vaccine, anti-TAT HIV vaccine, conjugated peptide vaccine, dendritic cell vaccine (such as DermaVir), gag-based DNA vaccine, GI-2010, gp41 HIV-1 vaccine, HIV vaccine (PIKA adjuvant), i-key/MHC class II antigen hybrid peptide vaccine, ITV-2, ITV-3, ITV-4, LIPO-5, multi-stage Env vaccine, MVA vaccine, Pennvax-GP, pp71-deficient HCMV vector HIV gag vaccine, rgp160 HIV vaccine, RNActive HIV vaccine, SCB-703, Tat Oyi vaccine, TBC-M4, UBI HIV gp120, Vacc-4x+romidepsin, variant gp120 peptide vaccine, rAd5gag-pol env A/B/C vaccine, DNA.HTI and MVA.HTI, VRC-HIVDNA016-00-VP+VRC-HIVADV014-00-VP, INO-6145, JNJ-9220, gp145 C.6980; eOD-GT8 60mer-based vaccine, PD-201401, env(A,B,C,A/E)/gag(C) DNA vaccine, gp120(A,B,C,A/E) protein vaccine, PDPHV-201401, Ad4-EnvCN54, EnvSeq-1 Envs HIV-1 vaccine (GLA-SE adjuvant), HIV p24gag prime-boost plasmid DNA vaccine, HIV-1iglb12 neutralizing VRC-01 antibody-stimulated anti-CD4 vaccine, arenavirus vector-based vaccine ( ), MVA-BN HIV-1 vaccine regimen, UBI HIV gp120, mRNA-based preventive vaccines, VPI-211, multimeric HIV gp120 vaccine (Fred Hutchinson Cancer Research Center), TBL-1203HI, CH505 TFchTrimer, CD40.HIVRI.Env vaccine, Drep-HIV-PT-1, mRNA-1644 and mRNA-1574.

Birth control pill combination therapy

In certain embodiments, the agents described herein are combined with birth control or contraceptive regimens. Therapeutic agents for birth control (contraception) that may be combined or co-administered include cyproterone acetate, desogestrel, dienogest, drospirenone, estradiol valerate, ethinyl estradiol, norethindrone, etonogestrel, levonorgestrel, levonorgestrel, linegestrel, medroxyprogesterone acetate, ethinyl estradiol methyl ether, mifepristone, misoprostol, nomegestrol acetate, norprogesterone acetate, norethisterone, norgestimate, ormeloxifene, sigsone acetate, ulipristal acetate, and any combination thereof.

In one embodiment, an agent disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with one, two, three, four or more additional therapeutic agents selected from: (efavirenz, tenofovir disoproxil fumarate, and emtricitabine); ( ; rilpivirine, tenofovir disoproxil fumarate, and emtricitabine); (elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine); (tenofovir disoproxil fumarate and emtricitabine; TDF+FTC); (tenofovir alafenamide and emtricitabine); (tenofovir alafenamide, emtricitabine, and rilpivirine); (tenofovir alafenamide, emtricitabine, cobicistat, and elvitegravir); BIKTARVY (bicagvir + emtricitabine + tenofovir alafenamide), adefovir; adefovir dipivoxil; cobicistat; emtricitabine; tenofovir; tenofovir alafenamide and elvitegravir; tenofovir alafenamide + elvitegravir (rectal formulation, HIV infection); tenofovir disoproxil; tenofovir disoproxil fumarate; tenofovir alafenamide; tenofovir alafenamide hemifumarate; (dulutegravir, abacavir and lamivudine); dolutegravir, abacavir sulfate and lamivudine; raltegravir; pegylated raltegravir; raltegravir and lamivudine; lamivudine + lopinavir + ritonavir + abacavir; maraviroc; tenofovir + emtricitabine + maraviroc, enfuvirtide; ( ; lopinavir and ritonavir); (zidovudine and lamivudine; AZT+3TC); ( ; abacavir sulfate and lamivudine; ABC+3TC); (abacavir sulfate, zidovudine and lamivudine; ABC+AZT+3TC); rilpivirine; rilpivirine hydrochloride; atazanavir sulfate and cobicistat; atazanavir and cobicistat; darunavir and cobicistat; atazanavir; atazanavir sulfate; dolutegravir; elvitegravir; ritonavir; atazanavir sulfate and ritonavir; darunavir; lamivudine; platinum; fosamprenavir; fosamprenavir calcium efavirenz; etravirine; nelfinavir; nelfinavir mesylate; interferon; didanosine; stavudine; indinavir; indinavir sulfate; tenofovir and lamivudine; zidovudine; nevirapine; saquinavir; saquinavir mesylate; aldesleukin; zalcitabine; tipranavir; amprenavir; delavirdine; delavirdine mesylate; Radha-108 (receptor alcohol); lamivudine and tenofovir disoproxil fumarate; efavirenz, lamivudine, and tenofovir disoproxil fumarate; phosphinothricin; lamivudine, nevirapine, and zidovudine; abacavir; and abacavir sulfate.

In some embodiments, one or more fusion polypeptides as disclosed herein or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined with HIV nucleoside or nucleotide inhibitors of reverse transcriptase and HIV non-nucleoside inhibitors of reverse transcriptase. In another specific embodiment, the agents disclosed herein or their pharmaceutical compositions are combined with nucleoside or nucleotide inhibitors of HIV reverse transcriptase and HIV protease inhibitory compounds. In additional embodiments, the agents disclosed herein or their pharmaceutical compositions are combined with nucleoside or nucleotide inhibitors of HIV reverse transcriptase, non-nucleoside inhibitors of HIV reverse transcriptase, and pharmacokinetic enhancers. In certain embodiments, the agents disclosed herein or their pharmaceutical compositions are combined with at least one HIV nucleoside inhibitor of reverse transcriptase, an integrase inhibitor, and a pharmacokinetic enhancer. In another embodiment, the agents disclosed herein or their pharmaceutical compositions are combined with two HIV nucleoside or nucleotide inhibitors of reverse transcriptase.

In one embodiment, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined with abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide, or tenofovir alafenamide hemifumarate.

In another embodiment, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined with tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir alafenamide, or tenofovir alafenamide hemifumarate.

In another embodiment, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined with a first additional therapeutic agent selected from abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate, and a second additional therapeutic agent selected from emtricitabine and lamivudine.

In yet another embodiment, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined with a first additional therapeutic agent selected from dolutegravir, cabotegravir, islatravir, darunavir, bicagavir, essavirine, rilpivirine, and lenacapasvir, and a second additional therapeutic agent selected from emtricitabine and lamivudine.

In another embodiment, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined with a first additional therapeutic agent and a second additional therapeutic agent selected from tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate, wherein the second additional therapeutic agent is emtricitabine.

One or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined with a first additional therapeutic agent (contraceptive) selected from the group consisting of cyproterone acetate, desogestrel, dienogest, drospirenone, estradiol valerate, ethinyl estradiol, norethindrone, etonogestrel, levonorgestrel, levonorgestrel, linegestrel, medroxyprogesterone acetate, ethinyl estradiol methyl ether, mifepristone, misoprostol, nomegestrol acetate, norprogesterone acetate, norethisterone, norgestimate, ormeloxifene, sigsone acetate, ulipristal acetate, and any combination thereof.

Gene therapy and cell therapy

In certain embodiments, one or more fusion polypeptides as disclosed herein or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNP) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined with gene or cell therapy regimens. Gene therapy and cell therapy include, but are not limited to, gene modifications that silence genes; gene methods that directly kill infected cells; infusion of immune cells, which are designed to replace most of the patient's own immune system to enhance the immune response to infected cells, or activate the patient's own immune system to kill infected cells, or find and kill infected cells; gene methods that modify cell activity to further change the endogenous immune response to infection. Examples of cell therapy include, but are not limited to, LB-1903, ENOB-HV-01, ENOB-HV-21, ENOB-HV-31, GOVX-B01, HSPC (LV-800, HIV infection) overexpressing ALDH1, AGT103-T, and SupT1 cell-based therapy. Examples of dendritic cell therapy include, but are not limited to, AGS-004. CCR5 gene editors include but are not limited to SB-728T, SB-728-HSPC. CCR5 gene inhibitors include but are not limited to Cal-1 and autologous CD34-positive hematopoietic progenitor cells (HIV infection/HIV-related lymphoma) transduced with lentiviral vector CCR5 shRNA/TRIM5α/TAR decoy. In some embodiments, CD4-positive T cells expressing C34-CCR5/C34-CXCR4 are co-administered with one or more fusion polypeptides. In some embodiments, the agents described herein are co-administered with autologous T cell therapy transduced with AGT-103 or AAV-eCD4-Ig gene therapy.

Gene editing

In certain embodiments, one or more fusion polypeptides as disclosed herein or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined with gene editors (e.g., HIV targeted gene editors). In various embodiments, the genome editing system can be selected from: CRISPR/Cas9 complexes, zinc finger nuclease complexes, TALEN complexes, homing endonuclease complexes, and meganuclease complexes. Exemplary HIV targeted CRISPR/Cas9 systems include, but are not limited to, EBT-101.

CAR-T cell therapy

In some embodiments, the agents described herein can be co-administered with a population of immune effector cells engineered to express a chimeric antigen receptor (CAR), wherein the CAR comprises an HIV antigen binding domain. HIV antigens include HIV envelope proteins or portions thereof, gp120 or portions thereof, CD4 binding sites on gp120, CD4-induced binding sites on gp120, N polysaccharides on gp120, V2 of gp120, and membrane proximal regions on gp41. Immune effector cells are T cells or NK cells. In some embodiments, T cells are CD4+ T cells, CD8+ T cells, or combinations thereof. Cells can be autologous or allogeneic. Examples of HIV CAR-T include A-1801, A-1902, convertible CAR-T, VC-CAR-T, CMV-N6-CART, anti-HIV duoCAR-T, anti-CD4CART cell therapy, CD4 CAR+C34-CXCR4+CCR5 ZFN T cells, dual anti-CD4CART-T cell therapy (CD4 CAR+C34-CXCR4 T cells), anti-CD4 MicAbody antibody + anti-MicAbody CAR T cell therapy (iNKG2D CAR, HIV infection), GP-120CAR-T therapy, and autologous hematopoietic stem cells genetically engineered to express CD4 CAR and C46 peptide.

TCR-T cell therapy

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined with a TCR-T cell population. TCR-T cells are engineered to target HIV-derived peptides present on the surface of virally infected cells, such as ImmTAV.

B-cell therapy

In certain embodiments, one or more fusion polypeptides as disclosed herein, or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides are combined with a population of B cells genetically modified to express a broadly neutralizing antibody such as 3BNC117 (Hartweger et al., J. Exp. Med. 2019, 1301; Moffett et al., Sci. Immunol. 4, eaax0644 (2019), May 17, 2019).

8. Test kit

Also provided is a kit, the kit includes one or more unit doses of fusion polypeptides as described herein or one or more of the composite fusion polypeptides or one or more polynucleotides encoding such fusion polypeptides or composite fusion polypeptides as described herein or one or more carriers expressing such fusion polypeptides or composite fusion polypeptides as described herein. In some embodiments, the kit includes two or more unit doses of fusion polypeptides as described herein or one or more of the composite fusion polypeptides or two or more polynucleotides encoding such fusion polypeptides or composite fusion polypeptides as described herein or two or more carriers expressing such fusion polypeptides or composite fusion polypeptides as described herein. In some embodiments, one or more unit doses are in a single container. In some embodiments, one or more unit doses are in two or more separate containers. In certain embodiments, the unit doses may be identical or different, for example, identical or different unit doses may be included, for example, polypeptides, polynucleotides, carriers, or combinations thereof may be included.

In various embodiments, the kit includes one or more pharmaceutical packages or one or more containers (e.g., vials, ampoules, prefilled syringes) containing one or more ingredients of the pharmaceutical compositions described herein, such as one or more fusion polypeptides as described herein or one or more polynucleotides encoding such fusion polypeptides as described herein or one or more vectors expressing such fusion polypeptides as described herein. In various embodiments, the kit includes one or more containers comprising one or more fusion polypeptides as described herein in the form of aqueous solutions or one or more polynucleotides encoding such fusion polypeptides as described herein or one or more vectors expressing such fusion polypeptides as described herein. In various embodiments, the kit includes one or more containers comprising one or more fusion polypeptides as described herein in a lyophilized form or one or more polynucleotides encoding such fusion polypeptides as described herein or one or more vectors expressing such fusion polypeptides as described herein.

In some embodiments, the kit includes one or more unit doses of one or more viral vectors capable of expressing the fusion polypeptide. In some embodiments, the unit dose of one or more viral vectors is within the range of about 10 ³ to about 10 ¹² viral focus forming units (FFU) or plaque forming units (PFU) or infectious units (IU) or viral particles (vp) per administration, for example, about 10 ⁴ to about 10 ⁷ viral FFU or PFU or IU or vp, for example, about 10 ³ to about 10 ⁴ , 10 ⁵ , 10 ⁶ , 10 ⁷ , 10 ⁸ , 10 ⁹ , 10 ¹⁰ , 10 ¹¹ , 10 ¹² , 10 ¹³ , 10 ¹⁴ or 10 ¹⁵ viral FFU or PFU or IU or vp.

In some embodiments, the kit includes a first fusion polypeptide and a second fusion polypeptide or one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, the first and second polypeptides comprising, in order from N-terminus to C-terminus, the following polypeptide fragments optionally bound or linked by one or more linkers:

SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17;

SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11;

SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21;

SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17;

SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11;

SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 15, 21 and 19;

SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17;

SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ ID NOs: 9, 13, 25, 23, 15 and 11;

SEQ ID NOs: 18, 26, 20, 4, 6 and 16, and SEQ ID NOs: 7, 21, 17, 5, 27 and 19;

SEQ ID NOs: 22, 24, 12, 14, 8 and 10, and SEQ ID NOs: 15, 25, 9, 23, 13 and 11;

SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10;

SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 7, 21, 5, 25, 33 and 19;

SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10;

SEQ ID NOs: 8, 30, 14, 12, 26 and 10, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11;

SEQ ID NOs: 7, 21, 5, 25, 33 and 19, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11;

SEQ ID NOs: 20, 32, 24, 4, 6 and 18, and SEQ ID NOs: 26, 30, 12, 14, 8 and 10;

SEQ ID NOs: 6, 20, 4, 24, 32 and 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10;

SEQ ID NOs: 7, 25, 19, 5, 33 and 21, and SEQ ID NOs: 15, 31, 9, 27, 13 and 11;

SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 20, 10 and 28;

SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28;

SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19;

SEQ ID NOs: 7, 19, 17 and 25, and SEQ ID NOs: 21, 27, 11 and 29;

SEQ ID NOs: 24, 16, 6 and 18, and SEQ ID NOs: 27, 11, 21 and 29;

SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 11, 27, 21 and 29;

SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29;

SEQ ID NOs: 22, 6, 20 and 28, and SEQ ID NOs: 23, 7, 21 and 29;

SEQ ID NOs: 22, 20, 6 and 28, and SEQ ID NOs: 7, 21, 23 and 29;

SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29;

SEQ ID NO: 22, 6, 16, 20, 18, 28, 26 and 10; or

· SEQ ID NO: 7, 21, 19, 17, 27, 25, 29 and 11.

In some embodiments, the kit includes one or more fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, which fusion polypeptides comprise or consist of the amino acid sequence of any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:70-101, 105-112, 200-209, 222-223 and 227. In some embodiments, the kit includes one or more fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, which fusion polypeptides comprise or consist of the amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223.

In some embodiments, the kit includes the following first and second fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a fusion polypeptide of SEQ ID NOs:70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:70 and 71, respectively;

a fusion polypeptide of SEQ ID NOs:72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:72 and 73, respectively;

a fusion polypeptide of SEQ ID NOs:74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively;

a fusion polypeptide of SEQ ID NOs:76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively;

a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:78 and 79, respectively;

a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:80 and 81, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively;

a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:90 and 91, respectively;

a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively;

a fusion polypeptide of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 96, respectively;

a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively;

a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 100, respectively;

· a fusion polypeptide of SEQ ID NOs:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 101, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively; or

· A fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively.

In some embodiments, the kit includes first, second, third, and fourth viral vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively;

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively;

c) a third viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; and

d) a fourth viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively.

In some embodiments, the kit includes a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively.

In some embodiments, the kit includes first, second, third, and fourth viral vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively;

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively;

c) a third viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; and

d) a fourth viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively.

In some embodiments, the kit includes first, second, third, and fourth viral vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively;

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively;

c) a third viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and

d) a fourth viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively.

In some embodiments, the kit includes first, second, third, and fourth viral vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively;

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively;

c) a third viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and

d) a fourth viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively.

In some embodiments, the kit includes a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively.

In some embodiments, the kit includes a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively;

In some embodiments, the kit includes a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively;

In some embodiments, the kit includes a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively;

In some embodiments, the kit includes a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively.

In some embodiments, the kit includes a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers:

a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; and

b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide comprising SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively.

In some embodiments, the kit includes first and second viral vectors comprising polynucleotides encoding the following first composite fusion polypeptide and second composite fusion polypeptide:

a) a first viral vector comprising a polynucleotide encoding a first composite fusion polypeptide comprising a composite fusion polypeptide comprising SEQ ID NO: 105, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105; and

b) a second viral vector comprising a polynucleotide encoding a first composite fusion polypeptide comprising a composite fusion polypeptide comprising SEQ ID NO: 109, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 109.

In some embodiments, the kit includes first and second viral vectors comprising polynucleotides encoding the following first composite fusion polypeptide and second composite fusion polypeptide:

a) a first viral vector comprising a polynucleotide encoding a first composite fusion polypeptide comprising a composite fusion polypeptide comprising SEQ ID NO: 107, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107; and

b) a second viral vector comprising a polynucleotide encoding a first composite fusion polypeptide comprising a composite fusion polypeptide comprising SEQ ID NO: 111, or a composite fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 111.

In some embodiments, the kit includes the following first and second fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides in order from N-terminus to C-terminus, optionally bound or linked by one or more linkers:

a fusion polypeptide of SEQ ID NOs:70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:70 and 71, respectively;

a fusion polypeptide of SEQ ID NOs:71 and 70, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:71 and 70, respectively;

a fusion polypeptide of SEQ ID NOs:72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:72 and 73, respectively;

a fusion polypeptide of SEQ ID NOs:73 and 72, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:73 and 72, respectively;

a fusion polypeptide of SEQ ID NOs:74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:74 and 75, respectively;

a fusion polypeptide of SEQ ID NOs:75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:75 and 74, respectively;

· a fusion polypeptide of SEQ ID NOs:76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:76 and 77, respectively;

a fusion polypeptide of SEQ ID NOs:77 and 76, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:77 and 76, respectively;

a fusion polypeptide of SEQ ID NOs:78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:78 and 79, respectively;

a fusion polypeptide of SEQ ID NOs:79 and 78, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:79 and 78, respectively;

a fusion polypeptide of SEQ ID NOs:80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:80 and 81, respectively;

a fusion polypeptide of SEQ ID NOs:81 and 80, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:81 and 80, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 83, respectively;

a fusion polypeptide of SEQ ID NOs:83 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:84 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 84, respectively;

a fusion polypeptide of SEQ ID NOs:86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 86, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:89 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:89 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 86, respectively;

a fusion polypeptide of SEQ ID NOs:86 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:86 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:82 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 82, respectively;

a fusion polypeptide of SEQ ID NOs:83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:83 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 83, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 87, respectively;

a fusion polypeptide of SEQ ID NOs:87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:87 and 88, respectively;

a fusion polypeptide of SEQ ID NOs:84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 84, respectively;

a fusion polypeptide of SEQ ID NOs:88 and 84, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:88 and 84, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 89, respectively;

a fusion polypeptide of SEQ ID NOs:89 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:89 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:85 and 101, respectively;

a fusion polypeptide of SEQ ID NOs: 101 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively;

a fusion polypeptide of SEQ ID NOs:90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:90 and 91, respectively;

a fusion polypeptide of SEQ ID NOs:91 and 90, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:91 and 90, respectively;

a fusion polypeptide of SEQ ID NOs:92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:92 and 93, respectively;

a fusion polypeptide of SEQ ID NOs:93 and 92, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:93 and 92, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 95, respectively;

a fusion polypeptide of SEQ ID NOs:95 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 94, respectively;

a fusion polypeptide of SEQ ID NOs:96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 97, respectively;

a fusion polypeptide of SEQ ID NOs:97 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:97 and 96, respectively;

a fusion polypeptide of SEQ ID NOs:94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:94 and 96, respectively;

a fusion polypeptide of SEQ ID NOs:96 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:96 and 94, respectively;

a fusion polypeptide of SEQ ID NOs:95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:95 and 97, respectively;

a fusion polypeptide of SEQ ID NOs:97 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:97 and 95, respectively;

a fusion polypeptide of SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;

a fusion polypeptide of SEQ ID NOs: 221 and 220, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 100, respectively;

a fusion polypeptide of SEQ ID NOs: 100 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively;

· a fusion polypeptide of SEQ ID NOs:99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 101, respectively;

a fusion polypeptide of SEQ ID NOs: 101 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively;

a fusion polypeptide of SEQ ID NOs:98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:98 and 99, respectively;

a fusion polypeptide of SEQ ID NOs:99 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:99 and 98, respectively;

a fusion polypeptide of SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or

· A fusion polypeptide of SEQ ID NOs: 101 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively.

In some embodiments, the kit includes a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226. In some embodiments, the kit includes a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NO: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NO: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226.

In some embodiments, the kit includes the following first and second polynucleotides, or one or more vectors comprising the following first and second polynucleotides:

· a polynucleotide of SEQ ID NOs: 130 and 132, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively;

· a polynucleotide of SEQ ID NOs: 130 and 134, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively;

· a polynucleotide of SEQ ID NOs: 131 and 133, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively;

· a polynucleotide of SEQ ID NOs: 131 and 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively;

· a polynucleotide of SEQ ID NOs: 132 and 136, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively;

· a polynucleotide of SEQ ID NOs: 133 and 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively;

· a polynucleotide of SEQ ID NOs: 133 and 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively;

· a polynucleotide of SEQ ID NOs: 134 and 136, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively;

· a polynucleotide of SEQ ID NOs: 135 and 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively;

· a polynucleotide of SEQ ID NOs: 138 and 141, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively;

· a polynucleotide of SEQ ID NOs: 138 and 144, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively;

· a polynucleotide of SEQ ID NOs: 139 and 142, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively;

· a polynucleotide of SEQ ID NOs: 139 and 145, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively;

· a polynucleotide of SEQ ID NOs: 140 and 146, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively;

· a polynucleotide of SEQ ID NOs: 142 and 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively;

· a polynucleotide of SEQ ID NOs: 143 and 149, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively;

· a polynucleotide of SEQ ID NOs: 145 and 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively;

· a polynucleotide of SEQ ID NOs: 150 and 152, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively;

· a polynucleotide of SEQ ID NOs: 150 and 155, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively;

· a polynucleotide of SEQ ID NOs: 151 and 153, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively;

· a polynucleotide of SEQ ID NOs: 151 and 156, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively;

· a polynucleotide of SEQ ID NOs: 152 and 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively;

· a polynucleotide of SEQ ID NOs: 153 and 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively;

· a polynucleotide of SEQ ID NOs: 154 and 157, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively;

· a polynucleotide of SEQ ID NOs: 155 and 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively;

· a polynucleotide of SEQ ID NOs: 156 and 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively;

· a polynucleotide of SEQ ID NOs: 160 and 161, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively;

· a polynucleotide of SEQ ID NOs: 162 and 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively;

· a polynucleotide of SEQ ID NOs: 164 and 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively;

· a polynucleotide of SEQ ID NOs: 166 and 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively;

· a polynucleotide of SEQ ID NOs: 210 and 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively;

· a polynucleotide of SEQ ID NOs: 212 and 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively;

· a polynucleotide of SEQ ID NOs: 214 and 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively;

· a polynucleotide of SEQ ID NOs: 216 and 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively;

· a polynucleotide of SEQ ID NOs: 218 and 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively;

a polynucleotide of SEQ ID NOs: 218 and 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or

· A polynucleotide of SEQ ID NOs: 225 and 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively.

In some embodiments, the kit includes first and second viral vectors comprising the following first polynucleotides and second polynucleotides:

a) a first vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 131 and 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; and

b) a second vector comprising the following first and second polynucleotides: polynucleotides comprising SEQ ID NOs: 133 and 137, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively. In some embodiments, the first and second viral vectors are adenoviral vectors.

In some embodiments, the kit includes first and second viral vectors comprising the following first polynucleotides and second polynucleotides:

a) a first vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 139 and 145, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; and

b) a second vector comprising the following first and second polynucleotides: polynucleotides comprising SEQ ID NOs: 142 and 148, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. In some embodiments, the first and second viral vectors are adenoviral vectors.

In some embodiments, the kit includes first and second viral vectors comprising the following first polynucleotides and second polynucleotides:

a) a first vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 140 and 146, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; and

b) a second vector comprising the following first and second polynucleotides: polynucleotides comprising SEQ ID NOs: 143 and 149, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. In some embodiments, the first and second viral vectors are lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vectors.

In some embodiments, the kit includes first and second viral vectors comprising the following first polynucleotides and second polynucleotides:

a) a first vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 150 and 152, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and

b) a second vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. In some embodiments, the first and second viral vectors are Cali mammalian arenavirus (also known as Pichinde mammalian arenavirus or Pichinde arenavirus) viral vectors.

In some embodiments, the kit includes first, second, third, and fourth viral vectors, each vector comprising a first and a second polynucleotide:

a) a first viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 140 and 146, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively;

b) a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 143 and 149, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively.

c) a third viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 150 and 152, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and

d) a fourth viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively.

In some embodiments, the kit includes first, second, third, and fourth viral vectors, each vector comprising a first and a second polynucleotide:

a) a first viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 150 and 152, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively;

b) a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 155 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively.

c) a third viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 151 and 153, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; and

d) a fourth viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 156 and 159, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. In some embodiments, one or more of the first, second, third, and fourth viral vectors are adenoviral vectors.

In some embodiments, the kit includes first, second, third, and fourth viral vectors, each vector comprising a first and a second polynucleotide:

a) a first viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 131 and 135, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively;

b) a second viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 133 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively.

c) a third viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 139 and 145, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; and

d) a fourth viral vector comprising the following first and second polynucleotides: comprising SEQ ID NOs: 142 and 148, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively.

In some embodiments, the kit includes first and second viral vectors comprising the following first polynucleotides and second polynucleotides:

a) a first vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 160 and 161, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; and

b) a second vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 162 and 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively.

In some embodiments, the kit includes first and second viral vectors comprising the following first polynucleotides and second polynucleotides:

a) a first vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 164 and 165, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively; and

b) a second vector comprising the following first and second polynucleotides: a polynucleotide comprising SEQ ID NOs: 166 and 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively.

In some embodiments, the kit includes first and second viral vectors comprising the following first polynucleotides and second polynucleotides:

a) a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210; and

b) a second viral vector comprising the following second polynucleotide: a polynucleotide comprising SEQ ID NO:211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:211.

In some embodiments, the kit includes first and second viral vectors comprising the following first polynucleotides and second polynucleotides:

a) a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212; and

b) a second viral vector comprising the following second polynucleotide: a polynucleotide comprising SEQ ID NO:213, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:213.

In some embodiments, the kit includes first and second viral vectors comprising the following first polynucleotides and second polynucleotides:

a) a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214; and

b) a second viral vector comprising the following second polynucleotide: a polynucleotide comprising SEQ ID NO:215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:215.

In some embodiments, the kit includes first and second viral vectors comprising the following first polynucleotides and second polynucleotides:

a) a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216; and

b) a second viral vector comprising the following second polynucleotide: a polynucleotide comprising SEQ ID NO:217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:217.

In some embodiments, the kit includes first and second viral vectors comprising the following first polynucleotides and second polynucleotides:

a) a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218; and

b) a second viral vector comprising the following second polynucleotide: a polynucleotide comprising SEQ ID NO:219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:219.

In some embodiments, the kit includes first and second viral vectors comprising the following first polynucleotides and second polynucleotides:

a) a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218; and

b) a second viral vector comprising the following second polynucleotide: a polynucleotide comprising SEQ ID NO:226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:226.

In some embodiments, the kit includes first and second viral vectors comprising the following first polynucleotides and second polynucleotides:

a) a first viral vector comprising a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225; and

b) a second viral vector comprising the following second polynucleotide: a polynucleotide comprising SEQ ID NO:226, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:226.

In some embodiments, the kit includes a composite fusion polypeptide or a vector comprising a polynucleotide encoding the composite fusion polypeptide, which composite fusion polypeptide comprises or consists of: an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the kit includes a composite fusion polypeptide or a vector comprising a polynucleotide encoding the composite fusion polypeptide, which composite fusion polypeptide comprises or consists of: an amino acid sequence of any one of SEQ ID NOs: 209, 222 and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 209, 222 and 223.

In various embodiments of the kit, the one or more fusion polypeptides do not comprise any polypeptide fragments corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In various embodiments of the kit, the one or more fusion polypeptides do not comprise any polypeptide fragment having an amino acid sequence of SEQ ID NOs: 35-47, or a fragment or subsequence thereof, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or a fragment or subsequence thereof.

In some embodiments, the kit also includes one or more additional therapeutic agents of one or more unit doses. For example, in some embodiments, the kit includes one or more agonists or activators of one or more Toll-like receptors (TLR). In some embodiments, TLR agonists or activators are selected from TLR2 agonists, TLR3 agonists, TLR4 agonists, TLR5 agonists, TLR7 agonists, TLR8 agonists and TLR9 agonists. In some embodiments, TLR7 agonists are selected from GS 9620 (Weisamod), R848 (Resiquimod), DS-0509, LHC-165 and TMX-101 (Imiquimod), and/or wherein TLR8 agonists are selected from GS-9688 (Sergantomod), R848 (Resiquimod) and NKTR-262 (double TLR7/TLR8 agonists).

In some embodiments, the kit includes one or more antagonists or inhibitors of inhibitory immune checkpoint proteins or receptors and/or one or more activators or agonists of stimulatory immune checkpoint proteins or receptors. In some embodiments, the one or more immune checkpoint proteins or receptors are selected from: CD27, CD70; CD40, CD40LG; CD47, CD48 (SLAMF2), transmembrane and immunoglobulin domain-containing protein 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3); V-set domain-containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunomodulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7H6); HERV-H LTR-associated 2 (HHLA2, B7H7); inducible T cell co-stimulator (ICOS, CD278); inducible T cell co-stimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30L); TNFRSF10A (CD261, DR4, TRAILR1), TNFRSF9 (CD137 ), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5, TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte-associated (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13B (BAFF); TNFRSF18 (GITR), TNFSF18 (GITRL); MHC class I polypeptide-related sequence A (MICA); MHC Class I polypeptide-related sequence B (MICB); CD274 (CD274, PDL1, PD-L1); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155); PVR-related immunoglobulin domain protein (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT ); T cell immunoglobulin and mucin domain-containing protein 4 (TIMD4; TIM4; hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); lymphocyte activation 3 (LAG3, CD223); signal transducer lymphocyte activation molecule family member 1 (SLAMF1, SLAM, CD150); lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6, CD352); SLAM family member 7 (SLAMF7, CD319); UL16 binding protein 1 (ULBP1); UL16 binding protein 2 (ULBP2 ); UL16 binding protein 3 (ULBP3); retinoic acid early transcript 1E (RAET1E; ULBP4); retinoic acid early transcript 1G (RAET1G; ULBP5); retinoic acid early transcript 1L (RAET1L; ULBP6); lymphocyte activation 3 (CD223); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314); killer cell lectin-like receptor C2 (KLRC2, CD159c, N KG2C); killer cell lectin-like receptor C3 (KLRC3, NKG2E); killer cell lectin-like receptor C4 (KLRC4, NKG2F); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor D1 (KLRD1); and SLAM family member 7 (SLAMF7). In some embodiments, the kit includes one or more blockers or inhibitors of one or more T cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the T cell inhibitory immune checkpoint protein or receptor is selected from: CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain-containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunomodulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte-associated (BTLA)); PVR-associated Immunoglobulin domain proteins (PVRIG, CD112R); T-cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activation 3 (LAG3, CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); and killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1). Lirelumab is an exemplary antibody that binds to and blocks the KIR2DL1/2L3 receptor.In some embodiments, the kit includes one or more agonists or activators of one or more T cell stimulatory immune checkpoint proteins or receptors. In some embodiments, the T cell stimulatory immune checkpoint protein or receptor is selected from: CD27, CD70, CD40, CD40LG; inducible T cell co-stimulator (ICOS, CD278); inducible T cell co-stimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). In some embodiments, the kit includes one or more NK cell inhibitory immune checkpoint protein or receptor one or more blockers or inhibitors. In some embodiments, the NK cell inhibitory immune checkpoint protein or receptor is selected from: killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A) (e.g., monalizumab (IPH2201)); and killer cell lectin-like receptor D1 (KLRD1, CD94). In some embodiments, the kit includes one or more agonists or activators of one or more NK cell stimulatory immune checkpoint proteins or receptors. In some embodiments, NK cell stimulatory immune checkpoint proteins or receptors are selected from CD16, CD226 (DNAM-1); killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314); and SLAM family member 7 (SLAMF7). In some embodiments, one or more immune checkpoint inhibitors include protein inhibitors of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, the protein or antibody inhibitor of CTLA4 is selected from: ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, C G-0161, ATOR-1144, PBI-5D3H5, FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/CTLA4), MGD-019 (PD-1/CTLA4), KN-046 (PD-1/CTLA4), MEDI-5752 (CTLA4/PD-1), XmAb-20717 (PD-1/CTLA4) and AK-104 (CTLA4/PD-1). In various embodiments, the co-administration of a protein or antibody inhibitor of CTLA4 increases the vaccine-induced T cell response compared to administration of one or more fusion polypeptides or polynucleotides encoding such fusion polypeptides, liposome complexes (e.g., LNPs) comprising such polynucleotides, or vectors expressing such fusion polypeptides in the absence of a protein or antibody inhibitor of CTLA4. In some embodiments, the protein inhibitor of PD-L1 (CD274) or PD-1 (PDCD1) is selected from: pembrolizumab, nivolumab, cemiplimab, pidilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK-301, PF-06801591, BGB-A317 (tislelizumab), elizumab), GLS-010(WBP-3055), AK-103(HX-008), AK-105, CS-1003, HLX-10, MGA-012, BI-754091, AGEN-2034, JS-001(toripalimab), JNJ-63723283, genolimzumab(CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, SHR-1210(camrelizumab), Sym-021, ABBV-181, PD1-PIK, BAT-1306(MSB001 0718C), CX-072, CBT-502, TSR-042 (dostarlimab), MSB-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308 (sintilimab), HLX-20, KL-A167, STI-A1014, STI-A1015 (IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/CTLA4), MGD -013(PD-1/LAG-3), FS-118(LAG-3/PD-L1)MGD-019(PD-1/CTLA4), KN-046(PD-1/CTLA4), MEDI-5752(CTLA4/PD-1), RO-7121661(PD-1/TIM-3), XmAb-20717(PD-1/CTLA4), AK-1 04 (CTLA4/PD-1), M7824 (PD-L1/TGFβ-EC domain), CA-170 (PD-L1/VISTA), CDX-527 (CD27/PD-L1), LY-3415244 (TIM3/PDL1) and INBRX-105 (4-1BB/PDL1). In some embodiments, one or more immune checkpoint inhibitors include small molecule inhibitors of CD274 (PDL1, PD-L1), programmed cell death 1 (PDCD1, PD1, PD-1), or CTLA4. In some embodiments, the small molecule inhibitor of CD274 or PDCD1 is selected from GS-4224, GS-4416, INCB086550, and MAX10181. In some embodiments, the small molecule inhibitor of CTLA4 includes BPI-002.

In some embodiments, the kit includes one or more antiviral agents. In some embodiments, the one or more antiviral agents are selected from: HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversal agents and capsid inhibitors.

Optionally associated with such container(s) may be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

9. Methods for designing fusion polypeptides that can be used to promote antiviral immune responses

Provided is a method for designing a vaccine construct or immunogen that can induce an immune response to one or more viral antigens in the human body. Immunogenic fusion polypeptides are designed using a combination of calculations, experience, and manual steps, and can be used to induce an immune response to highly variable viruses. These design methods can be used to produce immunogens that can induce an immune response to one or more viral antigens of a desired target virus (including but not limited to human immunodeficiency virus (HIV), hepatitis B virus (HBV), human papillomavirus (HPV), herpes simplex virus (HSV), Ebola virus, Zika virus, and chikungunya virus) in the human body. Generally speaking, the immunogen design method provides a vaccine construct designed for the following items: based on the maximum epitope coverage of a wide population, referred to herein as a "population" construct or antigen. Typically, the fragment comprising each construct represents one or more MHC I class and/or MHC II class T cell epitopes. The polypeptide fragments based on the population can be combined and assembled into immunogenic fusion polypeptides.

Most of the steps can be performed in a computer, but some steps can be performed manually (e.g., inclusion and/or exclusion of certain polypeptide sequences; selection of one or more linkers), and information can be incorporated based on experimental data (e.g., experimentally determined MHC class II epitopes). The input information is a viral sequence dataset (e.g., for HIV, an internal and publicly available HIV population dataset). As summarized in the flowchart of Figure 1, the vaccine design method involves at least 2 of the following steps, for example at least 3:

1. Identification of conserved regions. In naturally occurring viral sequences, all 9 amino acid fragments (9-mers) were considered potential T cell epitopes. 9-mer positions with at least 80% conservation in viral populations between patients were identified as conserved regions and included for further analysis.

2. Construct bivalent sequences from conserved regions. This can be done by using a graph-based algorithm. 9-mers are assembled from conserved regions to include the maximum number of naturally occurring 9-mers.

3. Arrange the polypeptide fragments to reduce or avoid the generation of human-recognizable new epitopes and cross-reactivity with human proteins at the junction. This can be accomplished by evaluating the MHC class I binding of the 9-mer around the junction, cross-recognition with host (e.g., human, dog, cat, horse) proteins, and if multiple insertion sequences are developed simultaneously, checking whether there are identical or substantially identical 9-mers between multiple antigen sequences. As used herein, "substantially identical" 9-mers have at least 5 of the 9 identical amino acid residues, such as at least 55% (5 of 9), such as at least 65% (6 of 9), such as at least 75% (7 of 9), such as at least 85% (8 of 9) identical amino acid residues.

In one aspect, these methods include screening the MHC peptide binding affinity of a group of candidate polypeptide fragments of a construct based on population/conservatism. One or more algorithms can be used to predict MHC binding affinity. Exemplary prediction algorithms include NetMHC (Vita et al., Nucleic Acids Res 2015 43: D405-D412), NetMHCpan (Andreatta and Nielsen Bioinformatics 2016 32: 511-517) and MHCflurry (O'Donnell et al., CellSyst 2018 7: 12-132). Other T cell epitope prediction tools are publicly available and are described, for example, in Sanchez-Trincado et al., J.Immunology Res. 2017, article number 2680160. Additional methods for identifying MHC-binding peptides include, for example, those employing machine learning tools as described in US 10,055,540, WO 2019/104203, and the "EDGE" tool described in Bulik-Sullivan et al., Nature Biotechnology 2019 37:55.

In some embodiments, the present disclosure provides methods for generating bivalent population/conservative-based constructs designed to capture the unique diversity of viral proteomes (e.g., HIV proteomes) by providing mathematically determined and improved coverage of all potential T cell epitopes, and ensuring that the epitopes in each polypeptide of the pair of constructed polypeptides retain the positional information of the original input viral sequence, for example, by retaining polypeptide fragments of the same order as those found in the naturally occurring viral proteome. Therefore, the resulting epitopes of the pair of polypeptides will be more similar to the epitopes of the naturally occurring viral sequences, thereby increasing the likelihood that they will elicit relevant T cell responses.

In general, the methods described herein include using a graph-based approach to initially provide a set of mathematically determined and improved PTEs for the coverage of all potential T cell epitopes ("PTEs") in a population of viral proteome sequences. Unlike similar graph-based vaccine design methods, the methods described herein only use adjacent PTEs that are also adjacent in the natural sequence to construct connected PTE fragments. This provides a construct that retains the positional information of the PTE in the sequence source set. Also unlike other graph-based methods, the methods described herein simultaneously construct a bivalent construct to provide maximum coverage of the most highly conserved PTEs in the population. The result is an initial bivalent vaccine construct that advantageously maximizes highly conserved PTEs that are most likely to be highly similar to conserved epitopes in the natural sequence. More advantageously, using only the most highly conserved PTEs reduces the possibility of escape mutants because highly conserved sequences are more likely to be essential for viral function.

The methods described herein usually start with the process identification of the conserved region bivalent sequence using the process referred to herein as "conservative analysis" or "conservative algorithm". These methods usually also include the step of using the process referred to herein as "conservative walking algorithm" or "CWA" to construct a bivalent vaccine construct with maximum epitope coverage while retaining the positional information of the PTE from the native sequence. Therefore, in some specific implementations, the initial step in the method is to identify a group of all conserved regions in the viral protein group for a selected group of viral genes. In the specific implementation for designing fusion polypeptide to cause an immune response to HIV-1, the group of HIV-1 viral genes is selected from two or more of Gag, Pol and Nef. In some specific implementations, the group of viral genes is composed of Gag, Pol and Nef. In some specific implementations, the group of viral genes is composed of Pol and Nef.

According to the method described herein, first the viral proteome sequence population is compared with a reference sequence (e.g., HIV reference sequence HXB2 identified by GenBank accession number K03455). The reference sequence of the polypeptide encoded by Gag, Nef and Pol genes is provided in Table A herein with SEQ ID NO:1-3. The initial input or "source" population of the viral proteome sequence is composed of sequences obtained from naturally occurring viruses. Such sequences can be publicly available, for example, from the HIV database maintained by Los Alamos National Laboratory, the U.S. Department of Health and Human Services and the National Institutes of Health. In some specific implementations of the methods described herein, the source viral sequence can be composed of sequences corresponding to specific viral groups and/or clades. In some specific implementations, in order to improve the identification of conserved regions and sequences, the input viral sequence can be limited to a single viral clade and/or group. In some specific implementations, the input viral sequence is limited to group M clade B sequences.

Alignment of source viral sequences with reference sequences can be achieved using a variety of alignment algorithms, such as the Fast Fourier Transform algorithm MAFFT. Katoh et al., 2002 Nucleic Acids Res. 30(14):3059-66. The underlying MAFFT software is publicly available and distributed, for example, under the Berkeley Software Distribution (BSD) license.

Next, the conservative algorithm is applied to the aligned sequences. For each sequence in the alignment, starting from the first amino acid position, the method moves one amino acid position at a time and generates all possible amino acid fragments of 9 amino acids in length, referred to herein as "9-mers". Therefore, for each sequence in the alignment, the algorithm generates a set of 9 amino acid subsequences ("9-mers") starting from the N-terminal amino acid, each of which overlaps the previous subsequence by eight amino acids, so that each sequence of length 1 in the alignment contains (1-8) 9-mers.

Next, for each 9-mer position, the method identifies the two most common unique 9-mers and their prevalence in the aligned set of source viral proteome sequences. In other words, starting at position i, the two most common unique 9-mers at each position are identified based on their frequency, calculated as the number of times a unique 9-mer occurs at position i in the alignment divided by the total number of sequences in the alignment.

Computationally, each sequence of length l contains l-8 9-mers. We define all 9-mers starting from position i as s _ij and the frequency as _fij , j = 1, 2, 3, ... m. There are a total of m unique 9-mers at position i. Every two unique 9-mers (s _iu , s _iv ) can form a 9-mer pair with frequency _fiu +f _iv . And each 9-mer itself can form a 9-mer pair, such as (s _iu , s _iu ), with frequency _fiu . Therefore, there are a total of m+(m–1)+(m–2)+…+2+1=m*(m+1)/2 9-mer pairs at each position.

The method then calculates the bivalent conservation of each 9-mer position by adding the proportion of the aligned source viral proteome sequence set containing either of the two most common 9-mers. To this end, the "bivalent conservation" of each position is calculated by adding the proportion of sequences in the alignment containing either of the two most common unique 9-mers. As used herein, "bivalent conservation" refers to the percentage of sequences containing a 9-amino acid fragment (9-mer) that is exactly the same as either of the two most common amino acid fragments at a 9-mer position.

Next, a new alignment of the conserved region is generated by extracting sequences in the alignment that have a desired bivalent conservation (e.g., greater than 80% or greater than 90% bivalent conservation, meaning that the two most common 9-mers at position i account for more than 80% or more than 90% of the 9-mers at that position in the new alignment of the conserved region). In other words, the method identifies conserved regions in the new alignment as those conserved regions in which the sum of the frequencies of the two most common 9-mers at each position is greater than a certain cutoff value (e.g., greater than 80% or greater than 90%). Therefore, the method also calculates the frequency of each pair of unique 9-mers at each position in the new alignment of the conserved region.

In some implementations, further selection criteria can be applied to conserved regions, such as limiting to regions with greater than 90% conservation and removing short stretches of less than 35 amino acids.

Using this modified set of conserved regions, certain implementations of the method apply CWA to construct bivalent sequence constructs. CWA connects 9-mer pairs at aligned adjacent positions of the conserved regions that share an overlap of eight amino acids.

Computationally, each 9-mer s contains 9 amino acids, which we write as s[x:y] to represent the amino acid subsequence from position x to y, with a total of y-x+1 amino acids:

_siu [2:9] == si+ _1p [1:8] and _siv [2:9] == si _+1q [1:8]

or

_siu [2:9] == si _+1q [1:8] and _siv [2:9] == si _+1p [1:8].

Next, the algorithm constructs a directed acyclic graph in which each 9-mer pair is a node, and the edges between adjacent nodes are formed by the 9-mer pairs connected in adjacent positions, and the weight of each edge is equal to the frequency of the downstream 9-mer pair. This directed acyclic graph is a positional De Brujin graph. Such graphs have been described in conjunction with the assembly of next-generation sequencing data, such as Ronen et al., Bioinformatics 2012 28: 188-196. The method also adds a source node, connecting it to all nodes in the first position; and a sink node, connecting it to all nodes in the last position. The weights are then reversed to find the best path from the source node to the sink node, where the best path is defined as the path with the largest sum of the frequencies of all 9-mer pairs in all paths from the source node to the sink node. For example, the task of finding the best path is performed using the Bellman–Ford algorithm. Typically, the Bellman-Ford algorithm calculates the shortest path from a single source vertex to all other vertices in a weighted directed graph, which consists of a set of vertices connected by edges, where the edges have directions associated with them. The calculation steps can be summarized as follows:

(4-1) Treat each 9-mer pair as a node and build edges between adjacent nodes in step 3;

(4-2) Add the source node and connect it to all nodes at the first position;

(4-3) Add the sink node and connect it to all nodes in the last position;

(4-4) The weight of each edge is equal to the frequency of the downstream 9-mer pair;

(4-5) Use the Bellman–Ford algorithm to invert all weights and find the best path.

The other step of the method is to build a bivalent vaccine sequence based on the best bivalent 9 aggressiveness to the path, and if the best bivalent 9 aggressiveness to the two 9 aggressiveness of adjacent positions in the path share 8 amino acid overlaps, then connect them. If the two 9 aggressiveness of adjacent positions in the best bivalent 9 aggressiveness path share eight amino acid overlaps, then build a bivalent construct by connecting them, thereby producing two sequences of the 9 aggressiveness connected, and they form a bivalent construct together. The adjacent 9 aggressiveness connected is to all having 8 amino acid overlaps, so they will be assembled into two sequences. For example, a 9 aggressiveness can be connected to (AIIIIIIIS (SEQ ID NO:190), MIIIIIIIII (SEQ ID NO:191)) and another 9 aggressiveness to (IIIIIIISK (SEQ ID NO:192), IIIIIIIIR (SEQ ID NO:184)), and form two sequences (bivalent sequences): AIIIIIIISK (SEQ ID NO:193) and MIIIIIIIR (SEQ ID NO:194).

Computationally, this method can be described as a bivalent vaccine sequence design algorithm based on positional De Brujin graphs, which includes the following 5 basic steps:

Step 1: Align all population sequences

Step 2: For each 9-mer position, find all unique 9-mers and their frequencies, and construct a set of 9-mer pairs with frequencies. Each sequence of length l contains l-8 9-mers. We define all 9-mers starting from position i as s _ij and the frequencies as _fij , j = 1, 2, 3, ... m. There are a total of m unique 9-mers at position i. Every two unique 9-mers (s _iu , s _iv ) can form a 9-mer pair with a frequency of _fiu +f _iv . And each 9-mer itself can form a 9-mer pair, such as (s _iu , s _iu ), with a frequency of _fiu . Therefore, there are a total of m+(m–1)+(m–2)+…+2+1=m*(m+1)/2 9-mer pairs at each position.

Step 3: If the 9-mer pairs in adjacent positions do not have any conflicting amino acids, connect them. As used herein, "conflicting amino acid residues" refer to different amino acid residues at overlapping positions between two 9-mers. Each 9-mer s contains 9 amino acids, which we write as s[x:y] to represent the amino acid subsequence from position x to y, a total of y-x+1 amino acids:

_siu [2:9] == si+ _1p [1:8] and _siv [2:9] == si _+1q [1:8]

or

_siu [2:9] == si _+1q [1:8] and _siv [2:9] == si _+1p [1:8]

Step 4: Find the best path from the first 9-mer position to the last position based on the sum of the frequencies of all 9-mers in the path. The basic idea is to model the maximum coverage bivalent vaccine construction problem as a classic graph theory problem, where the solution is to find the minimum path in a directed acyclic graph.

Step 5: construct a bivalent vaccine sequence based on the best bivalent 9-mer pair path, and connect two 9-mers at adjacent positions within the best bivalent 9-mer pair path if they share an overlap of 8 amino acids. Take the following case as an example:

Case 1: If _siu [2:9] = si _+1p [1:8] and _siv [2:9] = si _+1q [1:8], then connect _siu to si _+1p and _siv to si _+1q ;

Case 2: If _siu [2:9] = si _+1q [1:8] and _siv [2:9] = si _+1p [1:8], then connect _siu to si _+1q and _siv to si _+1p ;

Case 3: If _siu [2:9] = si _+1p [1:8] and _siv [2:9] = si _+1q [1:8] and _siu [2:9] = si _+1q [1:8] and _siv [2:9] = si _+1p [1:8], then the choice of connection is based on the prevalence of the two connections in the natural sequence:

Denote the prevalence of co-occurrence of s _ix and s _i+1y in the input sequence as C _ixy

If _Ciup + _Civq > _Ciuq + _Civp , connect _siu with si _+1p and _si +1q with si _+1q ;

If _Ciuq + _Civp > _Ciup + _Civq , then connect _siu with si _+1q and _si +1p with si _+1p ;

If _Ciup + _Civq = _Ciuq + _Civp , then backtrack and combine the prevalence of coexistence of 9-mer pairs in positions i-1 and i, until position 1. If there is no distinction between two different connections, then one is chosen at random.

In some implementations, the construct is further improved by performing a human proteome cross-recognition analysis, for example, by including a method of searching all 9-mers in the construct in a human proteome database such as UniProt to identify any 9-mers that have a certain amino acid sequence identity (e.g., at least 5 residues) with human peptides or share residues facing the T cell receptor (TCR) with human proteins. Any such 9-mers can then be excluded from the construct. In some implementations, the polypeptide fragments can be optionally rearranged, for example, by performing HLA binding analysis, human proteome cross-recognition analysis, or both analyses on the connected fragments to reduce or avoid harmful connection reactions. An exemplary method for reducing the presentation of the connection epitope of a new antigen in the context of designing an anti-cancer vaccine is described in WO 2019/104203. Alternatively, if multiple antigen sequences are developed, the polypeptide fragments can be rearranged to avoid the appearance of almost identical or identical 9-mers at the junction between the antigen sequences.

In some embodiments, the conserved regions are further defined by computer-performed one or more of the following steps: (i) removing short polypeptide fragments, such as polypeptide fragments of 35 or fewer amino acids in length (e.g., 9-35 amino acids in length); (ii) removing fragments that are weakly immunogenic or non-immunogenic in humans; (iii) removing fragments that are less than 90% conserved (in some cases, less than 80% conserved) in a predetermined sequence population; (iv) including additional fragments from HIV-1 proteins that are known to be immunogenic in humans (e.g., Env, Gag, Nef, and Pol) (see, e.g., epitope maps at hiv.lanl.gov/content/immunology/maps/maps.html; Fischer et al., Nat Med. (2007) 13(1): 100-6; and Addo et al., J Virol, (2003) 77(3): 2081-92).

In some implementations, adjacent polypeptide fragments can be optionally separated by a linker sequence, as described above. In some embodiments, one or more linker sequences include a cleavable linker, optionally also including an additional linker sequence located near the cleavable linker. Additional linkers can be another cleavable linker, a polyalanine linker, a polyglycine linker, a flexible linker or a rigid linker, as described above and herein. In some embodiments, the furin recognition site is before or located at the N-terminal of the 2A cleavable linker. In a specific implementation, in the case where the linker sequence comprises a foot-and-mouth disease virus (FMDV) cleavable peptide, FMDV 2A or its derivatives, additional linker sequences can be REKR (SEQ ID NO: 61) sequence or its derivatives. In some implementations, the linker is selected from a short polyalanine peptide, for example, composed of 2 to 4 alanine residues or having a peptide of sequence AAY (SEQ ID NO: 49) or AAX, wherein X is any amino acid residue (SEQ ID NO: 50).

In some embodiments, a linker is inserted between each adjacent conserved region of a bivalent polypeptide. In some embodiments, no linker is inserted between adjacent fragments of the same protein in a polypeptide, for example, when no deleterious junction epitopes are generated. A linker may be inserted between adjacent fragments of different proteins.

Example

The following examples are provided to illustrate but not to limit the claimed invention.

Example 1

Schematic illustration of the implementation of conservation analysis and conservative walking analysis (CWA) to generate bivalent vaccine constructs

This example describes the design of population-based bivalent polypeptide constructs through the implementation of conservation analysis and CWA to generate bivalent vaccine constructs based on conserved protein regions encoded by HIV-1 Gag, Nef and/or Pol genes.

First, we identified a set of all conserved regions in the viral proteome for a selected set of viral genes. In this example, the set of viral genes consisted of HIV-1 Gag, Pol, and Nef.

Computationally, the combination of the conservative algorithm and CWA is a bivalent vaccine sequence design algorithm based on the positional De Brujin graph, which includes the following five basic steps, as shown in Figure 3:

Step 1: Align a set of source viral proteome sequences with reference sequences.

In step 1, the source population of viral proteome sequences is compared with a reference sequence. In this embodiment, the reference sequence used is HIV-1 HXB2 identified by GenBank accession number K03455. The amino acid sequences of the HXB2 reference polypeptides Gag, Nef and Pol are provided in Table A herein as SEQ ID NOs: 1, 2 and 3, respectively. The source population of viral proteome sequences consists of sequences obtained from naturally occurring viruses. Such sequences can be publicly obtained, for example, from the HIV database maintained by Los Alamos National Laboratory, the U.S. Department of Health and Human Services and the National Institutes of Health (hiv.lanl.gov), which is a database of the sequence source population used in this embodiment. For the purpose of illustration, we will focus our analysis on a subset of viral sequences, here the sequences of group M clade B. Use a multiple alignment algorithm, particularly the fast Fourier transform algorithm MAFFT, for comparison. Katoh et al., (2002) Nucleic Acids Res.30(14):3059-66. The underlying MAFFT software is publicly available and distributed, for example, under the Berkeley Software Distribution (BSD) license.

Step 2: For each 9-mer position, find all unique 9-mers and their frequencies and construct a 9-mer with frequencies Body pair set

In step 2, we apply the conservative algorithm to the set of aligned sequences. For each sequence in the alignment, starting from the first amino acid at the N-terminus, the algorithm moves one amino acid position at a time to generate a set of all possible amino acid fragments of length 9 amino acids, called "9-mers". Therefore, for each sequence in the alignment, the algorithm generates a set of 9 amino acid subsequences ("9-mers") starting from the N-terminal amino acid, each of which overlaps the previous subsequence by eight amino acids, such that each sequence of length 1 in the alignment contains (1-8) 9-mers.

Next, for each 9-mer position, the method identifies the two most common unique 9-mers and their prevalence in the aligned set of source viral proteome sequences. In other words, starting at position i, the two most common unique 9-mers at each position are identified based on their frequency, calculated as the number of times a unique 9-mer occurs at position i in the alignment divided by the total number of sequences in the alignment.

Computationally, each sequence of length l contains l-8 9-mers. We define all 9-mers starting from position i as s _ij and the frequency as _fij , j = 1, 2, 3, ... m. There are a total of m unique 9-mers at position i. Every two unique 9-mers (s _iu , s _iv ) can form a 9-mer pair with frequency _fiu +f _iv . And each 9-mer itself can form a 9-mer pair, such as (s _iu , s _iu ), with frequency _fiu . Therefore, there are a total of m*(m+1)/2 9-mer pairs at each position.

The method then calculates the bivalent conservation of each 9-mer position by summing the proportion of the aligned source viral proteome sequence sets that contain either of the two most common 9-mers. To do this, the "bivalent conservation" of each position is calculated by summing the proportion of sequences in the alignment that contain either of the two most common unique 9-mers.

Next, a new alignment of the conserved region is generated by extracting sequences with the desired bivalent conservation in the alignment. In this embodiment, we use a bivalent conservation greater than 80% or greater than 90%, which means that the two most common 9-mers at position i account for more than 80% or more than 90% of the 9-mers at that position in the new alignment of the conserved region. In other words, the method identifies the conserved region in the new alignment as those in which the sum of the frequencies of the two most common 9-mers at each position is greater than a certain cutoff value (e.g., greater than 80% or greater than 90%). Therefore, the method also calculates the frequency of each pair of unique 9-mers at each position in the new alignment of the conserved region.

This is illustrated graphically in Figure 4A. Figure 4A shows a hypothetical set of 10 input natural sequences, each with a single amino acid variation within the first 9-mer. In this set of 10 sequences, the 9-mer with an "L" at the third amino acid position occurs 6 times, the 9-mer with an "I" at this position occurs 3 times, and the 9-mer with an "I" at this position but with a different amino acid in the first position occurs once. Therefore, the conservative algorithm selects the two most prevalent 9-mers, which together account for 90% of the possible 9-mers at this position in the sequence population.

Using this analysis, determine the distribution of highly conservative 9-mers in each position in all protein sequences in the colony. This is illustrated graphically in Fig. 4B. The figure shows the conservative distribution of proteins encoded by Gag gene p24 protein in 9,846 group M clade B input sequences obtained from Los Alamos HIV sequence database. The y-axis shows bivalent conservation, and the x-axis shows the position of 9-mer relative to the reference sequence (Gag p24 from HXB2). At the top of the figure, horizontal bars depict the conservative region as a region with at least 80% bivalent conservation using two of the most common 9-mers at each position. The dark grey line with squares has drawn the bivalent conservation using two of the most common 9-mers at each position, and the light grey line with diamonds shows the conservation of only the most common 9-mers at each position. This analysis shows that the identification of the structural conservative sequences of the input colony has been improved using two of the most common 9-mers.

We next applied further selection criteria to define conserved regions, including limiting to regions with greater than 90% bivalent conservation and removing short fragments of less than 35 amino acids, such as fragments 9–35 amino acids in length.

We also included some additional fragments from certain regions that have at least 80% bivalent conservation and are known to be highly immunogenic, particularly the Nef region corresponding to amino acids 64-99 of the reference sequence HXB2_K03455 (see, e.g., epitope maps at hiv.lanl.gov/content/immunology/maps/maps.html; Fischer et al., Nat Med. (2007) 13(1):100-6; and Addo et al., J Virol, (2003) 77(3):2081-92).

Step 3: If the 9-mer pairs in adjacent positions do not have any conflicting amino acids, they are connected.

Using this modified set of conserved regions, we applied CWA to construct bivalent sequence constructs. CWA connects 9-mer pairs at aligned adjacent positions of the conserved regions that share an overlap of eight amino acids.

Computationally, each 9-mer s contains 9 amino acids, and s[x:y] represents the amino acid subsequence from position x to y, with a total of y-x+1 amino acids:

_siu [2:9] == si+ _1p [1:8] and _siv [2:9] == si _+1q [1:8]

or

_siu [2:9] == si _+1q [1:8] and _siv [2:9] == si _+1p [1:8].

Step 4: Find the sum of the frequencies of all 9-mers in the path from the first 9-mer position to the last position. The best path for the configuration.

In step 4, the algorithm constructs a directed acyclic graph in which each 9-mer pair is a node, and the edges between adjacent nodes are formed by the 9-mer pairs connected in adjacent positions, and the weight of each edge is equal to the frequency of the downstream 9-mer pair. This directed acyclic graph is a positional De Brujin graph. Such a graph has been described in conjunction with the assembly of next-generation sequencing data, such as Ronen et al., Bioinformatics (2012) 28: 188-196.

In this embodiment, we add a source node and connect it to all nodes in the first position; and we add a sink node and connect it to all nodes in the last position. In a directed graph, a source node is a node with only outflows, and a sink node is a node with only inflows. Here, the source node is a dummy node connected to all 9-mer pairs of nodes in the first position, and the sink node is a dummy node connected to all 9-mer pairs of nodes in the last position.

We then invert all weights and find the best path from the source node to the sink node, where the best path is defined as the sum of the frequencies of all 9-mer pairs. The task of finding the best path is performed, for example, using the Bellman–Ford algorithm. In general, the Bellman–Ford algorithm computes the shortest path from a single source vertex to all other vertices in a weighted directed graph. A directed graph consists of a set of vertices connected by edges, where the edges have directions associated with them.

Computationally, the basic idea is to model the maximum coverage bivalent vaccine construction problem as a classic graph theory problem, where the solution is to find the minimum path in a directed acyclic graph. The computational steps are summarized as follows:

(4-1) Treat each 9-mer pair as a node and build edges between adjacent nodes in step 3;

(4-2) Add the source node and connect it to all nodes at the first position;

(4-3) Add the sink node and connect it to all nodes in the last position;

(4-4) The weight of each edge is equal to the frequency of the downstream 9-mer pair; and

(4-5) Use the Bellman–Ford algorithm to invert all weights and find the best path.

Step 5: Construct a bivalent vaccine sequence based on the best bivalent 9-mer pair path, and if the best bivalent 9-mer pair Two 9-mers at adjacent positions within the path were connected if they shared an overlap of 8 amino acids.

In step 5, if two 9 aggressiveness of adjacent positions in the best bivalent 9 aggressiveness path share eight amino acid overlaps, then bivalent constructs are built by connecting them, thereby producing two sequences of the 9 aggressiveness connected, and they form a bivalent construct together. The adjacent 9 aggressiveness of connection all has 8 amino acid overlaps, so they are assembled into two sequences. For example, a 9 aggressiveness pair (AIIIIIIIS (SEQ ID NO:190), MIIIIIIIII (SEQ ID NO:191)) is connected to another 9 aggressiveness pair (IIIIIIISK (SEQ ID NO:192), IIIIIIIIR (SEQ ID NO:184)), and two sequences (bivalent sequences) are formed: AIIIIIIISK (SEQ ID NO:193) and MIIIIIIIR (SEQ ID NO:194).

The method is illustrated graphically in Figures 5A to 5C. Figure 5A shows a set of 9 hypothetical source virus sequences that have 2 unique 9-mers in the first position and 3 unique 9-mers in the second adjacent position. The frequency of each sequence is indicated as "times" on the right side of the sequence, for example "x5" means that the sequence appears 5 times in the source set. Figure 5B depicts the construction of a positional De Brujin graph, where each node is a bivalent 9-mer pair. When two bivalent 9-mer pairs at adjacent positions share an overlap of eight amino acids, they are connected to form an edge. A directed acyclic graph is generated in this way. Figure 5C shows the discovery of the optimal path. As described above, the optimal path is defined based on the sum of the frequencies of all 9-mer pairs. This is achieved by finding the connection between adjacent 9-mers that provides the highest conservation with respect to the input sequence. Therefore, in Figure 5C, connecting two 9-mer pairs as shown in the top group of four pairs provides the following bivalent sequence:

GIIIIIIIIIK (SEQ ID NO: 195) × 0

AIIIIIIIIIH(SEQ ID NO:196)×0.

None of these sequences exist in the source sequence shown in FIG5A .

In contrast, joining two 9-mer pairs as shown in the bottom group of four pairs in Figure 5C provides the following bivalent sequence:

GIIIIIIIIIH (SEQ ID NO: 178) × 3

AIIIIIIIIIK (SEQ ID NO: 177) × 4.

Each of these is present 3 or 4 times respectively in the source sequence shown in Figure 5 A. Therefore, it is these second pairs of bivalent sequences that the algorithm selects because it maximizes conservation relative to the source sequence.

Computationally, this can be illustrated by the following example case:

Case 1: If _siu [2:9] = si _+1p [1:8] and _siv [2:9] = si _+1q [1:8], then connect _siu to si _+1p and _siv to si _+1q ;

Case 2: If _siu [2:9] = si _+1q [1:8] and _siv [2:9] = si _+1p [1:8], then connect _siu to si _+1q and _siv to si _+1p ;

Case 3: If _siu [2:9] = si _+1p [1:8] and _siv [2:9] = si _+1q [1:8] and _siu [2:9] = si _+1q [1:8] and _siv [2:9] = si _+1p [1:8], then the choice of connection is based on the prevalence of the two connections in the natural sequence:

Denote the prevalence of co-occurrence of s _ix and s _i+1y in the input sequence as C _ixy

If _Ciup + _Civq > _Ciuq + _Civp , connect _siu with si _+1p and _si +1q with si _+1q ;

If _Ciuq + _Civp > _Ciup + _Civq , then connect _siu with si _+1q and _si +1p with si _+1p ;

If _Ciup + _Civq = _Ciuq + _Civp , then backtrack and combine the prevalence of coexistence of 9-mer pairs in positions i-1 and i, until the first position. If there is no distinction between two different connections, then choose one at random.

This backtracking and co-occurrence prevalence approach takes into account the prevalence of peptides longer than 9 amino acids and further distinguishes the present algorithm from other graph-based methods.

Next, constructed sequences from regions that are not adjacent to each other in the native sequence (i.e., regions that cannot be combined according to the above CWA because they lack 8 amino acid overlap) were combined using one of the following three different linker strategies: 1. Direct fusion without any linker; 2. Insertion of an ‘AAA’ (SEQ ID NO: 48) linker between every two conserved regions; 3. Direct fusion of fragments within the same protein without any linker, and insertion of an F2A linker between fragments of different proteins.

An overview of the Conservative Walking Analysis (CWA) method is shown in FIGS. 1 and 2 .

Example 2

Schematic illustration of conservation analysis and conservation walking analysis (CWA) applied to proteins encoded by HIV-1 genes Implementation

This example describes similar implementations based on conserved HIV-1 regions of (1) Gag, Pol, and Nef or (2) Pol and Nef.

In Example 1 above, a conservative algorithm was applied to identify a group of all candidate conserved regions in the protein coding regions of the target genes Gag, Nef and Pol. In this example, we used (1) Gag, Pol and Nef, (2) Pol and Nef protein coding regions to produce different bivalent constructs. As in steps 1-2 of Example 1 above, we first aligned the source sequences and then applied a conservative algorithm to identify a group of all candidate conserved regions in the protein coding regions of the target genes (which are from (1) Gag and Nef, Pol or (2) Pol and Env). As described above, we then applied further selection criteria based on conservatism and known immunogenicity (see, for example, epitope maps at hiv.lanl.gov/content/immunology/maps/maps.html, and Fischer et al., Nat Med. (2007) 13(1): 100-6). Among certain sequences including polypeptide fragments encoded by the Pol gene, we excluded sequence fragments including one or both of the "YMDD" motif in reverse transcriptase (SEQ ID NO: 197) and the "DTG" motif in protease because they may affect one or both of the expression and maintenance of enzyme activity.

Using this modified set of conserved regions, we applied CWA to construct bivalent sequence constructs as in steps 3-5 of Example 1.

Some polypeptide fragments are connected by a polyalanine linker (e.g., AA, AAA (SEQ ID NO: 48) or AAY (SEQ ID NO: 49)), which is selected for confirmation purposes because it is a smaller flexible linker that is unlikely to have a significant effect on the protein structure. Some polypeptide fragments are connected by natural short linkers (e.g., K, I, LI, EE, PPV, LIK, KIL, QEE or SEG), which are selected from natural HIV protein sequences flanking the conserved polypeptide fragments to be fused. If we determine that the polypeptide fragments can be fused without generating harmful or undesirable connecting epitopes (e.g., connecting epitopes that may stimulate T cells that cross-react with self-antigens), the fusion method is used. If we determine that harmful or undesirable connecting epitopes may be generated, flexible linkers or natural short linkers are inserted between the polypeptide fragments.

For this example, we further analyzed the junctional regions where deleterious epitopes might be present and arranged the fragments to reduce or avoid the generation of such junctional epitopes.

Different arrangements of peptide fragments produce different linked 9-mers that can induce different ligation reactions. We developed a peptide fragment alignment tool to examine MHC binding affinity and cross-recognition with human peptides for all linked 9-mers in each arrangement. Our in-house developed peptide fragment alignment tool searches different arrangements of peptides and determines the best arrangement with the least ligation reaction based on the in silico prediction results of two analyses applied to the linked parts of the 9-mers described below: (1) in silico HLA binding analysis and (2) human proteome analysis to identify epitopes that may elicit T cells that can recognize self-antigens). The ligation reaction score between each two adjacent fragments is determined by the sum of the number of linked 9-mers predicted to have high binding affinity to the target HLA allele and the number of human proteins predicted to have peptides or T cell recognition motifs with any of the linked 9-mers. The score for each fragment arrangement is determined by the sum of the ligation reaction scores for all linked regions in each fragment arrangement.

1) When there are fewer than 15 peptide fragments, our in-house developed peptide fragment alignment tool searches all possible alignments and determines the best alignment with the minimum ligation reaction (lowest fragment alignment score).

2) When there are at least 15 peptide fragments, our in-house developed peptide fragment alignment tool uses a "greedy" strategy. It first creates all the linkers and then starts with the best linker based on the predicted ligation reaction. Next, it iteratively searches for the next compatible best linker and assembles all the peptide fragments.

Computer MHC class I (human HLA) binding analysis: Antigen processing, presentation and T cell receptor recognition are very complex processes that are not yet fully understood. Intracellular and extracellular antigens are processed in endosomal compartments, and the cytoplasm is processed by proteasomes and transported to endosomal compartments, such as ER, where their peptide fragments interact with MHC molecules. Stable peptide-MHC complexes are transported to the cell surface, where they can be recognized by T cells expressing TCR with appropriate specificity. One of the most selective steps in antigen processing and presentation is HLA binding. HLA binding affinity can be predicted using various tools (such as NetMHC or MHCflurry) or large internal data sets derived from immunopeptidome analysis, and confirmed by experimental binding data and epitopes defined from patient samples. These tools are publicly available and are described, for example, in Lundegarrd et al., Nucleic Acids Res. 2008 July 1; 36 (Web Server issue): W509-12 and O'Donnell et al., Cell Systems 2018 7: 129–132. In this example, we used NetMHC version 4.0. Default settings were used for all parameters in NetMHC, as well as input information for peptide sequences and HLA alleles. Predicted binding affinities with IC50 values less than 1,000 nM were considered low binding affinities.

Human proteome cross-recognition analysis: Epitopes similar to human peptides may induce one or more tolerogenic responses that may cross-react with self-antigens. We searched all 9-mers in our vaccine in public human protein databases (e.g., UniProt, NCBI). HIV peptide 9-mers were considered cross-conserved 9-mers if they had at least 5 residues of amino acid sequence identity with human peptide 9-mers and both were predicted to have high binding affinity for the same allele. We downloaded all human protein sequences from the UniProt database and built a tool to support efficient searching for a given 9-mer among all human protein 9-mers with up to 4 mismatches (at least 5 matches).

Figure 6 shows the results of the human proteome cross-recognition analysis. In this example, we searched for HIV-1 peptide 9-mers in the human protein database and identified all human protein 9-mers that shared a certain number of amino acids (tentatively at least 5) and were predicted to have high binding affinity to the same allele based on the computer MHC class I analysis described herein (e.g., IC50 less than about 1000nM or percentile rank within the top 5% of the polypeptide fragment population). Such HIV 9-mers that have both significant or high sequence identity with peptide fragments of human proteins (e.g., having at least 55% (5 of 9 amino acid residues), such as at least 65% (6 of 9 amino acid residues), such as at least 75% (7 of 9 amino acid residues), such as at least 85% (8 of 9 amino acid residues)) and high predicted MHC class I binding affinity were excluded because they may induce one or more tolerogenic responses that may cross-react with human self-antigens (defined herein as "harmful epitopes").

FIG7 illustrates how polypeptide fragment alignment analysis can reduce or eliminate the possible presentation of harmful or undesirable epitopes in junction regions. In the illustrated default alignment, the junction 9-mers between Seg 2 and Seg 3 and between Seg 3 and Seg 4 are predicted to produce junction sequences that are likely to induce tolerogenic or autoreactive responses in humans (e.g., have high MHC binding affinity based on computer HLA binding analysis or cross-recognition with human proteins based on human proteome cross-recognition analysis). We applied an algorithm that searches different alignments and identifies alignments that produce predicted junction sequences that are reduced or eliminated in terms of the potential to induce tolerogenic or autoreactive responses in humans. In addition, if multiple antigen sequences are developed, the polypeptide fragments are also rearranged to avoid the presence of identical or nearly identical 9-mers at the junctions between antigen sequences.

The fusion polypeptides and composite fusion polypeptides described herein are exemplary immunogenic fusion polypeptide sequences designed according to the immunogen design method described herein. Fusion polypeptides of SEQ ID NO: 70-101 (provided in Table E), particularly SEQ ID NO: 94-101 (immunogen version 1), which are polypeptide fragments encoded by HIV-1 Gag, Nef and Pol genes, and composite fusion polypeptides of SEQ ID NO: 105-112, 200-209, 222-223 and 227 (provided in Table F) are exemplary immunogenic fusion polypeptide sequences designed according to the method. Figure 8 provides a schematic diagram of a viral vector containing a fusion protein of immunogen version 1.

Example 3

Improved immunogen design using deep sequencing analysis and immunogenicity data: Immunogen version 2

In Example 1 above, a conservative algorithm was applied to identify a set of all candidate conserved regions in the protein coding regions of the target genes Gag, Nef, and Pol. In Example 2, we used the protein coding regions of (1) Gag, Pol, and Nef, and (2) Pol and Nef to generate different bivalent constructs. In this example, we describe the design of immunogen version 2 by combining deep sequencing data and immunogenicity data to identify which conserved regions from immunogen version 1 will be included in the shortened bivalent polypeptide construct. For the design of this improved immunogen, as in steps 1-2 of Example 1 above, we first aligned the source sequences and then applied the conservative walking algorithm (CWA) described herein to identify a set of all candidate conserved regions in the protein coding regions of the target genes. The target genes are Gag, Nef, and Pol, and we apply CWA to construct bivalent sequences in these regions, as shown in steps 3-5 of Example 1.

Intra-patient conservation analysis using deep sequencing. In addition to the 9-mers obtained from the downloaded population sequences, deep sequencing data of viruses from individuals chronically infected with HIV-1B subtype were used to identify intra-patient diversity within these conserved regions. In order to identify intra-patient 9-mer variants using deep sequencing data, deep sequencing data from N = 238 untreated subjects with chronic HIV infection were analyzed to assess intra-patient diversity within the conserved regions defined by CWA. In order to use deep sequencing data to assess intra-patient 9-mer variants, deep sequencing reads were assembled to generate subject-specific consensus sequences. The reads were aligned to the subject-specific consensus sequence and then mapped to HXB2 position coordinates based on the alignment of the subject-specific consensus sequence with the HXB2 reference sequence. At each 9-mer position, the corresponding sequencing read of 27 bp that completely covered the 9-mer was extracted and converted into a 9-mer amino acid sequence. Only 9-mer positions with a sequencing read depth ≥ 1000 were included in the analysis, and variants were analyzed at a cutoff frequency of 1%. The 9-mer variants were used to assess the quasispecies variant coverage of the bivalent vaccine sequence. Here, we define the intra-patient conservation of 9-mer positions as the percentage of patients (total N=238 samples) covered by the bivalent vaccine sequence without escape variants. A highly intra-patient conserved 9-mer is a 9-mer that is covered by the population-based bivalent vaccine sequence in >70% of patients without any escape variants. As described in Example 1, the intra-patient conservation of Pol, Gag, and Nef regions selected based on population conservation was evaluated.

Figure 10 provides a flow chart showing the basic method for designing immunogen version 2. The fusion polypeptides of SEQ ID NOs: 82-89 are exemplary amino acid sequences designed according to this method.

Known epitopes from the Los Alamos National Laboratory (LANL) database and epitopes identified by the Gilead ELISPOT assay. To assess the immunogenicity of previously identified conserved regions, described CD8+ T cell epitopes (e.g., from the LANL database) and ELISpot assays performed in-house were analyzed. Any 9-mer position in the conserved regions of Pol, Gag, and Nef with >1 mapped epitope defined by the ELISPOT assay or from the LANL database was considered an immunogenic region. Immunogenicity results were not limited to specific HLA alleles.

Figures 10A to 10C show the regions selected for immunogen version 2 by combining deep sequencing data and immunogenicity data. For each 9-mer position in the figure, intra-patient conservation is represented as a black horizontal line. The number of epitopes overlapping in each 9-mer region is shown as a stacked bar in the figure. We selected such amino acid 9-mers that have> 70% intra-patient conservation and overlap with epitopes reported by the LANL database or defined by ELISpot assays. After identifying the amino acid 9-mers for improved immunogens, those 9-mers from the same viral protein and continuous are connected (e.g., via a linker or direct fusion) to form the fusion amino acid fragments highlighted in the figure.

We used the protein coding regions of (1) Gag and Pol, and (2) Pol and Nef to generate different bivalent constructs. In the final step, we applied our internally developed polypeptide fragment alignment tool described in Example 2 to the fragments to reduce or eliminate the possible presentation of harmful or undesirable epitopes in the junction region. We anchored the Nef conserved sequence to the C-terminus of the vaccine sequence during the fragment rearrangement of immunogen 2 because our previous experiments showed that positioning the Nef fragment to the C-terminus of the vaccine sequence was more likely to induce an immune response. Figure 11 provides a schematic diagram of a viral vector containing a fusion protein (e.g., SEQ ID NO: 82-89) of immunogen version 2.

Improved median response and epitope density of immunogen design. In order to evaluate whether the shortened immunogen is rich in immunogenic regions, we compared the number of internally defined epitopes for each sample between fusion proteins designed according to the methods of Examples 1-2 (e.g., immunogen version 1; SEQ ID NO: 94-101) and fusion proteins designed according to the methods of Examples 1-3 (e.g., immunogen version 2; SEQ ID NO: 82-89). Figures 12A to 12B show that the median response remains stable under size changes. A total of 93 samples were analyzed. We measured the median number of epitopes identified in each sample. The median number of epitopes for immunogen version 2 was 4, while the median number of epitopes for immunogen 1 was 5. Two non-responders were observed using the shorter immunogen version 2. The epitope density was examined by evaluating the epitope rate. The epitope rate is defined as the number of epitopes defined in the in vitro clinical trial divided by the total number of potential epitopes in the immunogen. As shown in Table 1, the results of epitope rate analysis indicate that we maximized epitope density after the size of the fusion protein of immunogen version 1 (516-527 amino acids in length) was reduced to the fusion protein of immunogen version 2 (351-365 amino acids in length). The epitope rate of immunogen version 1 remained unchanged in immunogen version 2. We defined the epitope rate as the percentage of all 9-mers recognized as epitopes by the ELISpot assay (total number of epitopes/number of 9-mer positions).

Table 1

Epitope ratio analysis between immunogen versions 1 and 2

Example 4

Shortened construct suitable for expression from a single priming vector and a single boosting vector: Immunogen version 3

In this example, as in steps 1-2 of Example 1 above, we first aligned the source sequences and then applied CWA to identify a set of all candidate conserved regions in the protein coding regions of the target genes. In this example, the target genes are Gag, Nef, and Pol. We applied CWA to construct bivalent sequences in these regions, as shown in steps 3-5 of Example 1.

As in Example 3 above, we applied deep sequencing and immunogenicity data to identify a subset of highly conserved and immunogenic regions within immunogen version 1 that were retained in the shortened immunogen. Figure 13 provides a flow chart showing the basic method for fusion polypeptides of immunogen version 3. SEQ ID NO: 90-93 are exemplary fusion polypeptides designed according to this method. We used the same method as described in Example 3 to design a shortened bivalent fusion polypeptide (391-394 amino acids in length) of immunogen version 3, the length of which allowed four fusion polypeptides to be expressed from two viral vectors (e.g., two arenavirus vectors). Immunogenicity data showed that Gag p24 and Nef fragments (64-76) elicited a strong immune response, so Nef 64-76 was retained in immunogen version 3. For Pol, as described above, we identified a continuous region in Pol that had >75% intra-patient conservation and contained multiple epitopes defined by in vitro assays. Figures 14A to 14D show the regions selected for immunogen 3. We generated different bivalent constructs using the protein coding regions of (1) Gag and Pol, and (2) Pol and Nef. In the final step, we applied our in-house developed polypeptide fragment alignment tool described in Example 2 to the fragments to reduce or eliminate the possible presentation of harmful or undesirable epitopes in the junction region. The conserved subsequence of Nef is located at the C-terminus of the immunogen version 3 fusion polypeptide. Figure 15 provides a schematic diagram of a viral vector containing a fusion protein of immunogen version 3 (e.g., SEQ ID NO: 90-93).

Example 5

Viral expression vector containing immunogenic fusion polypeptide in immunogen 1

In this example, we generated viral expression vectors encoding computationally defined polypeptide fragments containing conserved regions of HIV-1 encoded by Gag, Nef and Pol genes as transgenes and demonstrated expression of the transgenes in mammalian cells. The polypeptide fragments containing the conserved regions were tandemly or linked by a variety of methods, including direct fusion, linking the regions by adding proteolytic cleavage site sequences or adding flexible linkers between the regions.

method

Evaluation of target gene expression in vitro. In order to improve the assembly of the viral vector encoding the vaccine expression cassette, the gene was cloned into a vector plasmid (ThermoFisherScientific) containing a restriction site for cloning the target gene and a GFP marker. DNA was transformed into One Shot TOP10 competent cells (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol and inoculated onto an LB agar plate supplemented with 100 μg/ml ampicillin. The plate was incubated overnight at 37 ° C. Single colonies were picked out from the plate and inoculated into 10 ml liquid LB+ ampicillin culture, and shaken overnight at 37 ° C with 250 rpm in an Eppendorf table shaker. Bacterial precipitation was processed using QIAprep Spin miniprep kit (Qiagen, Germantown, MD) according to the manufacturer's protocol to obtain plasmid DNA. The nucleic acid concentration was determined by reading the absorbance at 280 nm using NanoDrop ^TM 2000 (Thermo Scientific). To evaluate in vitro expression, adenovirus serotype 5 (Ad5) expression vectors expressing composite fusion proteins of SEQ ID NO: 105, 107, 109 or 111 were used to transduce monocyte-derived dendritic cells (moDCs) as outlined in Example 9 below. On day 2 after transduction, when cell viability was still >80%, they were evaluated by flow cytometry for GFP expression or precipitation. Cell lysates were evaluated for HIV-1 Gag p24 expression by ELISA.

The construction of the transgenic viral expression vector containing the encoding fusion polypeptide variant. The Ad5 vector expressing the vaccine immunogen defined by HIV-1 calculation was produced by in vitro recombination using standard methods (VectorBiolabs), and the vector was connected to the conservative HIV-1 sequence using various methods. The synthetic oligonucleotides using codon preference to improve human expression (IDT) were used to produce expression cassettes by PCR, and standard gene cloning techniques were used to place it under the control of the CMV promoter. The immunogen version 1 composite fusion polypeptide construct developed for this evaluation is listed in Table F, and schematically depicted in Figure 19.

result

The data depicted in Figure 20 demonstrate that all conserved region fusion polypeptide sequences were efficiently expressed (Figure 20A) and transduced (Figure 20B) as demonstrated by GFP expression and Gag p24 ELISA.

Example 6

Viral expression vector containing immunogenic fusion polypeptide in immunogen 2

This example evaluates in vitro target gene expression and construction of Ad5 viral expression vectors. A similar strategy was used to evaluate the expression of conserved region HIV immunogen 2 (SEQ ID NO: 82-89) as described above for immunogen version 1 fusion polypeptides in Example 5. Immunogen version 2 fusion polypeptide constructs are listed in Table E and schematically depicted in Figure 21.

result

The data depicted in Figures 22A-22B demonstrate that all of the conserved region polypeptide sequences resulted in efficient expression (Figure 22A) and transduction (Figure 22B) of polynucleotides encoding the fusion polypeptides of SEQ ID NOs: 82-89.

Example 7

Viral expression vector containing immunogenic fusion polypeptide in immunogen 3

This example evaluates in vitro target gene expression and construction of Ad5 viral expression vectors. A similar strategy was used to evaluate the expression of conserved region HIV immunogen 3 (SEQ ID NO: 90-93), as described above for immunogen version 1 fusion polypeptides in Example 5. Immunogen version 3 fusion polypeptide constructs are listed in Table E and schematically depicted in Figure 23.

result

The data depicted in Figures 24A-24B demonstrate that all of the conserved region polypeptide sequences resulted in efficient expression (Figure 24A) and transduction (Figure 24B) of polynucleotides encoding the fusion polypeptides of SEQ ID NOs: 90-93.

We then tested the efficiency of these constructs in eliciting T cell responses in vitro and in vivo in various viral vector systems.

Example 8

In vivo T cell activation assay

In this example, we evaluated the efficacy of in vivo T cell priming by vaccine constructs in a mouse model. To do this, we immunized groups of mice with Ad5 vectors expressing computationally defined conserved region vaccine immunogen sequences. We studied the magnitude and functional phenotype of these responses to determine the immunogenicity of the vaccine sequences.

The vaccine is administered in a homologous (relative to viral expression vector) primary immunity-boosting method. Each viral Ad5 vector in the primary immunity-boosting pair has a different rearrangement of the HIV gene fragment encoded in the fusion polypeptide construct. This gene rearrangement reduces or eliminates the formation of a ligation reaction. The vector is different in the size of the transgene that can be stably expressed. In the design of the vaccine immunogen, two complementary fusion polypeptides less than 600 amino acids in length are expressed from a single viral vector. A vector that can accommodate a larger transgene can, for example, use an F2A joint to combine two fragments (described herein as "composite fusion polypeptides; " see Table F). We use a vector expressing a composite fusion polypeptide, and in the presence and absence of an F2A joint, the immunogenicity of each individual fusion polypeptide sequence is tested in the primary immunity sequence and again in the primary immunity-boosting sequence. The vector containing the F2A joint also has an N-terminal tissue plasminogen (t-PA) signal peptide sequence (MDAMKRGLCCVLLLCGAVFVSAR (SEQ ID NO: 121)). Immunogen Version 1 fusion polypeptide constructs are listed in Table E and schematically depicted in Figure 25. Immunogen Version 1 composite fusion polypeptide constructs are listed in Table F and schematically depicted in Figure 19.

method

In vivo assessment of immunogenicity

Immunization. Balb/c mice, five or six weeks old, were immunized with 1×10 ⁹ PFU of Ad5 vector expressing HIV immunogen by intramuscular (IM) injection in both hind leg muscles. Vaccine vector was administered as 100 μl phosphate buffered saline (PBS) injection (50 μl/quadriceps). Mice were anesthetized with isoflurane prior to vaccine immunization. Animals were housed in an animal facility (Bioqual, Maryland) and experiments were performed according to approved IACUC protocols. A schematic diagram of the protocol is provided in FIG26 .

Single vector immunogenicity. Mice were randomly divided into 8 groups and primed with 1×10 ⁹ PFU of Ad5 vector expressing HIV immunogen (SEQ ID NO: 94-101, schematically depicted in FIG25 ) by intramuscular (IM) injection in both hind leg muscles and rested for 16 days before harvesting splenocytes. Immunogenicity was assessed by analyzing splenocytes by IFN-γ ELISpot assay as previously described (Miyahira et al., J Immunol Methods, (1995) 181(1):45-54).

ELISpot assay. Pre-coated strip ELISpot plates (Cellular Technologies Limited) were used for all ELISpot analyses. Briefly, 2×10 ⁵ splenocytes from immunized animals were inoculated into each well. A peptide pool with 15-mer peptides overlapping by 11 amino acid residues spanning HIV Gag, Pol and Nef conserved region sequences was used for IFN-γ ELISpot assay to evaluate vaccine immunogenicity. 2.5ng/ml PMA and 250ng/mL ionomycin and 1μg/mL ConA were used as positive controls. The plates were incubated overnight at 37°C in 5% CO ₂ for up to 18 hours. After stimulation overnight, the cells were removed from the plates and the wells were washed twice in PBS and then twice with PBS containing 0.05% Tween. Biotinylated anti-IFN-γ detection antibodies were then added to the plates for 2 hours at room temperature. The plates were then washed three times with PBS containing 0.05% Tween, and streptavidin-conjugated alkaline phosphatase (AP) was then added. The wells were then washed twice with 0.05% Tween-PBS, then washed twice with distilled water, and then a blue developer solution was added. The plates were then incubated at room temperature for 15 minutes, and then tap water was used to stop the reaction. The wells were then dried overnight, and spot forming units (SFU) were counted on an Immunospot ELISpot reader. The settings for all plates were the same, and the counts were expressed as SFU per 10 ⁶ splenocytes. A schematic diagram of the vector variant is provided in Figure 25, the immunization scheme is provided in Figure 26, and the results are shown in Figures 27 to 28.

Homologous prime-boost. Mice were randomly divided into 6 groups. Group 1 and group 2 mice were immunized with 1×10 ⁹ PFU of Ad5 vector expressing bivalent fusion polypeptides SEQ ID NO: 105 (Seq 94-F2A-95) and SEQ ID NO: 109 (Seq 98-F2A-99) with N-terminal t-PA leader sequence by intramuscular (im) injection in both hind leg muscles and rested for 16 days before harvesting spleen cells. Group 3 and group 4 mice were immunized with 1×10 9 PFU of Ad5 vector expressing bivalent fusion polypeptides SEQ ID NO: 107 (Seq 96-F2A-97) and SEQ ID NO: 111 (Seq 100-F2A-101) with N- ^terminal t-PA leader sequence by im injection in both hind leg muscles and rested for 16 days before harvesting spleen cells.

Groups 5 and 6 mice were immunized with 1×10 ⁹ PFU of Ad5 vectors Seq-94-F2A-95 (tPA-SEQ ID NO: 105) and Seq 96-F2A-97 (tPA-SEQ ID NO: 107) expressing the HIV immunogen used in Group 1 or Group 3, respectively, by im injection in both hind leg muscles and rested for 29 days before homologous boosting with vectors expressing the same antigen but rearranged to minimize ligation reactions (Seq 98-F2A-99 (tPA-SEQ ID NO: 109) and Seq 100-F2A-101 (tPA-SEQ ID NO: 111) immunogens used in Groups 2 and 4, respectively). Immunogenicity and cell phenotype were assessed by analyzing splenocytes at day 36 by ELISpot assay as previously described (Miyahira et al., J Immunol Methods, (1995) 181(1):45-54), and ICS was performed by flow cytometry at day 16 post-prime and day 36 post-prime/boost. A schematic diagram of the vector variants is provided in FIG19 , the immunization schedule is provided in FIG29 , and the results are shown in FIG30 to FIG31 .

Flow cytometry. Cell counts of prepared single cell suspensions were determined using a hemocytometer. 1×10 ⁶ cells/condition were stimulated with relevant HIV peptides for 6 hours (no more than 18 hours) in the presence of Golgi plugs. Washed cells were first surface stained with live dead Aqua (Thermo fisher L34957) dye and then incubated with a mixture of fluorescently conjugated anti-mouse antibodies at 4°C for 20 minutes. CD3 APC-Cy7 clone 17A2, CD4 PE-Cy7 clone GK 1.5, CD8 percp-Cy5.5 clone 53-6.7 were used for surface staining. After surface staining, the cells were fixed and permeabilized in preparation for intracellular cytokine staining. Briefly, 1×10 ⁶ cells stained with surface antibodies were incubated on ice for 25 minutes with 200 μl BD cytofix/cytoperm buffer. Subsequently, the cells were washed twice with 200 μl 1X Perm buffer each time and then incubated with an antibody mixture diluted with 100 μl Perm buffer per 1×10 ⁶ cells. A mixture of fluorophore-conjugated anti-mouse anti-IFN-γ APC clone XMG1.2, anti-IL-2PE clone JES6-5H4, and anti-TNF-α FITC clone MP6-XT22 was used for intracellular cytokine staining. The permeabilized cells were then washed twice with 100 μl Perm buffer and immediately analyzed using MACS Quantify version 2.13 (Miltenyi Biotech) on a MACSQUANT 10 analyzer and analyzed using FlowJo software version 10.7 (TreeStar).

result

Various viral Ad5 vector constructs expressing immunogenic version 1 fusion polypeptides (SEQ ID NOs: 94-101; depicted in Figure 25) were effective in eliciting T cell responses. As shown in Figure 26, the immunogenicity of these sequences was investigated in the Balb/C mouse model by IM immunization.

The primary bivalent fusion polypeptides SEQ ID NOs: 94-95 and the booster bivalent fusion polypeptides SEQ ID NOs: 98-99 with HIV-1 Gag, Pol and Nef sequence fragments induced a robust response to HIV-1 Gag (Figure 27A (i and ii)), a weak but detectable response to Pol proteins (protease, RT and integrase) (Figure 27A (iii to vi)). No response to HIV-Nef was detected in this model (Figure 27A (vii and viii)), which may be due to the previously described immunodominant pattern of the HIV-1 Gag epitope in Balb/c mice and reflects the lack of Nef epitopes that can be presented in Balb/c mice.

The primary bivalent fusion polypeptides SEQ ID NOs: 96-97 and the booster bivalent fusion polypeptides SEQ ID NOs: 100-101 with HIV-1Pol and Nef induced a robust response to HIV-1Pol, especially protease and RT (FIG. 28 (i and ii)), and a weaker response to Pol integrase (FIG. 28 (iii and iv)). No response to HIV-Nef was observed with this group of sequences (FIG. 28 (v and vi)), which confirms the observations from the previous group of sequences (FIG. 27A (vii and viii)).

To test whether combining these bivalent construct sequences designed to ensure >80% coverage of circulating HIV-1 viral sequences into a single construct affects immunogenicity, the individual sequences were combined using the F2A linker (SEQ ID NOs: 105, 107, 109, and 111) as shown in Figure 19. The composite fusion polypeptides each had an N-terminal tPA leader sequence. The bivalent fusion polypeptide pairs SEQ ID NOs:94 and 95 were combined into Seq 94-F2A-95 (tPA-SEQ ID NO: 105), SEQ ID NOs:96 and 97 were combined into Seq 96-F2A-Seq 97 (tPA-SEQ ID NO: 107), SEQ ID NOs:98 and 99 were combined into Seq 98-F2A-Seq 99 (tPA-SEQ ID NO: 109), and SEQ ID NOs: 100 and 101 were combined into Seq 100-F2A-Seq 101 (tPA-SEQ ID NO: 111).

To test immunogenicity, these combination sequences were tested by IM immunization in Balb/C mice (Figure 29), as single vectors in prime-only mode (Figure 30A) and in homologous prime-boost combination mode (Figure 30B). Sequences Seq 94-F2A-95 (tPA-SEQ ID NO: 105) and Seq 98-F2A-99 (tPA-SEQ ID NO: 107) were used as bivalent fusion polypeptides with HIV-1 Gag, Pol and Nef sequence fragments and tested as prime and boost sequences in homologous vector prime-boost combination mode. Seq 96-F2A-97 (tPA-SEQ ID NO: 109) and Seq 100-F2A-Seq 101 (tPA-SEQ ID NO: 111) were used as bivalent fusion polypeptides with HIV-1 Pol and Nef and tested as prime and boost sequences in homologous vector prime-boost combination mode. The prime and boost fusion polypeptides encode similar regions but are rearranged to reduce or eliminate the generation of de novo epitopes that resemble epitopes from the human proteome and to reduce or eliminate boosting of ligation reactions within the prime-boost sequence.

Combination sequences Seq 94-F2A-95 (tPA - SEQ ID NO: 105) and Seq 98-F2A-99 (tPA - SEQ ID NO: 109) were immunogenic when tested for immunogenicity as single primes or in prime/boost combinations ( FIG. 31A , responses to HIV-Gag (i), Pol (protease and RT (iii), Pol (integrase (v)), and Nef (vii), respectively, and FIG. 27 , responses to HIV-1 Gag (i and ii), Pol (protease, RT, and integrase (iii to vi)), and Nef (vii and viiii)). The bivalent sequences in tandem with F2A did not inhibit their immunogenicity. Overall, responses to HIV-1 Gag were robust, responses to Pol proteins (protease, RT, and integrase) were weak but detectable, and there was minimal response to HIV-Nef. The immunogenicity of the priming sequences Seq 94-F2A-95 (tPA - SEQ ID NO: 105) and Seq 98-F2A-99 (tPA - SEQ ID NO: 109) were immunogenic when tested for immunogenicity as single primes or in prime/boost combinations ( FIG. 31A , responses to HIV-Gag (i), Pol (protease and RT (iii), Pol (integrase (v)), and Nef (vii), respectively, and FIG. 27 , responses to HIV-1 Gag (i and ii), Pol (protease, RT, and integrase (iii to vi)), and Nef (vii and viiii)). The bivalent sequences in tandem with F2A did not inhibit their immunogenicity. Overall, responses to HIV-1 Gag were robust, responses to Pol proteins (protease, RT, and integrase) were weak but detectable, and there was minimal response to HIV-Nef. The responses induced by the booster sequence Seq 98-F2A-99 (tPA-SEQ ID NO: 109) were enhanced, particularly for Pol (integrase) ( FIG. 30B (vi)) and Nef ( FIG. 30B (viii)). No responses were generated to the F2A and tPA sequences.

The combined sequences Seq 96-F2A-97 (tPA-SEQ ID NO: 107) and Seq 100-F2A-101 (tPA-SEQ ID NO: 111) were immunogenic when tested for immunogenicity as a single prime or in a prime/boost combination, inducing robust responses to HIV-1 Pol, particularly protease and RT, while weaker responses were detected to integrase (Figure 31A (i to iv)). The magnitude of the IFN-γ ELISpot response to Pol (protease and RT, Figure 31B (i)) induced by the combined vector Seq 96-F2A-97 (tPA-SEQ ID NO: 107) was weaker than the response previously observed for the single vector expressing the fusion polypeptide of SEQ ID NO: 96 or 97 (Figure 28 (i)). Seq 96-F2A-97 (tPA-SEQ ID NO: 107) and Seq 100-F2A-101 (tPA-SEQ ID NO: 111) were sequentially administered to boost the response ( FIG. 31B (ii)). The response induced by the priming sequence Seq 96-F2A-97 (tPA-SEQ ID NO: 107) was enhanced by the boosting sequence Seq 100-F2A-101 (tPA-SEQ ID NO: 111), particularly against both Pol (integrase) ( FIG. 31B (iv)) and Nef ( FIG. 31B (vi)).

The ability to produce cytokines is a functional measure of effector and memory CD4+ and CD8+ T cells. We used both single vector prime immunization and homologous prime/boost immunization to evaluate the phenotypic and functional characteristics of CD4+ and CD8+ T cell responses generated following immunization with Ad5 vectors expressing composite fusion proteins of SEQ ID NO: 105, 107, 109 or 111. Responses were measured using ICS and flow cytometry.

Figures 32 to 35 show the immunogenicity of anti-HIV-1 Gag, Pol and Nef antigens by intracellular cytokine staining (ICS) after single vector immunization with Seq 94-F2A-95 (tPA-SEQ ID NO: 105) or Seq98-F2A-99 (tPA-SEQ ID NO: 109), as well as by homologous vector prime-boost immunization. The Y axis represents the proportion of CD8+ (i, ii and iii) or CD4+ (iv, v and vi) T cells that exhibit HIV-1 Gag (Figure 32), Pol (protease and RT) (Figure 33), Pol (integrase) (Figure 34) and Nef (Figure 35) specific responses by expressing the cytokines IFN-γ, IL-2 and TNF-α (as individual cytokines or cytokine combinations), as shown on the X axis. Antigen specificity values were obtained by subtracting controls without antigen stimulation to exclude nonspecific responses. Strong HIV-1 Gag-specific CD8+ and CD4+ T cell responses were observed in response to vaccination, demonstrating the most robust polyfunctionality in CD8+ T cells. Homologous prime-boost enhanced the polyfunctionality of CD8+ T cell responses. Even when generated, Pol (protease, RT, and integrase)-specific and Nef-specific CD8+ and CD4+ T cell responses generated after vaccination were weaker than Gag responses and tended to be monofunctional with limited boosting effects.

Figures 36 to 38 show the immunogenicity of anti-HIV-1 Pol and Nef antigens by intracellular cytokine staining (ICS) after single vector immunization with Seq 96-F2A-97 (tPA-SEQ ID NO: 107) or Seq100-F2A-101 (tPA-SEQ ID NO: 111), as well as by primary-boost immunization with homologous vectors. The Y axis represents the proportion of CD8+ (i, ii and iii) or CD4+ (iv, v and vi) T cells that express HIV-1 Pol (protease and RT) (Figure 36), Pol (integrase) (Figure 37) and Nef (Figure 38) specific responses by expressing cytokines IFN-γ, IL-2 and TNF-α (as individual cytokines or cytokine combinations), as shown on the X axis. Antigen-specific values were obtained by subtracting controls without antigen stimulation to exclude nonspecific responses. HIV-1Pol (protease and RT) specific CD4+ and CD8+ T cell responses were observed in response to vaccination, with CD8+ T cell responses being robust. Seq 100-F2A-101 (tPA-SEQ ID NO: 111) showed strong immunogenicity with multifunctionality (producing ≥ 2 cytokines). Low levels of Pol (integrase) and Nef specific CD4+ and CD8+ T cell responses were produced in response to vaccination, and higher responses were observed in CD4+ T cells. Seq 100-F2A-101 (tPA-SEQ ID NO: 111) confirmed and induced major monokine production. Homologous vector prime-boost immunization with a vector encoding a fusion polypeptide enhanced CD4+ and CD8+ T cell responses.

The data are consistent with the conclusion that the HIV-1 bivalent sequences tested above are immunogenic as single prime sequences or when combined with the F2A linker (except Seq 96-F2A-Seq97 (tPA-SEQ ID NO: 107) and are also immunogenic in homologous prime boost immunizations. The magnitude of the responses generated are antigen specific, CD4+ and CD8+, and express multifunctionality.

Example 9

In vitro assay demonstrating human T cell activation induced by immunogens 1-3

In this example, we established an in vitro method for testing the efficacy of vaccine constructs in expression vectors to prime T cells in humans. The application of this method in vaccinology allows the evaluation of antigen processing, presentation and T cell priming of transgenic cassettes in humans, as well as the study of immune parameters, including adjuvants and immunomodulators that may alter priming efficacy.

method

Purification of monocytes and maturation of monocyte-derived dendritic cells (moDCs). Freshly isolated or cryopreserved PBMCs were used in moDC-based T cell stimulation assays. CD14+ monocytes were purified from PBMCs of individuals infected or not infected with HIV, ART-naive or receiving ART using the EasySep Human Anti-CD14 Positive Selection Antibody Kit (StemCell Technologies). Flow cytometry was used to confirm that the purity of the isolated CD14+ monocytes was >90% before establishing the culture. To generate immature moDCs, 2×10 ⁶ purified CD14+ monocytes were cultured in 3 mL of moDC differentiation medium (complete RPMI 1640 containing 10% heat-inactivated fetal bovine serum, 1% penicillin-streptomycin/mL, 0.5 mM HEPES, 800 U/mL GM-CSF (Miltenyi Biotec) and 1000 U IL-4 (Miltenyi Biotec)) in 6-well culture plates. The plates were incubated at 37°C and 5% _CO2 for 6 days and monitored daily to ensure adherence of monocytes. To generate mature moDCs, adherent immature moDC cultures were supplemented with recombinant soluble CD40L (0.5 μg/ml), IFN-γ (1,000 U/ml), PGE2 (5 μM), TNF-α (10 ng/ml), IL-6 (100 ng/ml), and IL-1β (10 ng/ml), and 3 ml of moDC differentiation medium were added on day 6 and incubated for another 48 hours at 37°C and 5% _CO2 .

On day 8, adherent mature moDCs were separated using ice-cold PBS and a cell scraper to manually isolate moDCs. After the procedure, unattached cells were washed with moDC differentiation medium and transferred to a 50 ml centrifuge tube. The resulting cell mixture was centrifuged at 1500 rpm for 5 minutes at room temperature. Next, the supernatant was discarded and the cell pellet was resuspended in 5 ml moDC differentiation medium. Mature moDC fractions were separated and stained to characterize the differentiation phenotype of moDCs with anti-CD11c+, anti-HLA-DR+, anti-CD14-, anti-CD40+, anti-DCSIGN+, anti-CD83, anti-CD86, and anti-OX40L antibodies.

moDCs were transduced with adenovirus 5 (Ad5) viral vectors. Purified moDCs were harvested, washed twice in serum-free medium, and then resuspended in X-Vivo 15 (BioWhittaker, Walkersville, MD) at 10 ⁷ /ml. Prior to transduction, cells were equilibrated in a 37°C water bath for 20-30 minutes. Ad5 stocks expressing vaccine immunogens or empty vector controls were thawed on ice and added to the moDC suspension at a multiplicity of infection (MOI) of 500. The cells were gently mixed and immediately placed in a 37°C incubator. After 2 hours, warm moDC differentiation medium containing GM-CSF and IL-4 was added to dilute the moDCs to a final concentration of 10 ⁶ /ml. Transduced moDCs (4×10 ⁶ ) were transferred to a T75 cell culture flask and maintained at 37°C in 5% CO ₂ for an additional 48 hours before the addition of autologous PBMCs.

Co-culture of autologous PBMCs with moDCs. In experiments evaluating the immunogenicity of our conserved region vaccines, autologous PBMCs were counted and 80×10 ⁶ PBMCs were co-cultured with 4×10 ⁶ moDCs that had been transduced with Ad5 vectors expressing the vaccine immunogen or Ad5 empty vector controls. PBMC-moDC co-cultures were continued for 10 days in the presence of IL-2 (50 U/ml), IL-7 (10 ng/ml), efavirenz (0.1 μM), and elvitegravir (0.1 μM). Co-cultures of moDCs and PBMCs were established at a moDC:PBMC ratio of 1:20.

IFN-γ ELISpot assay. Pre-coated strip ELISpot plates (Cellular Technologies Limited) were used for all ELISpot analyses. In brief, 3×10 ⁴ cells from the 10th day moDC-PBMC culture were inoculated into each well. Vaccine-matched peptides consisting of 15-mers overlapping by 11 amino acids spanning the entire HIV conserved region immunogen were assembled into 384 ELISpot plates, with each individual well corresponding to a single 15-mer peptide and used in IFN-γ ELISpot assays to assess vaccine immunogenicity. For the positive control, 50 ng/ml PMA (Sigma) was added. The plates were incubated at 37°C, 5% CO ₂ for 24 hours. After 24 hours of stimulation, the cells were removed from the plates, and the wells were washed three times in PBS and then washed three times with PBS containing 0.05% Tween. The biotinylated anti-IFN-γ detection antibody was then added to the plate for 2 hours at room temperature. The plate was then washed three times with PBS containing 0.05% Tween, followed by the addition of streptavidin-conjugated alkaline phosphatase (AP). The wells were then washed twice with 0.05% Tween-PBS, then twice with distilled water, and then a blue color developer solution was added. The plate was then incubated at room temperature for 15 minutes, and then the reaction was stopped using tap water. The wells were then dried overnight, and the spot forming units (SFU) were counted on the Immunospot ELISpot reader. The settings for all plates were the same, and the counts were expressed as SFU per 3×10 ⁴ PBMCs. SFU was calculated as the number of spots in the test well minus the average number of spots in the culture medium control well. A positive response was defined as >3 times the SFU compared to the culture medium control well and >5 spots per well (3×10 ⁴ cells). The culture medium control well contained a culture medium reconstructed with a DMSO composition similar to that of the peptide-stimulated test well. Figure 39 depicts a schematic diagram outlining moDC-PBMC culture and ELISpot assays.

In vitro viral inhibition assay. The ability of vaccine-induced CD8+ T cells to inhibit HIV-1 infection of autologous CD4+ T cells was evaluated to determine cytotoxicity. CD4+ T cells were isolated from cryopreserved PBMCs using negative magnetic bead selection (StemCell Technologies), left to stand for 24 hours and cultured in RPMI and 10% FBS. After 24 hours, the cultured CD4+ T cells were washed, counted and added to 50 ml conical tubes and spin-inoculated with HIV-1BaL at a multiplicity of infection (MOI) of 0.01. Spin-inoculation was performed by centrifugation at 1200g for 2 hours. After infection, CD4+ T cells were washed twice and cultured in RPMI and 10% FBS and IL-2 (30U/ml) for 72 hours. After 72 hours, CD8+ T cells were isolated using negative magnetic bead selection (StemCell Technologies) at the end of the PBMC-moDC co-culture, labeled with CFSE and counted. At the same time, the cultured CD4+ T cells were washed, counted and inoculated in a U-bottom 96-well plate, where the ratio of vaccine-induced CD8+ T cells in RPMI and 10% FBS was 1:1. Three days after the co-culture of CD4+ T cells and CD8+ T cells, the cells were stained with viability dyes and surface markers, and then the intracellular detection of HIV-1 Gag (Beckman Coulter) was performed using an IC fixation/permeabilization kit (BD Biosciences) according to the manufacturer's protocol. The cells were incubated at 4°C for 30 minutes with a mixture of fluorescently conjugated anti-human antibodies. The stained cells were washed twice using FACS buffer (PBS, 2% FCS, 0.1% NaN ₃ ), collected by LSR II flow cytometer using FACSDiva software (BD), and analyzed using FlowJo software version 10.2 (TreeStar). For surface staining, cells were stained with anti-CD4 BV605 clone OKT4, anti-CD8 BV650 clone RPA-T8, anti-CD3 AF700 clone SK7, anti-CD20 BV421 clone 2H7, Live-dead Aqua dye (ThermoFischer). For intracellular detection of p24, cells were fixed and permeabilized using Cytofix/cytoperm buffer (BD Biosciences) and stained with anti-HIV Gagp24 PE (KC57). All experiments were performed in duplicate or triplicate depending on cell availability. Uninfected CD4+T cells were included as negative controls, and infected CD4+T cells cultured in the absence of CD8+T cells were used as 100% infectious controls. Productive infection was considered only when >0.1% p24 Gag+CD4- cells were detected for each independent sample by flow cytometry.

result

In this example, we used the in vitro T cell elicitation assay described herein to evaluate immunogenicity and decode the response of CD8+ T cells to vaccine immunogens (schematic diagram provided in Figure 39). We focused on determining the epitopes that induce antigen-specific T cell responses within the conserved region vaccine and evaluated the effects of pre-existing responses on inducing de novo responses. DCs derived from monocytes were transduced with viral vectors containing vaccine transgenes, which can induce autologous vaccine antigen-specific T cells in vitro. This assay can facilitate the preclinical evaluation of vaccine constructs and provide a useful tool for identifying immunogenic regions within conserved region vaccines in a wide range of participants before starting large-scale vaccine trials.

We completed an assessment of the immunogenicity of Immunogen 1 (SEQ ID NOs: 105, 107, 109, and 111) in N = 93 HIV-1+ participant samples. Patient-to-patient variability was observed in the transduction efficiency of moDCs, which may reflect differences in receptor expression facilitating uptake of viral vectors, as expected in a heterogeneous human population (Figures 40-41).

The heat map depicted in Figure 40 summarizes the distribution diagram of the breadth of the immune response to each HIV protein in all 93 participants after in vitro priming with SEQ ID NO: 105, 107, 109 and 111. Our data show that in vitro vaccination leads to induction of responses to conserved regions (≥1 epitope) in 80% (74/93) of the test samples, indicating that vaccination refocuses the immune response on the conserved region. In addition, although vaccination with conserved region vaccines enhances 25% of pre-existing detectable responses, 69% of all responses identified after vaccination are de novo T cell responses, mainly for conserved Gag and Pol epitopes that are not detected under pre-vaccine conditions (Ad5 empty vector control) (Figure 42). Vaccination also significantly enhances the breadth of the immune response to Gag, Pol and Nef antigens (median total breadth of response = 5, median Gag breadth = 2, median Pol breadth = 2 and median Nef breadth = 0; Figure 40). Detailed analysis further showed that vaccination significantly increased the proportion of participants who responded to ≥3 epitopes within each of Gag, Pol, and Nef (Figure 41). Given the data from the STEP trial, we chose to evaluate responses to greater than 3 epitopes. See Janes et al., J Infect Dis (2013) 208(8): 1231-1239; ClinicalTrials.gov identifier: NCT00095576.

To determine whether vaccine-induced CD8+ T cells can eliminate HIV-1 infected cells in vitro, we performed an HIV-1 viral suppression assay. CD4+ T cells from participants were infected with HIV-1BaL and co-cultured alone or in the presence of purified vaccine or empty vector-induced CD8+ T cells. Data from 51/68 participants, all of whom showed productive infection rates (≥0.1% p24 Gag+ cells) using HIV-1BaL (Figure 43), were used in our analysis. The data in Figure 44B show that CD8+ T cells from 69% (N=35/51) of participants showed increased HIV-1BaL in vitro suppression in the presence of CD8+ T cells triggered by the vaccine (SEQ ID NO: 105, 107, 109 and 111) compared to CD8+ T cells triggered by the empty vector. To assess whether there is an association between the breadth of the response and CD8+ T cell-mediated suppression of HIV-1BaL, we assessed breadth and cytotoxicity in each participant who demonstrated productive infection rates of HIV-1BaL (≥0.1% p24 Gag+ cells). The data in Figure 44B show a lack of correlation between the % residual Gag+ cells and the breadth of Gag/Pol, which may indicate that the quality of the response is more important.

We also evaluated the immunogenicity of immunogen version 2 (SEQ ID NO: 82-89) and immunogen version 3 (SEQ ID NO: 90-93) in N = 3 participants using the moDC-T cell priming assay described above. The data summarized in Figures 45A and 45B show the breadth and magnitude of the total, Gag, Pol, and Nef immune responses to each immunogen. For immunogen version 2, in vitro priming with the vaccine sequence resulted in responses extending from 2 to 14 independent epitopes in a single donor; for immunogen version 3, the median breadth of the response was 3.

Example 10

Non-human primate (NHP) arenavirus vector data

Heterologous prime-boost in non-human primates. Simian immunodeficiency virus infection in NHPs is used as a good model to evaluate the immunogenicity of HIV vaccine vectors. To evaluate the immunogenicity of replication-competent LCMV (TT1) and replication-competent PICV (TT2) vectors (e.g., vectors as described in WO2016075250 and WO2017198726) in NHPs, we developed vectors expressing full-length SIV proteins Gag, Env or Pol derived from the SIV _sme543 strain. The amino acid sequences are provided in Table 2. Healthy rhesus macaques from India were immunized by the IM route with arenavirus vectors. Vectors expressing Gag and Env (replication-attenuated Pichinde arenavirus (TT2) and replication-attenuated LCMV arenavirus (TT1)) were administered to the left quadriceps, while vectors expressing Pol (TT2 and TT1) were administered to the right quadriceps. The doses administered were as follows: 1×10 ⁶ RCV of TT2 Gag, 1×10 ⁶ RCV of TT2 Env, 1×10 ⁶ RCV of TT2 Pol1/Pol2, 4×10 ⁶ RCV of TT1 Gag, 4×10 ⁶ RCV of TT1 Env, and 2×10 ⁶ RCV of TT1 Pol1/Pol2. In the placebo group, NHPs were administered a placebo buffer solution consisting of 10 mM HEPES, 150 mM NaCl, 20 mM glycine, and 0.1% rhesus serum albumin.

IFN-γ ELISpot assay. Pre-coated strip ELISpot plates (MabTech) were used for all ELISpot analyses. In brief, 2×10 ⁵ PBMCs isolated from whole blood were inoculated into each well at each time point analyzed. SIV smE543 peptides consisting of 15-mers overlapping by 11 amino acids spanning the SIV immunogens Gag, Env and Pol were assembled into 96-well ELISpot plates at a final concentration of 1 μg/ml. To determine the breadth of responses to Gag, Env and Pol, sub-pools of 12, 16 or 23 peptides were tested at a final concentration of 1 μg/ml, respectively. Each sub-pool had 10 peptides consisting of 15-mers overlapping by 11 amino acids. Each sample was tested in duplicate. For the positive control, 5 μg/ml PHA (Sigma) was added. The culture medium control wells contained cell culture medium reconstituted with a DMSO composition similar to that of the peptide-stimulated test wells. The plates were incubated at 37°C, 5% CO ₂ for 20-24 hours. After overnight stimulation, the cells were removed from the plate and the wells were washed three times in PBS and then three times with PBS containing 0.05% Tween. Biotinylated anti-IFN-γ detection antibodies were then added to the plate for 2 hours at room temperature. The plate was then washed three times with PBS containing 0.05% Tween, followed by the addition of streptavidin-conjugated alkaline phosphatase (AP). The wells were then washed twice with 0.05% Tween-PBS, then twice with distilled water, and then a blue developer solution was added. The plate was then incubated at room temperature for 15 minutes, and then tap water was used to stop the reaction. The wells were then dried overnight, and the spot forming units (SFU) were counted on the Immunospot ELISpot reader. All plates were set the same, and the counts were expressed as SFU per 2×10 ⁵ PBMCs. In order to determine the appropriate spot counts using the CTL monochrome immunospot counting software, multiple parameters were normalized relative to the sample. Before nonspecific spots began to appear, the signal sensitivity was set to the highest value. The spot size was reduced to the extent that all true spots were counted but artifacts were not counted. Background signal reduction was set to avoid counting artifacts. SFU was calculated as the number of spots in the test wells minus the average number of spots in the medium control wells. A positive response was defined as >3-fold SFU compared to the medium control wells and >50 spots per 1×10 ⁶ PBMCs.

SIV attack and viral load.4 weeks after the last vaccine dose (i.e., the 32nd week of the study), all animals in the single intravenous (IV) inoculation attack study were administered to allologous SIV virus groups (SIVmac251, 8.19TCID ₅₀ ). The viral sequence of the attack virus was different from the vaccine sequence (SIVsme543). The AID50 of the SIVmac251 attack stock solution estimated by the IV approach was 0.29TCID _50. After the attack, the clinical and laboratory progress and viral load of all animals were monitored to determine the peak viral load (calculated in 2 weeks after the attack) and the set point viral load (calculated in 10-40 weeks after the attack). The plasma SIV viral load represented by copies/ml was quantitatively measured by two-step RT-PCR performed in duplicate.

result

Figure 47A shows the magnitude of the SIV-specific IFN-γ response assessed by IFN-γ ELISpot. Boosting by TT1 resulted in a robust increase in the response at week 14. The peak magnitude of the response observed 2 weeks after each vaccine dose was maintained with each subsequent boost.

Figure 47B shows the classification of animals receiving heterologous TT2/TT1 vaccines as moderate or high responders. This was based on the size of the peak response after each vaccine dose being less than or greater than 1000 SFU/million PBMCs, respectively. The majority of animals (17 of 24) were high responders, with all animals showing a positive response to at least one SIV immunogen.

Figures 48A to 48D demonstrate the magnitude of the peak SIV-specific IFN-γ response at 2 weeks after each vaccine dose. Peak Gag- and Pol-specific responses were maintained after doses 2, 3, and 4. Env-specific responses increased with each subsequent dose. After four doses of heterologous vaccine, positive responses to Gag, Env, and Pol were observed in at least 21 of 24 NHPs (response rate = 87.5%).

In terms of breadth, the highest overall SIV-specific breadth was observed after dose 3 compared to after doses 2 and 4. Similarly, significantly higher Env and Pol-specific breadth was observed after dose 3 compared to after doses 2 and 4. Gag-specific breadth was significantly higher after doses 3 and 4 compared to after dose 2. These results suggest that the breadth of responses induced by the TT2/TT1 vaccine to Gag, Env, and Pol-specific immunogens was induced 2 weeks after each vaccine booster dose. See, e.g., Figures 49A to 49D.

About SIV attack and viral load, after attack, compared with placebo group, reduced viral load was observed in TT2/TT1 group (Figure 50A). The median peak viral load measured 2 weeks after attack with SIVmac251 was 6.54log10 SIV copies/ml in TT2/TT1 group and 7.2log10 SIV copies/ml in placebo group. Compared with placebo group, a significant reduction in peak viral load was observed in NHP vaccinated with TT2/TT1 vaccine (**p=0.0046, Mann-Whitney t test) (Figure 50B). The set point viral load was calculated as the average SIV viral load within 10-40 weeks after attack. The median set point VL was 5.5log10 SIV copies/ml in TT2/TT1 group and 6.7log10 SIV copies/ml in placebo group. A significant reduction of 1.2 log10 SIV copies/ml in set point viral load was observed in TT2/TT1 vaccinated NHPs compared to the placebo group (*p=0.0291, Mann-Whitney t test) (Figure 50C). These data demonstrate the prophylactic efficacy of the heterologous TT2/TT1 prime-boost regimen of PICV/LMCV replication-attenuated arenavirus vectors encoding SIV immunogens in the SIV challenge model of NHPs.

Embodiment 11

Replication-attenuated arenavirus vector containing a transgene encoding a HIV-1 immunogen version 1 fusion polypeptide

In this example, we generated a replication-attenuated arenavirus-based viral vector encoding a computationally defined polypeptide antigen containing HIV-1 conserved regions encoded by the Gag, Nef and Pol genes as transgenes. Replication-attenuated arenavirus vectors based on Pichinde virus (PICV) and lymphocytic choriomeningitis virus (LCMV) were generated. The polypeptide fragments containing the conserved regions were tandemly or connected by different methods, including direct fusion or the addition of various flexible linkers between the regions. The transgene was isolated and encoded on two viral S fragments (NP fragment and GP fragment). In the first replication-attenuated LCMV vector, the NP fragment was replaced by a polynucleotide encoding a fusion polypeptide of SEQ ID NO:98, and the GP fragment was replaced by a polynucleotide encoding a fusion polypeptide of SEQ ID NO:100. In the second replication-attenuated LCMV vector, the NP fragment was replaced by a polynucleotide encoding a fusion polypeptide of SEQ ID NO:99, and the GP fragment was replaced by a polynucleotide encoding a fusion polypeptide of SEQ ID NO:101. In the first replicating attenuated PICV vector, the NP segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 94, and the GP segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 96. In the second replicating attenuated PICV vector, the NP segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 95, and the GP segment was replaced with a polynucleotide encoding a fusion polypeptide of SEQ ID NO: 97. Figure 25 provides a schematic diagram of a fusion polypeptide.

method

Construction and generation of replication attenuated arenavirus vectors containing HIV-1 fusion polypeptide transgenic polypeptide variants. Replication attenuated arenavirus vectors expressing HIV-1 computationally defined vaccine immunogens were produced as previously described (Kallert et al., Nat Commun. (2017) 8: 15327; See also, WO2016075250 and WO2017198726). In short, cDNA sequences were synthesized and subcloned into corresponding backbone plasmids. Plasmids of each viral genome fragment and plasmids expressing viral trans-acting factors NP and L were transfected into LCMV-GP complementing cells. Cell culture supernatants were harvested and further propagated on HEK293 suspension cells to generate vector raw materials (1st generation (P1)). The vectors developed for this evaluation are listed in Table 3 and schematically depicted in Figure 25.

Table 3

Arenavirus vector encoding HIV-1 immunogen 1 fusion polypeptide

Target gene expression was assessed by detecting the conserved region of Gag (p24). We assessed transgene expression by detecting the conserved region of Gag (p24) by immunoblotting or double immunostaining (DI). For immunoblot analysis, infected HEK293 cells were harvested and lysed before applying whole-cell lysates to acrylamide gel electrophoresis. After blotting, the membrane was incubated with mouse mAb [39/5.4A] to detect HIV1 p24 (Abcam (ab9071)), rabbit pAB ERK-2 (sc-154; Santa Cruz), or antibodies for detecting successful infection (rabbit pAb anti-LCMV-NP (University of Genf; Prof. Doron Merkler); mouse mAb anti-PICV-NP (University of Basel; Prof. Daniel Pinschewer).

Stable transgene integration was evaluated by continuous passage of viral vectors. We evaluated the transgene stability of replication attenuated arenavirus vectors by continuous passage of vector raw materials in HEK293 suspension cells. To this end, the infection titer of P1 raw materials was determined by focus formation assay, and HEK293 cells were infected with a multiplicity of infection (MOI) of 0.001. Progeny viruses were harvested 72 hours after infection and titrated again. The same principle was applied to infect more passages. After up to eight passages, virus-containing supernatant samples were analyzed by transgene PCR and/or DI staining. For transgene PCR analysis, RNA was extracted from the supernatant containing the virus, and then reverse transcribed and amplified by PCR using specific HIV transgene flanking primers. The PCR product was applied to gel electrophoresis analysis to evaluate the transgene PCR fragment length as an indicator of transgene stability.

result

HIV-1 fusion polypeptide transgene expression was assessed by immunoblotting analysis. We can verify the expression of Gag/Nef/Pol antigens by immunoblotting analysis of cell lysates measured in triplicate for each vector. The results are shown in Figure 52.

Stable integration of HIV-1 fusion polypeptide transgenes was assessed by serial passage. In order to assess whether the HIV-1 immunogen 1 transgene is stably encoded in a replicating attenuated arenavirus vector after several passages, we analyzed the cell culture supernatant and performed transgene PCR analysis. The passage level at which the majority (≥50%) of transgene-specific bands still show the expected full-length size is considered to be the last passage level with stable transgene insertion. The results are shown in Table 4 and Figures 53 to 56. In addition, where applicable, supernatant samples harvested from each passage step were applied to double immunostaining (DI staining) to determine the ratio of HIV-1 Gag and arenavirus-NP expression. The combination of the two results allows a more accurate assessment of the transgenic stability of the HIV-1 immunogen 1 transgene.

We found that replicating attenuated LCMV HIV antigen encoding vectors stably encoded the transgene up to passage level 7, whereas replicating attenuated PICV HIV antigen encoding vectors stably encoded the transgene up to passage levels 4 and 6.

Table 4

Summary table for assessing genetic stability of transgenic

Vector Name Arenavirus Transgenic stability (P) TT1-HIV-GNP1/PN1 LCMV P7 TT1-HIV-GNP2/PN2 LCMV P7 TT2-HIV-GNP1/PN1 PICV P6 TT2-HIV-GNP2/PN2 PICV P4

P# represents the number of generations

The replicating attenuated LCMV HIV antigen encoding vectors stably retained the transgenes encoding the fusion polypeptides SEQ ID NOs: 98 and 100 (TT1-HIV-GNP1/PN1) and SEQ ID NOs: 99 and 101 (TT1-HIV-GNP2/PN2) until passage level 7. However, the replicating attenuated PICV vector TT2-HIV-GNP1/PN1 stably retained the transgenes encoding the fusion polypeptides SEQ ID NOs: 94 and 96 until passage level 6, and the replicating attenuated PICV vector TT2-HIV-GNP2/PN2 stably retained the transgenes encoding the fusion polypeptides SEQ ID NOs: 95 and 97 until passage level 4.

Example 12

Replication-attenuated arenavirus vector containing a transgene encoding a HIV-1 immunogen version 2 fusion polypeptide

In this example, we generated a replication-attenuated arenavirus-based viral vector encoding a shorter computationally defined polypeptide antigen HIV-1 immunogen 2 containing HIV-1 conserved regions including Gag, Nef and Pol genes as transgenes. Replication-attenuated arenavirus vectors based on Pichinde virus (PICV) and lymphocytic choriomeningitis virus (LCMV) were generated. The polypeptide fragments containing the conserved regions were tandemly or linked by different methods, including direct fusion or the addition of various flexible linkers between the regions. The transgene was isolated and encoded on two viral S fragments (NP fragment and GP fragment). In the first replication-attenuated LCMV vector, the NP fragment was replaced by a polynucleotide encoding a fusion polypeptide of SEQ ID NO:84, and the GP fragment was replaced by a polynucleotide encoding a fusion polypeptide of SEQ ID NO:88. In the second replication-attenuated LCMV vector, the NP fragment was replaced by a polynucleotide encoding a fusion polypeptide of SEQ ID NO:85, and the GP fragment was replaced by a polynucleotide encoding a fusion polypeptide of SEQ ID NO:89. In the first replicating attenuated PICV vector, the NP segment was replaced with a polynucleotide encoding the fusion polypeptide of SEQ ID NO: 82, and the GP segment was replaced with a polynucleotide encoding the fusion polypeptide of SEQ ID NO: 86. In the second replicating attenuated PICV vector, the NP segment was replaced with a polynucleotide encoding the fusion polypeptide of SEQ ID NO: 83, and the GP segment was replaced with a polynucleotide encoding the fusion polypeptide of SEQ ID NO: 87. Figure 21 provides a schematic diagram of the fusion polypeptide.

method

The construction and generation of replication attenuated arenavirus vectors containing HIV-1 immunogen 2 transgenic polypeptide variants. The replication attenuated PICV and replication attenuated LCMV virus vectors expressing HIV-1 computationally defined vaccine immunogens were produced as previously described (Kallert et al., (2017) Nat. Comm., supra). In short, the cDNA sequence was synthesized and subcloned into the corresponding backbone plasmid. The plasmids of each viral genome fragment and the plasmids expressing viral trans-acting factors NP and L were transfected into LCMV-GP complementing cells. The cell culture supernatant was harvested and further propagated on HEK293 suspension cells to generate carrier raw materials (1st generation). The carriers developed for this evaluation are listed in Table 5 and schematically depicted in Figure 21.

Table 5

Arenavirus vector encoding HIV-1 immunogen 2 fusion polypeptide

Target gene expression was assessed by detecting the conserved region of Gag (p24). We assessed transgene expression by detecting the conserved region of Gag (p24) by immunoblotting or double immunostaining (DI). For immunoblot analysis, infected HEK293 cells were harvested and lysed before applying whole-cell lysates to acrylamide gel electrophoresis. After blotting, the membrane was incubated with mouse mAb [39/5.4A] to detect HIV1 p24 (Abcam (ab9071)), rabbit pAB ERK-2 (sc-154; Santa Cruz), or antibodies for detecting successful infection (rabbit pAb anti-LCMV-NP (University of Genf; Prof. Doron Merkler); mouse mAb anti-PICV-NP (University of Basel; Prof. Daniel Pinschewer).

Stable transgene integration was assessed by serial passaging of viral vectors. We assessed the transgene stability of replication-attenuated arenavirus vectors by serial passaging of vector starting materials in HEK293 suspension cells. To this end, the infectious titer of P1 starting materials was determined by focus formation assay and HEK293 cells were infected with an MOI of 0.001. Progeny viruses were harvested 72 h after infection and titrated again. The same principle was applied to infect more passages. After a maximum of eight passages, virus-containing supernatant samples were analyzed by transgene PCR and/or DI staining. For transgene PCR analysis, RNA was extracted from the virus-containing supernatant and subsequently reverse transcribed and amplified by PCR using specific HIV transgene flanking primers. PCR products were applied to gel electrophoresis analysis to assess transgene PCR fragment length as an indicator of transgene stability.

result

HIV immunogen 2 transgene expression was assessed by immunoblotting analysis. We verified the expression of Gag/Nef/Pol antigen by immunoblotting analysis of cell lysates of four (TT1-HIV (C2)-GP1/PN1) or two (TT1-HIV (C2)-GP2/PN2) parallel determinations (left figure) of each replication attenuated LCMV vector and a representative vector stock solution (right figure) of each replication attenuated PICV vector. We determined antigen expression by staining HIV-1 Gag-Pol to level 1 (P1) and 4 (P4) of passage. When dyed with Gag antibody, cells infected with TT2-HIV (C2)-GP2/PN2 showed additional bands of about 30kDa size. The result is shown in Figure 57.

Stable integration of HIV-1 immunogen 2 transgene was evaluated by serial passage. In order to evaluate whether the HIV-1 immunogen 2 transgene is stably encoded in the replicating attenuated arenavirus vector after several passages, we analyzed the cell culture supernatant and performed transgene PCR analysis. The passage level at which the majority (≥50%) of transgene-specific bands still show the expected full-length size is considered to be the last passage level with stable transgene insertion. The results are shown in Table 6 and Figures 58 to 61. In addition, where applicable, the supernatant samples harvested from each passage step were applied to double immunostaining (DI staining) to determine the ratio of HIV-1 Gag and replicating attenuated arenavirus-NP expression. The combination of the two results allows a more accurate assessment of the transgenic stability of the HIV-1 immunogen 2 transgene.

We found that replicating attenuated LCMV HIV antigen encoding vectors stably encoded the transgene greater than passage level 8, whereas replicating attenuated PICV HIV antigen encoding vectors stably encoded the transgene up to passage levels 6 and 8.

Table 6

Summary table for assessing genetic stability of transgenic plants

P# represents the number of generations

The replicating attenuated LCMV HIV antigen encoding vector stably retained the transgene encoding the fusion polypeptides SEQ ID NOs: 84 and 88 (TT1-HIV(C2)-GP1/PN1) and SEQ ID NOs: 85 and 89 (TT1-HIV(C2)-GP2/PN2) for greater than passage level 8. However, the replicating attenuated PICV vector TT2-HIV(C2)-GP1/PN1 stably retained the transgene encoding the fusion polypeptides SEQ ID NOs: 82 and 86 until passage level 8, while the replicating attenuated PICV vector TT2-HIV(C2)-GP2/PN2 stably retained the transgene encoding the fusion polypeptides SEQ ID NOs: 83 and 87 for greater than passage level 6.

Example 13

Vaccine and immunomodulator combinations

In non-human primates, administration of adenoviral vector-based vaccines encoding SIV immunogens in combination with checkpoint inhibitors such as αPD1 antibodies showed an increase in the persistence of vaccine-induced T cell responses, while the combination with αCTLA4 antibodies showed an increase in the size of T cell responses. See, Pan et al., Front Immunol. (2018) 9: 2415; and Loffredo et al., Poster P55, "Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting and Pre-Conference Programs"; November 8-12, 2017; National Harbor, MD). FLT3L-FLT3 interactions lead to the expansion and maturation of dendritic cells. Arenavirus-based vectors show dendritic cell tropism (Flatz et al., Nat Med (2010) 16 (3): 339-45). Therefore, we hypothesized that combining DC expansion with arenavirus vectors would enhance the immunogenicity observed with the TT2/TT1 replication-attenuated PICV/LCMV arenavirus vector prime-boost regimen.

method

Figure 62 provides a schematic diagram of the prime-boost immunization scheme in non-human primates (NHPs) using arenavirus vectors (TT2/TT1) in combination with immunomodulators. Healthy rhesus macaques of Indian origin were immunized with arenavirus vectors by intramuscular (IM) route and immunomodulators by intravenous (IV) route, thirteen (13) NHPs per group. Vectors TT2 (replication-attenuated picinder virus (PICV)) and TT1 (replication-attenuated LCMV)) expressing Gag and Env were administered to the left quadriceps, while vectors expressing Pol (TT2 and TT1) were administered to the right quadriceps. The doses administered were as follows: 1×10 ⁶ replication-competent viral particles (RCV) of TT2 Gag, Env, and Pol1/Pol2 vectors, 4×10 ⁶ RCV of TT1 Gag, Env, and 2×10 ⁶ RCV of TT1 Pol1/Pol2.

The heterologous TT2/TT1 vaccine was administered every 4 weeks for a total of 4 doses, either alone (Group 1, vaccine) or in combination with a checkpoint inhibitor (αPD1 antibody in Group 2, or αCTLA4 antibody in Group 3, each at 10 mg/kg) immediately after the vaccine. The FLT3L-Fc FLT3 agonist was administered 1 week before the vaccine dose (Group 4, 0.3 mg/kg).

IFN-γ ELISpot assay was performed as described in Example 10.

result

Figure 63 shows the size of SIV-specific IFN-γ responses assessed by IFN-γ ELISpot in peripheral blood. Compared with the TT2/TT1 vaccine alone, the addition of αCTLA4 antibodies together with TT2/TT1 vaccines resulted in a robust and sustained increase in the size of SIV-specific responses (p<0.05 at weeks 4, 6, 8, 10, 12, 14, and 16; two-way ANOVA with Dunnett's multiple comparison test). The combination with FLT3L-Fc FLT3 agonists also resulted in a significant increase in the size of SIV-specific responses after boosting (p<0.05 at weeks 8, 10, and 14; two-way ANOVA with Dunnett's multiple comparison test). The administration of αPD1 antibodies had no effect on the size of vaccine-induced T cell responses. Both the checkpoint inhibitor αCTLA4 antibody and the DC agonist FLT3L-Fc induced a significant increase in the peak size of T cell responses, which is consistent with the conclusion that vaccine-induced responses are enhanced by these immunomodulators.

About breadth, Figure 64 shows the highest total SIV-specific breadth observed 2 weeks after the last vaccine dose in the group receiving the vaccine in combination with αCTLA4 antibody or FLT3L-Fc FLT3 agonist. The administration of TT2/TT1 vaccine in combination with FLT3L-FcFLT3 agonist resulted in a significant increase in the breadth of Gag, Env and Pol specific responses. The administration of TT2/TT1 vaccine in combination with αCTLA4 antibody resulted in a significant increase in the breadth of Env and Pol specific responses. In summary, these results are consistent with the conclusion that the combination of heterologous TT2/TT1 vaccine with αCTLA4 antibody or FLT3L-Fc FLT3 agonist results in a significant increase in the breadth of SIV-specific T cell responses.

It should be understood that the embodiments and implementations described herein are for illustrative purposes only, and those skilled in the art will propose various modifications or changes based on these embodiments and implementations, and include these modifications or changes within the spirit and authority of this application and the scope of the appended claims. All publications, patents and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

Claims (504)

1. A fusion polypeptide comprising polypeptides of one or more human immunodeficiency virus-1 (HIV-1) proteins encoded by two or more HIV genes selected from gag, pol and nef. polypeptide fragment. 2. The fusion polypeptide according to claim 1, wherein the plurality of polypeptide fragments comprise or consist of polypeptide fragments encoded by HIV-1 genes pol and nef, and do not comprise HIV-1 genes env, Polypeptide fragments encoded by tat, reY, vpr, vif and vpu. 3. The fusion polypeptide according to any one of claims 1 to 2, wherein the plurality of polypeptide fragments comprise or consist of polypeptide fragments encoded by HIV-1 genes gag, pol and nef, and do not Contains polypeptide fragments encoded by HIV-1 genes env, tat, rev, vpr, vif and vpu. 4. The fusion polypeptide according to any one of claims 1 to 3, wherein the polypeptide fragment is derived from a conserved region in a viral proteome sequence population. 5. The fusion polypeptide of claim 4, wherein the conserved region is greater than 80%, 81%, 82%, 83%, 84%, 85% conserved between HIV-1 species in an inter-patient population ,86%,87%,88%,89%,90%,91%,92%,93%,94%,95%, 96%, 97%, 98% or 99%. 6. The fusion polypeptide of any one of claims 4 to 5, wherein the conserved region is in one or more of HIV-1 clades A-K, such as clades A, B, C, D and G. are conserved between recombinant forms of one or more of or one or more of HIV-1 clades A-K and combinations thereof. 7. The fusion polypeptide of any one of claims 1 to 6, comprising at least 4 and up to 6 polypeptide fragments, for example, 4, 5 or 6 polypeptide fragments. 8. The fusion polypeptide of any one of claims 1 to 7, wherein each polypeptide fragment is at least 10 amino acids in length, and is at most about 225 amino acids in length, such as at least 10 amino acids in length, and is in length For up to 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220 or 225 amino acids. 9. The fusion polypeptide according to any one of claims 1 to 8, wherein the full length of the fusion polypeptide comprises at least about 330 amino acids and at most about 550 amino acids, such as at least about 330 amino acids and at most about 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545 or 550 amino acids. 10. The fusion polypeptide according to any one of claims 1 to 9, wherein the full length of the fusion polypeptide is no longer than 550 amino acids, such as no longer than 545, 540, 535, 530, 525, 520, 515, 510 ,505,500,495,490,485,480,475,470,465,460,455,450,445,440,435,430,425,420,415,410,405,400,390,385,380 , 375, 370, 365, 360, 355, 350, 345, 340, 335 or 330 amino acids. 11. The fusion polypeptide of any one of claims 1 to 10, wherein the full length of the fusion polypeptide comprises at least 350 amino acids and at most 385 amino acids, such as at least 350 amino acids and at most 365 amino acids. 12. The fusion polypeptide of any one of claims 1 to 11, wherein each polypeptide fragment comprises or consists of one or more predicted T cell epitopes. 13. The fusion polypeptide according to any one of claims 1 to 12, said fusion polypeptide comprising one or more polypeptide fragments that are related to one or more species, for example within a single subject or between multiple patients. Multiple human HLA class I alleles (eg, 1, 2, 3, 4, 5, or 6 alleles) bind to or are presented by the alleles. 14. The fusion polypeptide of any one of claims 1 to 13, comprising one or more polypeptide fragments that bind to or are presented by at least a human A*0201 HLA class I molecule . 15. The fusion polypeptide of any one of claims 1 to 14, comprising one or more polypeptide fragments that are processed intracellularly and produced, for example, by one or more cells within a single subject. Individual HLA class II alleles (eg, 1, 2, 3, 4, 5, or 6 alleles) are presented. 16. The fusion polypeptide of any one of claims 1 to 15, wherein one or more of the polypeptide fragments are contiguous or fused to an adjacent fragment. 17. The fusion polypeptide of any one of claims 1 to 15, wherein one or more of the polypeptide fragments is bound to an adjacent fragment via one or more peptide linkers. 18. The fusion polypeptide of claim 17, wherein the one or more peptide linkers are selected from the group consisting of polyalanine, polyglycine, Gln-Glu-Glu (QEE) (SEQ ID NO: 51), lysine ( L), Isoleucine (I), Leu-Ile (LI), Lys-Ile-Leu (KIL) (SEQ ID NO: 52), Leu-Ile-Lys (LIK) (SEQ ID NO: 53), One or Many. 19. The fusion polypeptide of claim 18, wherein the flexible linker is selected from the group consisting of Gln-Glu-Glu (QEE) (SEQ ID NO: 51), Lysine (L), Isoleucine (I), Leu -Ile (LI), Lys-Ile-Leu (KIL) (SEQ ID NO: 52), Leu-Ile-Lys (LIK) (SEQ ID NO: 53), Pro-Pro-Val (PPV) (SEQ ID NO :54) and Ser-Glu-Gly(SEG) (SEQ ID NO:55). 20. The fusion polypeptide of claim 18, wherein the flexible linker comprises a polyalanine linker or a polyglycine linker. 21. The fusion polypeptide according to any one of claims 18 to 20, wherein the polyalanine linker comprises 2 or 3 consecutive alanine residues such as AA, AAA (SEQ ID NO: 48), AAY ( SEQ ID NO: 49) or AAX or consisting of said consecutive alanine residues, where X is any amino acid (e.g., A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, Y) (SEQ ID NO: 50). 22. The fusion polypeptide of claim 18, wherein the flexible linker comprises GG, GGS (SEQ ID NO: 57), GSG (SEQ ID NO: 58) or GGGS (SEQ ID NO: 59) or consists of the Item composition. 23. The fusion polypeptide of claim 18, wherein the cleavable linker is selected from the group consisting of 2A cleavable peptides (e.g., foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine Jieshen virus-1 (P2A) and Triton virus (T2A)), furin recognition/cleavage sequences (e.g., RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), and RRKR (SEQ ID NO: 62)), and Combinations, derivatives or variations thereof. 24. The fusion polypeptide of claim 23, wherein the cleavable linker comprises or consists of a furin recognition/cleavage site selected from: RAKR (SEQ ID NO:60), REKR (SEQ ID NO:61) and RRKR (SEQ ID NO:62). 25. The fusion polypeptide according to any one of claims 23 to 24, wherein the cleavable linker comprises ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66) or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67) at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99 % identical amino acid sequences either consist of the amino acid sequences described, or comprise ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66) or the amino acid sequence of or consisting of the amino acid sequence of EGRGSLLTCGDVEENPGP (SEQ ID NO: 67). 26. The fusion polypeptide according to any one of claims 1 to 25, said fusion polypeptide comprising two, three, four, five, six or more of said polypeptide fragments, said polypeptide fragments Contains corresponding to Gag 1-53, Gag 147-369, Pol 56-117, Pol 129-320, Pol 367-431, Pol 542-606, Pol 586-606, Pol 683-708, Pol747-827, Pol 840- 909, Pol 840-920, Pol 932-1003, Nef 64-76, Nef 64-99 or Nef 117-148 or consisting of the amino acid residues, wherein the Gag, Pol and Nef amino acid position numbers Correspond to SEQ ID NO: 1, 2 and 3 respectively. 27. The fusion polypeptide according to any one of claims 1 to 26, wherein the fusion polypeptide does not comprise a polypeptide corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321- 366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116 and Nef 149-206 or any polypeptide thereof or fragments or subsequences thereof Fragment, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NO: 1, 2 and 3 respectively. 28. The fusion polypeptide according to any one of claims 1 to 27, wherein the fusion polypeptide does not comprise the amino acid sequence having SEQ ID NO: 35-47 or a fragment or subsequence thereof, or is identical to SEQ ID NO: 35-47. Any of 47 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94 %, Any polypeptide fragment that is 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence or a fragment or subsequence thereof. 29. The fusion polypeptide according to any one of claims 1 to 28, comprising two, three, four, five, six or more selected from SEQ ID NOs: 4-33 polypeptide fragment. 30. The fusion polypeptide according to any one of claims 1 to 29, said fusion polypeptide comprising or consisting of the following polypeptide fragments, wherein the Gag, Pol and Nef amino acid position numbers respectively correspond to SEQ ID NO :1, 2 and 3: a) Corresponding to the following amino acid residues: Gag 1-53, Gag 147-369, Pol 683-708 and Nef 117-148; b) Corresponding to the following amino acid residues: Pol 56-117, Pol 129-320, Pol 367-431 and Nef 64-99; c) Corresponding to the following amino acid residues: Pol 542-606, Pol 747-827, Pol 840-920, Pol 932-1003 and Nef64-99; d) Corresponding to the following amino acid residues: Gag 1-53, Gag 147-369, Pol 683-708, Pol 747-827, Pol 840-920 and Nef 117-148; e) Corresponding to the following amino acid residues: Pol 56-117, Pol 129-320, Pol 367-431, Pol 542-606, Pol 932-1003 and Nef 64-99; f) Corresponding to the following amino acid residues: Gag 147-369, Pol 586-606, Pol 683-708 and Pol 840-920; g) Corresponding to the following amino acid residues: Pol 129-320, Pol 747-827, Pol 932-1003 and Nef 64-76; or h) Corresponds to the following amino acid residues: Gag: 147-369, Pol 747-827, Pol 840-909 and Nef 64-76. 31. The fusion polypeptide according to any one of claims 1 to 30, said fusion polypeptide comprising or consisting of the following polypeptide fragments: a) SEQ ID NO: 4, 6, 18 and 32, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 4, 6, 18 and 32 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; b) SEQ ID NO: 5, 7, 19 and 33, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; c) SEQ ID NO: 8, 10, 12 and 30, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with SEQ ID NO: 8, 10, 12 and 30. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; d) SEQ ID NO: 9, 11, 13 and 31, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 9, 11, 13 and 31 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; e) SEQ ID NO: 14, 20, 24, 26 and 30, or at least 80%, 81%, 82%, 83%, 84%, 85% with SEQ ID NO: 14, 20, 24, 26 and 30 respectively , 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; f) SEQ ID NO: 15, 21, 25, 27 and 31, or at least 80%, 81%, 82%, 83%, 84%, 85% with SEQ ID NO: 15, 21, 25, 27 and 31 respectively , 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; g) SEQ ID NO: 4, 6, 18, 20, 24 and 32, or at least 80%, 81%, 82%, 83%, 84 with SEQ ID NO: 4, 6, 18, 20, 24 and 32 respectively %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments ; h) SEQ ID NO: 5, 7, 19, 21, 25 and 33, or at least 80%, 81%, 82%, 83%, 84 with SEQ ID NO: 5, 7, 19, 21, 25 and 33 respectively %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments ; i) SEQ ID NO: 8, 10, 12, 14, 26 and 30, or at least 80%, 81%, 82%, 83%, 84 with SEQ ID NO: 8, 10, 12, 14, 26 and 30 respectively %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments ; j) SEQ ID NO: 9, 11, 13, 15, 27 and 31, or at least 80%, 81%, 82%, 83%, 84 with SEQ ID NO: 9, 11, 13, 15, 27 and 31 respectively %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments ; k) SEQ ID NO: 6, 16, 18 and 24, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; l) SEQ ID NO: 7, 17, 19 and 25, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 7, 17, 19 and 25 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; m) SEQ ID NO: 10, 20, 26 and 28, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; n) SEQ ID NO: 11, 21, 27 and 29, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 11, 21, 27 and 29. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; o) SEQ ID NO: 6, 20, 22 and 28, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with SEQ ID NO: 6, 20, 22 and 28 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; p) SEQ ID NO: 7, 21, 23 and 29, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 7, 21, 23 and 29 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; q) SEQ ID NO: 6, 16, 18 and 24, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 6, 16, 18 and 24 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; r) SEQ ID NO: 7, 17, 19 and 25, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with SEQ ID NO: 7, 17, 19 and 25 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; s) SEQ ID NO: 10, 20, 26 and 28, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 10, 20, 26 and 28. or 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; or t) SEQ ID NO: 11, 21, 27 and 29, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 11, 21, 27 and 29 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments. 32. The fusion polypeptide according to any one of claims 1 to 31, said fusion polypeptide comprising in order from the N terminus to the C terminus the following polypeptide fragments optionally combined or connected by one or more linkers or consisting of the following Polypeptide fragment composition: a) SEQ ID NO: 6, 4, 18 and 32, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; b) SEQ ID NO: 7, 5, 33 and 19, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 7, 5, 33 and 19 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; c) SEQ ID NO: 12, 30, 8 and 10, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with SEQ ID NO: 12, 30, 8 and 10 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; d) SEQ ID NO: 9, 31, 13 and 11, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 9, 31, 13 and 11 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; e) SEQ ID NO: 14, 26, 20, 30 and 24, or at least 80%, 81%, 82%, 83%, 84%, 85% with SEQ ID NO: 14, 26, 20, 30 and 24 respectively , 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; f) SEQ ID NO: 15, 31, 21, 27 and 25, or at least 80%, 81%, 82%, 83%, 84%, 85% with SEQ ID NO: 15, 31, 21, 27 and 25 respectively , 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; g) SEQ ID NO: 32, 18, 4 and 6, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; h) SEQ ID NO: 7, 33, 5 and 19, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 7, 33, 5 and 19 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; i) SEQ ID NO: 8, 30, 12 and 10, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; j) SEQ ID NO: 13, 31, 9 and 11, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with SEQ ID NO: 13, 31, 9 and 11 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; k) SEQ ID NO: 26, 30, 14, 20 and 24, or at least 80%, 81%, 82%, 83%, 84%, 85% with SEQ ID NO: 26, 30, 14, 20 and 24 respectively , 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; 1) SEQ ID NO: 31, 27, 15, 25 and 21, or at least 80%, 81%, 82%, 83%, 84%, 85% with SEQ ID NO: 31, 27, 15, 25 and 21 respectively , 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; m) SEQ ID NO: 24, 6, 4, 20, 18 and 32, or at least 80%, 81%, 82%, 83%, 84 with SEQ ID NO: 24, 6, 4, 20, 18 and 32 respectively %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments ; n) SEQ ID NO: 6, 20, 4, 24, 32 and 18, or at least 80%, 81%, 82%, 83%, 84 respectively with SEQ ID NO: 6, 20, 4, 24, 32 and 18 %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments ; o) SEQ ID NO: 7, 21, 5, 25, 33 and 19, or at least 80%, 81%, 82%, 83%, 84 with SEQ ID NO: 7, 21, 5, 25, 33 and 19 respectively %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments ; p) SEQ ID NO: 8, 30, 14, 12, 26 and 10, or at least 80%, 81%, 82%, 83%, 84 with SEQ ID NO: 8, 30, 14, 12, 26 and 10 respectively %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments ; q) SEQ ID NO: 8, 12, 30, 26, 14 and 10, or at least 80%, 81%, 82%, 83%, 84 with SEQ ID NO: 8, 12, 30, 26, 14 and 10 respectively %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments ; r) SEQ ID NO: 9, 13, 31, 27, 15 and 11, or at least 80%, 81%, 82%, 83%, 84 with SEQ ID NO: 9, 13, 31, 27, 15 and 11 respectively %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments ; s) SEQ ID NO: 20, 32, 24, 4, 6 and 18, or at least 80%, 81%, 82%, 83%, 84 respectively with SEQ ID NO: 20, 32, 24, 4, 6 and 18 %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments ; t) SEQ ID NO: 7, 25, 19, 5, 33 and 21, or at least 80%, 81%, 82%, 83%, 84 with SEQ ID NO: 7, 25, 19, 5, 33 and 21 respectively %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments ; u) SEQ ID NO: 26, 30, 12, 14, 8 and 10, or at least 80%, 81%, 82%, 83%, 84 with SEQ ID NO: 26, 30, 12, 14, 8 and 10 respectively %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments ; v) SEQ ID NO: 15, 31, 9, 27, 13 and 11, or at least 80%, 81%, 82%, 83%, 84 with SEQ ID NO: 15, 31, 9, 27, 13 and 11 respectively %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments ; w) SEQ ID NO: 24, 6, 16 and 18, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; x) SEQ ID NO: 7, 19, 17 and 25, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with SEQ ID NO: 7, 19, 17 and 25 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; y) SEQ ID NO: 24, 16, 6 and 18, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 24, 16, 6 and 18 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; z) SEQ ID NO: 7, 25, 17 and 19, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; aa) SEQ ID NO: 26, 20, 10 and 28, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; bb) SEQ ID NO: 21, 27, 11 and 29, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 21, 27, 11 and 29 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; cc) SEQ ID NO: 26, 10, 20 and 28, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID No: 26, 10, 20 and 28 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; dd) SEQ ID NO: 11, 27, 21 and 29, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 11, 27, 21 and 29 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; ee) SEQ ID NO: 22, 6, 20 and 28, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 22, 6, 20 and 28 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; ff) SEQ ID NO: 23, 7, 21 and 29, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 23, 7, 21 and 29 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; gg) SEQ ID NO: 22, 20, 6 and 28, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 22, 20, 6 and 28 or 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments; or hh) SEQ ID NO: 7, 21, 23 and 29, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequence fragments. 33. The fusion polypeptide of any one of claims 1 to 32, comprising or consisting of: SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227 The amino acid sequence of any one of them, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acids sequence. 34. The fusion polypeptide of any one of claims 1 to 33, comprising or consisting of: SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223 The amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223 is at least 80%, 81%, 82%, 83%, 84 %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence . 35. A composite fusion polypeptide comprising at least a first fusion polypeptide and a second fusion polypeptide independently selected from the fusion polypeptide according to any one of claims 1 to 34. 36. The composite fusion polypeptide of claim 35, comprising or consisting of the following first and second fusion polypeptides, optionally bound or connected through one or more linkers: A fusion polypeptide of SEQ ID NO: 70 and 71, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 70 and 71, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 72 and 73, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 72 and 73, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 74 and 75, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 74 and 75, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 76 and 77, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 76 and 77, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 78 and 79, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 78 and 79, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 80 and 81, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 80 and 81, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides A fusion polypeptide of SEQ ID NOs: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 92 and 93, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 92 and 93, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 96 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 220 and 221, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; or A fusion polypeptide of SEQ ID NO: 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 37. The composite fusion polypeptide according to any one of claims 35 to 36, comprising in order from the N-terminus to the C-terminus the following first fusions, optionally combined or connected by one or more linkers The polypeptide and the second fusion polypeptide may alternatively consist of the following fusion polypeptides: A fusion polypeptide of SEQ ID NO: 70 and 71, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 70 and 71, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 71 and 70, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 71 and 70, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 72 and 73, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 72 and 73, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 73 and 72, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 73 and 72, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 74 and 75, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 74 and 75, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 75 and 74, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 75 and 74, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 76 and 77, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 76 and 77, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 77 and 76, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 77 and 76, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 78 and 79, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 78 and 79, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 79 and 78, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 79 and 78, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 80 and 81, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 80 and 81, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 81 and 80, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 81 and 80, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 84, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 84, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 89 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 89 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 84, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 84, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 84, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 89 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 89 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 101 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 101 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 90 and 91, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 91 and 90, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 91 and 90, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 92 and 93, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 92 and 93, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 93 and 92, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 93 and 92, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 94, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 94, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 96 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 97 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 97 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 96 and 94, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 96 and 94, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 97 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 97 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 220 and 221, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 221 and 220, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 221 and 220, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 100 and 98, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 98, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 101 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 101 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 98, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 98, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; or A fusion polypeptide of SEQ ID NO: 101 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 101 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 38. The composite fusion polypeptide of any one of claims 35 to 37, wherein the first fusion polypeptide and the second fusion polypeptide are joined or linked by a cleavable linker. 39. The composite fusion polypeptide according to any one of claims 35 to 38, wherein the first fusion polypeptide and the second fusion polypeptide are combined or connected by a cleavable linker selected from the group consisting of: 2A cleavable peptide ( For example, foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine Tessin virus-1 (P2A), and Triton virus (T2A)), furin recognition/cleavage sequences (e.g., RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and RRKR (SEQ ID NO: 62)) and combinations, derivatives or variants thereof. 40. The composite fusion polypeptide of any one of claims 35 to 39, wherein the first fusion polypeptide and the second fusion polypeptide are combined or connected by a furin recognition/cleavage site selected from : RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and RRKR (SEQ ID NO: 62). 41. The composite fusion polypeptide of any one of claims 35 to 40, wherein the first fusion polypeptide and the second fusion polypeptide are combined or connected by a 2A cleavable peptide comprising the following Or consisting of: ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66) or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67) Amino acid sequence, or with ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66) or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67) ) Amino acid sequences that are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical. 42. The composite fusion polypeptide according to any one of claims 35 to 41, comprising or consisting of: SEQ ID NOs: 105-112, 200-209, 222-223 and 227 The amino acid sequence of any one, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences. 43. The composite fusion polypeptide according to any one of claims 35 to 42, comprising or consisting of: the amino acid sequence of any one of SEQ ID NO: 209, 222, 223 and 227 , or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences. 44. A composite fusion polypeptide comprising or consisting of the following: the amino acid sequence of any one of SEQ ID NO: 105-112, 200-209, 222-223 and 227, or the same as SEQ ID NO. NO: at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% any of 105-112, 200-209, 222-223 and 227 , 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences. 45. The composite fusion polypeptide according to claim 44, said composite fusion polypeptide comprising or consisting of: the amino acid sequence of any one of SEQ ID NO: 209, 222, 223 and 227, or the same as SEQ ID NO : any one of 209, 222, 223 and 227 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences. 46. The fusion polypeptide according to any one of claims 1 to 45 or the composite fusion polypeptide according to any one of claims 35 to 44, further comprising an N-terminal signal peptide or leader sequence. 47. The fusion polypeptide or composite fusion polypeptide of claim 46, wherein the signal peptide or leader sequence is selected from the group consisting of serum proteins, cytokines, chemokines, chaperones, invariant proteins and proteins that guide proteins to lysosomes. Source protein for body compartment proteins. 48. The fusion polypeptide or composite fusion polypeptide according to any one of claims 46 to 47, wherein the signal peptide or leader sequence is derived from a source protein selected from: colony stimulating factor 2 (CSF2, GM-CSF), Tissue plasminogen activator (PLAT, t-PA), C-C motif chemokine ligand 7 (CCL7, MCP-3), C-X-C motif chemokine ligand 10 (CXCL10, IP-10), Catenin β1 (CTNNB1), CD74 (p33; DHLAG; HLADG; Ia-GAMMA, invariant chain), serum albumin (ALB), polyubiquitin B/C (UBB/UBC), calreticulin (CALR), Vesicular stomatitis virus G protein (VSV-G), lysosome-associated membrane protein 1 (LAMP-1) and lysosome-associated membrane protein 2 (LAMP-2). 49. The fusion polypeptide or composite fusion polypeptide according to any one of claims 46 to 48, wherein the signal peptide or leader sequence is selected from the amino acid sequence of any one of SEQ ID NO: 115-126, or with Any one of SEQ ID NOs: 115-126 is a nucleic acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical. 50. The fusion polypeptide and composite fusion polypeptide according to any one of claims 46 to 49, wherein the fusion polypeptide and the composite fusion polypeptide are recombinantly produced or chemically synthesized. 51. The fusion polypeptide and composite fusion polypeptide according to any one of claims 46 to 50, wherein the fusion polypeptide and the composite fusion polypeptide are capable of inducing, promoting or stimulating an immune response in humans. 52. The fusion polypeptide and composite fusion polypeptide of any one of claims 46 to 51, wherein the fusion polypeptide and the composite fusion polypeptide are capable of inducing, promoting or stimulating a human immune response to HIV-1. 53. The fusion polypeptide and composite fusion polypeptide according to any one of claims 46 to 52, wherein the fusion polypeptide and the composite fusion polypeptide are capable of inducing, promoting or stimulating dendritic cells (DC) selected from the group consisting of monocyte-derived ), proliferation and/or activation of one or more cell types, CD8+ T cells and CD4+ T cells. 54. A polynucleotide comprising a nucleic acid sequence encoding one or more fusion polypeptides or composite fusion polypeptides according to any one of claims 1 to 53. 55. The polynucleotide of claim 54, wherein the polynucleotide comprises cDNA, mRNA, self-amplifying RNA (SAM, saRNA), self-replicating RNA or self-amplifying replicon RNA (RepRNA). 56. The polynucleotide of claim 55, wherein the polynucleotide comprises a self-replicating or self-amplifying alphavirus replicon. 57. The polynucleotide of any one of claims 54 to 56, comprising the nucleic acid sequence of any one of SEQ ID Nos: 130-167, 210-219 and 225-226, or At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 with any one of SEQ ID NOs: 130-167, 210-219 and 225-226 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical nucleic acid sequences. 58. The polynucleotide of any one of claims 54 to 57, comprising SEQ ID NO: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155 , 158, 225 and 226, or with the nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226 Any one of at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95 %, 96%, 97%, 98% or 99% identical nucleic acid sequences. 59. A liposome complex, such as a lipid nanoparticle (LNP), comprising a polynucleotide according to any one of claims 54 to 58. 60. An expression cassette comprising the polynucleotide of any one of claims 54 to 57 operably linked to one or more regulatory sequences. 61. The expression cassette of claim 60, wherein the polynucleotide is operably linked to and under the control of a constitutive promoter. 62. The expression cassette according to any one of claims 60 to 61, wherein the promoter is selected from the group consisting of CMV promoter, CAG promoter and EF1a promoter. 63. A vector comprising one or more polynucleotides according to any one of claims 54 to 57, or an expression cassette according to any one of claims 60 to 62. 64. The vector of claim 63, comprising or consisting of one or more polynucleotides encoding one or more fusion polypeptides from the N terminus to the C terminus. The termini comprise, in order, the following polypeptide fragments optionally bound or linked through one or more linkers: · SEQ ID NO: 6, 4, 16 and 26, and SEQ ID NO: 7, 5, 27 and 17; · SEQ ID NO: 12, 24, 8 and 10, and SEQ ID NO: 9, 25, 13 and 11; · SEQ ID NO: 14, 22, 18, 24 and 20, and SEQ ID NO: 15, 25, 19, 23 and 21; · SEQ ID NO: 26, 16, 4 and 6, and SEQ ID NO: 7, 27, 5 and 17; · SEQ ID NO: 8, 24, 12 and 10, and SEQ ID NO: 13, 25, 9 and 11; · SEQ ID NO: 22, 24, 14, 18 and 20, and SEQ ID NO: 25, 23, 15, 21 and 19; · SEQ ID NO: 20, 6, 4, 18, 16 and 26, and SEQ ID NO: 7, 19, 5, 21, 27 and 17; · SEQ ID NO: 8, 24, 14, 12, 22 and 10, and SEQ ID NO: 9, 13, 25, 23, 15 and 11; · SEQ ID NO: 18, 26, 20, 4, 6 and 16, and SEQ ID NO: 7, 21, 17, 5, 27 and 19; · SEQ ID NO: 22, 24, 12, 14, 8 and 10, and SEQ ID NO: 15, 25, 9, 23, 13 and 11; · SEQ ID NO: 24, 6, 4, 20, 18 and 32, and SEQ ID NO: 8, 30, 14, 12, 26 and 10; · SEQ ID NO: 24, 6, 4, 20, 18 and 32, and SEQ ID NO: 7, 21, 5, 25, 33 and 19; · SEQ ID NO: 24, 6, 4, 20, 18 and 32, and SEQ ID NO: 8, 30, 14, 12, 26 and 10; · SEQ ID NO: 8, 30, 14, 12, 26 and 10, and SEQ ID NO: 9, 13, 31, 27, 15 and 11; · SEQ ID NO: 6, 20, 4, 24, 32 and 18, and SEQ ID NO: 8, 12, 30, 26, 14 and 10; · SEQ ID NO: 7, 21, 5, 25, 33 and 19, and SEQ ID NO: 9, 13, 31, 27, 15 and 11; · SEQ ID NO: 20, 32, 24, 4, 6 and 18, and SEQ ID NO: 26, 30, 12, 14, 8 and 10; · SEQ ID NO: 7, 25, 19, 5, 33 and 21, and SEQ ID NO: 15, 31, 9, 27, 13 and 11; · SEQ ID NO: 24, 6, 16 and 18, and SEQ ID NO: 26, 20, 10 and 28; · SEQ ID NO: 24, 6, 16 and 18, and SEQ ID NO: 26, 10, 20 and 28; · SEQ ID NO: 24, 6, 16 and 18, and SEQ ID NO: 7, 25, 17 and 19; · SEQ ID NO: 7, 19, 17 and 25, and SEQ ID NO: 21, 27, 11 and 29; · SEQ ID NO: 24, 16, 6 and 18, and SEQ ID NO: 27, 11, 21 and 29; · SEQ ID NO: 7, 25, 17 and 19, and SEQ ID NO: 11, 27, 21 and 29; · SEQ ID NO: 7, 25, 17 and 19, and SEQ ID NO: 21, 27, 11 and 29; · SEQ ID NO: 22, 6, 20 and 28, and SEQ ID NO: 23, 7, 21 and 29; · SEQ ID NO: 22, 20, 6 and 28, and SEQ ID NO: 7, 21, 23 and 29; · SEQ ID NO: 26, 10, 20 and 28, and SEQ ID NO: 21, 27, 11 and 29; ·SEQ ID NO: 22, 6, 16, 20, 18, 28, 26 and 10; or • SEQ ID NO: 7, 21, 19, 17, 27, 25, 29 and 11. 65. The vector of any one of claims 63 to 64, comprising one or more polynucleotides encoding one or more fusion polypeptides comprising or consisting of: The amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or the same as SEQ ID NOs: 70-101, 105-112, 200-209, 222- Any of 223 and 227 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% , 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences. 66. The vector of any one of claims 63 to 65, said vector comprising one or more polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides, said fusion polypeptides or composite fusions The polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or the same as SEQ ID NOs: 82-83, 85- Any of 87, 98-101, 209 and 222-223 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences. 67. The vector of any one of claims 63 to 66, comprising one or more polynucleotides encoding, optionally via one or more linkers The following first fusion polypeptide and second fusion polypeptide are combined or linked: A fusion polypeptide of SEQ ID NO: 70 and 71, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 70 and 71, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 72 and 73, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 72 and 73, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 74 and 75, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 74 and 75, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 76 and 77, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 76 and 77, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 78 and 79, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 78 and 79, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 80 and 81, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 80 and 81, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 90 and 91, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 92 and 93, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 92 and 93, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 96 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 220 and 221, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; or A fusion polypeptide of SEQ ID NO: 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 68. The vector according to any one of claims 63 to 67, said vector comprising one or more polynucleotides encoding in sequence from the N-terminus to the C-terminus and The following first and second fusion polypeptides, optionally bound or linked by one or more linkers: A fusion polypeptide of SEQ ID NO: 70 and 71, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 70 and 71, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 71 and 70, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 71 and 70, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 72 and 73, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 72 and 73, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 73 and 72, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 73 and 72, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 74 and 75, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 74 and 75, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 75 and 74, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 75 and 74, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 76 and 77, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 76 and 77, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 77 and 76, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 77 and 76, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 78 and 79, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 78 and 79, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 79 and 78, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 79 and 78, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 80 and 81, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 80 and 81, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 81 and 80, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 81 and 80, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 84, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 84, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 89 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 89 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 84, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 84, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 84, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 89 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 89 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 90 and 91, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 91 and 90, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 91 and 90, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 92 and 93, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 92 and 93, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 93 and 92, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 93 and 92, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 94, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 94, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 96 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 97 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 97 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 96 and 94, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 96 and 94, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 97 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 97 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 220 and 221, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 221 and 220, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 221 and 220, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 100 and 98, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 98, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 101 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 101 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 98, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 98, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; or A fusion polypeptide of SEQ ID NO: 101 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 101 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 69. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 82 and 83, or at least 80%, 81%, 82% to any one of SEQ ID NO: 82 and 83, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 70. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 84 and 85, or at least 80%, 81%, 82% to any one of SEQ ID NO: 84 and 85, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 71. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 86 and 87, or at least 80%, 81%, 82% to any one of SEQ ID NO: 86 and 87, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 72. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 88 and 89, or at least 80%, 81%, 82% to any one of SEQ ID NO: 88 and 89, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 73. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 82 and 85, or at least 80%, 81%, 82% to any one of SEQ ID NO: 82 and 85, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 74. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 82 and 86, or at least 80%, 81%, 82% to any one of SEQ ID NO: 82 and 86, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 75. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 82 and 88, or at least 80%, 81%, 82% to any one of SEQ ID NO: 82 and 88, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 76. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 83 and 87, or at least 80%, 81%, 82% to any one of SEQ ID NO: 83 and 87, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 77. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 85 and 87, or at least 80%, 81%, 82% to any one of SEQ ID NO: 85 and 87, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 78. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 88 and 87, or at least 80%, 81%, 82% to any one of SEQ ID NO: 88 and 87, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 79. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 84 and 88, or at least 80%, 81%, 82% to any one of SEQ ID NO: 84 and 88, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 80. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 85 and 89, or at least 80%, 81%, 82% to any one of SEQ ID NO: 85 and 89, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 81. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 85 and 101, or at least 80%, 81%, 82% to any one of SEQ ID NO: 85 and 101, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 82. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 90 and 91, or at least 80%, 81%, 82% to any one of SEQ ID NO: 90 and 91, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 83. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 92 and 93, or at least 80%, 81%, 82% to any one of SEQ ID NO: 92 and 93, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 84. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 94 and 96, or at least 80%, 81%, 82% to any one of SEQ ID NO: 94 and 96, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 85. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 94 and 95, or at least 80%, 81%, 82% to any one of SEQ ID NO: 94 and 95, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 86. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 95 and 97, or at least 80%, 81%, 82% to any one of SEQ ID NO: 95 and 97, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 87. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 220 and 221, or at least 80%, 81%, 82% to any one of SEQ ID NO: 220 and 221, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 88. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 96 and 97, or at least 80%, 81%, 82% to any one of SEQ ID NO: 96 and 97, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 89. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 98 and 99, or at least 80%, 81%, 82% to any one of SEQ ID NO: 98 and 99, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 90. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 98 and 100, or at least 80%, 81%, 82% to any one of SEQ ID NO: 98 and 100, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 91. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 99 and 101, or at least 80%, 81%, 82% to any one of SEQ ID NO: 99 and 101, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 92. The vector of any one of claims 63 to 68, comprising one or more polynucleotides encoding, optionally via one or more linkers A first fusion polypeptide and a second fusion polypeptide bound or linked to: the fusion polypeptide of SEQ ID NO: 100 and 101, or at least 80%, 81%, 82% to any one of SEQ ID NO: 100 and 101, respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical fusion polypeptide. 93. The vector according to any one of claims 63 to 68, said vector comprising a polynucleotide encoding a composite fusion polypeptide comprising or consisting of: SEQ ID NO: 105-112, The amino acid sequence of any one of 200-209, 222-223 and 227, or at least 80%, 81%, 82 with any one of SEQ ID NO: 105-112, 200-209, 222-223 and 227 %,83%,84%,85%,86%,87%,88%,89%,90%,91%,92%,93%,94%,95%,96%,97%,98% or 99% identical amino acid sequence. 94. The vector of any one of claims 63 to 93, wherein the first and second fusion polypeptides do not comprise polypeptides corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128 , Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116 and Nef 149-206 or fragments or subsequences thereof Any polypeptide fragment, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NO: 1, 2 and 3 respectively. 95. The vector of any one of claims 67 to 94, wherein the first and second fusion polypeptides do not comprise the amino acid sequence having SEQ ID NO: 35-47, or fragments or subsequences thereof, or are identical to SEQ ID NO: 35-47. Any one of ID NO: 35-47 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% , 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence or any polypeptide fragment thereof or a fragment or subsequence thereof. 96. The vector of any one of claims 67 to 95, comprising a polynucleotide comprising or consisting of: SEQ ID NOs: 130-167, 210-219 and 225 - the nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or at least 80%, 81%, 82%, 83%, 84%, 85 %, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical nucleic acid sequences. 97. The vector of any one of claims 67 to 95, comprising a polynucleotide comprising or consisting of: SEQ ID NO: 139, 140, 142, 143, 145 , the nucleic acid sequence of any one of 146, 148, 149, 150, 152, 155, 158, 225 and 226, or the same as SEQ ID NO: 139, 140, 142, 143, 145, 146, 148, 149, 150 , any one of 152, 155, 158, 225 and 226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical nucleic acid sequences. 98. The vector of any one of claims 63 to 97, comprising the following first and second polynucleotides: The polynucleotide of SEQ ID NO: 130 and 132, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 130 and 134, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 130 and 134. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 131 and 133, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 131 and 135, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 132 and 136, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 133 and 135, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 133 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 134 and 136, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 135 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 135 and 137 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 138 and 141, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 138 and 141 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 138 and 144, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 138 and 144. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 139 and 142, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 139 and 142. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 139 and 145, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 139 and 145. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 140 and 146, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 142 and 148, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 142 and 148. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 143 and 149, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 143 and 149 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 145 and 148, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 150 and 152, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 150 and 155, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 150 and 155. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 151 and 153, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 151 and 153. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 151 and 156, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 152 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 152 and 158. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 153 and 159, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 153 and 159. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 154 and 157, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 154 and 157. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 155 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 155 and 158. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 156 and 159, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 156 and 159. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 160 and 161, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 160 and 161 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 162 and 163, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 164 and 165, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 166 and 167, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 210 and 211, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 210 and 211 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 212 and 213, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 214 and 215, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 216 and 217, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 218 and 219, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 218 and 219 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 218 and 226, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; or The polynucleotide of SEQ ID NO: 225 and 226, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 99. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 130 or SEQ ID NO: 131, or at least 80%, 81% or 82% identical to SEQ ID NO: 130 or SEQ ID NO: 131 respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotide, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 134 or SEQ ID NO: 135, or at least 80%, 81% or 82% identical to SEQ ID NO: 134 or SEQ ID NO: 135 respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotides. 100. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 132 or SEQ ID NO: 133, or at least 80%, 81% or 82% identical to SEQ ID NO: 132 or SEQ ID NO: 133 respectively , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotide, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 136 or SEQ ID NO: 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% The same polynucleotide. 101. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 139, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86, respectively, of SEQ ID NO: 139 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 145, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 145 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 102. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 142, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86, respectively, of SEQ ID NO: 142 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 148, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 148 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 103. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 140, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86, respectively, of SEQ ID NO: 140 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 146, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 146 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 104. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 143, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86, respectively, of SEQ ID NO: 143 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 149, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 149 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 105. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 150, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86, respectively, of SEQ ID NO: 150 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 152, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 152 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 106. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 151, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86, respectively, of SEQ ID NO: 151 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 153, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID No: 153 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 107. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 154, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86, respectively, of SEQ ID NO: 154 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 157, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 157 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 108. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 155, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86, respectively, of SEQ ID NO: 155 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 158 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 109. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 156, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86, respectively, of SEQ ID NO: 156 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 159, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 159 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 110. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 160, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86, respectively, of SEQ ID NO: 160 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 161, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 161 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 111. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 162, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86, respectively, of SEQ ID NO: 162 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 163, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 163 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 112. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 164, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86, respectively, of SEQ ID NO: 164 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 165, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 165 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 113. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 166, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86 respectively with SEQ ID NO: 166 %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 167, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 167 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 114. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 210, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 210 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 211, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 211 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 115. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 212, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 212 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 213, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 213 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 116. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 214, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 214 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 215, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 215 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 117. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 216, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 216 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 217, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 217 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 118. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 218, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 218 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 219, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 219 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 119. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 218, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 218 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 226, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 226 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 120. The vector of any one of claims 63 to 98, comprising the following first and second polynucleotides: a) A first polynucleotide comprising: the polynucleotide of SEQ ID NO: 225, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 225 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, and b) A second polynucleotide comprising: the polynucleotide of SEQ ID NO: 226, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% the same as SEQ ID NO: 226 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 121. The vector according to any one of claims 63 to 98, comprising: the polynucleotide of SEQ ID NO: 225, or at least 80%, 81%, 82%, 83% of the polynucleotide of SEQ ID NO: 225 %, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical of polynucleotides. 122. The vector according to any one of claims 63 to 98, comprising: the polynucleotide of SEQ ID NO: 226, or at least 80%, 81%, 82%, 83% of the polynucleotide of SEQ ID NO: 226 %, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical of polynucleotides. 123. The vector of any one of claims 67 to 122, wherein the first polynucleotide encoding the first fusion polypeptide and the second polynucleoside encoding the second fusion polypeptide The acid is located in a single open reading frame. 124. The vector of any one of claims 67 to 122, wherein the first polynucleotide encoding the first fusion polypeptide is located in a first open reading frame and encodes the second fusion polypeptide The second polynucleotide is located in the second open reading frame. 125. The vector of any one of claims 67 to 122, wherein the first polynucleotide encoding the first fusion polypeptide and the second polynucleoside encoding the second fusion polypeptide The acid is located in a single expression cassette. 126. The vector of any one of claims 67 to 122, wherein the first polynucleotide encoding the first fusion polypeptide is located in a first expression cassette, and the first polynucleotide encoding the second fusion polypeptide is The second polynucleotide is located in a second expression cassette. 127. The vector of any one of claims 63 to 126, wherein the vector is a plasmid vector, a bacterial vector or a viral vector. 128. The vector of any one of claims 63 to 127, wherein the vector is a viral vector. 129. The vector of any one of claims 63 to 128, wherein the viral vector is a DNA virus or an RNA virus. 130. The vector of any one of claims 63 to 129, wherein the viral vector is replication-deficient, replication-deficient, replication-attenuated or replication-competent. 131. The vector of any one of claims 63 to 130, wherein the viral vector is from a virus selected from the group consisting of adenovirus, adeno-associated virus, arenavirus, alphavirus, poxvirus, cytomegalovirus, Rhabdovirus, vesicular stomatitis virus, flavivirus, Malabar virus, and vaccinia virus. 132. The vector of any one of claims 63 to 131, wherein the viral vector is from the family Adenoviridae, Arenaviridae, Herpesviridae (e.g. cytomegalovirus), Poxviridae (e.g. Vaccinia) Viruses, such as modified vaccinia virus Ankara (MVA)), Flaviviridae (e.g., yellow fever virus), Rhabdoviridae (e.g., vesicular viruses, e.g., Malabar vesicular virus), Togaviridae (e.g., alphaviruses, e.g. Venezuelan equine encephalitis virus) is a taxonomic family of viruses. 133. The vector of any one of claims 63 to 132, wherein the viral vector is an arenavirus vector selected from the group consisting of Lymphocytic Choriomeningitis Mammalian Arenavirus (LCMV), Cardanos Lean mammalian arenavirus (also known as Pichand mammalian arenavirus or Pichand arenavirus), Guarnarreto virus (GTOV), Junin virus (JUNV), Lassa virus (LASV), Lu John virus (LUJV), Machupo virus (MACV), Sabia virus (SABV) and Whitewater Arroyo virus (WWAV). 134. The vector of claim 133, wherein the viral vector is an arenavirus vector selected from the group consisting of Lymphocytic Choriomeningitis Mammalian Arenavirus (LCMV) or Cali Mammalian Arenavirus (Also known as Pichand mammalian arenavirus or Pichand arenavirus). 135. The vector of any one of claims 133 to 134, wherein the arenavirus vector comprises a bisegmented genome. 136. The vector of any one of claims 133 to 134, wherein the arenavirus vector comprises a three-segmented genome. 137. The vector of any one of claims 63 to 132, wherein the viral vector is a human adenovirus or a simian adenovirus (eg, a chimpanzee adenovirus, a gorilla adenovirus, or a rhesus adenovirus). 138. The vector of claim 137, wherein the viral vector is an adenoviral vector selected from the group consisting of serotype 5 adenovirus (Ad5), serotype 26 adenovirus (Ad26), serotype 34 adenovirus ( Ad34), serotype 35 adenovirus (Ad35), serotype 48 adenovirus (Ad48), chimpanzee adenovirus (e.g., ChAd3 (AdC3), ChAd5 (AdC5), ChAd6 (AdC6), ChAd7 (AdC7), ChAd8 (AdC8 ), ChAd9(AdC9), ChAd10(AdC10), ChAd11(AdC11), ChAd17(AdC17), ChAd16(AdC16), ChAd19(AdC19), ChAd20(AdC20), ChAd22(AdC22), ChAd24(AdC24), ChAdY25, ChAd26 (AdC26), ChAd28(AdC28), ChAd30(AdC30), ChAd31(AdC31), ChAd37(AdC37), ChAd38(AdC38), ChAd43(AdC43), ChAd44(AdC44), ChAd55(AdC55), ChAd63(AdC63), ChAdV63 , ChAd68(AdC68), ChAd73(AdC73), ChAd82(AdC82), ChAd83(AdC83), ChAd143(AdC143), ChAd144(AdC144), ChAd145(AdC145), ChAd147(AdC147)), gorilla adenovirus (e.g., GC44 , GC45, GC46) and rhesus adenovirus (e.g., RhAd51, RhAd52, RhAd53, RhAd54, RhAd55, RhAd56, RhAd57, RhAd58, RhAd59, RhAd60, RhAd61, RhAd62, RhAd63, RhAd64, RhAd65, RhAd66). 139. A host cell comprising one or more polynucleotides according to any one of claims 54 to 57 or one or more polynucleotides according to any one of claims 63 to 138 or Various carriers. 140. The host cell of claim 139, wherein the one or more polynucleotides are not integrated into the host cell genome, eg, are episomal. 141. The host cell of claim 139, wherein the one or more polynucleotides are integrated into the host cell genome. 142. The host cell of any one of claims 139 to 141, wherein the host cell is a mammalian cell, such as a human cell. 143. The host cell of any one of claims 139 to 142, wherein the host cell is in vitro. 144. The host cell of any one of claims 139 to 142, wherein the host cell is in vivo. 145. An immunogenic composition comprising one or more of the fusion polypeptide or composite fusion polypeptide according to any one of claims 1 to 53, or according to claim 54 One or more polynucleotides according to any one of claims 57 to 57, or one or more liposome complexes (eg, LNPs) according to claim 59, or according to claims 63 to 130 One or more carriers as described in any one, and pharmaceutically acceptable carriers. 146. The immunogenic composition according to claim 145, comprising two or more fusion polypeptides according to any one of claims 1 to 53, or according to claim 54 Two or more polynucleotides according to any one of to 57, two or more liposome complexes (eg, LNPs) according to claim 59, or according to claims 63 to 130 Two or more vectors described in any one of them. 147. The immunogenic composition of any one of claims 145 to 146, wherein the one or more polynucleotides are DNA, cDNA, mRNA or self-replicating RA. 148. The immunogenic composition of any one of claims 145 to 147, comprising a first fusion polypeptide and a second fusion polypeptide or one or more vectors, the vector comprising One or more polynucleotides encoding said first and second fusion polypeptides, said first and second polypeptides comprising in sequence from the N-terminus to the C-terminus, optionally bound or linked by one or more linkers The following peptide fragments: · SEQ ID NO: 6, 4, 16 and 26, and SEQ ID NO: 7, 5, 27 and 17; · SEQ ID NO: 12, 24, 8 and 10, and SEQ ID NO: 9, 25, 13 and 11; · SEQ ID NO: 14, 22, 18, 24 and 20, and SEQ ID NO: 15, 25, 19, 23 and 21; · SEQ ID NO: 26, 16, 4 and 6, and SEQ ID NO: 7, 27, 5 and 17; · SEQ ID NO: 8, 24, 12 and 10, and SEQ ID NO: 13, 25, 9 and 11; · SEQ ID NO: 22, 24, 14, 18 and 20, and SEQ ID NO: 25, 23, 15, 21 and 19; · SEQ ID NO: 20, 6, 4, 18, 16 and 26, and SEQ ID NO: 7, 19, 5, 21, 27 and 17; · SEQ ID NO: 8, 24, 14, 12, 22 and 10, and SEQ ID NO: 9, 13, 25, 23, 15 and 11; · SEQ ID NO: 18, 26, 20, 4, 6 and 16, and SEQ ID NO: 7, 21, 17, 5, 27 and 19; · SEQ ID NO: 22, 24, 12, 14, 8 and 10, and SEQ ID NO: 15, 25, 9, 23, 13 and 11; · SEQ ID NO: 24, 6, 4, 20, 18 and 32, and SEQ ID NO: 8, 30, 14, 12, 26 and 10; · SEQ ID NO: 24, 6, 4, 20, 18 and 32, and SEQ ID NO: 7, 21, 5, 25, 33 and 19; · SEQ ID NO: 24, 6, 4, 20, 18 and 32, and SEQ ID NO: 8, 30, 14, 12, 26 and 10; · SEQ ID NO: 8, 30, 14, 12, 26 and 10, and SEQ ID NO: 9, 13, 31, 27, 15 and 11; · SEQ ID NO: 6, 20, 4, 24, 32 and 18, and SEQ ID NO: 8, 12, 30, 26, 14 and 10; · SEQ ID NO: 7, 21, 5, 25, 33 and 19, and SEQ ID NO: 9, 13, 31, 27, 15 and 11; · SEQ ID NO: 20, 32, 24, 4, 6 and 18, and SEQ ID NO: 26, 30, 12, 14, 8 and 10; · SEQ ID NO: 7, 25, 19, 5, 33 and 21, and SEQ ID NO: 15, 31, 9, 27, 13 and 11; ·SEQ ID Nos: 24, 6, 16 and 18, and SEQ ID NOs: 26, 20, 10 and 28; ·SEQ ID Nos: 24, 6, 16 and 18, and SEQ ID Nos: 26, 10, 20 and 28; · SEQ ID NO: 24, 6, 16 and 18, and SEQ ID NO: 7, 25, 17 and 19; · SEQ ID NO: 7, 19, 17 and 25, and SEQ ID NO: 21, 27, 11 and 29; · SEQ ID NO: 24, 16, 6 and 18, and SEQ ID NO: 27, 11, 21 and 29; · SEQ ID NO: 7, 25, 17 and 19, and SEQ ID NO: 11, 27, 21 and 29; · SEQ ID NO: 7, 25, 17 and 19, and SEQ ID NO: 21, 27, 11 and 29; · SEQ ID NO: 22, 6, 20 and 28, and SEQ ID NO: 23, 7, 21 and 29; · SEQ ID NO: 22, 20, 6 and 28, and SEQ ID NO: 7, 21, 23 and 29; · SEQ ID NO: 26, 10, 20 and 28, and SEQ ID NO: 21, 27, 11 and 29; ·SEQ ID NO: 22, 6, 16, 20, 18, 28, 26 and 10; or • SEQ ID NO: 7, 21, 19, 17, 27, 25, 29 and 11. 149. The immunogenic composition of any one of claims 145 to 148, comprising one or more fusion polypeptides, or a protein encoding one or more fusion polypeptides. or one or more vectors of multiple polynucleotides, the fusion polypeptide comprising or consisting of: any of SEQ ID NO: 70-101, 105-112, 200-209, 222-223 and 227 The amino acid sequence of item, or is at least 80%, 81%, 82%, 83%, 84%, 85% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227 %, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences. 150. The immunogenic composition of any one of claims 145 to 149, comprising one or more fusion polypeptides, or a protein encoding one or more fusion polypeptides. or one or more vectors of multiple polynucleotides, the fusion polypeptide comprising or consisting of: SEQ ID NOs: 82-83, 85-87, 98-101, 209, 222-223 and 227 The amino acid sequence of any one, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acids sequence. 151. The immunogenic composition of any one of claims 145 to 150, comprising the following first and second fusion polypeptides, one or more polynucleotides, or One or more vectors or one or more liposome complexes (e.g., LNPs) comprising one or more polynucleotides encoding, optionally, by a or The following first fusion polypeptide and second fusion polypeptide bound or connected by a plurality of linkers: A fusion polypeptide of SEQ ID NO: 70 and 71, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 70 and 71, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 72 and 73, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 72 and 73, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 74 and 75, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 74 and 75, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 76 and 77, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 76 and 77, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 78 and 79, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 78 and 79, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 80 and 81, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 80 and 81, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 90 and 91, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 92 and 93, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 92 and 93, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 96 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 220 and 221, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; or A fusion polypeptide of SEQ ID NO: 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 152. The immunogenic composition of any one of claims 145 to 151, comprising the following first and second fusion polypeptides, one or more polynucleotides, or One or more vectors or one or more liposome complexes (e.g., LNP) comprising one or more polynucleotides encoding from the N-terminus to the C-terminus The following first fusion polypeptide and second fusion polypeptide are combined or linked in sequence and optionally through one or more linkers: A fusion polypeptide of SEQ ID NO: 70 and 71, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 70 and 71, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 71 and 70, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 71 and 70, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 72 and 73, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 72 and 73, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 73 and 72, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 73 and 72, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 74 and 75, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 74 and 75, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 75 and 74, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 75 and 74, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 76 and 77, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 76 and 77, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 77 and 76, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 77 and 76, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 78 and 79, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 78 and 79, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 79 and 78, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 79 and 78, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 80 and 81, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 80 and 81, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 81 and 80, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 81 and 80, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 84, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 84, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 89 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 89 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 84, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 84, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 84, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 89 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 89 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 101 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 101 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 90 and 91, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 91 and 90, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 91 and 90, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 92 and 93, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 92 and 93, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 93 and 92, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 93 and 92, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 94, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 94, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 96 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 97 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 97 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 96 and 94, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 96 and 94, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 97 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 97 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 220 and 221, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 221 and 220, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 221 and 220, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 100 and 98, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 98, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 101 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 101 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 98, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 98, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; or A fusion polypeptide of SEQ ID NO: 101 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 101 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 153. The immunogenic composition of any one of claims 145 to 152, comprising first and second viral vectors or first and second viral vectors containing one or more polynucleotides. A second liposome complex (e.g., LNP), the one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 82 and 83, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 82 and 83, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 86 and 87, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 86 and 87, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 154. The immunogenic composition of any one of claims 145 to 152, comprising first and second viral vectors or first and second viral vectors containing one or more polynucleotides. A second liposome complex (e.g., LNP), the one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 84 and 85, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 84 and 85 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 88 and 89, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 88 and 89 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 155. The immunogenic composition of any one of claims 145 to 152, comprising first and second viral vectors or first and second viral vectors containing one or more polynucleotides. A second liposome complex (e.g., LNP), the one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 82 and 86 respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 83 and 87, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 156. The immunogenic composition of any one of claims 145 to 152, comprising first and second viral vectors or first and second viral vectors containing one or more polynucleotides. A second liposome complex (e.g., LNP), the one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 82 and 85, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 82 and 85 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 88 and 87, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 88 and 87, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 157. The immunogenic composition of any one of claims 145 to 152, comprising first and second viral vectors or first and second viral vectors containing one or more polynucleotides. A second liposome complex (e.g., LNP), the one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 82 and 88, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 82 and 88 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 85 and 87, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 85 and 87, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 158. The immunogenic composition of any one of claims 145 to 152, comprising first and second viral vectors or first and second viral vectors containing one or more polynucleotides. A second liposome complex (e.g., LNP), the one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 84 and 88, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 84 and 88 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 85 and 89, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 85 and 89, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 159. The immunogenic composition of any one of claims 145 to 152, comprising a viral vector or liposome complex containing one or more polynucleotides (e.g., or At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% with any one of SEQ ID NOs: 90 and 91, respectively , 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 160. The immunogenic composition of any one of claims 145 to 152, comprising a viral vector or liposome complex containing one or more polynucleotides (e.g., or At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% with any one of SEQ ID NOs: 92 and 93, respectively , 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 161. The immunogenic composition of any one of claims 145 to 152, comprising first and second viral vectors or first and second viral vectors containing one or more polynucleotides. A second liposome complex (e.g., LNP), the one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 94 and 95 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides: and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 96 and 97, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 96 and 97 respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 162. The immunogenic composition of any one of claims 145 to 152, comprising first and second viral vectors or first and second viral vectors containing one or more polynucleotides. A second liposome complex (e.g., LNP), the one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 94 and 96, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 94 and 96, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 95 and 97 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 163. The immunogenic composition of any one of claims 145 to 152, comprising first and second viral vectors or first and second viral vectors containing one or more polynucleotides. A second liposome complex (e.g., LNP), the one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 220 and 221, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 95 and 97 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 164. The immunogenic composition of any one of claims 145 to 152, comprising first and second viral vectors or first and second viral vectors containing one or more polynucleotides. A second liposome complex (e.g., LNP), the one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 98 and 100, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 99 and 101 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 165. The immunogenic composition of any one of claims 145 to 152, comprising first and second viral vectors or first and second viral vectors containing one or more polynucleotides. A second liposome complex (e.g., LNP), the one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 98 and 100, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 85 and 101, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 85 and 101 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 166. The immunogenic composition of any one of claims 145 to 152, comprising a viral vector or liposome complex containing one or more polynucleotides (e.g., LNP), said one or more polynucleotides encoding a first and second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 82 and 85, optionally joined or linked by one or more linkers, Or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with any one of SEQ ID NOs: 82 and 85 respectively %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 167. The immunogenic composition of any one of claims 145 to 152, comprising a viral vector or liposome complex containing one or more polynucleotides (e.g., LNP), said one or more polynucleotides encoding a first and second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 82 and 88, optionally bound or linked by one or more linkers, Or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with any one of SEQ ID NOs: 82 and 88 respectively %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 168. The immunogenic composition of any one of claims 145 to 152, comprising a viral vector or liposome complex containing one or more polynucleotides (e.g., LNP), said one or more polynucleotides encoding a first and second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 85 and 87, optionally bound or linked by one or more linkers, Or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with any one of SEQ ID NOs: 85 and 87 respectively %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 169. The immunogenic composition of any one of claims 145 to 152, comprising a viral vector or liposome complex containing one or more polynucleotides (e.g., LNP), said one or more polynucleotides encoding a first and second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 87 and 88, optionally bound or linked by one or more linkers, Or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with any one of SEQ ID NOs: 87 and 88 respectively %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 170. The immunogenic composition of any one of claims 145 to 152, comprising a viral vector or liposome complex containing one or more polynucleotides (e.g., LNP), said one or more polynucleotides encoding a first and second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 94 and 95, optionally bound or linked by one or more linkers, Or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with any one of SEQ ID NOs: 94 and 95 respectively %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 171. The immunogenic composition of any one of claims 145 to 152, comprising a viral vector or liposome complex containing one or more polynucleotides (e.g., LNP), said one or more polynucleotides encoding a first and second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 96 and 97, optionally bound or linked by one or more linkers, Or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with any one of SEQ ID NO: 96 and 97 respectively %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 172. The immunogenic composition of any one of claims 145 to 152, comprising a viral vector or liposome complex containing one or more polynucleotides (e.g., LNP), said one or more polynucleotides encoding a first and second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 98 and 99, optionally joined or linked by one or more linkers, Or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with any one of SEQ ID NO: 98 and 99 respectively %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 173. The immunogenic composition of any one of claims 145 to 152, comprising a viral vector or liposome complex containing one or more polynucleotides (e.g., LNP), said one or more polynucleotides encoding a first and second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 100 and 101, optionally bound or linked by one or more linkers, Or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with any one of SEQ ID NO: 100 and 101 respectively %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 174. The immunogenic composition of any one of claims 145 to 152, comprising a first viral vector or liposome complex (eg, LNP) and a second viral vector or A liposome complex (e.g., LNP), the first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide : A polypeptide comprising SEQ ID NO: 200 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polypeptide, the second viral vector or liposome complex (e.g., LNP) comprising the second A polynucleotide encoding a second polypeptide comprising the polypeptide of SEQ ID NO: 201 or at least 80%, 81%, 82%, 83%, 84% the same as SEQ ID NO: 201 , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polypeptides. 175. The immunogenic composition of any one of claims 145 to 152, comprising a first viral vector or liposome complex (eg, LNP) and a second viral vector or A liposome complex (e.g., LNP), the first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide : A polypeptide comprising SEQ ID NO: 202 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polypeptide, the second viral vector or liposome complex (e.g., LNP) comprising the second A polynucleotide encoding a second polypeptide comprising a polypeptide of SEQ ID NO: 203 or at least 80%, 81%, 82%, 83%, 84% identical to SEQ ID NO: 203 , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polypeptides. 176. The immunogenic composition of any one of claims 145 to 152, comprising a first viral vector or liposome complex (eg, LNP) and a second viral vector or A liposome complex (e.g., LNP), the first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide : A polypeptide comprising SEQ ID NO: 204 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polypeptide, the second viral vector or liposome complex (e.g., LNP) comprising the second A polynucleotide encoding a second polypeptide comprising a polypeptide of SEQ ID NO: 205 or at least 80%, 81%, 82%, 83%, 84% identical to SEQ ID NO: 205 , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polypeptides. 177. The immunogenic composition of any one of claims 145 to 152, comprising a first viral vector or liposome complex (eg, LNP) and a second viral vector or A liposome complex (e.g., LNP), the first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide : A polypeptide comprising SEQ ID NO: 105 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polypeptide, the second viral vector or liposome complex (e.g., LNP) comprising the second A polynucleotide encoding a second polypeptide comprising or at least 80%, 81%, 82%, 83%, 84% the same as SEQ ID NO: 107 , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polypeptides. 178. The immunogenic composition of any one of claims 145 to 152, comprising a first viral vector or liposome complex (eg, LNP) and a second viral vector or A liposome complex (e.g., LNP), the first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide : A polypeptide comprising SEQ ID NO: 206 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polypeptide, the second viral vector or liposome complex (e.g., LNP) comprising the second A polynucleotide encoding a second polypeptide comprising a polypeptide of SEQ ID NO: 207 or at least 80%, 81%, 82%, 83%, 84% identical to SEQ ID NO: 207 , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polypeptides. 179. The immunogenic composition of any one of claims 145 to 152, comprising a first viral vector or liposome complex (eg, LNP) and a second viral vector or A liposome complex (e.g., LNP), the first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide : A polypeptide comprising SEQ ID NO: 208 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polypeptide, the second viral vector or liposome complex (e.g., LNP) comprising the second A polynucleotide encoding a second polypeptide comprising or at least 80% identical to SEQ ID NO: 209 or SEQ ID NO: 227, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% , 98% or 99% identical polypeptides. 180. The immunogenic composition of any one of claims 145 to 152, comprising a first viral vector or liposome complex (eg, LNP) and a second viral vector or A liposome complex (e.g., LNP), the first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide : A polypeptide comprising SEQ ID NO: 222 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polypeptide, the second viral vector or liposome complex (e.g., LNP) comprising the second A polynucleotide encoding a second polypeptide comprising or at least 80% identical to SEQ ID NO: 209 or SEQ ID NO: 227, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% , 98% or 99% identical polypeptides. 181. The immunogenic composition of any one of claims 145 to 152, comprising a first viral vector or liposome complex (eg, LNP) and a second viral vector or A liposome complex (e.g., LNP), the first viral vector or liposome complex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide : A polypeptide comprising SEQ ID NO: 222 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polypeptide, the second viral vector or liposome complex (e.g., LNP) comprising the second A polynucleotide encoding a second polypeptide comprising a polypeptide of SEQ ID NO: 223 or at least 80%, 81%, 82%, 83%, 84% of SEQ ID NO: 223 , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polypeptides. 182. The immunogenic composition of any one of claims 145 to 181, wherein the first and second viral vectors are lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vectors. 183. The immunogenic composition of any one of claims 145 to 181, wherein the first and second viral vectors are Cali mammalian arenavirus (also known as Pichand mammalian arenavirus or Pichend Arenavirus) viral vectors. 184. The immunogenic composition of any one of claims 145 to 181, wherein the first and second viral vectors are adenoviral vectors, such as chimpanzee adenoviral vectors (ChAd). 185. The immunogenic composition of any one of claims 145 to 184, comprising a polynucleotide comprising or consisting of: SEQ ID No: 130 - the nucleic acid sequence of any one of 167, 210-219 and 225-226, or at least 80%, 81%, 82% identical to any one of SEQ ID NO: 130-167, 210-219 and 225-226 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical nucleic acid sequences. 186. The immunogenic composition of any one of claims 145 to 184, comprising a polynucleotide comprising or consisting of: SEQ ID NO: 139 , the nucleic acid sequence of any one of 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or the same as SEQ ID NO: 139, 140, 142, 143, 145 , any one of 146, 148, 149, 150, 152, 155, 158, 225 and 226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% , 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical nucleic acid sequences. 187. The immunogenic composition of any one of claims 145 to 186, comprising the following first polynucleotide and a second polynucleotide, or comprising the following first polynucleotide One or more vectors of nucleotides and second polynucleotide: The polynucleotide of SEQ ID NO: 130 and 132, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 130 and 134, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 130 and 134. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 131 and 133, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 131 and 135, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 132 and 136, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 133 and 135, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 133 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 134 and 136, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 135 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 135 and 137 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 138 and 141, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 138 and 141 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 138 and 144, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 138 and 144. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 139 and 142, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 139 and 142. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 139 and 145, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 139 and 145. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 140 and 146, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 142 and 148, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 142 and 148. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 143 and 149, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 143 and 149 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 145 and 148, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 150 and 152, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 150 and 155, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 150 and 155. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 151 and 153, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 151 and 153. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 151 and 156, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 152 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 152 and 158. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 153 and 159, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 153 and 159. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 154 and 157, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 154 and 157. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 155 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 155 and 158. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 156 and 159, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 156 and 159. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 160 and 161, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 160 and 161 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 162 and 163, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 164 and 165, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 166 and 167, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 210 and 211, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 210 and 211 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 212 and 213, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 214 and 215, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 216 and 217, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 218 and 219, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 218 and 219 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 218 and 226, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; or The polynucleotide of SEQ ID NO: 225 and 226, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 188. The immunogenic composition of any one of claims 145 to 187, comprising first and second polynucleotides comprising: Viral vector or first and second liposome complex (e.g., LNP): a) A first vector or a first liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 131 and 135, or SEQ ID NOs: 131 and 135, respectively. Any one of NO: 131 and 135 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second carrier or a second liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 133 and 137, or SEQ ID NOs: 133 and 137, respectively. Any one of NO: 133 and 137 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 189. The immunogenic composition of any one of claims 145 to 187, comprising first and second polynucleotides comprising: Viral vector or first and second liposome complex (e.g., LNP): a) A first vector or first liposome complex (eg, LNP) comprising first and second polynucleotides: the polynucleotides comprising SEQ ID NO: 139 and 145, or SEQ ID NO: 139 and 145, respectively. Any one of NO: 139 and 145 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second carrier or a second liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 142 and 148, or SEQ ID NOs: 142 and 148, respectively. NO: any one of 142 and 148 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 190. The immunogenic composition of any one of claims 145 to 187, comprising first and second polynucleotides comprising: Viral vector or first and second liposome complex (e.g., LNP): a) A first vector or first liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 140 and 146, or SEQ ID NOs: 140 and 146, respectively. NO: any one of 140 and 146 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second carrier or a second liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 143 and 149, or SEQ ID NOs: 143 and 149, respectively. Any one of NO: 143 and 149 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 191. The immunogenic composition of claim 190, wherein the first and second viral vectors are lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vectors. 192. The immunogenic composition of any one of claims 145 to 187, comprising first and second polynucleotides comprising the following: Viral vector or first and second liposome complex (e.g., LNP): a) A first vector or first liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 150 and 152, or SEQ ID NOs: 150 and 152, respectively. NO: any one of 150 and 152 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second carrier or a second liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleotide comprising SEQ ID NO: 154 and 157 or SEQ ID NO: 155 and 158 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87% with any one of SEQ ID NO: 154 and 157 or SEQ ID NO: 155 and 158, respectively , 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 193. The immunogenic composition of claim 192, wherein the first and second viral vectors are Cali mammalian arenavirus (also known as Pichand mammalian arenavirus or Pichand arenavirus Viruses) viral vectors. 194. The immunogenic composition of any one of claims 145 to 187, comprising first and second polynucleotides comprising the following: Viral vector or first and second liposome complex (e.g., LNP): a) A first vector or first liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 151 and 153, or SEQ ID NOs: 151 and 153, respectively. Any one of NO: 151 and 153 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second carrier or a second liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 156 and 159, or SEQ ID NOs: 156 and 159, respectively. NO: any one of 156 and 159 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 195. The immunogenic composition of any one of claims 192 and 194, wherein the first and second viral vectors are adenoviral vectors. 196. The immunogenic composition of any one of claims 145 to 187, comprising first and second viral vectors or a first viral vector containing one or more polynucleotides and a second liposome complex (e.g., LNP): a) The first viral vector or first liposome complex (eg, LNP), which comprises the polynucleotide of SEQ ID NO: 160, or is at least 80%, 81%, 82% identical to SEQ ID NO: 160 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotide; and b) The second viral vector or second liposome complex (eg, LNP), which contains the polynucleotide of SEQ ID NO: 161, or is at least 80%, 81%, 82% identical to SEQ ID NO: 161 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotides. 197. The immunogenic composition of any one of claims 145 to 187, comprising first and second viral vectors or a first viral vector containing one or more polynucleotides and a second liposome complex (e.g., LNP): a) The first viral vector or first liposome complex (eg, LNP), which comprises the polynucleotide of SEQ ID NO: 162, or is at least 80%, 81%, 82% identical to SEQ ID NO: 162 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotide; and b) The second viral vector or second liposome complex (eg, LNP), which contains the polynucleotide of SEQ ID NO: 163, or is at least 80%, 81%, 82% identical to SEQ ID NO: 163 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotides. 198. The immunogenic composition of any one of claims 145 to 187, comprising first and second viral vectors or first viral vectors containing one or more polynucleotides and a second liposome complex (e.g., LNP): a) The first viral vector or first liposome complex (eg, LNP), which comprises the polynucleotide of SEQ ID NO: 164, or is at least 80%, 81%, 82% identical to SEQ ID NO: 164 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotide; and b) The second viral vector or second liposome complex (eg, LNP), which contains the polynucleotide of SEQ ID NO: 165, or is at least 80%, 81%, 82% identical to SEQ ID NO: 165 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotides. 199. The immunogenic composition of any one of claims 145 to 187, comprising first and second viral vectors or a first viral vector containing one or more polynucleotides and a second liposome complex (e.g., LNP): a) The first viral vector or first liposome complex (eg, LNP), which comprises the polynucleotide of SEQ ID NO: 166, or is at least 80%, 81%, 82% identical to SEQ ID NO: 166 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotide; and b) The second viral vector or second liposome complex (eg, LNP), which contains the polynucleotide of SEQ ID NO: 167, or is at least 80%, 81%, 82% identical to SEQ ID NO: 167 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotides. 200. The immunogenic composition of any one of claims 145 to 187, comprising first and second viral vectors or first viral vectors containing one or more polynucleotides and a second liposome complex (e.g., LNP): a) The first viral vector or first liposome complex (eg, LNP), which comprises the polynucleotide of SEQ ID NO: 210, or is at least 80%, 81%, 82% identical to SEQ ID NO: 210 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotide; and b) The second viral vector or second liposome complex (eg, LNP), which contains the polynucleotide of SEQ ID NO: 211, or is at least 80%, 81%, 82% identical to SEQ ID NO: 211 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotides. 201. The immunogenic composition of any one of claims 145 to 187, comprising first and second viral vectors or first viral vectors containing one or more polynucleotides and a second liposome complex (e.g., LNP): a) The first viral vector or first liposome complex (eg, LNP), which contains the polynucleotide of SEQ ID NO: 212, or is at least 80%, 81%, 82% identical to SEQ ID NO: 212 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotide; and b) The second viral vector or second liposome complex (eg, LNP), which contains the polynucleotide of SEQ ID NO: 213, or is at least 80%, 81%, 82% identical to SEQ ID NO: 213 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotides. 202. The immunogenic composition of any one of claims 145 to 187, comprising first and second viral vectors or a first viral vector containing one or more polynucleotides and a second liposome complex (e.g., LNP): a) The first viral vector or first liposome complex (eg, LNP), which comprises the polynucleotide of SEQ ID NO: 214, or is at least 80%, 81%, 82% identical to SEQ ID NO: 214 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotide; and b) The second viral vector or second liposome complex (eg, LNP), which contains the polynucleotide of SEQ ID NO: 215, or is at least 80%, 81%, 82% identical to SEQ ID NO: 215 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotides. 203. The immunogenic composition of any one of claims 145 to 187, comprising first and second viral vectors or first viral vectors containing one or more polynucleotides and a second liposome complex (e.g., LNP): a) The first viral vector or first liposome complex (eg, LNP), which contains the polynucleotide of SEQ ID NO: 216, or is at least 80%, 81%, 82% identical to SEQ ID NO: 216 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotide; and b) The second viral vector or second liposome complex (eg, LNP), which contains the polynucleotide of SEQ ID NO: 217, or is at least 80%, 81%, 82% identical to SEQ ID NO: 217 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotides. 204. The immunogenic composition of any one of claims 145 to 187, comprising first and second viral vectors or first viral vectors containing one or more polynucleotides and a second liposome complex (e.g., LNP): a) The first viral vector or first liposome complex (eg, LNP), which comprises the polynucleotide of SEQ ID NO: 218, or is at least 80%, 81%, 82% identical to SEQ ID NO: 218 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotide; and b) The second viral vector or second liposome complex (eg, LNP), which contains the polynucleotide of SEQ ID NO: 219, or is at least 80%, 81%, 82% identical to SEQ ID NO: 219 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotides. 205. The immunogenic composition of any one of claims 145 to 187, comprising first and second viral vectors or first viral vectors containing one or more polynucleotides and a second liposome complex (e.g., LNP): a) The first viral vector or first liposome complex (eg, LNP), which comprises the polynucleotide of SEQ ID NO: 218, or is at least 80%, 81%, 82% identical to SEQ ID NO: 218 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotide; and b) The second viral vector or second liposome complex (eg, LNP), which contains the polynucleotide of SEQ ID NO: 226, or is at least 80%, 81%, 82% identical to SEQ ID NO: 226 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotides. 206. The immunogenic composition of any one of claims 145 to 187, comprising first and second viral vectors or a first viral vector containing one or more polynucleotides and a second liposome complex (e.g., LNP): a) The first viral vector or first liposome complex (eg, LNP), which comprises the polynucleotide of SEQ ID NO: 225, or is at least 80%, 81%, 82% identical to SEQ ID NO: 225 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotide; and b) The second viral vector or second liposome complex (eg, LNP), which contains the polynucleotide of SEQ ID NO: 226, or is at least 80%, 81%, 82% identical to SEQ ID NO: 226 , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99 % identical polynucleotides. 207. The immunogenic composition of any one of claims 145 to 206, comprising a composite fusion polypeptide, a vector or liposome complex comprising a polynucleotide encoding a composite fusion polypeptide. (e.g., LNP), the composite fusion polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NO: 105-112, 200-209, 222-223, and 227, or with SEQ ID NO: Any of 105-112, 200-209, 222-223 and 227 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90 %, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences. 208. The immunogenic composition of any one of claims 145 to 207, comprising a composite fusion polypeptide, a vector or liposome complex comprising a polynucleotide encoding a composite fusion polypeptide. (e.g., LNP), the composite fusion polypeptide comprising or consisting of: the amino acid sequence of any one of SEQ ID NO: 209, 222, 223, and 227, or the amino acid sequence of any one of SEQ ID NO: 209, 222, 223, and Any of 227 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94 %, 95%, 96%, 97%, 98% or 99% identical amino acid sequences. 209. The immunogenic composition of any one of claims 145 to 208, wherein the one or more fusion polypeptides do not comprise polypeptides corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116 and Nef 149-206 or their Any polypeptide fragment of a fragment or subsequence, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NO: 1, 2 and 3 respectively. 210. The immunogenic composition of any one of claims 145 to 209, wherein the one or more fusion polypeptides do not comprise the amino acid sequence having SEQ ID NO: 35-47 or a fragment or subsequence thereof , or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence or any polypeptide fragment thereof. 211. The immunogenic composition of any one of claims 145 to 210, comprising a single vector comprising one or more polypeptides encoding first and second fusion polypeptides. Polynucleotides. 212. The immunogenic composition of any one of claims 145 to 211, further comprising one or more of an adjuvant, a detergent, a micelle former, and an oil. 213. The immunogenic composition of any one of claims 145 to 212, formulated for administration via a route selected from: intravenous, intramuscular, intradermal, Subcutaneous, intranodal, and mucosal (e.g., buccal, intranasal, intrarectal, intravaginal). 214. The immunogenic composition of any one of claims 145 to 213, formulated as a liquid, suspension or emulsion. 215. The immunogenic composition of any one of claims 145 to 213, wherein the composition is lyophilized. 216. A kit comprising one or more unit doses of one or more fusion polypeptides according to any one of claims 1 to 53, or one or more fusion polypeptides according to any one of claims 54 to 57 One or more polynucleotides according to the item, or one or more vectors according to any one of claims 63 to 130, or one or more vectors according to any one of claims 145 to 215 or multiple immunogenic compositions. 217. The kit of claim 216, wherein the one or more unit doses are in a single container. 218. The kit of claim 216, wherein the one or more unit doses are in two or more separate containers. 219. The kit of any one of claims 216 to 218, comprising one or more containers selected from the group consisting of vials, ampoules and prefilled syringes. 220. The kit of any one of claims 216 to 219, comprising one or more containers comprising the one or more fusion polypeptides, one or more polynucleosides Aqueous solution of acid or one or more carriers. 221. The kit of any one of claims 216 to 220, wherein the one or more unit doses are the same. 222. The kit of any one of claims 216 to 220, wherein the one or more unit doses are different. 223. A kit according to any one of claims 216 to 222, comprising one or more unit doses of one or more viral vectors according to any one of claims 63 to 130 , wherein the unit dose is in the range of about 10 ³ to about 10 ¹² viral focus-forming units (FFU) or plaque-forming units (PFU) or infectious units (IU) or viral particles (vp), for example, about 10 ⁴ to about 10 ⁷ viral FFU or PFU or IU or vp, for example, about 10 ³ to about 10 ⁴ , 10 ⁵ , 10 ⁶ , 10 ⁷ , 10 ⁸ , 10 ⁹ , 10 ¹⁰ , 10 ¹¹ , 10 ¹² , 10 ¹³ , 10 ¹⁴ or 10 ¹⁵ viruses FFU or PFU or IU or vp. 224. A kit according to any one of claims 216 to 223, comprising two or more fusion polypeptides according to any one of claims 1 to 53, or according to claim 54 Two or more polynucleotides according to any one of claims 63 to 130, or two or more vectors according to any one of claims 63 to 130. 225. The kit of any one of claims 216 to 224, comprising a first fusion polypeptide and a second fusion polypeptide or one or more vectors comprising one or more polynucleotides, The one or more polynucleotides encoding the first and second fusion polypeptides comprising, in order from the N-terminus to the C-terminus, optionally bound by one or more linkers or The following polypeptide fragments are connected: · SEQ ID NO: 6, 4, 16 and 26, and SEQ ID NO: 7, 5, 27 and 17; · SEQ ID NO: 12, 24, 8 and 10, and SEQ ID NO: 9, 25, 13 and 11; · SEQ ID NO: 14, 22, 18, 24 and 20, and SEQ ID NO: 15, 25, 19, 23 and 21; · SEQ ID NO: 26, 16, 4 and 6, and SEQ ID NO: 7, 27, 5 and 17; · SEQ ID NO: 8, 24, 12 and 10, and SEQ ID NO: 13, 25, 9 and 11; · SEQ ID NO: 22, 24, 14, 18 and 20, and SEQ ID NO: 25, 23, 15, 21 and 19; · SEQ ID NO: 20, 6, 4, 18, 16 and 26, and SEQ ID NO: 7, 19, 5, 21, 27 and 17; · SEQ ID NO: 8, 24, 14, 12, 22 and 10, and SEQ ID NO: 9, 13, 25, 23, 15 and 11; · SEQ ID NO: 18, 26, 20, 4, 6 and 16, and SEQ ID NO: 7, 21, 17, 5, 27 and 19; · SEQ ID NO: 22, 24, 12, 14, 8 and 10, and SEQ ID NO: 15, 25, 9, 23, 13 and 11; · SEQ ID NO: 24, 6, 4, 20, 18 and 32, and SEQ ID NO: 8, 30, 14, 12, 26 and 10; · SEQ ID NO: 24, 6, 4, 20, 18 and 32, and SEQ ID NO: 7, 21, 5, 25, 33 and 19; · SEQ ID NO: 24, 6, 4, 20, 18 and 32, and SEQ ID NO: 8, 30, 14, 12, 26 and 10; · SEQ ID NO: 8, 30, 14, 12, 26 and 10, and SEQ ID NO: 9, 13, 31, 27, 15 and 11; · SEQ ID NO: 6, 20, 4, 24, 32 and 18, and SEQ ID NO: 8, 12, 30, 26, 14 and 10; · SEQ ID NO: 7, 21, 5, 25, 33 and 19, and SEQ ID NO: 9, 13, 31, 27, 15 and 11; · SEQ ID NO: 20, 32, 24, 4, 6 and 18, and SEQ ID NO: 26, 30, 12, 14, 8 and 10; · SEQ ID NO: 7, 25, 19, 5, 33 and 21, and SEQ ID NO: 15, 31, 9, 27, 13 and 11; · SEQ ID NO: 24, 6, 16 and 18, and SEQ ID NO: 26, 20, 10 and 28; · SEQ ID NO: 24, 6, 16 and 18, and SEQ ID NO: 26, 10, 20 and 28; · SEQ ID NO: 24, 6, 16 and 18, and SEQ ID NO: 7, 25, 17 and 19; ·SEQ ID Nos: 7, 19, 17 and 25, and SEQ ID NOs: 21, 27, 11 and 29; · SEQ ID NO: 24, 16, 6 and 18, and SEQ ID NO: 27, 11, 21 and 29; · SEQ ID NO: 7, 25, 17 and 19, and SEQ ID NO: 11, 27, 21 and 29; · SEQ ID NO: 7, 25, 17 and 19, and SEQ ID NO: 21, 27, 11 and 29; · SEQ ID NO: 22, 6, 20 and 28, and SEQ ID NO: 23, 7, 21 and 29; · SEQ ID NO: 22, 20, 6 and 28, and SEQ ID NO: 7, 21, 23 and 29; · SEQ ID NO: 26, 10, 20 and 28, and SEQ ID NO: 21, 27, 11 and 29; ·SEQ ID NO: 22, 6, 16, 20, 18, 28, 26 and 10; or • SEQ ID NO: 7, 21, 19, 17, 27, 25, 29 and 11. 226. The kit of any one of claims 216 to 225, comprising one or more fusion polypeptides, one or more polynucleotides encoding one or more fusion polypeptides. One or more carriers or one or more liposome complexes (LNP), the fusion polypeptide comprises or consists of: SEQ ID NO: 70-101, 105-112, 200-209, 222- The amino acid sequence of any one of 223 and 227, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% The same amino acid sequence. 227. The kit of any one of claims 216 to 226, comprising one or more fusion polypeptides, one or more polynucleotides encoding one or more fusion polypeptides. One or more carriers or one or more liposome complexes (LNP), the fusion polypeptide comprises or consists of: SEQ ID NO: 82-83, 85-87, 98-101, 209, The amino acid sequence of any one of 222-223 and 227, or at least 80%, 81% consistent with any one of SEQ ID NO: 82-83, 85-87, 98-101, 209, 222-223 and 227 , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98 % or 99% identical amino acid sequence. 228. The kit of any one of claims 216 to 227, comprising a first fusion polypeptide and a second fusion polypeptide, or one or more polynucleotides comprising: A vector, said one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: A fusion polypeptide of SEQ ID NO: 70 and 71, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 70 and 71, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 72 and 73, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 72 and 73, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 74 and 75, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 74 and 75, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 76 and 77, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 76 and 77, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 78 and 79, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 78 and 79, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 80 and 81, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 80 and 81, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 90 and 91, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 92 and 93, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 92 and 93, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 96 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 220 and 221, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; or A fusion polypeptide of SEQ ID NO: 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 229. The kit of any one of claims 216 to 228, comprising the following first and second fusion polypeptides, one or more vectors comprising one or more polynucleotides or one or more liposome complexes (e.g., LNPs) encoding one or more polynucleotides bound or linked sequentially from the N-terminus to the C-terminus and optionally via one or more linkers The following first fusion polypeptide and second fusion polypeptide: A fusion polypeptide of SEQ ID NO: 70 and 71, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 70 and 71, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 71 and 70, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 71 and 70, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 72 and 73, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 72 and 73, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 73 and 72, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 73 and 72, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 74 and 75, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 74 and 75, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 75 and 74, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 75 and 74, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 76 and 77, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 76 and 77, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 77 and 76, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 77 and 76, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 78 and 79, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 78 and 79, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 79 and 78, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 79 and 78, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 80 and 81, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 80 and 81, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 81 and 80, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 81 and 80, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 84, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 84, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 89 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 89 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 84, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 84, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 84, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 89 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 89 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 101 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 101 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 90 and 91, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 91 and 90, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 91 and 90, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 92 and 93, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 92 and 93, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 93 and 92, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 93 and 92, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 94, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 94, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 96 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 97 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 97 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 96 and 94, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 96 and 94, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 97 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 97 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 220 and 221, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 221 and 220, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 221 and 220, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 100 and 98, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 98, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 101 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 101 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 98, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 98, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; or A fusion polypeptide of SEQ ID NO: 101 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 101 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 230. The kit of any one of claims 216 to 229, comprising first, second, third and fourth viral vectors or liposomes containing one or more polynucleotides Complexes (e.g., LNPs), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 82 and 83, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 84 and 85, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; c) A third viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 86 and 87, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and d) A fourth viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 88 and 89, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 231. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes containing one or more polynucleotides (e.g., LNP ), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 82 and 86, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 83 and 87, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 232. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes containing one or more polynucleotides (e.g., LNP ), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NOs: 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NOs: 82 and 85. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 88 and 87, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 233. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes containing one or more polynucleotides (e.g., LNP ), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 82 and 88, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 85 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 234. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes (eg, LNPs), the first and second viruses The vector or liposome complex (e.g., LNP) contains one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: a) A first viral vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 200, or with SEQ ID NO: 200 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide; and b) A second viral vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 201, or with SEQ ID NO: 201 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 235. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes (eg, LNPs), the first and second viruses The vector or liposome complex (e.g., LNP) contains one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: a) A first viral vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 202, or with SEQ ID No: 202 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide; and b) A second viral vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 203, or with SEQ ID NO: 203 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 236. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes (eg, LNPs), the first and second viruses The vector or liposome complex (e.g., LNP) contains one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: a) A first viral vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 204, or with SEQ ID NO: 204 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide; and b) A second viral vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 205, or with SEQ ID NO: 205 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 237. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes (eg, LNPs), the first and second viruses The vector or liposome complex (e.g., LNP) contains one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: a) A first viral vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 105 or 206, or with SEQ ID NO: 105 or 206, respectively. ID NO: 105 or 206 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94 %, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 107 or 207, or a fusion polypeptide with SEQ ID NO: 107 or 207, respectively. ID NO: 107 or 207 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94 %, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 238. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes (eg, LNPs), the first and second viruses The vector or liposome complex (e.g., LNP) contains one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: a) A first viral vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 208, or with SEQ ID NO: 208 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide; and b) a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, Or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92 with SEQ ID NO: 209 or SEQ ID NO: 227 %, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 239. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes (eg, LNPs), the first and second viruses The vector or liposome complex (e.g., LNP) contains one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: a) A first viral vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 222, or with SEQ ID NO: 222 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide; and b) a second viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, Or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92 with SEQ ID NO: 209 or SEQ ID NO: 227 %, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 240. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes (eg, LNPs), the first and second viruses The vector or liposome complex (e.g., LNP) contains one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide: a) A first viral vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 222, or with SEQ ID NO: 222 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide; and b) A second viral vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 223, or with SEQ ID NO: 223 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 241. The kit of any one of claims 216 to 229, comprising first, second, third and fourth viral vectors or liposomes containing one or more polynucleotides Complexes (e.g., LNPs), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 82 and 86, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 83 and 87, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; c) A third viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 84 and 88, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and d) A fourth viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 242. The kit of any one of claims 216 to 229, comprising first, second, third and fourth viral vectors or liposomes containing one or more polynucleotides Complexes (e.g., LNPs), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 82 and 86, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 83 and 87, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; c) A third viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 98 and 100. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and d) A fourth viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 99 and 101 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 243. The kit of any one of claims 216 to 229, comprising first, second, third and fourth viral vectors or liposomes containing one or more polynucleotides Complexes (e.g., LNPs), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 82 and 86, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 83 and 87, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; c) A third viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 98 and 100. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and d) A fourth viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 85 and 101 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 244. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes containing one or more polynucleotides (e.g., LNP ), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 90 and 91, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 92 and 93, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 92 and 93, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 245. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes containing one or more polynucleotides (e.g., LNP ), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NOs: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NOs: 94 and 96, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 95 and 97. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 246. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes containing one or more polynucleotides (e.g., LNP ), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 220 and 221. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 95 and 97. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 247. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes (eg, LNPs), the first and second viruses The vector or liposome complex (e.g., LNP) contains one or more polynucleotides encoding a first and second composite fusion polypeptide, respectively: a) A first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first composite fusion polypeptide comprising: the amino acid of SEQ ID NO: 222 Sequence, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence, and b) A second viral vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a second composite fusion polypeptide comprising: SEQ ID NO: 209 or SEQ ID NO: The amino acid sequence of 227, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, respectively, with SEQ ID NO: 209 or SEQ ID NO: 227. 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences. 248. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes (e.g., LNP), the second viral vector or liposome complex A plastid complex (e.g., LNP) includes one or more polynucleotides encoding a first composite fusion polypeptide and a second composite fusion polypeptide, respectively: a) a first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding a first composite fusion polypeptide comprising: the amino acid sequence of SEQ ID NO: 222, or At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94 with SEQ ID NO: 222 %, 95%, 96%, 97%, 98% or 99% identical amino acid sequence, and b) a second viral vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a second composite fusion polypeptide comprising: the amino acid sequence of SEQ ID NO: 223, or At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, respectively with SEQ ID NO: 223 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences. 249. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes containing one or more polynucleotides (e.g., LNP ), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 94 and 95. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 250. The kit of any one of claims 216 to 229, comprising first and second viral vectors or liposome complexes containing one or more polynucleotides (e.g., LNP ), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 98 and 100. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 99 and 101 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 251. The kit of any one of claims 216 to 229, comprising first, second, third and fourth viral vectors or liposomes containing one or more polynucleotides Complexes (e.g., LNPs), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising: one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 96 A fusion polypeptide, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90, respectively, of any one of SEQ ID NOs: 94 and 96 %, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; or encoding one or more of the following first fusion polypeptide and second fusion polypeptide Polynucleotide: a fusion polypeptide comprising SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85% with any one of SEQ ID NO: 220 and 221, respectively , 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 95 and 97. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; c) A third viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 98 and 100. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and d) A fourth viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 99 and 101 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 252. The kit of any one of claims 216 to 229, comprising first, second, third and fourth viral vectors or liposomes containing one or more polynucleotides Complexes (e.g., LNPs), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 94 and 95. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; c) A third viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 98 and 99, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and d) A fourth viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO: 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 100 and 101 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 253. The kit of any one of claims 230 to 252, wherein the viral vector is a lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vector. 254. The kit of any one of claims 230 to 252, wherein the viral vector is Cali mammalian arenavirus (also known as Pichand mammalian arenavirus or Pichand arenavirus) Viral vectors. 255. The kit of any one of claims 230 to 252, wherein the viral vector is an adenoviral vector, such as a chimpanzee adenoviral vector (ChAd). 256. The kit of any one of claims 216 to 255, comprising a polynucleotide comprising or consisting of: SEQ ID NOs: 130-167, 210-219 and any one of 225-226, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NOs: 130-167, 210-219 and 225-226 , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical nucleic acid sequences. 257. The kit of any one of claims 216 to 256, comprising a polynucleotide comprising or consisting of: SEQ ID NO: 139, 140, 142, 143 , the nucleic acid sequence of any one of 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or the same as SEQ ID NO: 139, 140, 142, 143, 145, 146, 148, 149 , any one of 150, 152, 155, 158, 225 and 226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% , 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical nucleic acid sequences. 258. The kit of any one of claims 216 to 257, comprising the following first polynucleotide and a second polynucleotide, comprising the following first polynucleotide and a second polynucleotide. One or more carriers of nucleotides or one or more liposomal complexes (e.g., LNP): The polynucleotide of SEQ ID NO: 130 and 132, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 130 and 134, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 130 and 134. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 131 and 133, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 131 and 135, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 132 and 136, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 133 and 135, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 133 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 134 and 136, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 135 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 135 and 137 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 138 and 141, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 138 and 141 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 138 and 144, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 138 and 144. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 139 and 142, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 139 and 142. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 139 and 145, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 139 and 145. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 140 and 146, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 142 and 148, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 142 and 148. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 143 and 149, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 143 and 149 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 145 and 148, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 150 and 152, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 150 and 155, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 150 and 155. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 151 and 153, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 151 and 153. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 151 and 156, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 152 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 152 and 158. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 153 and 159, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 153 and 159. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 154 and 157, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 154 and 157. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 155 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 155 and 158. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 156 and 159, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 156 and 159. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 160 and 161, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 160 and 161 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 162 and 163, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 164 and 165, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 166 and 167, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 210 and 211, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 210 and 211 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 212 and 213, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 214 and 215, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 216 and 217, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 218 and 219, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 218 and 219 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 218 and 226, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; or The polynucleotide of SEQ ID NO: 225 and 226, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 259. The kit of any one of claims 216 to 258, comprising first and second viral vectors or liposomes containing first and second polynucleotides Complex (e.g., LNP): a) A first vector or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleotide comprising SEQ ID NO: 131 and 135, or SEQ ID NO: 131, respectively and any one of 135 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second carrier or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleotide comprising SEQ ID NO: 133 and 137, or SEQ ID NO: 133, respectively and any one of 137 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 260. The kit of any one of claims 216 to 258, comprising first and second viral vectors or liposomes containing first and second polynucleotides Complex (e.g., LNP): a) A first vector or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleotide comprising SEQ ID NO: 139 and 145, or SEQ ID NO: 139, respectively and any one of 145 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second carrier or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleotide comprising SEQ ID NO: 143 and 149, or SEQ ID NO: 139, respectively and any one of 145 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 261. The kit of any one of claims 216 to 260, comprising first, second, third and fourth viral vectors or liposome complexes (eg, LNPs), each The carrier or liposome complex (e.g., LNP) contains first and second polynucleotides: a) A first viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 131 and 135, or SEQ ID NO: 131 and 135, respectively. : Any one of 131 and 135 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; b) A second viral vector or liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 133 and 137, or SEQ ID NO: 133 and 137, respectively. : any one of 133 and 137 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; c) A third viral vector or liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 139 and 145, or SEQ ID NO: 139 and 145, respectively. : any one of 139 and 145 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and d) A fourth viral vector or liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 142 and 148, or SEQ ID NO: 142 and 148, respectively. : any one of 142 and 148 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 262. The kit of any one of claims 216 to 258, comprising first and second viral vectors or liposomes containing first and second polynucleotides Complex (e.g., LNP): a) A first vector or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleotide comprising SEQ ID NO: 140 and 146, or SEQ ID NO: 140, respectively and any one of 146 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second carrier or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleotide comprising SEQ ID NO: 143 and 149, or SEQ ID NO: 143, respectively and any one of 149 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 263. The kit of claim 262, wherein the first and second viral vectors are lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vectors. 264. The kit of any one of claims 216 to 258, comprising first and second viral vectors or liposomes containing first and second polynucleotides Complex (e.g., LNP): a) A first vector or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleotide comprising SEQ ID NO: 150 and 152, or SEQ ID NO: 150, respectively and any one of 152 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) a second carrier or liposome complex (e.g., LNP) comprising first and second polynucleotides: polynucleotides comprising SEQ ID NO: 154 and 157 or SEQ ID NO: 155 and 158, Or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 265. The kit of claim 264, wherein the first and second viral vectors are Cali mammalian arenavirus (also known as Pichand mammalian arenavirus or Pichand arenavirus) virus carrier. 266. The kit of any one of claims 216 to 258 and 262 to 265, comprising first, second, third and fourth viral vectors or liposome complexes (e.g., LNP ), each vector or liposome complex (e.g., LNP) comprising a first and a second polynucleotide: a) A first viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 140 and 146, or SEQ ID NO: 140 and 146, respectively. : any one of 140 and 146 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; b) A second viral vector or liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 143 and 149, or SEQ ID NO: 143 and 149, respectively. : any one of 143 and 149 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; c) A third viral vector or liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 150 and 152, or SEQ ID NO: 150 and 152, respectively. : any one of 150 and 152 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and d) A fourth viral vector or liposome complex (e.g., LNP) comprising first and second polynucleotides: a polynucleoside comprising SEQ ID NO: 154 and 157 or SEQ ID NO: 155 and 158 acid, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 267. The kit of any one of claims 216 to 258, comprising first, second, third and fourth viral vectors or liposome complexes (eg, LNPs), each The carrier or liposome complex (e.g., LNP) contains first and second polynucleotides: a) A first viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 150 and 152, or SEQ ID NO: 150 and 152, respectively. : any one of 150 and 152 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; b) A second viral vector or liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 155 and 158, or SEQ ID NO: 155 and 158, respectively. : any one of 155 and 158 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; c) A third viral vector or liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 151 and 153, or SEQ ID NO: 151 and 153, respectively. : any one of 151 and 153 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and d) A fourth viral vector or liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 156 and 159, or SEQ ID NO: 156 and 159, respectively. : any one of 156 and 159 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 268. The kit of claim 267, wherein one or more of the first, second, third and fourth vectors are adenoviral vectors. 269. The kit of any one of claims 216 to 258, comprising first and second viral vectors or liposomes containing first and second polynucleotides Complex (e.g., LNP): a) A first vector or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleotide comprising SEQ ID NO: 160 and 161, or SEQ ID NO: 160, respectively and any one of 161 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second carrier or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleotide comprising SEQ ID NO: 162 and 163, or SEQ ID NO: 162, respectively and any one of 163 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 270. The kit of any one of claims 216 to 258, comprising first and second viral vectors comprising a first polynucleotide and a Two polynucleotides: a) A first vector or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleotide comprising SEQ ID NO: 164 and 165, or SEQ ID NO: 164, respectively and any one of 165 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second carrier or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleotide comprising SEQ ID NO: 166 and 167, or SEQ ID NO: 166, respectively and any one of 167 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 271. The kit of any one of claims 216 to 258, comprising (a) a first carrier or liposome complex (eg, LNP) and (b) a second carrier or lipid a body complex (e.g., LNP), the first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide: a polynucleotide comprising SEQ ID NO: 210 or a polynucleotide with SEQ ID NO: 210 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98% or 99% identical polynucleotide, the second vector or liposome complex (e.g., LNP) comprising the following second polynucleotide: the polynucleoside comprising SEQ ID NO: 211 Acid or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% with SEQ ID NO:211 , 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 272. The kit of any one of claims 216 to 258, comprising (a) a first carrier or liposome complex (eg, LNP) and (b) a second carrier or lipid a body complex (e.g., LNP), the first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide: a polynucleotide comprising SEQ ID NO: 212 or a polynucleotide with SEQ ID NO: 212 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98% or 99% identical polynucleotide, the second vector or liposome complex (e.g., LNP) comprising the following second polynucleotide: the polynucleoside comprising SEQ ID NO: 213 Acid or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% with SEQ ID NO:213 ,94%,95%,96%, 97%, 98% or 99% identical polynucleotides. 273. The kit of any one of claims 216 to 258, comprising (a) a first carrier or liposome complex (eg, LNP) and (b) a second carrier or lipid a body complex (e.g., LNP), the first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide: a polynucleotide comprising SEQ ID NO: 214 or a polynucleotide with SEQ ID NO: 214 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98% or 99% identical polynucleotide, the second vector or liposome complex (e.g., LNP) comprising the following second polynucleotide: the polynucleoside comprising SEQ ID NO: 215 acid or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% with SEQ ID NO:215 , 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 274. The kit of any one of claims 216 to 258, comprising (a) a first carrier or liposome complex (eg, LNP) and (b) a second carrier or lipid a body complex (e.g., LNP), the first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide: a polynucleotide comprising SEQ ID NO: 216 or a polynucleotide with SEQ ID NO: 216 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98% or 99% identical polynucleotide, the second vector or liposome complex (e.g., LNP) comprising the following second polynucleotide: the polynucleoside comprising SEQ ID NO: 217 acid or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% with SEQ ID NO:217 ,94%,95%,96%, 97%, 98% or 99% identical polynucleotides. 275. The kit of any one of claims 216 to 258, comprising (a) a first carrier or liposome complex (eg, LNP) and (b) a second carrier or lipid a body complex (e.g., LNP), the first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide: a polynucleotide comprising SEQ ID NO: 218 or a polynucleotide with SEQ ID NO: 218 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98% or 99% identical polynucleotide, the second vector or liposome complex (e.g., LNP) comprising the following second polynucleotide: the polynucleoside comprising SEQ ID NO: 219 acid or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% with SEQ ID NO:219 , 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 276. The kit of any one of claims 216 to 258, comprising (a) a first carrier or liposome complex (eg, LNP) and (b) a second carrier or lipid a body complex (e.g., LNP), the first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide: a polynucleotide comprising SEQ ID NO: 218 or a polynucleotide with SEQ ID NO: 218 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98% or 99% identical polynucleotide, the second vector or liposome complex (e.g., LNP) comprising the following second polynucleotide: the polynucleoside comprising SEQ ID NO: 226 Acid or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% with SEQ ID NO:226 , 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 277. The kit of any one of claims 216 to 258, comprising (a) a first carrier or liposome complex (eg, LNP) and (b) a second carrier or lipid a body complex (e.g., LNP), the first carrier or liposome complex (e.g., LNP) comprising a first polynucleotide: a polynucleotide comprising SEQ ID NO: 225 or a polynucleotide with SEQ ID NO: 225 At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98% or 99% identical polynucleotide, the second vector or liposome complex (e.g., LNP) comprising the following second polynucleotide: the polynucleoside comprising SEQ ID NO: 226 Acid or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% with SEQ ID NO:226 , 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 278. The kit of any one of claims 216 to 277, comprising a composite fusion polypeptide, a vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a composite fusion polypeptide, The composite fusion polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or the amino acid sequence of any one of SEQ ID NOs: 105-112, 200- Any of 209, 222-223 and 227 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92 %, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences. 279. The kit of any one of claims 216 to 278, comprising a composite fusion polypeptide, a vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a composite fusion polypeptide, The composite fusion polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NO:209, 222 and 223, or is at least 80%, 81% identical to any one of SEQ ID NO:209, 222 and 223. %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence. 280. The kit of any one of claims 216 to 279, wherein the one or more fusion polypeptides do not comprise polypeptides corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118- 128. Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116 and Nef149-206 or their fragments or subunits Any polypeptide fragment of a sequence wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NO: 1, 2 and 3 respectively. 281. The kit of any one of claims 216 to 280, wherein the one or more fusion polypeptides do not comprise the amino acid sequence having SEQ ID NO: 35-47, or a fragment or subsequence thereof, or with At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92 of any one of SEQ ID NOs: 35-47 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence or any polypeptide fragment thereof. 282. The kit of any one of claims 216 to 281, further comprising one or more unit doses of one or more additional therapeutic agents. 283. The kit of claim 282, comprising one or more agents that activate latent HIV, such as one or more latency reversal agents (LRA). 284. The kit of any one of claims 282 to 283, comprising one or more LRAs selected from: agonists of one or more toll-like receptors (TLRs) or Activator, histone deacetylase (HDAC) inhibitor, proteasome inhibitor, protein kinase C (PKC) activator, Smyd2 inhibitor, BET-bromodomain 4 (BRD4) inhibitor, ionomycin, apoptosis Inhibitor of protein (IAP) antagonists and second mitochondria-derived activator mimetics of caspase (SMAC). 285. The kit of any one of claims 282 to 284, comprising one or more agonists or activators of one or more toll-like receptors (TLRs). 286. The kit of claim 285, wherein the TLR agonist or activator is selected from the group consisting of TLR2 agonist, TLR3 agonist, TLR4 agonist, TLR5 agonist, TLR7 agonist, TLR8 agonist and TLR9 agonist. . 287. The kit of any one of claims 285 to 286, wherein the TLR7 agonist is selected from the group consisting of GS9620 (visamod), R848 (resiquimod), DS-0509, LHC-165 and TMX-101 (imiquimod), and/or wherein the TLR8 agonist is selected from the group consisting of GS-9688 (selgantomod), R848 (resiquimod), and NKTR-262 (dual TLR7/TLR8 agonist agent). 288. The kit of any one of claims 282 to 287, comprising one or more interleukin receptors of interleukins selected from the group consisting of IL-2, IL-7, IL-12 and IL-15. Body agonists. 289. The kit of claim 288, comprising one or more cytokines selected from the group consisting of: IL-2, IL-7, IL-12, IL-15, and variants thereof. 290. The kit of any one of claims 282 to 289, comprising one or more innate immune activators. 291. The kit of claim 290, wherein the one or more innate immune activators comprise an agonist of a receptor selected from: fms-related tyrosine kinase 3 (FLT3), interferon gene stimulation agent (STING) receptor, DExD/H box helicase 58 (DDX58; Also known as RIG-I), nucleotide-binding oligomerization domain-containing protein 2 (NOD2). 292. The kit of any one of claims 282 to 291, comprising an agonist of fms-related tyrosine kinase 3 (FLT3). 293. The kit of any one of claims 282 to 292, comprising one or more antagonists or inhibitors of inhibitory immune checkpoint proteins or receptors and/or stimulatory immune tests One or more activators or agonists of dot proteins or receptors. 294. The kit of claim 293, wherein the one or more immune checkpoint proteins or receptors are selected from the group consisting of: CD27, CD70; CD40, CD40LG; CD47, CD48 (SLAMF2), Globulin domain protein 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3); T cell activation inhibitor containing V-set domain 1 (VTCN1, B7H4); V-set immunomodulatory receptors (VSIR, B7H5, VISTA); Immunoglobulin superfamily member 11 (IGSF11, VSIG3); Natural killer cell cytotoxic receptor 3 ligand 1 (NCR3LG1, B7H6 ); HERV-H LTR-associated 2 (HHLA2, B7H7); inducible T cell costimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 ( TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30L); TNFRSF10A (CD261, DR4, TRAILR1), TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5 , TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13B (BAFF); TNFRSF18 (GITR) , TNFSF18 (GITRL); MHC class I peptide-related sequence A (MICA); MHC class I peptide-related sequence B (MICB); CD274 (CD274, PDL1, PD-L1); Programmed cell death 1 (PDCD1, PD1, PD -1); Cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); poliovirus Receptor (PVR) cell adhesion molecule (PVR, CD155); PVR-related immunoglobulin domain-containing protein (PVRIG, CD112R); T-cell immune receptor with Ig and ITIM domains (TIGIT); T-cell immunity-containing Globulin and mucin domain protein 4 (TIMD4; TIM4; Hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); Galectin 9 (LGALS9); Lymphocyte activation 3 (LAG3, CD223); Signaling Transduced lymphocyte activation molecule family member 1 (SLAMF1, SLAM, CD150); lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6, CD352); SLAM family member 7 (SLAMF7, CD319); UL16 Binding protein 1 (ULBP1); UL16 binding protein 2 (ULBP2); UL16 binding protein 3 (ULBP3); Retinoic acid early transcript 1E (RAET1E; ULBP4); Retinoic acid early transcript 1G (RAET1G; ULBP5); xanthate early transcript 1L (RAET1L; ULBP6); lymphocyte activation 3 (CD223); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell lectin Killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); Killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314); Killer cell lectin-like receptor C2 (KLRC2, CD159c, NKG2C); Killer cell lectin-like receptor Body C3 (KLRC3, NKG2E); Killer cell lectin-like receptor C4 (KLRC4, NKG2F); Killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); Killer cell immunoglobulin Killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 2 (KIR2DL2); Killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 3 (KIR2DL3); Killer cell immunoglobulin-like Receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor D1 (KLRD1); and SLAM family member 7 (SLAMF7). 295. The kit of any one of claims 293 to 294, comprising one or more blockers or inhibition of one or more T cell inhibitory immune checkpoint proteins or receptors agent. 296. The kit of claim 295, wherein the T cell inhibitory immune checkpoint protein or receptor is selected from: CD274 (CD274, PDL1, PD-L1); Programmed cell death 1 ligand 2 (PDCD1LG2 , PD-L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD276 (B7H3); T containing V-set domain Cell activation inhibitor 1 (VTCN1, B7H4); V-set immune regulatory receptors (VSIR, B7H5, VISTA); Immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML) ; CD272 (B and T lymphocyte associated (BTLA)); PVR-related immunoglobulin domain-containing proteins (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); Lymphocyte Activation 3 ( LAG3, CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 1 (KIR, CD158E1); Killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 1 (KIR2DL1); Killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 3 (KIR2DL3); and killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 1 ( KIR3DL1). 297. The kit of any one of claims 293 to 296, comprising one or more agonists or activators of one or more T cell stimulating immune checkpoint proteins or receptors . 298. The kit of claim 297, wherein the T cell inhibitory immune checkpoint protein or receptor is selected from: CD27, CD70; CD40, CD40LG; inducible T cell costimulator (ICOS, CD278); Inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). 299. The kit of any one of claims 293 to 298, comprising one or more blockers or inhibition of one or more NK cell inhibitory immune checkpoint proteins or receptors agent. 300. The kit of claim 299, wherein the NK cell inhibitory immune checkpoint protein or receptor is selected from the group consisting of: killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 1 ( KIR, CD158E1); Killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 1 (KIR2DL1); Killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 2 ( KIR2DL2); Killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 3 (KIR2DL3); Killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 1 (KIR3DL1) ; Killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); and killer cell lectin-like receptor D1 (KLRD1, CD94). 301. The kit of any one of claims 293 to 300, comprising one or more agonists or activators of one or more NK cell stimulating immune checkpoint proteins or receptors . 302. The kit of claim 301, wherein the NK cell stimulating immune checkpoint protein or receptor is selected from the group consisting of: CD16, CD226 (DNAM-1); Killer cell lectin-like receptor K1 (KLRK1, NKG2D , CD314); and SLAM family member 7 (SLAMF7). 303. The kit of any one of claims 293 to 302, wherein the one or more immune checkpoint inhibitors comprise protein inhibition of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4 agent. 304. The kit of any one of claims 293 to 303, comprising an antibody that binds CTLA4. 305. The kit of claim 303 or claim 304, wherein the protein or antibody inhibitor of CTLA4 is selected from: ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS- 986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, CG-0161, ATOR-1144, PBI-5D3H5, FPT-155(CTLA4/PD-L1/CD28), PF-06936308(PD-1/CTLA4), MGD-019(PD-1/CTLA4), KN-046 (PD-1/CTLA4), MEDI-5752(CTLA4/PD-1), XmAb-20717(PD-1/CTLA4) and AK-104(CTLA4/PD-1). 306. The kit according to claim 303, wherein the protein inhibitor of PD-L1 (CD274) or PD-1 (PDCD1) is selected from the group consisting of: pembrolizumab, nivolumab, cimelimab, Pidtilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK- 301. PF-06801591, BGB-A317 (tislelizumab), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, HLX-10, MGA- 012, BI-754091, AGEN-2034, JS-001 (toripalimab), JNJ-63723283, jenosumab (CBT-501), LZM-009, BCD-100, LY-3300054, SHR- 1201, SHR-1210 (camrelizumab), Sym-021, ABBV-181, PD1-PIK, BAT-1306 (MSB0010718C), CX-072, CBT-502, TSR-042 (dortalizumab ), MSB-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308 (sintilimab), HLX-20, KL-A167, STI -A1014, STI-A1015(IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, FPT-155(CTLA4/PD-L1/CD28), PF-06936308(PD-1/CTLA4 ), MGD-013(PD-1/LAG-3), FS-118(LAG-3/PD-L1)MGD-019(PD-1/CTLA4), KN-046(PD-1/CTLA4), MEDI -5752(CTLA4/PD-1), RO-7121661(PD-1/TIM-3), XmAb-20717(PD-1/CTLA4), AK-104(CTLA4/PD-1), M7824(PD-L1 /TGFβ-EC domain), CA-170 (PD-L1/VISTA), CDX-527 (CD27/PD-L1), LY-3415244 (TIM3/PDL1) and INBRX-105 (4-1BB/PDL1). 307. The kit of any one of claims 293 to 306, wherein the one or more immune checkpoint inhibitors comprise CD274 (PDL1, PD-L1), programmed cell death 1 (PDCD1, PD1 , PD-1) or small molecule inhibitors of CTLA4. 308. The kit of claim 307, wherein the small molecule inhibitor of CD274 or PDCD1 is selected from the group consisting of: GS-4224, GS-4416, INCB086550 and MAX10181. 309. The kit of claim 307, wherein the small molecule inhibitor of CTLA4 comprises BPI-002. 310. The kit of any one of claims 282 to 309, further comprising one or more antiviral agents. 311. The kit of claim 310, wherein the one or more antiviral agents are selected from: HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic sites ( or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors and capsid inhibitors. 312. A method for eliciting an immune response against human immunodeficiency virus (HIV) in a subject in need thereof, said method comprising administering to said subject a method according to any one of claims 145 to 215 The immunogenic composition of one item. 313. The immunogenic composition according to any one of claims 145 to 215 for use as a medicament. 314. A method of treating or preventing human immunodeficiency virus (HIV) in a subject in need thereof, said method comprising administering to said subject a method according to any one of claims 145 to 215 immunogenic compositions. 315. The immunogenic composition of any one of claims 145 to 215 for the treatment or prevention of human immunodeficiency virus (HIV) in a subject in need thereof Methods. 316. The method or use of any one of claims 312 to 315, comprising administering a single vector comprising one or more polypeptides encoding a first fusion polypeptide and a second fusion polypeptide. glycosides. 317. The method or use of any one of claims 312 to 315, wherein two or more fusion polypeptides, two or more composite fusion polypeptides, two or more genes encoding said fusion polypeptides are combined A plurality of polynucleotides, two or more viral expression vectors comprising polynucleotides encoding the fusion polypeptide, two or more liposome complexes (e.g., LNPs), or two or more The immunogenic composition is administered to the subject simultaneously or in parallel. 318. The method of any one of claims 312 to 317, wherein two or more fusion polypeptides or two or more polynucleotides encoding said fusion polypeptides or two or more viruses The expression vector is in the form of a bivalent antigen composition. 319. The method of any one of claims 312 to 318, comprising administering a first fusion polypeptide and a second fusion polypeptide, first and second polypeptides encoding the first and second fusion polypeptides. nucleotides, one or more vectors, one or more liposome complexes (e.g., LNP) comprising one or more polynucleotides encoding the first and second fusion polypeptides, the first The first and second polypeptides comprise, in order from the N-terminus to the C-terminus, the following polypeptide fragments optionally bound or linked by one or more linkers: · SEQ ID NO: 6, 4, 16 and 26, and SEQ ID NO: 7, 5, 27 and 17; · SEQ ID NO: 12, 24, 8 and 10, and SEQ ID NO: 9, 25, 13 and 11; · SEQ ID NO: 14, 22, 18, 24 and 20, and SEQ ID NO: 15, 25, 19, 23 and 21; · SEQ ID NO: 26, 16, 4 and 6, and SEQ ID NO: 7, 27, 5 and 17; · SEQ ID NO: 8, 24, 12 and 10, and SEQ ID NO: 13, 25, 9 and 11; · SEQ ID NO: 22, 24, 14, 18 and 20, and SEQ ID NO: 25, 23, 15, 21 and 19; · SEQ ID NO: 20, 6, 4, 18, 16 and 26, and SEQ ID NO: 7, 19, 5, 21, 27 and 17; · SEQ ID NO: 8, 24, 14, 12, 22 and 10, and SEQ ID NO: 9, 13, 25, 23, 15 and 11; · SEQ ID NO: 18, 26, 20, 4, 6 and 16, and SEQ ID NO: 7, 21, 17, 5, 27 and 19; · SEQ ID NO: 22, 24, 12, 14, 8 and 10, and SEQ ID NO: 15, 25, 9, 23, 13 and 11; · SEQ ID NO: 24, 6, 4, 20, 18 and 32, and SEQ ID NO: 8, 30, 14, 12, 26 and 10; · SEQ ID NO: 24, 6, 4, 20, 18 and 32, and SEQ ID NO: 7, 21, 5, 25, 33 and 19; · SEQ ID NO: 24, 6, 4, 20, 18 and 32, and SEQ ID NO: 8, 30, 14, 12, 26 and 10; · SEQ ID NO: 8, 30, 14, 12, 26 and 10, and SEQ ID NO: 9, 13, 31, 27, 15 and 11; · SEQ ID NO: 6, 20, 4, 24, 32 and 18, and SEQ ID NO: 8, 12, 30, 26, 14 and 10; · SEQ ID NO: 7, 21, 5, 25, 33 and 19, and SEQ ID NO: 9, 13, 31, 27, 15 and 11; · SEQ ID NO: 20, 32, 24, 4, 6 and 18, and SEQ ID NO: 26, 30, 12, 14, 8 and 10; · SEQ ID NO: 7, 25, 19, 5, 33 and 21, and SEQ ID NO: 15, 31, 9, 27, 13 and 11; · SEQ ID NO: 24, 6, 16 and 18, and SEQ ID NO: 26, 20, 10 and 28; · SEQ ID NO: 24, 6, 16 and 18, and SEQ ID NO: 26, 10, 20 and 28; · SEQ ID NO: 24, 6, 16 and 18, and SEQ ID NO: 7, 25, 17 and 19; · SEQ ID NO: 7, 19, 17 and 25, and SEQ ID NO: 21, 27, 11 and 29; · SEQ ID NO: 24, 16, 6 and 18, and SEQ ID NO: 27, 11, 21 and 29; · SEQ ID NO: 7, 25, 17 and 19, and SEQ ID NO: 11, 27, 21 and 29; · SEQ ID NO: 7, 25, 17 and 19, and SEQ ID NO: 21, 27, 11 and 29; · SEQ ID NO: 22, 6, 20 and 28, and SEQ ID NO: 23, 7, 21 and 29; · SEQ ID NO: 22, 20, 6 and 28, and SEQ ID NO: 7, 21, 23 and 29; · SEQ ID NO: 26, 10, 20 and 28, and SEQ ID NO: 21, 27, 11 and 29; ·SEQ ID NO: 22, 6, 16, 20, 18, 28, 26 and 10; or • SEQ ID NO: 7, 21, 19, 17, 27, 25, 29 and 11. 320. The method of any one of claims 312 to 319, comprising administering one or more fusion polypeptides, one or more polynucleotides encoding one or more fusion polypeptides, comprising One or more vectors, one or more liposome complexes (e.g., LNPs) of one or more polynucleotides of one or more fusion polypeptides comprising The following or consisting of: the amino acid sequence of any one of SEQ ID NO: 70-101, 105-112, 200-209, 222-223 and 227, or the same as SEQ ID NO: 70-101, 105-112, Any of 200-209, 222-223 and 227 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% , 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences. 321. The method of any one of claims 312 to 320, comprising administering one or more fusion polypeptides, one or more polynucleotides encoding one or more fusion polypeptides, comprising One or more vectors, one or more liposome complexes (e.g., LNPs) of one or more polynucleotides of one or more fusion polypeptides comprising The following or consisting of: the amino acid sequence of any one of SEQ ID NO: 82-83, 85-87, 98-101, 209 and 222-223, or the same as SEQ ID NO: 82-83, 85-87, Any of 98-101, 209 and 222-223 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% , 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences. 322. The method of any one of claims 312 to 321, comprising administering the following first and second fusion polypeptides, one or more polynucleotides, comprising one or more polynucleosides One or more carriers or one or more liposome complexes (e.g., LNPs) of acid, the one or more polynucleotides encoding the following optionally bound or linked by one or more linkers First fusion polypeptide and second fusion polypeptide: A fusion polypeptide of SEQ ID NO: 70 and 71, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 70 and 71, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 72 and 73, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 72 and 73, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 74 and 75, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 74 and 75, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 76 and 77, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 76 and 77, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 78 and 79, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 78 and 79, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 80 and 81, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 80 and 81, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 90 and 91, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 92 and 93, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 92 and 93, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 96 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 220 and 221, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; or A fusion polypeptide of SEQ ID NO: 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 323. The method of any one of claims 312 to 322, comprising administering a first fusion polypeptide and a second fusion polypeptide, one or more vectors comprising one or more polynucleotides, or One or more liposome complexes (e.g., LNPs), the one or more polynucleotides encoding the following bound or linked in sequence from the N-terminus to the C-terminus and optionally through one or more linkers First fusion polypeptide and second fusion polypeptide: A fusion polypeptide of SEQ ID NO: 70 and 71, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 70 and 71, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 71 and 70, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 71 and 70, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 72 and 73, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 72 and 73, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 73 and 72, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 73 and 72, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 74 and 75, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 74 and 75, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 75 and 74, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 75 and 74, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 76 and 77, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 76 and 77, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 77 and 76, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 77 and 76, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 78 and 79, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 78 and 79, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 79 and 78, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 79 and 78, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 80 and 81, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 80 and 81, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 81 and 80, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 81 and 80, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 84, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 84, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 89 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 89 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 82, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 87 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 87 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 84, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 84, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 84, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 89 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 89 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 101 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 101 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 90 and 91, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 91 and 90, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 91 and 90, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 92 and 93, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 92 and 93, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 93 and 92, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 93 and 92, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 94, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 94, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID Nos: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NOs: 96 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 97 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 97 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 96 and 94, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 96 and 94, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 97 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 97 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 20 and 221, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 221 and 220, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 221 and 220, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 100 and 98, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 98, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 101 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 101 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 98, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 98, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; or A fusion polypeptide of SEQ ID NO: 101 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 101 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 324. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 82 and 83, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 82 and 83, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides, and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:86 and 87, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO:86 and 87 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 325. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:84 and 85, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO:84 and 85 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides, and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:88 and 89, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO:88 and 89 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 326. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:82 and 86, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO:82 and 86 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides, and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:83 and 87, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO:83 and 87, respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 327. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:82 and 88, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO:82 and 88 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides, and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:85 and 87, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO:85 and 87, respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 328. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:82 and 85, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO:82 and 85 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides, and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:88 and 87, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO:88 and 87, respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 329. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:84 and 88, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO:84 and 88, respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides, and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:85 and 89, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO:85 and 89 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 330. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 98 and 100, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides, and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:85 and 101, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO:85 and 101 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 331. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 94 and 95, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides, and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 96 and 97, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 96 and 97, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 332. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 94 and 96, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 94 and 96, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides, and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 95 and 97, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 333. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 220 and 221, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides, and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 95 and 97, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 334. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first polynucleotide or a first viral vector or a first liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 98 and 100, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides, and b) A second polynucleotide or a second viral vector or a second liposome complex (e.g., LNP) comprising one or more polynucleotides encoding the following: A fusion polypeptide and a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84% with any one of SEQ ID NO: 99 and 101 respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 335. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing first and second polynucleotides. (e.g., LNP), the first and second polynucleotides encoding the following first and second fusion polypeptides: a) A first polynucleotide or a first viral vector or a first liposome complex (eg, LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 200 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (eg, LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 201 A fusion polypeptide, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% with SEQ ID NO:201 , 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 336. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing first and second polynucleotides. (e.g., LNP), the first and second polynucleotides encoding the following first and second fusion polypeptides: a) A first polynucleotide or a first viral vector or a first liposome complex (eg, LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 202 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (eg, LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 203 A fusion polypeptide, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% with SEQ ID NO:203 , 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 337. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing first and second polynucleotides. (e.g., LNP), the first and second polynucleotides encoding the following first and second fusion polypeptides: a) A first polynucleotide or a first viral vector or a first liposome complex (eg, LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 204 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (eg, LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 205 A fusion polypeptide, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% with SEQ ID NO:205 , 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 338. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing first and second polynucleotides. (e.g., LNP), the first and second polynucleotides encoding the following first and second fusion polypeptides: a) A first polynucleotide or a first viral vector or a first liposome complex (eg, LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 105 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (eg, LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 107 A fusion polypeptide, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% with SEQ ID NO:107 , 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 339. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing first and second polynucleotides. (e.g., LNP), the first and second polynucleotides encoding the following first and second fusion polypeptides: a) A first polynucleotide or a first viral vector or a first liposome complex (eg, LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 206 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (eg, LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 207 A fusion polypeptide, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% with SEQ ID NO:207 , 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 340. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing first and second polynucleotides. (e.g., LNP), the first and second polynucleotides encoding the following first and second fusion polypeptides: a) A first polynucleotide or a first viral vector or a first liposome complex (eg, LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 208 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (eg, LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 209 or a fusion polypeptide of SEQ ID NO:227, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% with SEQ ID NO:209 or SEQ ID NO:227 , 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 341. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing first and second polynucleotides. (e.g., LNP), the first and second polynucleotides encoding the following first and second fusion polypeptides: a) A first polynucleotide or a first viral vector or a first liposome complex (eg, LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 222 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (eg, LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 209 or a fusion polypeptide of SEQ ID NO:227, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% with SEQ ID NO:209 or SEQ ID NO:227 , 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 342. The method of any one of claims 312 to 323, comprising administering first and second viral vectors or first and second liposome complexes containing first and second polynucleotides. (e.g., LNP), the first and second polynucleotides encoding the following first and second fusion polypeptides: a) A first polynucleotide or a first viral vector or a first liposome complex (eg, LNP) comprising a polynucleotide encoding a first fusion polypeptide comprising SEQ ID NO: 222 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second polynucleotide or a second viral vector or a second liposome complex (eg, LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising SEQ ID NO: 223 A fusion polypeptide, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% with SEQ ID NO:223 , 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 343. The method of any one of claims 312 to 323, comprising administering a viral vector or liposome complex (e.g., LNP), the viral vector or liposome complex (e.g., LNP ) comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: SEQ ID NO: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or any one of SEQ ID NO: 90 and 91, respectively. 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 344. The method of any one of claims 312 to 323, comprising administering a viral vector or liposome complex (e.g., LNP), the viral vector or liposome complex (e.g., LNP ) comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: SEQ ID NO: 92 and 93, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or any one of SEQ ID NO: 92 and 93, respectively. 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 345. The method of any one of claims 324 to 344, wherein the first and second viral vectors are lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vectors. 346. The method of any one of claims 324 to 344, wherein the first and second viral vectors are Cali mammalian arenavirus (also known as Pichand mammalian arenavirus or Pichand arenavirus) viral vectors. 347. The method of any one of claims 324 to 344, wherein the first and second viral vectors are adenoviral vectors, such as chimpanzee adenoviral vectors (ChAd). 348. The method of any one of claims 324 to 347, wherein the first and second viral vectors or first and second liposome complexes (eg, LNPs) are co-administered in parallel. 349. The method of any one of claims 312 to 348, comprising administering a polynucleotide comprising or consisting of: SEQ ID NOs: 130-167, 210-219 and The nucleic acid sequence of any one of 225-226, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical nucleic acid sequences. 350. The method of any one of claims 312 to 349, comprising administering a polynucleotide comprising or consisting of: SEQ ID NO: 139, 140, 142, 143, The nucleic acid sequence of any one of 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or the same as SEQ ID NO: 139, 140, 142, 143, 145, 146, 148, 149, Any one of 150, 152, 155, 158, 225 and 226 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical nucleic acid sequences. 351. The method of any one of claims 312 to 350, comprising administering a first polynucleotide and a second polynucleotide, comprising: One or more carriers or one or more liposome complexes of glycosides (e.g., LNP): The polynucleotide of SEQ ID NO:130 and 132, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 130 and 134, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 130 and 134. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 131 and 133, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 131 and 135, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 132 and 136, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 133 and 135, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 133 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 134 and 136, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 135 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 135 and 137 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 138 and 141, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 138 and 141 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 138 and 144, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 138 and 144. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 139 and 142, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 139 and 142. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 139 and 145, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 139 and 145. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 140 and 146, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 142 and 148, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 142 and 148. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 143 and 149, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 143 and 149 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 145 and 148, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 150 and 152, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 150 and 155, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 150 and 155. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 151 and 153, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 151 and 153. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 151 and 156, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 152 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 152 and 158. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 153 and 159, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 153 and 159. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 154 and 157, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 154 and 157. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 155 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 155 and 158. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 156 and 159, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 156 and 159. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 160 and 161, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 160 and 161 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 162 and 163, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 164 and 165, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; or The polynucleotide of SEQ ID NO: 166 and 167, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 210 and 211, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 210 and 211 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 212 and 213, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 214 and 215, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 216 and 217, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 218 and 219, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, with any one of SEQ ID NO: 218 and 219 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 218 and 226, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; The polynucleotide of SEQ ID NO: 225 and 226, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 352. The method of any one of claims 312 to 351, comprising administering first and second viral vectors or first and second viral vectors containing first and second polynucleotides. Diliposome complex (e.g., LNP): a) A first vector or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleotide comprising SEQ ID NO: 140 and 146, or SEQ ID NO: 140, respectively and any one of 146 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second carrier or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleotide comprising SEQ ID NO: 143 and 149, or SEQ ID NO: 143, respectively and any one of 149 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, wherein the first and second viral vectors are lymphocytic choriomeningitis mammalian arenavirus (LCMV) viruses carrier. 353. The method of any one of claims 312 to 352, comprising administering first and second viral vectors or first and second viral vectors containing first and second polynucleotides. Diliposome complex (e.g., LNP): a) A first vector or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleotide comprising SEQ ID NO: 150 and 152, or SEQ ID NO: 150, respectively and any one of 152 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) a second carrier or liposome complex (e.g., LNP) comprising first and second polynucleotides: polynucleotides comprising SEQ ID NO: 154 and 157 or SEQ ID NO: 155 and 158, Or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides, wherein the first and second viral vectors are card mammalian arenavirus (also known as Pichand mammalian arenavirus or Pichand arenavirus) viral vector. 354. The method of any one of claims 312 to 323, comprising administering a composite fusion polypeptide, a vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a composite fusion polypeptide, The composite fusion polypeptide comprises or consists of the following: the amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or the amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209 Any one of , 222-223 and 227 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% , 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequences. 355. The method of any one of claims 312 to 323, comprising administering a composite fusion polypeptide, a vector or liposome complex (eg, LNP) comprising a polynucleotide encoding a composite fusion polypeptide, The composite fusion polypeptide comprises or consists of the following: the amino acid sequence of any one of SEQ ID NO:209, 222 and 223, or at least 80%, 81% with any one of SEQ ID NO:209, 222 and 223 , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98 % or 99% identical amino acid sequence. 356. The method of any one of claims 312 to 355, wherein the one or more fusion polypeptides do not comprise polypeptides corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128 , Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116 and Nef149-206 or fragments or subsequences thereof Any polypeptide fragment, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NO: 1, 2 and 3 respectively. 357. The method of any one of claims 312 to 356, wherein the one or more fusion polypeptides do not comprise the amino acid sequence having SEQ ID NO:35-47, or a fragment or subsequence thereof, or are identical to SEQ ID NO:35-47. At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% of any one of ID NOs: 35-47 , 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence or any polypeptide fragment thereof or a fragment or subsequence thereof. 358. The method of any one of claims 312 to 357, wherein the subject is infected, suspected of being infected, or at risk of being infected by HIV-1. 359. The method of any one of claims 312 to 358, wherein the subject is chronically infected with HIV-1. 360. The method of any one of claims 312 to 359, wherein the subject is acutely infected with HIV-1. 361. The method of any one of claims 312 to 360, wherein the subject has Fiebig stage IV or earlier, eg, Fiebig stage III, Fiebig stage II, or Fiebig stage I HIV-1 infection. 362. The method of any one of claims 312 to 361, wherein the fusion polypeptide, the composite fusion polypeptide, the polynucleotide, the vector, the liposome complex (e.g., LNP ) and/or the immunogenic composition is administered via a route selected from the group consisting of intravenous, intramuscular, intradermal, subcutaneous, intranodal, and mucosal (eg, buccal, intranasal, intrarectal, intravaginal). 363. The method of any one of claims 312 to 362, comprising administering from about ¹⁰ to about ¹⁰ viral focus forming units (FFU) or plaque forming units (PFU) per administration or Infectious units (IU) or virus particles (vp), for example about 10 ⁴ to about 10 ⁷ viral FFU or PFU or IU or vp, for example about 10 ³ to about 10 ⁴ , 10 ⁵ , 10 ⁶ , 10 ⁷ , 10 ⁸ , 10 ⁹ , 10 ¹⁰ , 10 ¹¹ , 10 ¹² , 10 ¹³ , 10 ¹⁴ or 10 ¹⁵ virus FFU or PFU or IU or vp. 364. The method of any one of claims 312 to 363, comprising a prime-boost regimen comprising administering a priming composition at a first time point and at one or more One or more boosting compositions are administered at subsequent time points. 365. The method of claim 364, comprising repeating the prime-boost regimen for one or more iterations. 366. The method of any one of claims 364 to 365, wherein the priming composition and the one or more boosting compositions are administered at least 1 week, 2 weeks, 3 weeks, or 1 months, such as at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months. 367. The method of any one of claims 364 to 366, wherein the priming composition and the boosting composition comprise the same immunogenic composition. 368. The method of any one of claims 364 to 366, wherein the priming composition and the boosting composition comprise different immunogenic compositions. 369. The method of any one of claims 364 to 366, wherein the priming composition and the boosting composition comprise the same fusion polypeptide(s) and the same viral expression vector. 370. The method of any one of claims 364 to 366, wherein the priming composition and the boosting composition comprise different fusion polypeptides and/or different viral expression vectors. 371. The method of claim 370, comprising priming with a first viral expression vector and boosting with a second viral expression vector. 372. The method of any one of claims 364 to 371, wherein the prime-boost regimen includes: a) Prime with one or more viral expression vectors and boost with one or more polynucleotides, wherein the one or more polynucleotides comprise DNA, cDNA, mRNA or self-replicating RNA; b) priming with one or more polynucleotides, wherein the one or more polynucleotides comprise DNA, cDNA, mRNA or self-replicating RNA, and boosted with one or more viral expression vectors; c) Prime with one or more viral expression vectors and boost with one or more viral expression vectors, wherein the one or more viral expression vectors and the booster composition in the priming composition The one or more viral expression vectors in are from the same, related or unrelated taxonomic family; d) priming with one or more replication-deficient viral expression vectors and boosting with one or more replication-deficient viral expression vectors, wherein the one or more replication-deficient viruses in the priming composition The expression vector and the one or more replication-deficient viral expression vectors in the boosting composition are from the same, related or unrelated taxonomic family; e) Prime with one or more replication-attenuated viral expression vectors and boost with one or more replication-attenuated viral expression vectors, wherein the one or more replication-attenuated viral expression vectors in the priming composition The virulent viral expression vector and the one or more replication-attenuated viral expression vectors in the boosting composition are from the same, related or unrelated taxonomic family; f) Prime with one or more replication-deficient viral expression vectors and boost with one or more replication-attenuated viral expression vectors; g) Prime with one or more replication-attenuated viral expression vectors and boost with one or more replication-deficient viral expression vectors; h) Prime with one or more lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral expression vectors and boost with one or more Pichand mammalian arenavirus viral expression vectors; i) Prime with one or more Pichand mammalian arenavirus viral expression vectors and boost with one or more lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral expression vectors; j) Prime with one or more replication-deficient Pichand mammalian arenavirus expression vectors and express with one or more replication-deficient lymphocytic choriomeningitis mammalian arenavirus (LCMV) viruses Carrier reinforcement; k) Prime with one or more replication-deficient lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral expression vectors and express with one or more replication-deficient Pichand mammalian arenavirus viruses Carrier reinforcement; l) Prime with one or more arenavirus expression vectors and boost with one or more adenovirus expression vectors; m) priming with one or more adenovirus viral expression vectors and boosting with a boosting composition comprising one or more arenavirus viral expression vectors; n) priming with one or more adenoviral viral expression vectors and boosting with a boosting composition comprising one or more RNA molecules (e.g., mRNA, self-amplifying or self-replicating RNA); o) Prime with one or more RNA molecules (e.g., mRNA, self-amplifying or self-replicating RNA) and boost with a boosting composition comprising one or more adenovirus viral expression vectors; p) priming with one or more chimpanzee adenovirus (ChAd) expression vectors and boosting with a boosting composition comprising one or more self-amplifying or self-replicating RNAs (saRNA or samRNA); q) priming with one or more self-amplifying or self-replicating RNA (saRNA or samRNA) and boosting with a boosting composition comprising one or more chimpanzee adenovirus (ChAd) expression vectors; r) Prime with one or more poxvirus expression vectors and boost with one or more arenavirus expression vectors; s) priming with one or more arenavirus viral expression vectors and boosting with a boosting composition comprising one or more poxvirus viral expression vectors; t) Prime with one or more poxvirus viral expression vectors and boost with one or more adenovirus viral expression vectors; or u) Prime with one or more adenovirus viral expression vectors and boost with a boost composition comprising one or more poxvirus viral expression vectors. 373. The method of any one of claims 364 to 372, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising the following first and second fusion polypeptides, one or more vectors comprising one or more polynucleotides or one or Liposomal complexes (e.g., LNPs), the one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked by one or more linkers: A fusion polypeptide of SEQ ID NO: 70 and 71, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 70 and 71, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 72 and 73, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 72 and 73, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 74 and 75, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 74 and 75, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 76 and 77, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 76 and 77, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 78 and 79, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 78 and 79, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 80 and 81, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 80 and 81, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 90 and 91, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 92 and 93, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 92 and 93, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID Nos: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NOs: 96 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 220 and 221, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; or A fusion polypeptide of SEQ ID NO: 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and 2) Boost with an immunogenic composition comprising the following first and second fusion polypeptides, one or more vectors comprising one or more polynucleotides or one or more A liposome complex (e.g., LNP), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: A fusion polypeptide of SEQ ID NO: 70 and 71, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 70 and 71, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 72 and 73, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 72 and 73, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 74 and 75, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 74 and 75, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 76 and 77, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 76 and 77, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 78 and 79, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 78 and 79, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 80 and 81, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 80 and 81, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 83, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 86 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 85, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 86, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 82 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 83 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 88 and 87, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 84 and 88, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 89, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 85 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 90 and 91, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 92 and 93, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 92 and 93, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 95, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 96 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 94 and 96, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 95 and 97, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 220 and 221, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 100, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 99 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; A fusion polypeptide of SEQ ID NO: 98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 98 and 99, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; or A fusion polypeptide of SEQ ID NO: 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87 with any one of SEQ ID NO: 100 and 101, respectively %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 374. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising the following first and second fusion polypeptides, one or more vectors comprising one or more polynucleotides, one or Liposomal complexes (e.g., LNPs), the one or more polynucleotides encoding the following first and second fusion polypeptides optionally bound or linked by one or more linkers: a) A fusion polypeptide of SEQ ID NO: 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; b) A fusion polypeptide of SEQ ID NO: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 96 and 97, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; c) A fusion polypeptide of SEQ ID NO: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; d) A fusion polypeptide of SEQ ID NO:220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 220 and 221, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and/or e) A fusion polypeptide of SEQ ID NO:95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and 2) Boost with an immunogenic composition comprising the following first and second fusion polypeptides, one or more vectors comprising one or more polynucleotides or one or more A liposome complex (e.g., LNP), the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A fusion polypeptide of SEQ ID NO:98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO:98 and 99, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; b) A fusion polypeptide of SEQ ID NO:100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 100 and 101, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; c) A fusion polypeptide of SEQ ID NO:98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO:98 and 100, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and/or d) A fusion polypeptide of SEQ ID NO:99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 375. The method of any one of claims 364 to 374, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), said one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising: one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 96 A fusion polypeptide, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90, respectively, of any one of SEQ ID NOs: 94 and 96 %, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; or encoding one or more of the following first fusion polypeptide and second fusion polypeptide Polynucleotide: a fusion polypeptide comprising SEQ ID NO: 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85% with any one of SEQ ID NO: 220 and 221, respectively , 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 95 and 97, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and 2) Boosting with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP ), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 98 and 100, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 99 and 101, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 376. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding optionally A first fusion polypeptide and a second fusion polypeptide that comprise a fusion polypeptide of SEQ ID NO:82 and 85, or are at least 80% identical to any one of SEQ ID NO:82 and 85, respectively, bound or linked by one or more linkers. , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% identical fusion polypeptides; and 2) Boost with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding, optionally, A first fusion polypeptide and a second fusion polypeptide bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 87 and 88, or at least 80% identical to any one of SEQ ID NOs: 87 and 88, respectively; 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% , 98% or 99% identical fusion polypeptides. 377. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, said first viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides, said One or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NO:82 and 85, or a fusion polypeptide of SEQ ID NO:82 and 85, respectively, optionally joined or linked by one or more linkers. : any one of 82 and 85 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide; the second viral vector or liposome complex (e.g., LNP) comprises one or more polynucleotides , the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 87 and 88, respectively, optionally bound or linked by one or more linkers. At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92 of any one of SEQ ID NOs: 87 and 88 %, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 378. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding optionally A first fusion polypeptide and a second fusion polypeptide that comprise a fusion polypeptide of SEQ ID NO:82 and 88, or are at least 80% identical to any one of SEQ ID NO:82 and 88, respectively, bound or linked by one or more linkers. , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% identical fusion polypeptides; and 2) Boost with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding, optionally, A first fusion polypeptide and a second fusion polypeptide bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO:85 and 87, or at least 80% identical to any one of SEQ ID NO:85 and 87, respectively, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% , 98% or 99% identical fusion polypeptides. 379. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a virus containing a first viral vector or liposome complex (e.g., LNP) and the second virus Immunogenic compositions of vectors or liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides, The one or more polynucleotides encode a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 82 and 88, respectively, optionally bound or linked by one or more linkers. At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% of any one of SEQ ID NOs: 82 and 88 , 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide; the second viral vector or liposome complex (e.g., LNP) comprises one or more polypeptides nucleotides, the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 85 and 87, optionally joined or linked by one or more linkers, or At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% with any one of SEQ ID NOs: 85 and 87, respectively , 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 380. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding optionally A first fusion polypeptide and a second fusion polypeptide that comprise a fusion polypeptide of SEQ ID NO:94 and 95, or are at least 80% identical to any one of SEQ ID NO:94 and 95, respectively, bound or linked by one or more linkers. , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% identical fusion polypeptides; and 2) Boost with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding, optionally, A first fusion polypeptide and a second fusion polypeptide bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO:96 and 97, or at least 80% associated with any one of SEQ ID NO:96 and 97, respectively, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% , 98% or 99% identical fusion polypeptides. 381. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a virus containing a first viral vector or liposome complex (e.g., LNP) and the second virus Immunogenic compositions of vectors or liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides, The one or more polynucleotides encode a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 94 and 95, respectively, optionally bound or linked by one or more linkers. At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% of any one of SEQ ID NOs: 94 and 95 , 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide; the second viral vector or liposome complex (e.g., LNP) comprises one or more polypeptides nucleotides, the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 96 and 97, optionally joined or linked by one or more linkers, or At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% with any one of SEQ ID NOs: 96 and 97, respectively , 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 382. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding optionally A first fusion polypeptide and a second fusion polypeptide that comprise a fusion polypeptide of SEQ ID NO:94 and 96, or are at least 80% identical to any one of SEQ ID NO:94 and 96, respectively, bound or linked by one or more linkers. , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% identical fusion polypeptides; and 2) Boost with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding, optionally, A first fusion polypeptide and a second fusion polypeptide bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO:95 and 97, or at least 80% associated with any one of SEQ ID NO:95 and 97, respectively, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% , 98% or 99% identical fusion polypeptides. 383. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding optionally A first fusion polypeptide and a second fusion polypeptide that comprise a fusion polypeptide of SEQ ID NO:220 and 221, or are at least 80% identical to any one of SEQ ID NO:220 and 221, respectively, bound or linked by one or more linkers. , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% identical fusion polypeptides; and 2) Boost with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding, optionally, A first fusion polypeptide and a second fusion polypeptide bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO:95 and 97, or at least 80% associated with any one of SEQ ID NO:95 and 97, respectively, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% , 98% or 99% identical fusion polypeptides. 384. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a virus containing a first viral vector or liposome complex (e.g., LNP) and the second virus Immunogenic compositions of vectors or liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides, The one or more polynucleotides encode a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 94 and 96, respectively, optionally bound or linked by one or more linkers. At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% of any one of SEQ ID NOs: 94 and 96 , 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide; the second viral vector or liposome complex (e.g., LNP) comprises one or more polypeptides nucleotides, the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 95 and 97, optionally joined or linked by one or more linkers, or At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% with any one of SEQ ID NOs: 95 and 97, respectively , 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 385. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a virus containing a first viral vector or liposome complex (e.g., LNP) and the second virus Immunogenic compositions of vectors or liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising one or more polynucleotides, The one or more polynucleotides encode a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 220 and 221, respectively, optionally joined or linked by one or more linkers. At least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% of any one of SEQ ID NOs: 220 and 221 , 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide; the second viral vector or liposome complex (e.g., LNP) comprises one or more polypeptides nucleotides, the one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NOs: 95 and 97, optionally bound or linked by one or more linkers, Or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with any one of SEQ ID NO: 95 and 97 respectively %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 386. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding optionally A first fusion polypeptide and a second fusion polypeptide that comprise a fusion polypeptide of SEQ ID NO:94 and 95, or are at least 80% identical to any one of SEQ ID NO:94 and 95, respectively, bound or linked by one or more linkers. , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% identical fusion polypeptides; and 2) Boost with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding, optionally, A first fusion polypeptide and a second fusion polypeptide bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NOs: 98 and 99, or at least 80% associated with any one of SEQ ID NOs: 98 and 99, respectively, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% , 98% or 99% identical fusion polypeptides. 387. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleoside Acid encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO: 105, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88 with SEQ ID NO: 105 %, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides; and 2) Boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleotide Encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO: 109, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% with SEQ ID NO: 109 , 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides. 388. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleoside Acid encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO: 105 or 206, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86% with SEQ ID NO: 105 or 206, respectively , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides; and 2) Boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleotide Encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO: 107 or 207, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively with SEQ ID NO: 107 or 207 A composite fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. 389. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding the following First fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:105 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 with SEQ ID NO:105 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide, the second viral vector or liposome complex (e.g. , LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NO: 107 or at least 80%, 81%, 82%, 83%, 84% of SEQ ID NO: 107 %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides . 390. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding the following First fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:206 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 with SEQ ID NO:206 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide, the second viral vector or liposome complex (e.g. , LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NO:207 or at least 80%, 81%, 82%, 83%, 84% of SEQ ID NO:207 %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides . 391. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleoside Acid encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO: 208, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88 with SEQ ID NO: 208 %, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides; and 2) Boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleotide Encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO:209 or SEQ ID NO:227, or at least 80%, 81%, 82%, 83%, 84% with SEQ ID NO:209 or SEQ ID NO:227 , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides . 392. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleoside Acid encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO: 222, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88 with SEQ ID NO: 222 %, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides; and 2) Boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleotide Encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO:209 or SEQ ID NO:227, or at least 80%, 81%, 82%, 83%, 84% with SEQ ID NO:209 or SEQ ID NO:227 , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides . 393. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleoside Acid encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO: 222, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88 with SEQ ID NO: 222 %, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides; and 2) Boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleotide Encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO:223, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% with SEQ ID NO:223 , 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides. 394. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding the following First fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:208 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 with SEQ ID NO:208 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide, the second viral vector or liposome complex (e.g. , LNP) comprising a polynucleotide encoding a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:209 or SEQ ID NO:227 or at least 80% identical to SEQ ID NO:209 or SEQ ID NO:227 %, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 395. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding the following First fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:222 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 with SEQ ID NO:222 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide, the second viral vector or liposome complex (e.g. , LNP) comprising a polynucleotide encoding a second fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:209 or SEQ ID NO:227 or at least 80% identical to SEQ ID NO:209 or SEQ ID NO:227 %, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 396. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding the following First fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:222 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 with SEQ ID NO:222 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide, the second viral vector or liposome complex (e.g. , LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NO:223 or at least 80%, 81%, 82%, 83%, 84% of SEQ ID NO:223 %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides . 397. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding optionally A first fusion polypeptide and a second fusion polypeptide that comprise a fusion polypeptide of SEQ ID NO:96 and 97, or are at least 80% identical to any one of SEQ ID NO:96 and 97, respectively, bound or linked by one or more linkers. , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% identical fusion polypeptides; and 2) Boost with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding, optionally, A first fusion polypeptide and a second fusion polypeptide bound or linked by one or more linkers: a fusion polypeptide comprising SEQ ID NO: 100 and 101, or at least 80% identical to any one of SEQ ID NO: 100 and 101, respectively, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% , 98% or 99% identical fusion polypeptides. 398. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleoside Acid encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO: 107, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88 with SEQ ID NO: 107 %, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides; and 2) Boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleotide Encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO: 111, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% with SEQ ID NO: 111 , 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides. 399. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleoside Acid encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO: 200, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88 with SEQ ID NO: 200 %, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides; and 2) Boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleotide Encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO:201, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% with SEQ ID NO:201 , 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides. 400. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding the following First fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:200 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 with SEQ ID NO:200 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide, the second viral vector or liposome complex (e.g. , LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NO:201 or at least 80%, 81%, 82%, 83%, 84% of SEQ ID NO:201 %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides . 401. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleoside Acid encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO: 202, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88 with SEQ ID NO: 202 %, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides; and 2) Boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleotide Encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO:203, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% with SEQ ID NO:203 , 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides. 402. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding the following First fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:202 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 with SEQ ID NO:202 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide, the second viral vector or liposome complex (e.g. , LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NO:203 or at least 80%, 81%, 82%, 83%, 84% of SEQ ID NO:203 %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides . 403. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleoside Acid encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO:204, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88 with SEQ ID NO:204 %, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides; and 2) Boosting with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) comprising a polynucleotide, the polynucleotide Encoding the following composite fusion polypeptide: a composite fusion polypeptide comprising SEQ ID NO:205, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% with SEQ ID NO:205 , 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical composite fusion polypeptides. 404. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising a polynucleotide encoding the following First fusion polypeptide: a fusion polypeptide comprising SEQ ID NO:204 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 with SEQ ID NO:204 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide, the second viral vector or liposome complex (e.g. , LNP) comprising a polynucleotide encoding a second fusion polypeptide comprising a fusion polypeptide of SEQ ID NO:205 or at least 80%, 81%, 82%, 83%, 84% of SEQ ID NO:205 %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides . 405. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), said one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO:82 and 83, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO:86 and 87, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and 2) Boosting with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP ), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO:84 and 85, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO:88 and 89, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 406. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), said one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO:83 and 87, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and 2) Boosting with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP ), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a) A first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion of SEQ ID NOs: 84 and 88 polypeptide, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% with any one of SEQ ID NOs: 84 and 88, respectively , 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides; and b) A second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising a fusion of SEQ ID NOs: 85 and 89 polypeptide, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% with any one of SEQ ID NO:85 and 89, respectively , 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 407. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), said one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO:83 and 87, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and 2) Boosting with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP ), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 98 and 100, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 99 and 101, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 408. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), said one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO:83 and 87, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and 2) Boosting with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP ), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 98 and 100, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 409. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), said one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 98 and 100, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 99 and 101, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and 2) Boosting with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP ), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO:83 and 87, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 410. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP), said one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO: 98 and 100, respectively. A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and 2) Boosting with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes containing one or more polynucleotides (e.g., LNP ), the one or more polynucleotides encoding the following first and second fusion polypeptides, optionally bound or linked by one or more linkers: a) A first viral vector or liposome complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; and b) a second viral vector or liposomal complex (eg, LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide below : A fusion polypeptide comprising SEQ ID NO:83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or any one of SEQ ID NO:83 and 87, respectively. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptides. 411. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding optionally A first fusion polypeptide and a second fusion polypeptide of the fusion polypeptide of SEQ ID NO:90 and 91, or at least 80% of any one of SEQ ID NO:90 and 91, respectively, bound or linked by one or more linkers , 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98% or 99% identical fusion polypeptides; and 2) Boost with an immunogenic composition comprising a viral vector or liposome complex (e.g., LNP) containing one or more polynucleotides encoding, optionally, A first fusion polypeptide and a second fusion polypeptide bound or linked by one or more linkers: the fusion polypeptide of SEQ ID NO:92 and 93, or at least 80% of any one of SEQ ID NO:92 and 93, respectively, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% , 98% or 99% identical fusion polypeptides. 412. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes (e.g., LNP), said first and second viral vectors or first and second liposome complexes (e.g., LNP) Diliposome complexes (e.g., LNP) contain the following polynucleotides: a) A first viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 131 and 135, or SEQ ID NO: 131 and 135, respectively. : any one of 131 and 135 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 133 and 137, or SEQ ID NO: 133 and 137, respectively. : any one of 133 and 137 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and 2) Boosting with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes (e.g., LNP), said first and second viral vectors or first and second Liposome complexes (e.g., LNP) contain the following polynucleotides: a) A first viral vector or liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 139 and 145, or SEQ ID NO: 139 and 145, respectively. : any one of 139 and 145 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 142 and 148, or SEQ ID NO: 142 and 148, respectively. : any one of 142 and 148 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 413. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes (e.g., LNP), said first and second viral vectors or first and second liposome complexes (e.g., LNP) Diliposome complexes (e.g., LNP) contain the following polynucleotides: a) A first viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 140 and 146, or SEQ ID NO: 140 and 146, respectively. : any one of 140 and 146 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second viral vector or liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 143 and 149, or SEQ ID NO: 143 and 149, respectively. : any one of 143 and 149 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and 2) Boosting with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes (e.g., LNP), said first and second viral vectors or first and second Liposome complexes (e.g., LNP) contain the following polynucleotides: a) A first viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 150 and 152, or SEQ ID NO: 150 and 152, respectively. : any one of 150 and 152 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleoside comprising SEQ ID NO: 154 and 157 or SEQ ID NO: 155 and 158 acid, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 414. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes (e.g., LNP), said first and second viral vectors or first and second liposome complexes (e.g., LNP) Diliposome complexes (e.g., LNP) contain the following polynucleotides: a) A first viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 150 and 152, or SEQ ID NO: 150 and 152, respectively. : any one of 150 and 152 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides: a polynucleoside comprising SEQ ID NO: 154 and 157 or SEQ ID NO: 155 and 158 acid, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and 2) Boosting with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes (e.g., LNP), said first and second viral vectors or first and second Liposome complexes (e.g., LNP) contain the following polynucleotides: a) A first viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 140 and 146, or SEQ ID NO: 140 and 146, respectively. : any one of 140 and 146 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second viral vector or liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 143 and 149, or SEQ ID NO: 143 and 149, respectively. : any one of 143 and 149 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 415. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes (e.g., LNP), said first and second viral vectors or first and second liposome complexes (e.g., LNP) Diliposome complexes (e.g., LNP) contain the following polynucleotides: a) A first viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 150 and 152, or SEQ ID NO: 150 and 152, respectively. : any one of 150 and 152 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second viral vector or liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 155 and 158, or SEQ ID NO: 155 and 158, respectively. : any one of 155 and 158 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and 2) Boosting with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes (e.g., LNP), said first and second viral vectors or first and second Liposome complexes (e.g., LNP) contain the following polynucleotides: a) A first viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 151 and 153, or SEQ ID NO: 151 and 153, respectively. : any one of 151 and 153 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 156 and 159, or SEQ ID NO: 156 and 159, respectively. : any one of 156 and 159 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 416. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes (e.g., LNP), said first and second viral vectors or first and second liposome complexes (e.g., LNP) Diliposome complexes (e.g., LNP) contain the following polynucleotides: a) A first viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 150 and 152, or SEQ ID NO: 150 and 152, respectively. : any one of 150 and 152 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second viral vector or liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 155 and 158, or SEQ ID NO: 155 and 158, respectively. : any one of 155 and 158 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and 2) Boosting with an immunogenic composition comprising first and second viral vectors or first and second liposome complexes (e.g., LNP), said first and second viral vectors or first and second Liposome complexes (e.g., LNP) contain the following polynucleotides: a) A first viral vector or liposome complex (e.g., LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 139 and 145, or SEQ ID NO: 139 and 145, respectively. : any one of 139 and 145 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides; and b) A second viral vector or liposome complex (eg, LNP) comprising first and second polynucleotides comprising the polynucleotides of SEQ ID NO: 142 and 148, or SEQ ID NO: 142 and 148, respectively. : any one of 142 and 148 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 417. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a first and Second polynucleotide: a polynucleotide comprising SEQ ID NO: 160 and 161, or at least 80%, 81%, 82%, 83%, 84% identical to any one of SEQ ID NO: 160 and 161, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides ;as well as 2) Boost with an immunogenic composition comprising a second viral vector or liposome complex (e.g., LNP) comprising the first and third following Dipolynucleotide: a polynucleotide comprising SEQ ID NO:162 and 163, or at least 80%, 81%, 82%, 83%, 84%, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 418. The method of any one of claims 364 to 373, wherein the prime-boost regimen includes: 1) Prime with an immunogenic composition comprising a first viral vector or liposome complex (e.g., LNP) comprising a first and Second polynucleotide: a polynucleotide comprising SEQ ID NO: 164 and 165, or at least 80%, 81%, 82%, 83%, 84% identical to any one of SEQ ID NO: 164 and 165, respectively , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides ;as well as 2) Boost with an immunogenic composition comprising a second viral vector or liposome complex (e.g., LNP) comprising the first and third following Dipolynucleotide: a polynucleotide comprising SEQ ID NO: 166 and 167, or at least 80%, 81%, 82%, 83%, 84%, or at least 80%, 81%, 82%, 83%, 84%, or any one of SEQ ID NO: 166 and 167, respectively. 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 419. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising the following first polynucleotide: comprising SEQ ID The polynucleotide of NO:210, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with SEQ ID NO:210 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotide, the second viral vector or liposome complex (e.g., LNP) comprising Second polynucleotide: a polynucleotide comprising SEQ ID NO:211, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 420. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising the following first polynucleotide: comprising SEQ ID The polynucleotide of NO:212, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with SEQ ID NO:212 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotide, the second viral vector or liposome complex (e.g., LNP) comprising Second polynucleotide: a polynucleotide comprising SEQ ID NO:213, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 421. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising the following first polynucleotide: comprising SEQ ID The polynucleotide of NO:214, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with SEQ ID NO:214 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotide, the second viral vector or liposome complex (e.g., LNP) comprising Second polynucleotide: a polynucleotide comprising SEQ ID NO:215, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 422. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising the following first polynucleotide: comprising SEQ ID The polynucleotide of NO:216, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with SEQ ID NO:216 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotide, the second viral vector or liposome complex (e.g., LNP) comprising Second polynucleotide: a polynucleotide comprising SEQ ID NO:217, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 423. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising the following first polynucleotide: comprising SEQ ID The polynucleotide of NO:218, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with SEQ ID NO:218 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotide, the second viral vector or liposome complex (e.g., LNP) comprising Second polynucleotide: a polynucleotide comprising SEQ ID NO:219, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 424. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising the following first polynucleotide: comprising SEQ ID The polynucleotide of NO:218, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with SEQ ID NO:218 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotide, the second viral vector or liposome complex (e.g., LNP) comprising Second polynucleotide: a polynucleotide comprising SEQ ID NO:226, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 425. The method of any one of claims 364 to 373, wherein the prime-boost regimen comprises: using a complex containing a first viral vector or liposome (e.g., LNP) and a second viral vector or Immunogenic compositions of liposome complexes (e.g., LNP) priming and boosting, the first viral vector or liposome complex (e.g., LNP) comprising the following first polynucleotide: comprising SEQ ID The polynucleotide of NO:225, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 with SEQ ID NO:225 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotide, the second viral vector or liposome complex (e.g., LNP) comprising Second polynucleotide: a polynucleotide comprising SEQ ID NO:226, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical polynucleotides. 426. The method of any one of claims 364 to 425, wherein the viral vector in the priming composition is a lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vector, and The viral vector in the booster composition is a Cali mammalian arenavirus (also known as Pichand mammalian arenavirus or Pichand arenavirus) viral vector. 427. The method of any one of claims 364 to 425, wherein the viral vector in the priming composition is Cali mammalian arenavirus (also known as Pichand mammalian arenavirus or Pichender Arenavirus) viral vector, and the viral vector in the booster composition is a lymphocytic choriomeningitis mammalian arenavirus (LCMV) viral vector. 428. The method of any one of claims 364 to 425, wherein the viral vector in the priming composition and the viral vector in the boosting composition are adenoviral vectors, such as chimpanzee adenovirus vectors Viral vector (ChAd). 429. The method of any one of claims 374 to 428, wherein the viral vector in the priming composition and the viral vector in the boost composition are replication deficient. 430. The method of any one of claims 374 to 428, wherein the viral vector in the priming composition and the viral vector in the boosting composition are replication attenuated. 431. The method of any one of claims 312 to 430, wherein the subject is not receiving antiretroviral therapy (ART), or ART is interrupted prior to administration of the one or more compositions. 432. The method of any one of claims 312 to 431, wherein ART is interrupted after one or more administrations of the composition. 433. The method of any one of claims 312 to 432, further comprising administering to the subject one or more additional therapeutic agents, such as two, three, four or more additional therapeutic agents. 434. The method of claim 433, comprising co-administering one or more agents that activate latent HIV, such as one or more latency reversal agents (LRA). 435. The method of any one of claims 433 to 434, wherein the one or more LRAs are selected from: agonists or activators of one or more toll-like receptors (TLRs), histones Deacetylase (HDAC) inhibitor, proteasome inhibitor, protein kinase C (PKC) activator, Smyd2 inhibitor, BET-bromodomain 4 (BRD4) inhibitor, ionomycin, inhibitor of apoptosis protein (IAP) ) antagonist as well as a second mitochondrial-derived activator mimetic of caspase (SMAC). 436. The method of any one of claims 433 to 435, comprising co-administering one or more agonists or activators of one or more toll-like receptors (TLRs). 437. The method of claim 436, wherein the TLR agonist or activator is selected from the group consisting of a TLR2 agonist, a TLR3 agonist, a TLR4 agonist, a TLR5 agonist, a TLR7 agonist, a TLR8 agonist, and a TLR9 agonist. 438. The method of any one of claims 436 to 437, wherein the TLR7 agonist is selected from the group consisting of GS 9620 (visamod), R848 (resiquimod), DS-0509, LHC-165 and TMX-101 (imiquimod), and/or wherein the TLR8 agonist is selected from the group consisting of GS-9688 (selgantomod), R848 (resiquimod), and NKTR-262 (dual TLR7/TLR8 agonist agent). 439. The method of any one of claims 433 to 438, comprising co-administering one or more interleukin receptors of interleukins selected from the group consisting of IL-2, IL-7, IL-12 and IL-15. Body agonists. 440. The method of claim 439, comprising co-administering one or more cytokines selected from: IL-2, IL-7, IL-12, IL-15, and variants thereof. 441. The method of any one of claims 433 to 440, comprising co-administering one or more innate immune activators. 442. The method of claim 441, wherein the one or more innate immune activators comprise an agonist of a receptor selected from: fms-related tyrosine kinase 3 (FLT3), interferon gene stimulator (STING) receptor, DExD/H box helicase 58 (DDX58; Also known as RIG-I), nucleotide-binding oligomerization domain-containing protein 2 (NOD2). 443. The method of any one of claims 433 to 442, comprising co-administering an agonist of fms-related tyrosine kinase 3 (FLT3). 444. The method of claim 443, wherein the vaccine-induced T cell response is increased compared to administration of the immunogenic composition alone. 445. The method of any one of claims 433 to 444, comprising co-administering one or more antagonists or inhibitors of inhibitory immune checkpoint proteins or receptors and/or stimulatory immune checkpoints One or more activators or agonists of dot proteins or receptors. 446. The method of claim 445, wherein the one or more immune checkpoint proteins or receptors are selected from: CD27, CD70; CD40, CD40LG; CD47, CD48 (SLAMF2), transmembrane and immunoglobulin-containing Protein domain protein 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3); V-set domain-containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immune regulatory receptors (VSIR, B7H5, VISTA); Immunoglobulin superfamily member 11 (IGSF11, VSIG3); Natural killer cell cytotoxic receptor 3 ligand 1 (NCR3LG1, B7H6) ; HERV-H LTR-related 2 (HHLA2, B7H7); inducible T cell costimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4 , OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30L); TNFRSF10A (CD261, DR4, TRAILR1), TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5, TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13B (BAFF); TNFRSF18 (GITR), TNFSF18 (GITRL); MHC class I peptide-related sequence A (MICA); MHC class I peptide-related sequence B (MICB); CD274 (CD274, PDL1, PD-L1); programmed cell death 1 (PDCD1, PD1, PD- 1); Cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); poliovirus receptor body (PVR) cell adhesion molecules (PVR, CD155); PVR-related immunoglobulin domain-containing proteins (PVRIG, CD112R); T cell immune receptors (TIGIT) with Ig and ITIM domains; T cell immune spheres Protein and mucin domain protein 4 (TIMD4; TIM4; hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); lymphocyte activation 3 (LAG3, CD223); signal transduction Lymphocyte activation molecule family member 1 (SLAMF1, SLAM, CD150); lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6, CD352); SLAM family member 7 (SLAMF7, CD319); UL16 binding Protein 1 (ULBP1); UL16 binding protein 2 (ULBP2); UL16 binding protein 3 (ULBP3); Retinoic acid early transcript 1E (RAET1E; ULBP4); Retinoic acid early transcript 1G (RAET1G; ULBP5); Retinoic acid acid early transcript 1L (RAET1L; ULBP6); lymphocyte activation 3 (CD223); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell lectin-like Receptor C1 (KLRC1, NKG2A, CD159A); Killer lectin-like receptor K1 (KLRK1, NKG2D, CD314); Killer lectin-like receptor C2 (KLRC2, CD159c, NKG2C); Killer lectin-like receptor C3 (KLRC3, NKG2E); Killer cell lectin-like receptor C4 (KLRC4, NKG2F); Killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); Killer cell immunoglobulin Killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 2 (KIR2DL2); Killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 3 (KIR2DL3); Killer cell immunoglobulin-like receptor body, three Ig domains, and long cytoplasmic tail 1 (KIR3DL1); killer lectin-like receptor D1 (KLRD1); and SLAM family member 7 (SLAMF7). 447. The method of any one of claims 445 to 446, comprising co-administering one or more blockers or inhibitions of one or more T cell inhibitory immune checkpoint proteins or receptors agent. 448. The method of claim 447, wherein the T cell inhibitory immune checkpoint protein or receptor is selected from the group consisting of: CD274 (CD274, PDL1, PD-L1); Programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD276 (B7H3); T cells containing V-set domain Activation inhibitor 1 (VTCN1, B7H4); V-set immune regulatory receptors (VSIR, B7H5, VISTA); Immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); PVR-related immunoglobulin domain-containing proteins (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); Lymphocyte Activation 3 (LAG3 , CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 ( KIR, CD158E1); Killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 1 (KIR2DL1); Killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 2 ( KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 3 (KIR2DL3); and killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 1 (KIR3DL1 ). 449. The method of any one of claims 445 to 446, comprising co-administering one or more agonists or activators of one or more T cell stimulating immune checkpoint proteins or receptors . 450. The method of claim 449, wherein the T cell inhibitory immune checkpoint protein or receptor is selected from: CD27, CD70; CD40, CD40LG; inducible T cell costimulator (ICOS, CD278); inducible Type T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 ( GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); poliovirus receptor (PVR) cell adhesion molecule ( PVR, CD155). 451. The method of any one of claims 445 to 446, comprising co-administering one or more blockers or inhibitions of one or more NK cell inhibitory immune checkpoint proteins or receptors agent. 452. The method of claim 451, wherein the NK cell inhibitory immune checkpoint protein or receptor is selected from the group consisting of killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 1 (KIR , CD158E1); Killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); Killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2 ); Killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); Killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); Killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); and killer cell lectin-like receptor D1 (KLRD1, CD94). 453. The method of any one of claims 445 to 446, comprising co-administering one or more agonists or activators of one or more NK cell stimulating immune checkpoint proteins or receptors . 454. The method of claim 453, wherein the NK cell stimulating immune checkpoint protein or receptor is selected from the group consisting of: CD16, CD226 (DNAM-1); Killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314); and SLAM family member 7 (SLAMF7). 455. The method of any one of claims 445 to 448, wherein the one or more immune checkpoint inhibitors comprise a protein inhibitor of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4 . 456. The method of claim 455, comprising co-administering an antibody that binds CTLA4. 457. The method of claim 456, wherein the vaccine-induced T cell response is increased compared to administration of the immunogenic composition alone. 458. The method of any one of claims 455 to 457, wherein the protein or antibody inhibitor of CTLA4 is selected from: ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS -986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044 , CG-0161, ATOR-1144, PBI-5D3H5, FPT-155(CTLA4/PD-L1/CD28), PF-06936308(PD-1/CTLA4), MGD-019(PD-1/CTLA4), KN- 046(PD-1/CTLA4), MEDI-5752(CTLA4/PD-1), XmAb-20717(PD-1/CTLA4) and AK-104(CTLA4/PD-1). 459. The method of claim 455, wherein the protein inhibitor of PD-L1 (CD274) or PD-1 (PDCD1) is selected from the group consisting of: pembrolizumab, nivolumab, cimelimumab, pembrolizumab, Delizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK-301 , PF-06801591, BGB-A317 (tislelizumab), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, HLX-10, MGA-012 , BI-754091, AGEN-2034, JS-001 (toripalimab), JNJ-63723283, jenosumab (CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201 , SHR-1210 (camrelizumab), Sym-021, ABBV-181, PD1-PIK, BAT-1306 (MSB0010718C), CX-072, CBT-502, TSR-042 (dotalizumab) , MSB-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308 (sintilimab), HLX-20, KL-A167, STI- A1014, STI-A1015(IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, FPT-155(CTLA4/PD-L1/CD28), PF-06936308(PD-1/CTLA4) , MGD-013(PD-1/LAG-3), FS-118(LAG-3/PD-L1)MGD-019(PD-1/CTLA4), KN-046(PD-1/CTLA4), MEDI- 5752(CTLA4/PD-1), RO-7121661(PD-1/TIM-3), XmAb-20717(PD-1/CTLA4), AK-104(CTLA4/PD-1), M7824(PD-L1/ TGFβ-EC domain), CA-170 (PD-L1/VISTA), CDX-527 (CD27/PD-L1), LY-3415244 (TIM3/PDL1) and INBRX-105 (4-1BB/PDL1). 460. The method of any one of claims 445 to 448, wherein the one or more immune checkpoint inhibitors comprise CD274 (PDL1, PD-L1), programmed cell death 1 (PDCD1, PD1, Small molecule inhibitors of PD-1) or CTLA4. 461. The method of claim 460, wherein the small molecule inhibitor of CD274 or PDCD1 is selected from the group consisting of: GS-4224, GS-4416, INCB086550 and MAX10181. 462. The method of claim 460, wherein the small molecule inhibitor of CTLA4 comprises BPI-002. 463. The method of any one of claims 433 to 462, further comprising administering to the subject one or more antiviral agents. 464. The method of claim 463, wherein the one or more antiviral agents are selected from the group consisting of: HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic sites (or Allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors and capsid inhibitors. 465. The method of any one of claims 433 to 464, further comprising administering to the subject one or more anti-HIV antibodies or antigen-binding fragments thereof. 466. The method of claim 465, wherein the one or more anti-HIV antibodies or antigen-binding fragments thereof bind HIV gp120. 467. The method of any one of claims 465 to 466, wherein the anti-HIV antibody or antigen-binding fragment thereof comprises a broadly neutralizing antibody. 468. The method of any one of claims 465 to 467, wherein the one or more anti-HIV antibodies or antigen-binding fragments thereof that bind, inhibit and/or neutralize HIV with a broad spectrum of anti-HIV Competes with or contains the VH and VL variable domains of antibodies (bNAbs). 469. The method of any one of claims 465 to 468, wherein the one or more anti-HIV antibodies or antigen-binding fragments thereof that bind, inhibit and/or neutralize HIV are combined with gp120 selected from Epitope or region binding: i. The third variable loop (V3) containing the N332 oligomannose glycan and/or the high mannose patch; ii.CD4 binding site (CD4bs); iii. The second variable ring (V2) and/or the Env trimer vertex; iv.gp120/gp41 interface; or The silent side of v.gp120. 470. The method of any one of claims 465 to 469, wherein the antibody or antigen-binding fragment thereof that binds, inhibits and/or neutralizes HIV is combined with the third variable loop (V3) and/or Binds to an epitope or region of gp120 in the high mannose patch of the N332 oligomannose glycan and competes with or contains the VH and VL regions of an antibody selected from: GS-9722, PGT-121, PGT- 121.414, PGT-122, PGT-123, PGT-124, PGT-125, PGT-126, PGT-128, PGT-130, PGT-133, PGT-134, PGT-135, PGT-136, PGT-137, PGT-138, PGT-139, 10-1074, 10-1074-J, GS-2872, VRC24, 2G12, BG18, 354BG8, 354BG18, 354BG42, 354BG33, 354BG129, 354BG188, 354BG411, 354BG426, DH270.1, DH27 0. 6. PGDM12, VRC41.01, PGDM21, PCDN-33A, BF520.1 and VRC29.03. 471. The method of any one of claims 465 to 470, wherein the antibody or antigen-binding fragment thereof binds to an epitope or region of gp120 in the CD4 binding site (CD4bs) and is selected from The VH and VL regions of the following antibodies compete with or contain these regions: b12, F105, VRC01, VRC07, VRC07-523, VRC03, VRC06, VRC06b01, VRC08, VRC0801, NIH45-46, GS-9723, GS-5423, 3BNC117, 3BNC60, VRC-PG04, PGV04, CH103, 44-VRC13.01, 1NC9, 12A12, N6, N49-P7, NC-Cow1, IOMA, CH235 and CH235.12, N49P6, N49P7, N49P11, N49P9 and N60P25. 472. The method of any one of claims 465 to 471, wherein the antibody or antigen-binding fragment thereof that binds, inhibits and/or neutralizes HIV is combined with the second variable loop (V2) and/or An epitope or region of gp120 in the Env trimer apex binds and competes with or contains the VH and VL regions of an antibody selected from: PG9, PG16, PGC14, PGG14, PGT-142, PGT-143, PGT -144, PGT-145, CH01, CH59, PGDM1400, CAP256, CAP256-VRC26.08, CAP256-VRC26.09, CAP256-VRC26.25, PCT64-24E and VRC38.01. 473. The method of any one of claims 465 to 472, wherein the antibody or antigen-binding fragment binds to an epitope or region of gp120 in the gp120/gp41 interface and binds to an antibody selected from The VH and VL regions compete with or contain these regions: PGT-151, CAP248-2B, 35O22, 8ANC195, ACS202, VRC34, and VRC34.01. 474. The method of any one of claims 465 to 473, wherein the antibody or antigen-binding fragment thereof that binds, inhibits and/or neutralizes HIV binds to an epitope or region of the silent face of gp120, and Competes with or contains the VH and VL regions of an antibody selected from: VRC-PG05 and SF12. 475. The method of any one of claims 465 to 474, wherein the antibody or antigen-binding fragment thereof that binds, inhibits and/or neutralizes HIV with gp41 in the membrane proximal region (MPER) Epitope or region binding. 476. The method of any one of claims 465 to 475, wherein the antibody or antigen-binding fragment thereof that binds, inhibits and/or neutralizes HIV with gp41 in the membrane proximal region (MPER) An epitope or region binds and competes with or contains the VH and VL regions of an antibody selected from: 10E8, 10E8v4, 10E8-5R-100cF, 4E10, DH511.11P, 2F5, 7b2, and LN01. 477. The method of any one of claims 465 to 476, wherein the antibody or antigen-binding fragment thereof that binds, inhibits and/or neutralizes HIV binds to an epitope or region of the gp41 fusion peptide, and Competes with or contains the VH and VL regions of an antibody selected from: VRC34 and ACS202. 478. The method of any one of claims 312 to 477, wherein the one or more fusion polypeptides, composite fusion polypeptides are administered one or more times, optionally in combination with one or more additional therapeutic agents. , polynucleotide, vector, liposome complex (e.g., LNP) or immunogenic composition, the subject is without antiretroviral therapy (ART) for at least 3 months, at least 6 months Months, at least 1 year, at least 2 years, at least 3 years or more without symptoms of HIV or AIDS. 479. The method of any one of claims 312 to 478, wherein the one or more fusion polypeptides, composite fusion polypeptides are administered one or more times, optionally in combination with one or more additional therapeutic agents , polynucleotide, vector, liposome complex (e.g., LNP) or immunogenic composition, the subject is without antiretroviral therapy (ART) for at least 3 months, at least 6 months Months, at least 1 year, at least 2 years, at least 3 years or more having a viral load copy/ml of blood of less than 500, for example less than 400, less than 300, less than 200, less than 100, less than 50. 480. A method of designing a fusion polypeptide capable of eliciting an immune response to one or more viral target antigens, the method comprising: a) Computer identification of one or more sequence conserved regions in a population of polypeptide sequences encoded by viral genes, said population being derived from a population of viruses among patients; b) in silico identifying the two most prevalent polypeptide sequences from the one or more conserved regions identified in step a) and generating multivalent polypeptide fragments from the conserved regions; and c) Arranging the polypeptide fragments to reduce or avoid the creation of deleterious epitopes at the junctions between the polypeptide fragments. 481. The method of claim 480, wherein step (c) comprises reducing or eliminating binding to a specific HLA allele with a predicted IC50 value of less than about 1000 nM or within the top 5% of the population of polypeptide fragments at a percentile rank of connected 9-mers. 482. A method of designing a fusion polypeptide capable of eliciting an immune response to one or more viral target antigens, the method comprising: a) computer identification of one or more sequence conserved regions in a first population of polypeptide sequences encoded by viral genes, said first population being derived from an inter-patient viral population; b) optionally, in silico identification of the two most prevalent polypeptide sequences from said one or more conserved regions identified in step a); and c) Arranging the retained polypeptide fragments into one or more contiguous fusion polypeptides such that the linkers joining the polypeptide fragments avoid or reduce the generation of linkers capable of binding human MHC class I or Human MHC class II molecules or epitopes with a percentile rank within the top 5% of the population of polypeptide fragments. 483. The method of any one of claims 480 to 482, wherein step (c) comprises reducing or eliminating at least 55% (5 out of 9 amino acid residues), e.g. at least 65% ( Viral polypeptides with an amino acid sequence identity of at least 75% (6 out of 9 amino acid residues), e.g. at least 75% (7 out of 9 amino acid residues), e.g. at least 85% (8 out of 9 amino acid residues) 9 aggregate. 484. The method of any one of claims 480 to 483, wherein the multivalent polypeptide fragment is a bivalent polypeptide fragment. 485. The method of any one of claims 480 to 484, further comprising identifying, for example, using deep sequencing data, polypeptide sequences encoded by viral genes within one or more sequence conserved regions in an intra-patient population. Steps for variant subsequences. 486. The method of claim 485, further comprising identifying conserved regions of the polypeptide encoded by the viral gene such that at least 70% of the variant subsequences within the one or more sequence conserved regions in the patient population are within Steps within a bivalent polypeptide fragment. 487. The method of any one of claims 480 to 486, further comprising shortening the length of the fusion polypeptide, for example, by at least 10%, 15%, 20%, 25%, 30% or more, The step of retaining a polypeptide fragment subsequence comprising (i) an in silico predicted and (ii) an in vitro confirmed epitope. 488. A method for generating a multivalent antigen, the method comprising computationally constructing a set of multivalent amino acid sequences within a structurally conserved region of a population of viral proteome sequences by a method comprising the following steps: (a) Comparing the viral proteome sequence population; (b) For each sequence in said alignment, generate a set of nine amino acid subsequences ("9-mers") starting at the N-terminal amino acid, each subsequence overlapping the preceding subsequence by eight amino acids, such that Each sequence of length l in the alignment contains (1-8) 9-mers; (c) Calculate the frequency of each unique 9-mer starting at position i in each sequence of the alignment and identify the two or more most common unique 9-mers at each position ; (c)(1) wherein the frequency is calculated as the number of times the unique 9-mer occurs at position i in the alignment divided by the total number of sequences in the alignment; (d) calculating multivalent conservation at each position by adding the proportion of sequences in said alignment that contain either of said two or more most common unique 9-mers; (e) generating an alignment of conserved regions by extracting sequences in said alignment that have greater than 80% or greater than 90% multivalent conservation; (f) determining the frequency of each unique pair of 9-mers at each position in the alignment of the conserved region; (g) linking 9-mer pairs at adjacent positions of the alignment of the conserved regions, the positions sharing an overlap of eight amino acids; (h) generating the directed acyclic graph, wherein each 9-mer pair is a node, and edges between adjacent nodes are formed by the 9-mer pairs connected in the adjacent positions, each The edge weight is equal to the frequency of downstream 9-mer pairs, ·Add the source node and connect it with all nodes in the first position, · Add the sink node and connect it with all nodes at the last position, and ·Invert all weights; (i) Find the best path from the source node to the sink node in the directed acyclic graph, wherein the best path is based on the sum of the frequencies of all 9-mer pairs in the directed acyclic graph Defined; (j) If two or more 9-mers at adjacent positions within the optimal bivalent 9-mer pathway share an overlap of eight amino acids, a multivalent antigen is constructed by joining them, resulting in a linked 9-mer Two or more sequences that together form a multivalent antigen; and (k) Optionally, rearrange the polypeptide fragments to reduce or avoid the creation of deleterious epitopes at junctions between polypeptide fragments. 489. The method of claim 488, wherein the multivalent conservation is a bivalent conservation, and wherein the multivalent antigen is a bivalent antigen. 490. The method of any one of claims 488 to 489, wherein in step (a) the conserved region is further defined by performing one or more of the following steps: (i) remove fragments that are less than 35 amino acids in length (e.g., from 9 amino acids to 10, 15, 20, 25, 30 or 35 amino acids in length); (ii) remove fragments determined to have less than 90% multivalent (e.g., bivalent) conservation; (iii) remove fragments determined to be weakly immunogenic or non-immunogenic (e.g., as demonstrated in vitro or in vivo); and/or (iv) Include additional fragments that are determined to be immunogenic (eg, as demonstrated in vitro or in vivo). 491. The method of any one of claims 488 to 490, wherein the step of rearranging the peptide fragments to reduce or avoid the generation of deleterious epitopes is by including in silico HLA binding analysis and human proteome cross-recognition analysis. One or more methods. 492. The method of any one of claims 488 to 491, further comprising inserting a linker sequence between one or more adjacent fragments. 493. The method of any one of claims 488 to 492, wherein the method further comprises by removing percentile ranks in the population of polypeptide fragments that bind to a specific HLA allele with a predicted IC50 value of less than about 1000 nM. to improve the multivalent (e.g., bivalent) antigen generated in step (h) by linking 9-mers within the first 5%. 494. The method of any one of claims 488 to 493, wherein the method further comprises removing a peptide that is at least 55% (5 out of 9 amino acid residues), e.g., at least 65% (9) identical to a human peptide. 6 out of 9 amino acid residues), e.g. at least 75% (7 out of 9 amino acid residues), e.g. at least 85% (8 out of 9 amino acid residues) amino acid sequence identity or with a human protein A 9-mer of the same T cell receptor (TCR) facing residues to improve the multivalent (eg bivalent) antigen produced in step (h). 495. The method of any one of claims 488 to 494, further comprising rearranging the polypeptide fragments to reduce or avoid the creation of deleterious epitopes at junctions between polypeptide fragments. 496. The method of claim 495, wherein the step of rearranging the peptide fragments to reduce or avoid the generation of deleterious epitopes is by a method comprising one or more of in silico HLA binding analysis and human proteome cross-recognition analysis method. 497. The method of any one of claims 488 to 496, further comprising identifying, for example, using deep sequencing data, polypeptide sequences encoded by viral genes within one or more sequence conserved regions in an intra-patient population. Steps for variant subsequences. 498. The method of claim 497, further comprising identifying conserved regions of the polypeptide encoded by the viral gene such that at least 70% of the variant subsequences within the one or more sequence conserved regions in the patient population are within Steps within a bivalent polypeptide fragment. 499. The method of any one of claims 480 to 498, further comprising shortening the length of the fusion polypeptide, for example, by at least 10%, 15%, 20%, 25%, 30% or more, The step of retaining a polypeptide fragment subsequence comprising (i) an in silico predicted and (ii) an in vitro confirmed epitope. 500. The method of any one of claims 480 to 499, wherein the one or more viral target antigens are from a mammalian virus, such as a human virus. 501. The method of any one of claims 480 to 500, wherein the one or more viral target antigens are from a virus selected from the group consisting of human immunodeficiency virus (HIV), hepatitis B virus (HBV) , human papillomavirus (HPV), herpes simplex virus (HSV), Ebola virus, Zika virus and chikungunya virus. 502. The method of any one of claims 480 to 501, wherein the inter-patient viral population is from a population of patients who are not receiving antiretroviral therapy (ART). 503. The method of any one of claims 480 to 501, wherein the inter-patient viral population is from a population of patients who have received antiretroviral therapy (ART). 504. A fusion polypeptide prepared according to the method of any one of claims 480 to 503, wherein the fusion polypeptide elicits an immune response to a virus in a mammal, such as a human.